
<html lang="en"     class="pb-page"  data-request-id="941ffe30-9449-4358-baa0-3eb8a63e898c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-2;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.7b00498;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies" /></meta><meta name="dc.Creator" content="Jian  Wu" /></meta><meta name="dc.Creator" content="Suresh  Kumar" /></meta><meta name="dc.Creator" content="Feng  Wang" /></meta><meta name="dc.Creator" content="Hui  Wang" /></meta><meta name="dc.Creator" content="Lijia  Chen" /></meta><meta name="dc.Creator" content="Patrick  Arsenault" /></meta><meta name="dc.Creator" content="Michael  Mattern" /></meta><meta name="dc.Creator" content="Joseph  Weinstock" /></meta><meta name="dc.Description" content="Ubiquitin specific protease 7 (USP7), the most widely studied among the nearly 100 deubiquitinating enzymes, supports cancer by positively affecting tumor growth and negatively affecting the patien..." /></meta><meta name="Description" content="Ubiquitin specific protease 7 (USP7), the most widely studied among the nearly 100 deubiquitinating enzymes, supports cancer by positively affecting tumor growth and negatively affecting the patien..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 18, 2017" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00498" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00498" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00498" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00498" /></link>
        
    
    

<title>Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00498" /></meta><meta property="og:title" content="Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0016.jpeg" /></meta><meta property="og:description" content="Ubiquitin specific protease 7 (USP7), the most widely studied among the nearly 100 deubiquitinating enzymes, supports cancer by positively affecting tumor growth and negatively affecting the patient’s immune response to tumors. Great interest exists, therefore, in developing USP7 inhibitors for clinical evaluation. While the proteasome inhibitor field has enjoyed clinical success, very few clinically appropriate effectors of deubiquitinating (protease) or ubiquitinating (ligase) enzymes have appeared. The ubiquitin protease/ligase field is moving from the initial discovery of potent, selective modulators with cell proof of concept and in vivo activity to the optimization of these molecules to impart drug-like properties or the discovery of new inhibitor scaffolds by improved screening or rational design. This Perspective focuses on the current status of USP7 inhibitors from various organizations active in developing these compounds for the clinic and suggests undertakings that are both achievable and necessary to lead to successful clinical outcomes for USP7 inhibitors in cancer treatment." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00498"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00498">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00498&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00498&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00498&amp;href=/doi/10.1021/acs.jmedchem.7b00498" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 422-443</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01346" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.7b01272" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Wu">Jian Wu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suresh++Kumar">Suresh Kumar</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Wang">Feng Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Wang">Hui Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lijia++Chen">Lijia Chen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Arsenault">Patrick Arsenault</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Mattern">Michael Mattern</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-8595-000X" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph++Weinstock">Joseph Weinstock</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Progenra, Inc., 277 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 484-328-1724. E-mail: <a href="/cdn-cgi/l/email-protection#e08d81949485928ea090928f87858e9281ce838f8d"><span class="__cf_email__" data-cfemail="1e737f6a6a7b6c705e6e6c71797b706c7f307d7173">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00498&amp;href=/doi/10.1021%2Facs.jmedchem.7b00498" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 422–443</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 2, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 March 2017</li><li><span class="item_label"><b>Published</b> online</span>18 August 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 January 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00498" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00498</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D422%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJian%2BWu%252C%2BSuresh%2BKumar%252C%2BFeng%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D2%26contentID%3Dacs.jmedchem.7b00498%26title%3DChemical%2BApproaches%2Bto%2BIntervening%2Bin%2BUbiquitin%2BSpecific%2BProtease%2B7%2B%2528USP7%2529%2BFunction%2Bfor%2BOncology%2Band%2BImmune%2BOncology%2BTherapies%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D443%26publicationDate%3DJanuary%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00498"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4089</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00498" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Suresh&quot;,&quot;last_name&quot;:&quot;Kumar&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Lijia&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Arsenault&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Mattern&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;Weinstock&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;422-443&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00498&quot;},&quot;abstract&quot;:&quot;Ubiquitin specific protease 7 (USP7), the most widely studied among the nearly 100 deubiquitinating enzymes, supports cancer by positively affecting tumor growth and negatively affecting the patient’s immune response to tumors. Great interest exists, therefore, in developing USP7 inhibitors for clinical evaluation. While the proteasome inhibitor field has enjoyed clinical success, very few clinically appropriate effectors of deubiquitinating (protease) or ubiquitinating (ligase) enzymes have appeared. The ubiquitin protease/ligase field is moving from the initial discovery of potent, selective modulators with cell proof of concept and in vivo activity to the optimization of these molecules to impart drug-like properties or the discovery of new inhibitor scaffolds by improved screening or rational design. This Perspective focuses on the current status of USP7 inhibitors from various organizations active in developing these compounds for the clinic and suggests undertakings that are both achievable and necessar&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00498&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00498" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00498&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00498" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00498&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00498" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00498&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00498&amp;href=/doi/10.1021/acs.jmedchem.7b00498" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00498" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00498" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00498%26sid%3Dliteratum%253Aachs%26pmid%3D28768102%26genre%3Darticle%26aulast%3DWu%26date%3D2018%26atitle%3DChemical%2BApproaches%2Bto%2BIntervening%2Bin%2BUbiquitin%2BSpecific%2BProtease%2B7%2B%2528USP7%2529%2BFunction%2Bfor%2BOncology%2Band%2BImmune%2BOncology%2BTherapies%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D2%26spage%3D422%26epage%3D443%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/jmcmar.2018.61.issue-2/20180125/jmcmar.2018.61.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Ubiquitin specific protease 7 (USP7), the most widely studied among the nearly 100 deubiquitinating enzymes, supports cancer by positively affecting tumor growth and negatively affecting the patient’s immune response to tumors. Great interest exists, therefore, in developing USP7 inhibitors for clinical evaluation. While the proteasome inhibitor field has enjoyed clinical success, very few clinically appropriate effectors of deubiquitinating (protease) or ubiquitinating (ligase) enzymes have appeared. The ubiquitin protease/ligase field is moving from the initial discovery of potent, selective modulators with cell proof of concept and <i>in vivo</i> activity to the optimization of these molecules to impart drug-like properties or the discovery of new inhibitor scaffolds by improved screening or rational design. This Perspective focuses on the current status of USP7 inhibitors from various organizations active in developing these compounds for the clinic and suggests undertakings that are both achievable and necessary to lead to successful clinical outcomes for USP7 inhibitors in cancer treatment.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/61/2"><issue-title>Inducing Protein Degradation as a Therapeutic Strategy</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86208" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86208" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 2004, three pioneers of the ubiquitin pathway (Drs. Aaron Ciechanover, Irwin Rose, and Avram Hershko) were awarded the Nobel Prize in Chemistry;<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> in the previous year, the USFDA had approved bortezomib/Velcade (<b>1</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), a proteasome inhibitor, for treatment of refractory relapsed multiple myeloma.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> It seemed that the next few years would see a barrage of new drugs to treat all classes of disease by acting on the ubiquitin pathway’s conjugating and deconjugating enzymes, as well as the proteasome. Today, nearly a decade and a half later, only four additional ubiquitin pathway associated drugs have been approved, despite significant discovery efforts by pharmaceutical companies and others. Two of these drugs [carfilzomib/Kyprolis (<b>3</b>) and ixazomib/Ninlaro (<b>5</b>)] (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) are proteasome inhibitors, and two [lenalidomide/Revlimid (<b>2</b>) and pomalidomide/Pomalyst (<b>4</b>)] (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) are derivatives of thalidomide.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3-5)</a> The first immunomodulatory drug (IMiD), <b>2</b>, was used clinically before it was known that the cellular pharmacology of this drug class entailed binding to cereblon, a component of certain ubiquitin E3 ligases (ubiquitin conjugating enzymes), thereby interfering with the ability of the ligases to recognize and bind their target proteins.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> Attempts to mine the ubiquitin proteasome pathway for new drug targets continue, and in this Perspective, the development of inhibitors of one ubiquitin deconjugating enzyme, USP7, a promising anticancer target, will be examined to see how it may yet be possible to make a safe and efficacious drug starting with a small molecule ubiquitin protease inhibitor. Critical considerations for the development of effective USP7 inhibitors will be discussed, including the pro-oncogenic and immune modulatory activities of USP7, identification of tools and technologies for discovery and development of USP7 inhibitors, and medicinal chemistry considerations in the progression from lead to preclinical development of those inhibitors.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Ubiquitin Proteasome Pathway: USFDA Approved Drugs<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0014.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last"><a href="http://www.fda.gov" class="extLink">www.fda.gov</a>.</p></div></div><div></div></div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">1.1 Ubiquitin Pathway: Mechanisms</h3><div class="NLM_p">The ubiquitin signaling system has emerged as a fundamental regulatory component of various cellular processes.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> Through a cascade of enzymatic reactions, proteins are selectively modified with ubiquitin, which then provides a multitude of signals downstream that ultimately determine the fate of the modified protein (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Protein ubiquitination is dynamic, and ubiquitin is removed from proteins by enzymes called deubiquitinases (DUBs). There are approximately 100 DUBs in the human genome. Ubiquitin specific proteases (USPs), which represent the largest family of DUBs, are isopeptidases that belong to the cysteine protease family, whose members share a conserved catalytic triad. Among DUBs, ubiquitin specific protease 7 (USP7), also known as herpes-associated ubiquitin specific protease (HAUSP), is the most widely studied DUB.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Ubiquitin pathway and inhibitors: Ubiquitin is activated by E1 in an ATP dependent adenylation reaction forming E1–Ub thioester. Activated Ub is transferred to the active site cysteine of an E2 enzyme in a transthiolation reaction to generate E2–Ub thioester, which is subsequently transferred in an E3 ligase dependent manner to the ε-amino group of lysine in a substrate. Substrates modified with lysine 48-linked polyubiquitin chains are degraded by the proteasome. Alternately, ubiquitin can be removed from the substrate by deubiquitinating enzymes called DUBs. Representative examples of small molecule inhibitors that perturb E2, E3, and DUBs are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">1.2 Approved Drugs from the Ubiquitin Proteasome Pathway</h3><div class="NLM_p last">Many molecularly targeted drugs in current use alter cellular physiology by acting on enzymes that catalyze post-translational modification of their substrates, the most obvious example being kinase inhibitors currently in the clinic.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> Another example comes from the ubiquitin-proteasome pathway, in which the protein tag ubiquitin is conjugated to or deconjugated from the ε-amino groups of lysines of specific target proteins (see above), resulting in modulations of cellular half-life, activity, and compartmentalization of target proteins. The large numbers of E3 ligases (several hundred) and DUBs (approximately one hundred) present unique opportunities for selectively targeting the ubiquitin pathway.<a onclick="showRef(event, 'ref8 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref8 ref13 ref14">(8, 13, 14)</a> The ubiquitin pathway is characterized by levels of complexity beyond that of multiple enzymes; a single ubiquitin may be conjugated to a target protein or to another ubiquitin, the latter resulting in polyubiquitin chains, which can be linear or branched and attached to one of several ubiquitin lysines.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18">(15-18)</a> Thus, modulation of a target molecule by a ubiquitin protease or ligase occurs as part of a complex regulatory environment. The proteasome itself constitutes a target class apart from ubiquitin ligases and proteases; this multiprotein structure captures polyubiquitinated proteins, removes ubiquitin, and degrades the target protein through various constituent protease activities. In recent years, ubiquitin-based anticancer drug development has focused on all five molecular target classes (E1, E2, E3, DUBs and proteasomes). To the surprise of many, it was the proteasome inhibitor <b>1</b> that became the first marketed ubiquitin pathway drug; it was approved by the USFDA in 2003 for treatment of cancer (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Approvals of proteasome inhibitors have been limited to multiple myeloma, which appears to be particularly sensitive to proteasome inhibitors, and certain types of lymphoma.<a onclick="showRef(event, 'ref2 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref2 ref19 ref20 ref21">(2, 19-21)</a> In early 2017, there were three proteasome inhibitors on the market in the USA, the newest (<b>5</b>) having an oral formulation.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Compounds <b>1</b> and <b>5</b> are covalent drugs with boronic acid groups, and <b>3</b> is a reactive epoxide based on a peptide-derived natural product. Additional proteasome inhibitors have been and are being evaluated in clinical trials as both single agents and components of combination protocols against multiple myeloma as well as other types of cancer including refractory solid tumors [<a href="https://clinicaltrials.gov/" class="extLink">clinicaltrials.gov</a>].<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> The only other marketed drugs with a connection to the ubiquitin pathway are derivatives of thalidomide (see above). Compound <b>2</b> was approved originally in 2005 in combination with dexamethasone for patients who had received at least one prior therapy.<a onclick="showRef(event, 'ref4 ref25'); return false;" href="javascript:void(0);" class="ref ref4 ref25">(4, 25)</a> In 2013, a second thalidomide derivative, <b>4</b>, was approved for patients with multiple myeloma whose disease had progressed following treatment with other drugs.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">1.3 Ubiquitin Pathway Experimental Drugs Other than Proteasome Inhibitors in Clinical Trials</h3><div class="NLM_p">While numerous trials with FDA-approved as well as experimental proteasome inhibitors are ongoing (combinations, oral administration, extension to cancers other than multiple myelomas and certain leukemias; please see <a href="https://clinicaltrials.gov/" class="extLink">clinicaltrials.gov</a>), comparatively few trials are underway for E3 ligases and deubiquitinases. Moreover, as can be seen in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, two of the E3 ligase compounds that entered clinical trials appear not to be currently under active study. Nevertheless, at least one small molecule inhibitor of each enzyme class of the ubiquitin pathway, with the exception of E2, has advanced from the discovery stage to clinical development (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Three of these experimental drugs are either E3 ligase inhibitors [(JNJ-26854165/serdemetan (8), GDC-0152 (<b>9)</b>] (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>)<a onclick="showRef(event, 'ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29">(26-29)</a> or antagonists of the binding of an E3 ligase (MDM2) to its substrate protein (p53) (RG7388/idasanutlin, 7).<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> MLN 4924/pevonedistat (6), an inhibitor of the E1 activating enzyme of the ubiquitin-like protein Nedd8, has undergone numerous Phase I/II trials.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> The most recent (2015) ubiquitin pathway entrant to clinical trials, VLX1570 (<b>10</b>), is a competitive inhibitor of proteasome-associated deubiquitinase activities (USP14 and UCHL-5).<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> It is clear, then, that compounds acting on deubiquitinases and E3 ligases have lagged behind, relative to proteasome inhibitors, in clinical development. An overview of various inhibitors targeting E1, E2, E3, and DUBs has been published recently.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Ubiquitin Pathway Enzyme Antagonists in Clinical Trial<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0015.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last"><a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a>.</p></div></div><div></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">2 USP7: A Major Procancer Enzyme</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.1 Substrates and Functions</h3><div class="NLM_p">USP7 is a cysteine protease that was originally identified as a binding partner of ICP0 (Infected Cell Polypeptide 0), an immediate-early gene of the Herpes simplex virus 1 (HSV-1).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Since then, numerous proteins have been identified as potential substrates or binding partners of USP7.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> USP7 is present in complexes with binding partners including several E3 ligases<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and appears to be essential for normal physiological functions. Conventional germ line knockout of USP7 in mice results in embryonic lethality between days E6.5 and E7.5, underlying the essential role of USP7 in growth and development.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Conditional deletion of USP7 in neural progenitors inhibits neuronal cell development, decreases cortex thickness, and causes perinatal lethality.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In addition, both heterozygous deletion (or mutation) and genomic duplication of USP7 have been associated with neurological and behavioral phenotypes, indicating that the role of USP7 is complex and context-dependent.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42, 43)</a> USP7 also plays an essential role in DNA replication.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Many of the well characterized substrates of USP7 play critical roles in tumor suppression or progression, cell signaling, epigenetic control, DNA damage repair, and immune responses. USP7-dependent dysregulation of its substrates’ stability and functions has been reported to be essential for the initiation, progression, or recurrence of a series of tumors, including but not limited to lung cancer, colorectal cancer, breast cancer, neuroblastoma, medulloblastoma, and prostate cancer.<a onclick="showRef(event, 'ref45 ref46 ref47 ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47 ref48 ref49 ref50">(45-50)</a></div><div class="NLM_p">p53 is a critical tumor suppressor, and mutations in p53 are found in more than 50% of human cancers. USP7 plays an important role in antagonizing p53 functions through multiple mechanisms. HDM2 is one of the major E3 ubiquitin ligases that downregulate p53 via the ubiquitin proteasome pathway. HDMX, which is a binding partner of HDM2, also inhibits the function of p53 through tight binding to the N-terminal transcription activation domain of p53.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Both HDM2 and HDMX are deubiquitylated and stabilized by USP7.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52, 53)</a> Therefore, knockout or knock-down of USP7 protein or inhibition of USP7 enzymatic activity results in downregulation of HDM2/HDMX, leading to stabilization of p53 protein and subsequent activation of the p53 pathway. In addition, USP7 inhibits the expression of p53 as well as the expression of its downstream transcriptional targets by stabilizing lysine specific demethylase 1 (LSD1)<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and histone methyltransferase 1A (KMT1A), both epigenetic modulators of gene transcription. USP7 also stabilizes E3 ligase UHRF1 (Ubiquitin-like, containing PHD and RING finger domains, 1) and Dnmt1 (DNA methyl transferase 1), critical regulators of DNA methylation and epigenetic gene silencing.</div><div class="NLM_p">In addition to the p53 pathway, USP7 regulates the functions of tumor suppressors such as PTEN and FOXO proteins (FOXO1/4), both of which require monoubiquitination for their proper localization and function.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55, 56)</a> By removing ubiquitin from monoubiquitinated PTEN and FOXO1/4, USP7 antagonizes their tumor suppressor functions.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56, 57)</a> The protein p14<sup>ARF</sup> acts as a tumor suppressor by inhibiting ribosome biogenesis or initiating p53-dependent cell cycle arrest and apoptosis. By deubiquitinating and stabilizing Trip12, an E3 ligase for p14<sup>ARF</sup>, USP7 enables downregulation of p14<sup>ARF</sup>, thereby attenuating its tumor suppressor activity.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> In addition, USP7 regulates the stability of MEL18, BMI1, and UbE2E1, three protein components of the polycomb repressive complex 1 (PRC1), which are responsible for histone H2A monoubiquitination and gene silencing of p16INK4α, a tumor suppressor protein.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><div class="NLM_p">In its role as a cancer-promoting enzyme, USP7 not only antagonizes tumor repressors but also positively regulates the stability and functions of several oncoproteins, including N-MYC, which is dysregulated in a number of advanced-stage human tumors and has been reported as a driver of neuroblastoma (NB) tumorigenesis.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> USP7 has been identified as a regulator of N-MYC, and USP7 expression induces deubiquitination and stabilization of N-MYC.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Hypoxia-inducible factor 1α (HIF-1α) plays a major role in cancer biology, specifically in angiogenesis, tumor cell survival, metastasis, and generation of resistance to chemotherapy and radiotherapy.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> A recent study discovered that hypoxia-induced K63 polyubiquitination of USP7 by the E3 ligase HectH9 enhanced the ability of USP7 to deubiquitinate and stabilize HIF-1α.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> REST is a critical transcription factor in regulating neural progenitor cell self-renewal; neural tumors, such as medulloblastomas and neuroblastomas, normally express high levels of REST, and forced expression of REST can induce malignant transformation of neural progenitors. USP7 has been demonstrated to regulate and stabilize this oncoprotein.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">Abnormally altered cell signaling pathways often drive tumorigenesis. For example, hyperactivation of the Sonic hedgehog (Shh) pathway drives development of medulloblastoma, dysregulation of the Wnt/β-catenin pathway is associated with colorectal tumor growth, and malfunctioning of the androgen receptor signaling pathway is a common cause of prostate cancer initiation and progression. USP7 has been reported to positively regulate the activity of these three pathways by stabilizing their transcription factors Gli,<a onclick="showRef(event, 'ref46 ref62'); return false;" href="javascript:void(0);" class="ref ref46 ref62">(46, 62)</a> β-catenin,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> and androgen receptor,<a onclick="showRef(event, 'ref63 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref63 ref64 ref65">(63-65)</a> respectively.</div><div class="NLM_p">Tumor cells typically produce higher than normal levels of reactive oxygen species, increasing the extent of DNA damage.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Accordingly, functional DNA repair pathways are beneficial for tumor cell survival. In addition, DNA damage responses are associated with the generation of resistance to chemotherapy.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> USP7 regulates multiple DNA repair pathways, and loss of USP7 reduces the tolerance of cells to genotoxic agents.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> For example, the antitumor activity of certain alkylating chemotherapy drugs is largely attenuated by the overexpression of alkylation repair proteins such as ALKBH2 and ALKBH3 in cancer cells. USP7 is reported to deubiquitinate and stabilize ALKBH2/3, and the loss of USP7 in tumor cells greatly sensitizes them to alkylating agents, suggesting that USP7 inhibitors could be explored as sensitizers in alkylating agent-based chemotherapy protocols.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p">Thus, USP7 is a critical node in various cancer signaling pathways, and USP7 inhibitors are predicted to have intrinsic antitumor activity (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). In addition to its tumor supportive role, USP7 promotes the evasion of tumors from immune surveillance and killing by stabilizing proteins that are essential for regulatory T cells (T<sub>reg</sub>) to suppress tumoricidal effector T cells (T<sub>eff</sub>) in the tumor microenvironment. This immune regulatory role of USP7 is discussed in detail in the following section (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Multimodal antitumor activities of USP7 inhibitors. USP7 inhibitors exhibit intrinsic antitumor activities by downregulating protumorigenic proteins and extrinsic immune mediated antitumor activities by attenuating T<sub>reg</sub> functions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.2 Therapeutic Application of USP7 Inhibitors in Neoplastic Disease</h3><div class="NLM_p">Part of the renewed and increased interest in developing USP7 inhibitors for cancer treatment stems from the recent demonstration that, in addition to protecting tumor cells directly from apoptosis-associated tumoricidal effects, USP7 plays a role in the capacity of tumors to evade detection and killing by the host immune system. Several chemical biology studies have been conducted in an attempt to validate USP7 as a target of both growth and survival of tumors and their ability to evade surveillance and killing by the host immune system.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66, 67)</a> It is important to note, however, that the various chemical tools described in the literature to date lack the selectivity, potency, and pharmacokinetic properties required to validate the role of USP7 in tumor biology with complete certainty. Nonetheless, the data generated thus far are intriguing and warrant continued efforts to develop drug-like molecules with improved potency and selectivity that can be employed with confidence to confirm the roles of USP7 in tumor biology suggested by the initial studies.</div><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">2.2.1 USP7 Inhibitors in Direct Regulation of Tumors</h4><div class="NLM_p">Many cancers, including multiple myeloma, neuroblastoma, squamous cell carcinoma, hepatocellular carcinoma, lung cancer, glioblastoma, ovarian cancer, breast cancer, and colorectal cancer, overexpress USP7; this overexpression has been correlated with poor prognosis in neuroblastoma and in lung and colorectal cancers.<a onclick="showRef(event, 'ref45 ref50 ref54 ref58 ref66 ref68 ref69 ref70 ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref45 ref50 ref54 ref58 ref66 ref68 ref69 ref70 ref71 ref72">(45, 50, 54, 58, 66, 68-72)</a> Chauhan et al. obtained the first evidence of <i>in vivo</i> antitumor activity of USP7 inhibitors when they demonstrated that P5091 (<b>17</b>, <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>) inhibits multiple myeloma growth in MM1.S xenograft models.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Inhibition of USP7 in multiple myeloma cells results in destabilization of HDM2 and upregulation of p53 and p21 tumor suppressors, ultimately leading to apoptosis.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> In addition, treatment with <b>17</b> overcomes multiple myeloma’s resistance to the proteasome inhibitor bortezomib and also synergizes with DNA damaging agents such as etoposide and doxorubicin in killing multiple myeloma cells <i>in vitro</i>.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Most recently, Das et al. showed that <b>17</b> inhibits multiple myeloma activity in synergy with RRx-001, a novel hypoxia selective epigenetic agent, by downregulating Dnmt1.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Thus, there is strong rationale for clinical evaluation of USP7 inhibitors alone or in combination with existing multiple myeloma therapies to further increase therapeutic efficacy.</div><div class="NLM_p">In 2012, Fan et al. reported that P22077 (<b>19</b>, <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>), a close analog of <b>17</b>, induces apoptosis in neuroblastoma (NB) cells in a p53 dependent manner.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> USP7 inhibition by <b>19</b> promotes downregulation of HDM2 and upregulation of p53 in p53 wild-type NB cells.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Compound <b>19</b> significantly augments the cytotoxic effects of doxorubicin and etoposide in NB cells with an intact USP7–HDM2–p53 axis.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Moreover, treatment with <b>19</b> sensitizes chemoresistant NB cells to chemotherapy. In an orthotopic NB mouse model, <b>19</b> was shown to significantly inhibit xenograft tumor growth of three different NB cell lines.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">In 2016, Tavana et al. described USP7 as a critical regulator of the proto-oncogene N-Myc, which is amplified in several cancers including neuroblastoma (NB).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> RNAi mediated knockdown in cancer cell lines or genetic ablation of USP7 in mouse brain was shown to destabilize N-Myc, leading to inhibition of N-Myc function. More importantly, treatment with the USP7 inhibitors <b>17</b> or <b>19</b> promoted ubiquitination and downregulation of N-myc protein levels in <i>MYC-N</i> gene amplified NB cells without significantly altering the <i>MYC-N</i> mRNA levels. Treatment with <b>19</b> also promotes apoptosis in p53 proficient NB cells and markedly suppresses the growth of <i>MYC-N</i> amplified human neuroblastoma cell lines in xenograft models. Remarkably, intraperitoneal (ip) administration of <b>19</b> at 20 mg/kg daily for 15 days was well tolerated. No weight loss or other health problems were observed during treatment, and no abnormalities were found after full necropsy at the end of treatment. Similarly, wild-type mice treated with 20 mg/kg daily dosage for a 30-day period were found to have no signs of weight loss, lethargy, or microscopic tissue damage.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> These studies strongly suggest that USP7 inhibitors may be effective in the treatment of human NB by suppressing N-Myc activities irrespective of cellular p53 wild-type or mutant status.</div><div class="NLM_p">Most recently, An et al. demonstrated that USP7 positively regulates Wnt signaling in colorectal cancers.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> USP7 knockdown inhibits proliferation of colorectal cancer cell lines with differing p53 status. USP7 inhibition by treatment with <b>17</b> attenuates Wnt signaling by promoting the ubiquitination and subsequent degradation of β-catenin. Treatment with <b>17</b> inhibits proliferation and induces apoptosis in colorectal cancer cell lines <i>in vitro</i>. Treatment of HCT116 xenografts in nude mice using ip administration of <b>17</b> at 15 and 25 mg/kg, inhibited tumor growth. Further investigation demonstrated reduction in levels of β-catenin and Wnt target genes (Axin, c-Myc and Survivin). These results indicated inhibition of Wnt signaling <i>in vivo</i> under these conditions. In addition to USP7, its closest homologue, USP47, also stabilizes β-catenin. Interestingly, <b>17</b> was demonstrated to inhibit USP47 <i>in vitro</i> with a potency similar to that of USP7. Therefore, concomitant inhibition of USP47 by <b>17</b> in the <i>in vivo</i> experiment above could also have contributed to the downregulation of β-catenin.</div><div class="NLM_p">USP7 regulates the stability and function of PHF8, a histone demethylase necessary for DNA damage response (DDR).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Acting through PHF8 and RNF168, USP7 regulates both homologous DNA repair (HR) and nonhomologous end joining (NHEJ) repair processes. USP7 mediated stabilization of PHF8 leads to upregulation of cyclin A2, a critical mediator of cell growth and proliferation. USP7 promotes breast carcinogenesis through the USP7/PHF8/cyclin A2 axis. Knockdown of USP7 in the breast cancer cell line MCF7 results in changes in the expression of 1477 genes and significantly abrogates tumor growth in athymic mice.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Thus, USP7 inhibitors could also be pursued for therapeutic intervention in breast cancer alone or in combination with chemo- or radiotherapies.</div><div class="NLM_p">USP7 overexpression in glioblastoma is associated with disease progression and poor prognosis.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Yi et al. identified lysine specific demethylase 1 (LSD1) as a USP7 substrate in glioblastoma cells.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Knockdown of USP7 inhibits the growth of glioblastoma cells <i>in vitro</i> by modulating p53 pathways. This study supports the notion that USP7 inhibitors could be efficacious against glioblastoma.</div><div class="NLM_p">USP7 is expressed at elevated levels in several ovarian cancer cell lines compared to nontumorigenic immortalized ovarian surface epithelial cells.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> In addition, ovarian cancer tissues express significantly higher levels of USP7 than do nontumor tissues, and knockdown of USP7 inhibits the proliferation of ovarian cancer cells. Targeting USP7 may thus represent a novel strategy for treating ovarian cancer.</div><div class="NLM_p">Hyperactivation of the Shh pathway is a hallmark of medulloblastoma (MB), the most common pediatric brain tumor.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Although Shh pathway inhibitors are being evaluated for treating MB, central nervous system and skeletal muscle developmental toxicities due to Shh inhibition could pose serious challenges, particularly in younger infants.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Recently Zhan et al. demonstrated that knockdown of USP7 inhibits the growth and migration of medulloblastoma (MB) cells.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Further, USP7 knockout using the CRISPR/Cas9 system in MB cells suppresses their growth and metastasis. USP7 targeting inhibits the Shh pathway and decreases glioma-associated oncogene homologue (Gli) protein levels without affecting the p53 pathway. More importantly, treatment with USP7 inhibitors <b>17</b> or <b>19</b> blocks the proliferation and migration of MB cells <i>in vitro</i>. Thus, selective USP7 inhibition has potential as a treatment option for MB; it remains to determine, however, whether these promising <i>in vitro</i> results translate to the clinic.</div><div class="NLM_p last">Zhang et al. identified Ki-67, the known proliferation marker of malignant tumors, as a USP7 substrate in NSCLC.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Expression levels of both Ki-67 and USP7 are positively correlated with degree of carcinoma malignancy. USP7 interacts with Ki-67 in non-small-cell lung cancer (NSCLC), leading to deubiquitination and stabilization of Ki-67, and inhibition of USP7 by <b>19</b> results in accumulation of ubiquitinated Ki-67 and its subsequent downregulation. Moreover, knockdown of USP7 in NSCLC cells suppresses tumor growth in nude mice<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> in addition to sensitizing NSCLC cells to gemcitabine and docetaxel.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Collectively, this study suggests that USP7/Ki-67 is an attractive therapeutic target in NSCLC cells in addition to being a potential prognostic marker. USP7 inhibitors again could be efficacious as single agents or in combination with radio- or chemotherapies.</div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">2.2.2 USP7 in Immune Regulation</h4><div class="NLM_p">Cytotoxic T cells and natural killer cells are capable of killing tumors. Within the tumor microenvironment, Foxp3<sup>+</sup> T<sub>reg</sub> can be highly immunosuppressive; limiting the antitumor responses of T<sub>eff</sub> such as CD8<sup>+</sup> T cells, thereby promoting tumor growth and progression.<a onclick="showRef(event, 'ref74 ref75 ref76 ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref74 ref75 ref76 ref77 ref78">(74-78)</a> Thus, a promising new cancer immunotherapy avenue is the attenuation of T<sub>reg</sub> suppressive functions.<a onclick="showRef(event, 'ref79 ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref79 ref80 ref81 ref82">(79-82)</a> The T<sub>reg</sub> lineage and its immunosuppressive functions are determined primarily by the lineage specific transcription factor Foxp3, which is subject to several post-translational modifications, including acetylation and ubiquitination.<a onclick="showRef(event, 'ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref83 ref84 ref85">(83-85)</a> Tip60, a histone acetyl transferase, exerts a dominant role in promoting acetylation, multimerization, and functioning of Foxp3 in T<sub>reg</sub>.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><div class="NLM_p">The role of USP7 in immune regulation became apparent when van Loosdregt et al. showed that USP7 interacts with Foxp3 in T<sub>reg</sub>; knockdown of USP7 impaired T<sub>reg</sub> functions in an <i>ex vivo</i> T<sub>eff</sub> suppression assay.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Notably, adoptive transfer of wild-type T<sub>reg</sub> prevented colitis development in mice while transfer of T<sub>reg</sub> with their USP7 knocked down failed to suppress T<sub>eff</sub> -mediated colitis development. In these seminal experiments it was shown that USP7 deubiquitinates Foxp3, thereby preventing its proteasomal degradation.</div><div class="NLM_p">The critical role of USP7 in maintaining T<sub>reg</sub> suppressive functions became evident when Wang et al. provided genetic evidence that developmental deletion of USP7 in T<sub>reg</sub> cells (USP7<sup>–/–</sup> T<sub>reg</sub>) induces lethal systemic autoimmunity in mice.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> USP7 deletion alters the T<sub>reg</sub> gene expression signature and dampens the suppressive activity of T<sub>reg</sub> cells. Interestingly, USP7<sup>–/–</sup> T<sub>reg</sub> cells proliferate actively, indicating the dominance of p53 independent pathways in these cells. In stark contrast to the wild-type T<sub>reg</sub>, USP7<sup>–/–</sup> T<sub>reg</sub> express more IFNγ and IL-2. All of these data suggest that inhibition of USP7 impairs T<sub>reg</sub> cell function and potentially promotes antitumor immunity. Pharmacologic blockade of USP7 may therefore provide an avenue for effective cancer immunotherapy.</div><div class="NLM_p">Notably, incubation with the USP7 inhibitor <b>17</b> and its more potent analog P217564 (IC<sub>50</sub> = 0.58 μM, structure not disclosed) have been shown to abrogate the suppressive activity of T<sub>reg</sub>.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> While USP7 inhibitor treatment promotes ubiquitination of both Foxp3 and Tip60 and inhibits formation of Foxp3 multimers, USP7 inhibitor treatment or USP7 deletion in T<sub>reg</sub> leads to a dramatic decrease in Tip60 protein level, suggesting that Tip60 plays a dominant role in regulating the function of T<sub>reg</sub> cells, potentially by promoting the acetylation, multimerization and function of Foxp3. Thus, pharmacologic inhibition of USP7 impairs T<sub>reg</sub> cell function, likely through Tip60 and Foxp3 dependent mechanisms.</div><div class="NLM_p">USP7 protein levels and overall activity are similar in T<sub>reg</sub> and T<sub>eff</sub>. The role of USP7 in T<sub>eff</sub>, however, is unclear. To address the effect of USP7 inhibitors on T<sub>eff</sub>, Wang et al. injected mice with P217564 and isolated T<sub>reg</sub> and T<sub>eff</sub>, which were evaluated using <i>ex vivo</i> functional assays. Most interestingly, USP7 inhibitor treated T<sub>eff</sub> exhibited resistance to suppression by T<sub>reg.</sub><a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Although the precise mechanism behind this resistance remains to be established, these data indicate that treatment with USP7 inhibitors <i>in vivo</i> does not impair the T<sub>eff</sub> functions, which are critical for their antitumor immune response.</div><div class="NLM_p">Using two distinct syngeneic tumor models, Wang et al. demonstrated antitumor activity of USP7 inhibitors <i>in vivo</i>. In the T<sub>reg</sub> dependent syngeneic TC1 lung tumor and AE17 mesothelioma models, USP7 inhibitor were shown to exert statistically significant antitumor activity and, more importantly, to promote the accumulation of tumor-antigen specific CD8<sup>+</sup> T cells in the tumor microenvironment.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> These tumor specific CD8+ T cells produced IFNγ, potentially helping to break immune tolerance. This study also demonstrated that USP7 inhibitor treatment decreases intratumoral accumulation of Foxp3<sup>+</sup> T<sub>reg</sub> cells. The same tumors, grown in syngeneic immunodeficient mice, were seen to be refractory to USP7 inhibitors given at the same dose, suggesting that under the conditions employed, USP7 inhibitors exerted activity against TC1 and AE17 predominantly by inhibiting T<sub>reg</sub> functions, promoting an antitumor immune response. Notably, both TC1 and AE17 cancer cells have reduced levels of USP7, MDM2, and p53 compared to the multiple myeloma cells (MM1.S) that are responsive to USP7 inhibitor treatment in immunodeficient animals.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Thus, those tumors that overexpress USP7 and its substrates may be more sensitive to the direct antitumor activity of USP7 inhibitors, whereas tumors with relatively high levels of suppressive T<sub>reg</sub> in their tumor microenvironment will also be responsive to the immune mediated antitumor activity of USP7 inhibitors. Moreover, USP7 inhibitors were shown to confer significant therapeutic benefit when used in combination with biologicals commonly used in immune oncology protocols (vaccines as well as anti-PD1 monoclonal antibodies) in mice bearing AE17 tumors and TC1 tumors, respectively.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><div class="NLM_p">Dnmt1 and UHRF1 are two additional critical modulators of the function and development of T<sub>reg</sub>. In 2013, Wang et al. demonstrated that deletion of Dnmt1, but not Dnmt3a, decreases the numbers and function of T<sub>reg</sub> and that, conditional deletion of Dnmt1 in mouse T<sub>reg</sub> leads to lethal autoimmunity by 3 to 4 weeks of age.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> This phenotype is strikingly similar to that of mice with a USP7<sup>–/–</sup> deletion in their T<sub>reg</sub>. Conditional deletion of Dnmt1 downregulates global DNA methylation and causes alterations in T<sub>reg</sub>-specific expression of several hundred genes. This study established that Dnmt1, whose stability is regulated by USP7, is also essential for the maintenance of T<sub>reg</sub> development and function. Obata et al. demonstrated that deletion of UHRF1 results in a failure of colonic T<sub>reg</sub> development.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(89)</a> Although the precise role of UHRF1 in T<sub>reg</sub> functions remains to be established, this study linked yet another USP7 substrate to immune regulation.</div><div class="NLM_p">USP7 is expressed in a wide variety of tissues, and the emergence of several potential substrates could pose concerns regarding on-target toxicity in clinical applications of USP7 inhibitors.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> As discussed earlier, germ line deletion of USP7 results in early embryonic lethality in mice and mutations resulting in haploinsufficiency of USP7 leads to a spectrum of neurodevelopmental and behavioral phenotypes in humans.<a onclick="showRef(event, 'ref40 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref42">(40, 42)</a> In addition, USP7 is essential for DNA replication, and USP7 inhibitors strongly inhibit replication origin firing in a p53 independent manner.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Therapeutic blockade of USP7 using small molecule inhibitors could potentially impact normal neuronal development as well as DNA replication, genomic integrity and proliferation of normal cells. Thus, careful evaluation of toxicities associated with small molecule USP7 inhibitors is critical to establish the therapeutic window. Apart from T<sub>reg</sub> cells, USP7 inhibitors might affect other cell populations that express Tip60 and other USP7 substrates. Several preclinical <i>in vivo</i> studies have demonstrated that USP7 inhibitors such as <b>17</b>, <b>19</b>, and P217564 are well tolerated at doses that reduce tumor growth in mice and exert antitumor activities against a variety of cancers including multiple myeloma, neuroblastoma, lung tumors, and colon cancer.<a onclick="showRef(event, 'ref47 ref50 ref66 ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref47 ref50 ref66 ref67 ref68">(47, 50, 66-68)</a> More important, T<sub>reg</sub> are relatively small in number (∼5–10% of total CD4<sup>+</sup> T cell population)<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(90)</a> and appear to be hypersensitive to USP7 inhibitors.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Thus, USP7 inhibitors could preferentially attenuate Foxp3<sup>+</sup> T<sub>reg</sub> functions while sparing the host effector CD8<sup>+</sup> T cells. Pharmacologic modulation of T<sub>reg</sub> cells using USP7 inhibitors offers a new way to break immune tolerance in the tumor microenvironment. Suppression of T<sub>reg</sub> functions by inhibiting USP7 could result in potential autoimmunity. Treatment of mice with P217564 at its therapeutically efficacious dose did not result in autoimmunity, indicating a safe therapeutic window. However, more studies are needed to determine clinical relevance of these observations, and strategies to harness the immune system to fight cancer must take potential autoimmunity and its therapeutic management into consideration.</div><div class="NLM_p last">Collectively, these studies show that USP7 inhibitors confer significant benefit when used either as monotherapy in syngeneic tumor models or in combination with other forms of immunotherapy to promote antitumor activity. It will be interesting to see whether their potential dual antitumor activity will translate to the clinical setting.</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">3 USP7: Catalytic Mechanism and 3-D Crystal Structure</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The USP7 protein contains a single catalytic domain (residues 208–560), an N-terminal tumor necrosis factor-receptor (TRAF)-like domain (residues 53–208), and five C-terminal ubiquitin-like (Ubl) domains (residues 560–1102). Each domain exhibits unique characters and functions.</div><div class="NLM_p">The five ubiquitin-like domains (UBL-1–5) can interact with USP7 partners such as ICP0, GMPS (guanosine monophosphate synthetase) and UHRF1.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(91)</a> A crystal structure of ICP0 peptide 617-GPRKCARKTRH-627 with the USP7 C-terminal UBL domains (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WPI">4WPI</a>) shows that the peptide binds onto a shallow surface area at UBL-2 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(92)</a> The key residues involved in the protein–protein interactions (PPIs) are K620 and K624 of ICP0, which form salt bridges with D762 and D764 of USP7, respectively. The key consensus binding motif was confirmed as KXXXK, which was also found in GMPS and UHRF1 to enable their binding with UBL-2. Additionally, upon the binding of GMPS, UBL-4 and -5 have been shown to participate in the allosteric activation of USP7 through a GMPS mediated mechanism, which regulates p53 level.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(92, 93)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Cocrystal structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WPI">4WPI</a>) of ICP0 peptide (green) with USP7 C-terminal UBL-123 domain (gray); (B) key interactions between ICP0 peptide (green) and USP7 UBL-2 domain (gray).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The N-terminal TRAF domain of USP7 has been reported to bind to substrates such as p53 and MDM2 in a mutually exclusive manner, illustrated by the superimposed cocrystal structures of p53 (358–363)–TRAF (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FOO">2FOO</a>) and MDM2 (142–147)–TRAF (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FOP">2FOP</a>) (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(94, 95)</a> Both peptides adopted similar conformations as well as interactions with the TRAF pocket residues including F118, I154, D164, W165, G166, and F167. The key recognition motif can be summarized as PXXS, which accounted for 359-PGGS-362 in p53, and 144-PSSS-147 in MDM2. Interestingly, another consensus motif AXXS in both p53 and MDM2 also showed up as a TRAF binder, represented by the p53 site 364-AHSS-367 and 225-DAGVS-229.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(94, 95)</a> Shi and co-workers also observed that the MDM2 peptide was a stronger binder compared to the p53 peptide.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(95)</a> The selectivity between p53 and MDM2 suggests that inhibition of the TRAF domain of USP7 can potentially destabilize MDM2 more than p53, which can be an attractive target for designing small molecule inhibitors.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Superimposed cocrystal structures (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FOO">2FOO</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FOP">2FOP</a>) of p53 peptide (green), MDM2 peptide (orange), and USP7 N-terminal TRAF domain (gray); (B) key interactions between substrate peptides (green and orange) and USP7 TRAF pocket (gray).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although multiple crystal structures showing the interactions between USP7 domains and various peptide substrates have been reported in the literature, very little information is available on the binding between full length USP7 and its substrates. In fact, in addition to the key motif interactions mentioned above, unknown protein–protein interactions, including p53–UBL45 and HDM2–UBL45, have been suggested as contributing to the binding of these substrates.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(96)</a> Increased structural understanding of these interactions is necessary to identify potential “hot spots” for the binding of small molecule inhibitors with USP7.</div><div class="NLM_p">The catalytic domain of USP7 has been reviewed in the literature.<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(97, 98)</a> As a cysteine isopeptidase, USP7 has a catalytic domain whose conformation shows significant structural flexibility.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(99)</a> Interestingly, this conformational change is unique compared to other USPs including USP8, USP14, and USP4.<a onclick="showRef(event, 'ref92 ref99'); return false;" href="javascript:void(0);" class="ref ref92 ref99">(93, 100)</a> In its nonactive conformation (shown in red), the catalytic cysteine C223 is located far away from H464 and D481, autoinhibiting the catalytic activity of USP7 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Upon the binding of ubiquitin (shown in cyan), the catalytic domain is activated, represented by the shift of three switching loops (residues including K281-Q296, F409–N418, and G458–H464 highlighted in green) surrounding the ubiquitin tail (V70–G76), as well as by the formation of the activated catalytic triad (highlighted in green) (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Overlay of Apo-USP7 (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4M5X">4M5X</a>) with Ub-bound USP7 (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JTV">5JTV</a>). Ub-bound USP7 catalytic domain flexible loops are colored in green, Apo-USP7 catalytic domain flexible loops are colored in red, and ubiquitin is colored in cyan. (B) Shift of catalytic trial residues (C223, H464, and D481) upon the binding of ubiquitin. Inactive conformation is shown in gray, while the active conformation is shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The catalytic mechanism is illustrated in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>. When the catalytic triad assumes its active conformation, the hydrogen bond between Asp481 and His464 locks His464 into a favorable location toward the vicinity of Cys223, which in turn results in the deprotonation of the thiol of Cys223 to reveal the nucleophile. The thiol anion then attacks the carbonyl group of the isopeptide bond between the substrate N-terminal lysine and the ubiquitin C-terminal glycine to form a tetrahedral intermediate, which collapses and ejects the free lysine from the substrate, while ubiquitin is attached to the Cys223 of USP7 through a thioester linkage. Next, a molecule of water protonates His464 and hydrolyzes the thioester bond to release Cys223 and the ubiquitin C-terminal glycine.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Catalytic mechanism of USP7.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">4 Assays Available To Identify USP7 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Robust and sensitive biochemical assays are necessary to characterize the enzymatic functions of DUBs <i>in vitro</i> as well as to conduct high throughput screening to identify potential inhibitors. In cells, DUBs catalyze the cleavage of isopeptide linkages between ubiquitin and a substrate protein or between two ubiquitin molecules. Preparation of specific ubiquitinated substrates in quantities sufficient to develop robust high throughput screening assays remains a challenge, and several nonphysiological substrates have been developed as alternatives to monitor activities of DUBs such as USP7 (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). One of the earliest substrates to be developed was ubiquitin-7-amido-4-methylcoumarin (Ub-AMC), where the carboxy-terminal glycine of ubiquitin is fused with the AMC fluorophore using a transpeptidation method.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(101)</a> Upon incubation with DUBs such as USP7, the ubiquitin moiety is cleaved and the AMC fluorophore is released allowing its emission at 460 nm (λ<sub>ex</sub> = 380 nm), the assay readout. The simplicity and robustness of the Ub-AMC based assay led to its widespread use and commercial adaptation into high throughput screening platforms. It was recognized, however, that the excitation wavelength of AMC fluorophore in the UV range (380 nm) constituted a major limitation, as compounds that fluoresce or absorb at this wavelength could interfere with the assay. Moreover, AMC is conjugated to the ubiquitin through an aromatic amide bond rather than the physiological isopeptide linkage cleaved by DUBs.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Various DUB substrates: (A) C-terminal fusion of ubiquitin with fluorophore resulting in Ub-AMC and Ub-Rh110 substrates. (B) Ubiquitin fusion to the amino-terminus of reporter enzymes PLA2 and EKL to generate coupled reporter substrates. (C) Internally quenched fluorescent diubiquitins. (D) Fluorescently labeled substrate derived peptide containing isopeptide linked ubiquitin as substrate for fluorescence polarization assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Later screening assays addressed some of the issues associated with the Ub-AMC assay. Fusion of the fluorophore rhodamine 110 to the carboxy terminus of ubiquitin generated the Ub-Rh110 substrate (Ub-Rh110).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(102)</a> Upon cleavage by DUBs, the released rhodamine-glycine emits intense fluorescence at 485 nM when excited, improving sensitivity compared to Ub-AMC. Ub-Rh110 has been utilized in high throughput screening campaigns to discover DUB inhibitors. Ubiquitin carboxy-terminus fusion with aminoluciferin (Ub-AML) generated a highly sensitive substrate.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(103)</a> Cleavage of ubiquitin from Ub-AML releases aminoluciferin, which is subsequently used by luciferase to generate a chemiluminescent signal. Ub-AML based assays are also suitable for high throughput screening. Ubiquitin-reporter enzyme fusion substrates have also been developed to measure DUB activity. In the first generation assay, ubiquitin was fused to the amino-terminus of reporter enzyme phospholipase A2 (PLA2).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(104)</a> Since the catalytic activity of PLA2 requires a free amino-terminus, ubiquitin fusion inactivates the PLA2 enzyme. However, upon cleavage of the ubiquitin by the DUB, the active PLA2 is released, and it subsequently converts 2-(6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-1-hexadecanoyl-<i>sn</i>-glycero-3-phosphocholine (NBD C6-HPC) to the fluorophore 7-nitrobenz-2-oxa-1,3-diazole (NBD), whose fluorescence can be monitored using excitation and emission wavelengths of 475 and 550 nm, respectively. Like the Ub-AMC and Ub-Rh110 based assays, this coupled assay employs cleavage of a linear amide bond, not the physiological isopeptide bond; it does, however, feature cleavage of two polypeptide entities rather than a small molecule fused to a polypeptide.</div><div class="NLM_p">Ubiquitin fused to the amino-terminus of reporter enzyme enterokinase light chain (EKL) is a second-generation DUB substrate for a coupled assay.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(105)</a> Cleavage of ubiquitin by DUBs releases active EKL whose activity can be monitored using internally quenched FRET peptide substrates such as QXL520-DDDDKGSK-FAM (excitation 490 nm/emission 520 nm) and QXL570-DDDDKGSK-TAMRA (excitation 540 nm/emission 590 nm). The Ub-EKL assay offers increased sensitivity and diminished interference from autofluorescence of test compounds. In addition, this reporter-based assay can be used in a multiplex format to monitor activity of more than one isopeptidase at the same time.</div><div class="NLM_p">Several recently developed assays could be used to screen for USP7 inhibitors. For example, a monoubiquitinated peptide from the USP7 substrate PTEN (amino acids 5–21) containing a fluorescent label (TAMRA) at the amino-terminus has been developed as a USP7 specific substrate.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(106)</a> Cleavage of the ubiquitin by USP7 releases the TAMRA (5-carboxytetramethylrhodamine)-labeled peptide whose fluorescence polarization can be monitored using a plate reader. This assay has the advantage of employing the native isopeptide linkage in its DUB substrate. Diubiquitin substrates are another relatively new class of substrate allowing for continuous measurement of true isopeptidase activity. The C-terminus of wild-type ubiquitin is conjugated via an isopeptide bond to lysine 48 (K48) or lysine 63 (K63) of a second ubiquitin molecule to form an internally quenched fluorescent FRET pair (IQF). Each ubiquitin is labeled with single molecule of either a fluorescent reporter (for example, TAMRA) or a quenching fluorophore (for example, QXL). DUB mediated cleavage of the IQF DiUb leads to the release of the quencher and resultant increase in fluorescence.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(107)</a></div><div class="NLM_p">Recently, Ritorto et al. developed a sensitive assay to quantify DUB enzyme activity using matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(108)</a> In this assay, various diubiquitin isomers are cleaved by DUBs and the monoubiquitin released is quantified using an <sup>15</sup>N-ubiquitin internal standard. This assay allows determination of potency and specificity of DUB inhibitors and is configurable for high throughput screening to discover novel DUB inhibitors.</div><div class="NLM_p last">In addition to monitoring activity of purified USP7, it is critical to develop cell based assays to characterize USP7 inhibitors. Activity-based probes such as ubiquitin-vinyl methyl ester (Ub-VME) can be used to measure the activity of cellular DUBs, including USP7.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(109)</a> Incubation of cell lysates with Ub-VME results in covalent modification of the active site cysteine of DUBs, increasing the molecular weight of the free DUBs by 8 kDa, which can subsequently be detected by Western blotting. In addition, target engagement can be determined using cellular thermal shift assays (CETSA), in which the interaction of a DUB, for example, USP7, with a compound results in its thermal stabilization or destabilization.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(110)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">5 Development of Selective USP7 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45238" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45238" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">5.1 USP7 Inhibitors from Hybrigenics</h3><div class="NLM_p">Hybrigenics conducted a Ub-AMC based high throughput screen of 65 092 compounds for novel USP7 inhibitors, which resulted in the identification of the cyano-indenopyrazine derivative HBX 41,108 (<b>11</b>, <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) with an IC<sub>50</sub> of 0.42 μM.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(111)</a> While <b>11</b> is selective against many families of proteases, it inhibits caspase 3 and multiple DUBs. Compound <b>11</b> was disclosed as a reversible uncompetitive inhibitor. The chloro-substituent is required for USP7 inhibition with reasonable potency, and the corresponding hydroxyl analog (<b>12</b>) is completely inactive. Molecular docking indicated that the compound may interact specifically with the active, ubiquitin-bound conformation of the core. In a later publication from the original group,<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(112)</a> it was shown that <b>11</b> was more potent against USP8 (IC<sub>50</sub> = 96 nM) than against USP7 (420 nM, <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of reported USP7 inhibitors from Hybrigenics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2010, Lopez et al. published a patent describing a series of pyrrole compounds as USP7 selective inhibitors.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(113)</a> The most potent compound disclosed in the patent is compound <b>13</b> with an IC<sub>50</sub> of 1.6 μM (Ub-AMC assay). No binding mechanism is proposed, but <b>13</b> exhibits good selectivity over the small panel of other enzymes tested (USP8, USP5, UCH-L1, UCH-L3, caspase 3, IC<sub>50</sub>s > 200 μM).</div><div class="NLM_p">In 2012, 9-chloro derivatives of amidotetrahydroacridine were reported by Reverdy et al. as a new family of USP7 inhibitors.<a onclick="showRef(event, 'ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref113 ref114">(114, 115)</a> HBX 19,818 (<b>14</b>, <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) was identified as a USP7 inhibitor with an IC<sub>50</sub> of 28 μM from a high throughput screen of 36 000 compounds using Ub-AMC as the substrate. Subsequent optimization led to the more potent compound <b>15,</b> with an IC<sub>50</sub> of 8.2 μM. These compounds showed good selectivity for USP7 when tested against other human USPs and other DUBs. An interesting property of the compounds is their covalent irreversible mode of action in inhibiting the USP7 target enzyme. In support of this property, pretreatment of USP7 with the compounds prevents the active site from reacting with an active site-specific probe, Ub-vinyl sulfone. An aromatic chlorine activated by the tetrahydroacridine system may render this mechanism possible. Molecular docking of the inhibitor positioned the Cl substituent in the proximity of the active site Cys, in agreement with the proposed mechanism, while a required positively charged amine substituent interacted with negatively charged residues. In cellular models, these active-site targeting inhibitors were shown to bind directly and specifically to USP7 and modulate the steady-state levels of several USP7 substrates.</div><div class="NLM_p">In 2014, a new family of quinazolin-4-one based compounds were claimed as selective USP7 inhibitors.<a onclick="showRef(event, 'ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref115 ref116">(116, 117)</a> The patent application describes 30 examples of compounds that were synthesized, and their inhibition of USP7 was characterized using recombinant and biochemical assays. These compounds can block labeling of USP7, but not of USP8, USP5, USP10, CYLD, or UCH-L3, with Ub-VME. Their IC<sub>50</sub> values for USP7 inhibition in cell lysates are in the range of 25–50 μM. A series of experiments was designed to understand better the mechanism of inhibition. The compounds appear to have the characteristics of reversible inhibitors, as judged by measuring enzyme activity recovery using gel filtration, large dilution assays, and native electrospray ionization mass spectrometry. Compound <b>16</b> (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) is the most potent inhibitor (IC<sub>50</sub> = 15 μM) of the USP7 activity in this series.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(114)</a></div><div class="NLM_p last">Hybrigenics researchers were among the first to describe a small molecule, <b>11</b>, as having USP7 inhibitory activities, and since then <b>11</b> has been extensively used as a tool compound. Compound <b>11</b> inhibits cell growth and induces apoptosis in HCT116 (human colon carcinoma) cells by activating p53.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(111)</a> Notably, <b>11</b> has been used to demonstrate the cellular role of USP7 in regulating TNF-α induced apoptosis, nucleotide excision repair, DNA damage response, circadian rhythm, histone methylation, and lipid and glucose metabolism, as well as the activity of the PRC1 complex. In these studies, USP7 knock-down was employed to further corroborate the results obtained using a USP7 inhibitor.<a onclick="showRef(event, 'ref71 ref117 ref118 ref119 ref120 ref121 ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref71 ref117 ref118 ref119 ref120 ref121 ref122 ref123">(71, 118-124)</a> However, the nonselective nature of this compound limits its utility as a USP7 inhibitor. The relatively more selective compound <b>14</b> is one of the first irreversible USP7 inhibitors reported, and irreversibility may play an important role in the physiological mechanisms of USP7 inhibitors. To date, <i>in vivo</i> antitumor activity has not been described for this compound.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">5.2 USP7 Inhibitors from Progenra</h3><div class="NLM_p">Progenra identified <b>17</b> (USP7 IC<sub>50</sub> = 4.2 μM, <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>) from screening a diversity-based library of small molecules for USP7 inhibitors using the ubiquitin-phospholipase A2 enzyme (Ub-PLA2) reporter assay.<a onclick="showRef(event, 'ref66 ref124'); return false;" href="javascript:void(0);" class="ref ref66 ref124">(66, 125)</a> Compound <b>17</b> is highly selective and exhibits little or no inhibition activity against numerous USP variants (USP2, USP5, USP8, USP15, USP20, USP21, USP28) or other protease classes, such as caspase, cathepsins, calpain, metalloproteases, and serine proteases.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Of the proteases tested, only USP47, the DUB most closely related to USP7, was found to be as susceptible as USP7 to inhibition by <b>17</b>. Comparison of the halogen substituents of the 5-arylsulfanyl moiety of the 2-acetyl-4-nitro-5-arylsulfanylthiophenes demonstrates that the unsubstituted phenyl analog P22074 (<b>18</b>) is not active as a USP7 antagonist, whereas all of the 5-mono and dihalo phenylsulfanylthiophenes exhibit USP7 inhibitory activity.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> In addition, the dichloro analogs and difluoro analog <b>19</b> are more potent than the monochloro analogs. In the cellular context, <b>17</b> induces apoptosis in multiple myeloma cells that are resistant to bortezomib therapy,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> is well tolerated, inhibits tumor growth, and prolongs survival in human multiple myeloma and B cell leukemia xenograft models. Further, combinations of <b>17</b> with lenalidomide, SAHA (an HDAC inhibitor), or dexamethasone trigger synergistic antitumor activity in multiple myeloma <i>in vitro</i>. These preclinical data demonstrate the efficacy of USP7 inhibitors in multiple myeloma disease models and validate USP7 as a therapeutic target, providing a basis for future clinical studies on USP7 inhibitors in patients resistant to proteasome inhibitors.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of USP7 inhibitors from Progenra.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Characterization of <b>17</b> in biological matrices was limited, as it produces a very low MS signal at biologically relevant concentrations. Activity-based chemical proteomics was utilized to determine the potency and selectivity of USP7 inhibitors in cultured cell models. The selectivity of <b>19</b> in inhibiting USP7 in cells was demonstrated by activity-based quantitative mass spectrometry.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(109)</a> In contrast, PR-619 (<b>20</b>), a nonselective DUB inhibitor, has been confirmed to be a broad inhibitor of DUB activity.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(109)</a> Further, <b>19</b> inhibits neuroblastoma growth in xenograft models, as demonstrated in two independent laboratories. In the more recent study reported by Tavana et al, <b>19</b>, administered by ip injection at 20 mg/kg daily for 15 days in an orthotopic neuroblastoma mouse model, showed significant inhibition of xenograft growth.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The lack of apparent toxicities indicated that the compound was well tolerated in mice.</div><div class="NLM_p">Compound <b>19</b> is detectable at relevant concentrations, but it exhibits low recovery from glutathione (GSH) solutions and poor plasma stability <i>in vitro</i>.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(125)</a> To address issues regarding potency and developability, analogs of <b>17</b> were designed and synthesized, leading to improvements in potency, solubility, and metabolic reactivity profile.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(125)</a> Given that the nitro group could contribute to reactivity by way of thiol displacement, a series of potentially less reactive cyano compounds was prepared. The data showed that nitro groups in the thiophene series play an important but nonexclusive role in achieving USP7 inhibitory activity. The thiophene-4-nitro group was replaced by a cyano group in certain compounds with little or no loss in USP7 inhibition potency. Replacement of the nitro group in the thiophene series with other electron-withdrawing groups drastically reduces inhibition of purified USP7. It was also found that carboxyamides at C2 provide an opportunity to prepare compounds with enhanced aqueous solubility while maintaining activity against USP7. One of the most potent analogs <b>21</b> (USP7 IC<sub>50</sub> = 0.42 μM, <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>) demonstrates enhanced stability, as illustrated by reduced GSH reactivity (80% recovery) and excellent plasma stability (97% recovery). Consistent with other compounds in this series, compound <b>21</b> is a selective USP7 inhibitor and does not inhibit representative USPs (USP2, USP5, USP8, USP21, and USP28; IC<sub>50</sub> > 32 μM) or other proteases such as calpain-1, caspase 3, and 20S proteasome.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(125)</a> Another important finding was the identification of 3,5-dichloro-4-pyridylsulfide as a replacement for the substituted phenyl sulfides at the 5-position of the thiophene. This group increased the solubility and USP7 inhibition potency.</div><div class="NLM_p">Compound <b>17</b> and its analogs robustly suppress T<sub>reg</sub> functions, thereby restoring the proliferation and activity of T<sub>eff</sub><i>ex vivo</i>. In a recent publication, <b>17</b> and P217564 were reported to have potent and long-lasting inhibitory effects on murine T<sub>reg</sub> function <i>in vitro</i>.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> For instance, 2 h of preincubation of P217564 with T<sub>reg</sub> almost completely abrogated their ability to suppress T<sub>eff</sub> cell proliferation <i>ex vivo</i>. These sustained inhibitory effects on T<sub>reg</sub> function are remarkable given the brief preincubation and are indicative of essentially irreversible USP7 inhibition. In studies using full length USP7 or just its catalytic domain, preincubation with P217564 was seen to prevent its interaction with an active site-directed probe, Ub-VME. Most importantly, P217564 treatment at 6.0 mg/(kg·day) was shown to decrease the growth of TC1 lung tumors significantly in immunocompetent mice, while having no effect on tumor growth when tested at the same dosing in immunodeficient mice. The lack of activity in immunodeficient mice could be attributed to the relatively lower level of USP7 present in the TC1 tumor cells, which likely made their growth less sensitive to USP7 inhibition.</div><div class="NLM_p last">Recently, a new series of thiophene-based USP7 inhibitors have been described as covalent irreversible inhibitors of USP7 for cancer treatment through immune modulation.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(126)</a> In this new series, some compounds have been designed with the sulfone incorporated into a small ring, which may restrict the motion of the oxygen and coordinate better with the enzyme. Benzothiophene-1,1-dioxide is shown as one example, and it results in <b>22</b> (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>), which was demonstrated to have an IC<sub>50</sub> of 100 nM. However, the 2–3 double bond of the thiophene ring may be reactive toward Michael additions and thus a potential source of off-target reactivity. Compound <b>23</b>, the 2,3-dihydrobenzothiophene-1,1-dioxide analog, does not have a vinyl sulfone moiety but inhibits USP7 inhibition with an IC<sub>50</sub> of 130 nM, similar to that of <b>22</b>. Another way of decreasing the Michael acceptor potential of the double bond is to introduce a 3-methyl group. Compound <b>24</b> has an IC<sub>50</sub> of 170 nM, while <b>25</b>, the 3-methyl-2,3-dihydro analog, has an IC<sub>50</sub> of 75 nM. Compound <b>26</b> increases the solubility of <b>25</b> by introducing a solubilizing moiety, giving rise to a reduced cLogP (3.7), and can form salts to further increase solubility. Using an LC-MS based analytical method, it was found that preincubation of the catalytic core domain from wild-type USP7 enzyme (USP7<sup>WT</sup>) with active compounds resulted in a covalent addition of part of the inhibitor to the USP7 enzyme at a ratio of 1:1. This covalent modification of the enzyme is dependent on the presence of active site cysteine C223, as mutation of cysteine 223 to alanine (USP7<sup>C223A</sup>) results in complete elimination of adduct formation.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">5.3 USP7 Inhibitors from FORMA Therapeutics</h3><div class="NLM_p">FORMA Therapeutics recently claimed a new family of 4-hydroxy piperidines as noncovalent USP7 inhibitors (<b>27</b>–<b>31</b>, <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>).<a onclick="showRef(event, 'ref126 ref127 ref128 ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref126 ref127 ref128 ref129 ref130">(127-131)</a> Optimization showed that R could be a wide variety of ring systems (pyrrolopyrimidines, pyrazolopyrimidines, pyrrololotriazinones, imidazotriazinones, quinazolinones, azaquinazolinones, thieno-pyrimidinones, isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones). These R groups were found to be capable of increasing USP7 inhibition potency. The 4-hydroxy piperidine group, which was retained in a majority of the potent compounds, may be an important pharmacophore for USP7. One of FORMA’s most potent compounds, <b>29</b>, has an IC<sub>50</sub> for USP7 < 200 nM (Ub-Rh110 assay). No detailed selectivity or cell data have been reported.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of USP7 inhibitors from FORMA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">5.4 USP7 Inhibitors from Genentech</h3><div class="NLM_p">In 2016, Genentech Inc. published a patent describing 2-aminopyridine compounds as USP7 inhibitors and claimed their potential value for the treatment of cancer and immune disorders such as inflammation (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>).<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(132)</a> The hit identification started with an NMR based fragment screening of 4862 compounds against the USP7 catalytic domain. The primary hits were confirmed to bind to the enzyme active site by X-ray crystallography. Using shape-based virtual screening combined with NMR site-mapping, the expanded hits were found to bind to a unique site on the palm portion of USP7 within a 0.5 nm distance from the catalytic triad. One of their optimization efforts was focused on converting the early stage compound <b>32</b> (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>) with two phenol groups into a more “druglike” and potent USP7 inhibitor. A range of phenol isosteres were incorporated to overcome possible pharmacokinetic and toxicological limitations. A substantial loss in USP7 inhibition potency was observed when using nonclassical bioisosteres such as phenyl acetamide, phenyl carbamate, and phenyl methane sulfonamide. A significant finding from this exercise is that one of the two phenol groups could be successfully replaced by either benzamide or 1H indazole with a resultant increase in USP7 potency. Evidence for the involvement of hydrogen bond formation in the success of this bioisosteric replacement with 1H indazole was provided by the lack of activity observed with the <i>N</i>-methylpyrrolo analog. The most potent analog disclosed in the patent is compound <b>33</b>, which inhibits USP7 with an IC<sub>50</sub> of 0.98 μM (Ub-Rho 110 assay) and little or no inhibition of USP5 and USP47. Regarding biological effects, <b>34</b> was seen to cause an increase in ubiquityl-MDM2 in SJSA-1 cells at low serum conditions (IC<sub>50</sub> = 2 μM).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of USP7 inhibitors from Genentech.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Genentech has pioneered the structure-based approach in discovering novel USP7 inhibitors and has demonstrated their cellular activities. To date, no ADME or <i>in vivo</i> efficacy data have been reported for these compounds. Structure-based approaches have a reasonable potential to yield a new generation of USP7 inhibitors with improved selectivity and, possibly, alternative modes of inhibition, for example, allosteric inhibitors.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">5.5 USP7 Inhibitors from China Pharmaceutical University</h3><div class="NLM_p">Considering thiazole as a bioisosteric structure of thiophene with decreased electron density, Chen and colleagues recently focused their attention on converting <b>17</b> and <b>19</b> (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>) into a new class of thiazole derivative.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(133)</a> Preliminary SAR studies revealed that the 4-nitro group in the thiazole series seemed to be critical for USP7 potency. Replacement of nitro in compound <b>35</b> (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>) with hydrogen made the compound nearly inactive. No other nitro replacement was discussed. Compound <b>36</b> (USP7 IC<sub>50</sub> = 6.1 μM), the thiazole analog of <b>19</b>, was shown to be more potent than the parent <b>19</b> (USP7 IC<sub>50</sub> = 19 μM, Ub-Rho 110 assay). In bioactivity studies, however, it was found that <b>36</b> was a less potent inhibitor of HCT-116 cell growth than <b>19</b>. No biochemical selectivity data were reported. Consistent with findings reported by Progenra, the 3,5-dichloro-4-pyridyl group is retained in the most potent analog <b>37</b> (IC<sub>50</sub> = 0.67 μM). Results of docking studies indicated that 3,5-dichloro-4-pyridyl of <b>37</b> matched in a hydrophobic groove of the catalytic domain of USP7, which consists of series of aromatic amino acid residues. Based on these docking results, it was hypothesized that <b>19</b> and <b>37</b> bind to the ubiquitin binding pocket to competitively inhibit the binding of ubiquitin to USP7.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of USP7 inhibitors from China Pharmaceutical University.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In a patent application, the inventors from the China Pharmaceutical University group disclosed thiazole derivatives to be useful as antitumor agents.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(134)</a> In addition to the thiazole compounds discussed in the application, a new series of thiazole compounds were synthesized and tested for their ability to inhibit <i>in vitro</i> proliferation of the human multiple myeloma cell line RPMI-8226. Compound <b>38</b> (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>) is a representative example lacking a nitro group. Compared to <b>37</b>, <b>38</b> has a weaker IC<sub>50</sub> for growth inhibition (22 μM), which further suggests that electron-withdrawing substituents on the thiazole group are beneficial for anti-USP7 activity. In the same assay, <b>17</b> had been shown to be more potent (12 μM) than <b>38</b>. The thiazole groups of USP7 inhibitors are predicted to function as irreversible inhibitors similar to the nitrothiophene series. No selectivity data and <i>in vivo</i> data have been reported for the thiazole series.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">5.6 USP7 Inhibitors from Natural Sources</h3><div class="NLM_p">Recent efforts in the areas of natural product isolation, synthesis, and screening have identified a variety of USP7 inhibitory compounds derived from natural sources. The Tsukamoto research group from Kumamoto University reported the first natural product USP7 inhibitor, spongiacidin C (<b>39</b>, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>), obtained from screening the extracts of 700 marine invertebrates using the Ub-Rh110 assay.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(135)</a> Compound <b>39</b>, a pyrrole alkaloid isolated from the marine sponge <i>Stylissa massa,</i> showed USP7 inhibition activity (IC<sub>50</sub> = 3.8 μM). The close structural analogs debromohymenialdisine (<b>40</b>) and hymenialdisine (<b>41</b>) have much weaker inhibitory activities (20% inhibition at 20 μM for both compounds). This result indicates that the presence of a hydantoin ring in <b>39,</b> rather than an aminoimidazolinone ring in <b>40</b> and <b>41,</b> is essential to USP7 inhibition. A small panel of cysteine proteases were assayed to evaluate selectivity. Compound <b>39</b> was found to inhibit USP21 (IC<sub>50</sub> = 17 μM) in addition to USP7, but not to inhibit USP2, USP8, or SENP1 over the tested dose range (<i>C</i><sub>max</sub> = 32 μM). However, <b>39</b> did not inhibit growth of HCT116 cells <i>in vitro</i> and its effect on USP7 activity in cells, if any, remains to be determined. Notably, <b>40</b> and <b>41</b> have been described as nonselective kinase inhibitors.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(136)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of USP7 inhibitors from natural sources.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Xestoquinone (<b>42</b>, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>), a pentacyclic quinone isolated from the marine sponge <i>Petrosia alfiani,</i> was identified as a potent USP7 inhibitor, with an IC<sub>50</sub> of 0.13 μM.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(137)</a> Together with <b>42</b>, its structural dimer <b>43</b> and trimer <b>44</b> were isolated from the same species. Both <b>43</b> and <b>44</b> showed potent inhibitory activities against USP7 with IC<sub>50</sub>s of 0.49 and 0.75 μM, respectively. From the point of view of chemical structure, compound <b>42</b> possesses two electrophilic reactivity centers, C-1 and either C-14 or C-15, which could be attracted to the cysteine residue of USP7. However, although the C-14 and C-15 electrophilic centers were blocked in trimer <b>44</b>, this compound still showed USP7 inhibitory activity.</div><div class="NLM_p">Wang et al. reported on a screening campaign conducted with pentacyclic triterpenoid natural products to find USP7 inhibitors, using the Ub-AMC assay.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(138)</a> Six compounds were found to inhibit USP7 in the screen. Among them, ursolic acid (<b>45</b>, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>) was the most potent inhibitor (IC<sub>50</sub> = 7.0 μM); this compound also inhibited USP47, but with reduced potency as compared with USP7 (IC<sub>50</sub> = 26 μM). Compound <b>45</b> was also shown to bind to USP7 in cells by the use of a cellular thermal shift assay.</div><div class="NLM_p">The same group published results of screening 350 drugs or drug-like compounds for USP7 inhibition, employing the Ub-AMC protease assay; they identified the synthetic triterpenoid C-28 methyl ester of 2-cyano-3,12-dioxoolen-1,9-dien-28-oic acid (CDDO-Me, <b>46</b>, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>), also known as bardoxolone methyl, which was found to inhibit USP7 with an IC<sub>50</sub> = 14 μM.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Compound <b>46</b> contains an electrophilic Michael acceptor in ring A (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>). Michael addition of proteins having reactive cysteine residues to the reactive α,β-unsaturated double bond of <b>46</b> would be expected to form reversible or irreversible covalent bonds and trigger biological activity. However, the corresponding analog with the reduced double bond in ring A inhibits USP7 with similar potency (IC<sub>50</sub> = 25 μM). The authors in fact have described <b>46</b> as a reversible inhibitor of USP7 whose activity is unrelated to the Michael acceptor of ring A. Selectivity studies showed that <b>46</b> also inhibits USP2 (IC<sub>50</sub> = 22 μM), but not cathepsin B or cathepsin D (no inhibition at concentrations of 100 μM in both cases). In HO8910 and SKOV3 xenograft model studies, <b>46</b> was reported to inhibit USP7 <i>in vivo</i> and to retard tumor growth.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The diverse molecular targets identified for <b>46</b> include Kelch-like ECH-associated protein 1 (Keap1), IκB kinase β (IKKβ), and peroxisome-activator receptor γ (PPARγ). Although <b>46</b> was evaluated in the clinic for kidney disease (diabetic nephropathy), the phase III trial was terminated owing to an increased rate of adverse cardiovascular events with <b>46</b> over placebo.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(139)</a> Thus, any clinical development of <b>46</b> as a USP7 inhibitor for anticancer applications would be challenging and require mitigation of the adverse cardiac effects.</div><div class="NLM_p last">While the data have shown that the specific moieties or functional groups of these natural products affect their USP7 inhibition activities, it is not very clear how these organic molecules interact with the cysteine protease. Thus, detailed SAR studies, computational chemistry studies, and X-ray cocrystal studies would be helpful to explain their mechanism of USP7 inhibition. In addition, since there is some indication that the compounds are exerting predicted USP7-associated activities in cells, the series may be a candidate for further study in terms of PK/ADME properties if potency and selectivity can be improved.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">6 Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75784" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75784" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compelling data accumulated over the past decade have established USP7 as an oncology target. In addition to genetic data obtained by knockouts, conditional deletion, and RNAi mediated knockdowns, chemical biology data employing small molecule inhibitors of USP7 have played a major role in validating USP7 as a preclinical therapeutic target in cancers. Whereas USP7 deletions and knockdowns result in either complete or partial removal of USP7 protein, small molecule inhibitors allow fine-tuning of USP7 activity while potentially maintaining its interaction with other proteins. In moving from the stage of developing excellent tool compounds for translational research to that of developing anticancer drugs, however, one of the major challenges lies in developing potent and selective USP7 inhibitors with drug-like properties. To judge from the available literature, this challenge remains. To date, all of the USP7 inhibitors described appear to inhibit one or more related USPs with similar potencies. For example, although they are among the most selective USP7 inhibitors described, compounds <b>17</b> and <b>19</b> used in several <i>in vivo</i> efficacy studies also inhibit USP47 with similar potency. Under such circumstances, it becomes difficult to establish the relative contribution arising from inhibiting individual USPs to the observed antitumor efficacy of a given compound. In addition, potential off-target activity of these two structurally similar USP7 inhibitors against unrelated targets could contribute to antitumor efficacy. On the other hand, while entirely selective USP7 inhibitors may be desirable to limit side effects, inhibiting more than one USP might be beneficial in inhibiting tumor growth. Precedent for such multitarget inhibition can be found in the kinase field, where dual and multiple kinase inhibitors have shown remarkable anticancer properties in the clinic.<a onclick="showRef(event, 'ref139 ref140'); return false;" href="javascript:void(0);" class="ref ref139 ref140">(140, 141)</a> Moreover, the only USP inhibitor that has advanced to the Phase I clinical stage is a dual-specific inhibitor of UCHL5 and USP14. While multiple target therapy may be an attractive avenue, establishing a therapeutic window will be critical for the development of multi-USP inhibitors. Structurally guided design and development will be crucial to generating maximally selective USP7 inhibitors. In this regard, knowledge of the physiological form of the active site of USP7 bound to ubiquitin, its substrate (e.g., Tip60 in the case of T<sub>reg</sub> suppression), and any other proteins with which it may be complexed in cells will be helpful. In addition, as has been pointed out by others in recent summaries of ubiquitin-based therapeutics, fine-tuning of assays and introduction of novel assays with increased physiological relevance will help to identify high quality inhibitors.<a onclick="showRef(event, 'ref36 ref96 ref141'); return false;" href="javascript:void(0);" class="ref ref36 ref96 ref141">(36, 97, 142)</a> Both NMR based screening for USP7 selective binders and high throughput screening to identify compounds that selectively inhibit USP7 interaction with specific substrates have the potential to offer valuable starting points for future development of selective USP7 inhibitors.</div><div class="NLM_p">Although USP7 inhibitors have shown <i>in vivo</i> efficacy against a variety of tumors over a range of doses, very limited <i>in vitro</i> ADME and no <i>in vivo</i> pharmacokinetics data have been presented in the literature for these inhibitors. This gap in development was pointed out in a recent review,<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(97)</a> and in the case of USP7, it still remains a challenge, to judge from what is publicly disclosed. The availability of USP7 inhibitors with drug-like and well-defined pharmacokinetics properties will be essential for making progress in the therapeutic arena. These properties, however, should be considered in the context of the mechanism of inhibition of USP7. As pointed out above, both reversible and irreversible inhibitors of the enzyme have been identified. Recently, molecular targeted drugs that are covalent inhibitors of other enzymes, for example, kinases, have been approved by the FDA, signaling a new and expanded way of looking at the developability profile of an experimental drug and putative clinical candidate.<a onclick="showRef(event, 'ref142 ref143 ref144'); return false;" href="javascript:void(0);" class="ref ref142 ref143 ref144">(143-145)</a> In comparison with reversible inhibitors, selective covalent irreversible USP7 inhibitors offer potential advantages. For example, a relatively short duration of treatment could result in sustained USP7 inhibition and prolonged biological effects, leading to improved therapeutic efficacy.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(146)</a> Moreover, development of covalent USP7 inhibitors may be governed by pharmacokinetics parameters that differ from those for reversible inhibitors, particularly with respect to half-life and clearance. Given the tissue-wide expression and functional importance of USP7 in normal cells, selective irreversible inhibitors with fast metabolic clearance could help in mitigating potential on-target as well as off-target toxicities. It should be kept in mind, however, that potential immunogenicity of protein adducts resulting from covalent inhibitors could generate allergic responses or drug hypersensitivity reactions.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(146)</a></div><div class="NLM_p">USP7 inhibitors have shown remarkable antitumor efficacy as single agents against a variety of tumor models. As in the case of other protumorigenic proteins, USP7 overexpressed in a tumor establishes a dependence on its presence for the tumor’s growth and, thus, increased susceptibility of the tumor to USP7 inhibitors. A case in point is multiple myeloma, which is characterized by a tremendous level of USP7 overexpression compared to normal cells and exquisite sensitivity to USP7 inhibitor treatment.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> USP7 expression in tumors could serve as a predictive biomarker in future clinical studies. The observation that USP7 inhibitor synergizes with approved cytotoxic chemotherapy agents <i>in vitro</i> in addition to overcoming resistance against bortezomib opens up avenues for exploring the <i>in vivo</i> efficacy of USP7 inhibitors in combination with chemotherapy agents.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> In particular, combinations with radiation, DNA damaging agents,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> kinase inhibitors, or epigenetic modulators<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> are likely to yield improved therapies.</div><div class="NLM_p">In addition to its established role in tumor progression, the essential role of USP7 in maintaining T<sub>reg</sub> cell functions makes it a highly valuable immune-oncology target. T<sub>reg</sub> are remarkably sensitive to USP7 inhibition due to their unique dependence on USP7 substrates to maintain their suppressive functions. Most important, functions of CD8<sup>+</sup> T<sub>eff</sub>, the critical players in mounting an effective antitumor immune response, remain unaffected by USP7 inhibitor treatment.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> A protein becomes the true substrate of USP7 only when it is ubiquitinated. Therefore, the sensitivity of a particular cell or tissue to USP7 inhibition is likely to depend on the level of USP7 as well as the presence and dynamics of substrate ubiquitination machinery and any compensatory mechanisms. Clearly, additional studies are required to unravel the precise mechanisms behind the differences in sensitivity of various immune effector cell types to USP7 inhibition. From a therapeutic perspective, selective attenuation of T<sub>reg</sub> functions within the tumor microenvironment would greatly improve antitumor responses elicited by immunotherapies. As such, combination studies with immune checkpoint blockades such as anti-PD1 antibody, anti-CTLA4 antibodies, and vaccines will provide valuable insights into the therapeutic utility of USP7 inhibitors.</div><div class="NLM_p last">In summary, the biology, particularly the immune oncology mechanisms recently elucidated, but also the more classical tumoricidal mechanisms, indicates that USP7 inhibitors would be useful drugs. Numerous small molecules representing diverse pharmacophores have been found to have USP7 inhibition properties. The biochemical and cellular characterization as well as <i>in vivo</i> efficacy of lead compounds described in publications and patents must now be complemented by extensive pharmacokinetics, pharmacodynamic, and toxicology studies. Although more challenging, identification and development of substrate-specific and allosteric USP7 inhibitors is likely to yield more specific and targeted therapies.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00498">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82258" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82258" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00498" class="ext-link">10.1021/acs.jmedchem.7b00498</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00498/suppl_file/jm7b00498_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00498/suppl_file/jm7b00498_si_001.csv">jm7b00498_si_001.csv (3.38 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00498" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30373" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30373" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Mattern</span> - <span class="hlFld-Affiliation affiliation">Progenra, Inc., 277 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8595-000X" title="Orcid link">http://orcid.org/0000-0002-8595-000X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#640905101001160a2414160b03010a16054a070b09"><span class="__cf_email__" data-cfemail="dab7bbaeaebfa8b49aaaa8b5bdbfb4a8bbf4b9b5b7">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Wu</span> - <span class="hlFld-Affiliation affiliation">Progenra, Inc., 277 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suresh Kumar</span> - <span class="hlFld-Affiliation affiliation">Progenra, Inc., 277 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Wang</span> - <span class="hlFld-Affiliation affiliation">Progenra, Inc., 277 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Wang</span> - <span class="hlFld-Affiliation affiliation">Progenra, Inc., 277 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lijia Chen</span> - <span class="hlFld-Affiliation affiliation">Progenra, Inc., 277 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Arsenault</span> - <span class="hlFld-Affiliation affiliation">Progenra, Inc., 277 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph Weinstock</span> - <span class="hlFld-Affiliation affiliation">Progenra, Inc., 277 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52175" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52175" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Jian Wu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=BIO-d47e2119-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jian Wu</b> is an Associate Director, R&D, at Progenra, Inc. Dr. Wu has a B.S. degree in Medicinal Chemistry from the China Pharmaceutical University in Nanjing and a Ph.D. degree in Organic Chemistry from Wayne State University, Detroit, MI. After postdoctoral research at the University of Pennsylvania, Dr. Wu joined Progenra in 2009 and has led medicinal chemistry team in the company’s various ubiquitin ligase and deubiquitinase drug discovery projects targeting cancer and other diseases.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Suresh Kumar</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=BIO-d47e2124-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Suresh Kumar</b>, Senior Director, R&D at Progenra, Inc., has a B.S. degree in Chemistry, Physics, and Mathematics and an M.S. degree in Biochemistry from the University of Kerala, India, and a Ph.D. in Molecular Biology from the Indian Institute of Science, Bangalore. After postdoctoral research at the University of Pennsylvania, Dr. Kumar joined Progenra in 2007 and has been in charge of validating Progenra’s therapeutic targets and providing cell proof of concept for the company’s preclinical compounds. He now heads drug discovery efforts at Progenra.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Feng Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=BIO-d47e2129-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Feng Wang</b>, Assistant Director, R&D, Progenra, Inc., has a B.S. degree in Biology and an M.S. in Biochemistry from Xiamen University, China, and a Ph.D. degree in Microbiology from the University of Texas at Austin, TX. Dr. Wang joined Progenra at the beginning of 2015 and has been working on various projects in cancer- and neurodegenerative disease-based drug discovery. His studies, one of which defined the irreversible mechanism of inhibition of a class of Progenra’s small molecule inhibitors of the deubiquitinating enzyme USP7, are directed at determining mechanism of action and establishing proof of concept for Progenra compounds.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Hui Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=BIO-d47e2134-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hui Wang</b>, Senior Scientist, Chemistry Department, Progenra, Inc., has a B.S. degree in Applied Chemistry and an M.S. degree in Organic Chemistry from Lanzhou University, China, and a Ph.D. degree in Organic Chemistry from Dartmouth College, New Hampshire. Dr. Wang practiced medicinal chemistry as an Associate Director at PharmaBlock R&D Co. Ltd., in China and at Scripps Research Institute before joining Progenra in 2016 as a principal medicinal chemist. He has been instrumental in synthesizing SAR compounds for Progenra’s USP7 inhibitor program.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Lijia Chen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=BIO-d47e2139-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lijia Chen</b>, Senior Scientist, Chemistry Department, Progenra Inc., has a B.S. degree in Pharmaceutical Sciences from the China Pharmaceutical University, Nanjing, and a Ph.D. degree in Pharmaceutical Sciences from the University of Maryland School of Pharmacy. In his academic career, Dr. Chen gained experience in medicinal chemistry and structural biology; his dissertation research topic was the synthesis and evaluation of Mcl-1 inhibitors. Having joined Progenra in 2016, Dr. Chen currently works on USP7 inhibitor chemical optimization and rational design.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Patrick Arsenault</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=BIO-d47e2144-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Patrick Arsenault</b>, Assistant Director, R&D, Progenra Inc., has a B.S. degree in Biology from the University of Massachusetts, Amherst, and a Ph.D. degree in Plant Biochemistry and Molecular Biology from the Worcester Polytechnic Institute, Massachusetts. In Dr. Arsenault’s postdoctoral studies at the University of Pennsylvania, he gained considerable experience in drug discovery and preclinical drug development. At Progenra, he leads efforts in assay development and high throughput screening for effectors of ubiquitin pathway enzymes for preclinical development.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Michael Mattern</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=BIO-d47e2149-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Michael Mattern</b>, Vice President, Progenra, Inc., has a B.S. degree in Chemistry from Muhlenberg College, Pennsylvania, and a Ph.D. degree from Princeton University in Biochemical Sciences and Molecular Biology. Dr. Mattern worked for several years at the Laboratory of Molecular Pharmacology at the National Cancer Institute/NIH, Bethesda MD, in experimental cancer therapeutics and at GSK Pharmaceuticals in Oncology drug discovery before cofounding Progenra, Inc.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Joseph Weinstock</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=BIO-d47e2154-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Joseph Weinstock</b>, Senior Director, Progenra, Inc., is the head of Medicinal Chemistry at Progenra. Dr. Weinstock has a B.S. degree in Chemistry from Rutgers University, NJ, and a Ph.D. in Organic Chemistry from the University of Rochester, NY. He was a Director in the Medicinal Chemistry department of GSK (and legacy organization) R&D for many years and was responsible for the synthesis of several marketed drugs, including the antihypertensive agent Dyazide, the angiotensin II antagonist Tevetan, and the renal vasodilator Fenoldopam.</p></figure></div><div class="ack" id="ACK-d47e2159-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14634" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14634" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work has been funded in part by Grant Number CA 174037, awarded to Progenra, Inc., by the National Cancer Institute, National Institutes of Health. We thank Dr. David Newman for a critical reading of the manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i32" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i32"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i33" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i33"> Abbreviations Used</h2><tr><td class="NLM_term">DUB</td><td class="NLM_def"><p class="first last">deubiquinating enzyme</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration required to inhibit 50% of growth or enzyme activity</p></td></tr><tr><td class="NLM_term">HAUSP</td><td class="NLM_def"><p class="first last">herpes-associated ubiquitin specific protease</p></td></tr><tr><td class="NLM_term">IMiD</td><td class="NLM_def"><p class="first last">immunomodulatory drug</p></td></tr><tr><td class="NLM_term">MB</td><td class="NLM_def"><p class="first last">medulloblastoma</p></td></tr><tr><td class="NLM_term">MYCN</td><td class="NLM_def"><p class="first last">N-myc gene</p></td></tr><tr><td class="NLM_term">NB</td><td class="NLM_def"><p class="first last">neuroblastoma</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">Shh</td><td class="NLM_def"><p class="first last">sonic hedgehog</p></td></tr><tr><td class="NLM_term">T<sub>reg</sub></td><td class="NLM_def"><p class="first last">regulatory T cells</p></td></tr><tr><td class="NLM_term">T<sub>eff</sub></td><td class="NLM_def"><p class="first last">effector T cells</p></td></tr><tr><td class="NLM_term">USP7</td><td class="NLM_def"><p class="first last">ubiquitin specific protease 7</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24861" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24861" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 146 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Giles, J.</span><span> </span><span class="NLM_article-title">Chemistry Nobel for trio who revealed molecular death-tag</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">431</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="refDoi"> DOI: 10.1038/431729a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2F431729a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2004&pages=729&author=J.+Giles&title=Chemistry+Nobel+for+trio+who+revealed+molecular+death-tag&doi=10.1038%2F431729a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F431729a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F431729a%26sid%3Dliteratum%253Aachs%26aulast%3DGiles%26aufirst%3DJ.%26atitle%3DChemistry%2520Nobel%2520for%2520trio%2520who%2520revealed%2520molecular%2520death-tag%26jtitle%3DNature%26date%3D2004%26volume%3D431%26spage%3D729%26doi%3D10.1038%2F431729a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Bortezomib: a novel therapy approved for multiple myeloma</span> <span class="citation_source-journal">Clin. Adv. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16258456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BD2MrnvVCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=596-600&author=P.+G.+Richardsonauthor=K.+C.+Anderson&title=Bortezomib%3A+a+novel+therapy+approved+for+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib: a novel therapy approved for multiple myeloma</span></div><div class="casAuthors">Richardson Paul G; Anderson Kenneth C</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">596-600</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">Cellular homeostasis requires routine degradation of key regulatory proteins, including tumor suppressor gene products, transcription factors, cell-cycle proteins and their inhibitors, as well as damaged and misfolded proteins.  A critical part of this process is mediated by the 26S proteasome, a multi-subunit enzyme found in the nucleus and cytoplasm of all eukaryotic cells.  Because of its essential role in many cellular processes controlling growth and survival, the proteasome has been identified as a potential target for cancer therapy.  Drugs known to inhibit proteasome activity have been shown to induce cell-cycle arrest and programmed cell death (apoptosis).  The impact of this finding is heightened by research showing that cancer cells are more sensitive to the proapoptotic effects of proteasome inhibition than normal cells.  Preclinical evidence using bortezomib, the only proteasome inhibitor to enter clinical trials, suggests that proteasome inhibition may be effective in the treatment of hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, and inhibiting tumor cell adhesion and production of growth factors by acting on molecules such as nuclear factor-kappaB.  Further preclinical evidence suggests that the antitumor effects of cytotoxic chemotherapy or radiotherapy may be enhanced by the addition of a proteasome inhibitor.  Bortezomib was recently approved for the treatment of multiple myeloma.  It is currently being investigated, both as a single agent and in combination, in phase I and II trials in a variety of tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOfAcXvzm18T0SWnHPWbmmfW6udTcc2eZ9wTpvgbl-3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrnvVCqsQ%253D%253D&md5=1f5722a7647672435cb2c72096f6b71a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DBortezomib%253A%2520a%2520novel%2520therapy%2520approved%2520for%2520multiple%2520myeloma%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2003%26volume%3D1%26spage%3D596%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Cejalvo, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Rubia, J.</span><span> </span><span class="NLM_article-title">Which therapies will move to the front line for multiple myeloma?</span> <span class="citation_source-journal">Expert Rev. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span><span class="refDoi"> DOI: 10.1080/17474086.2017.1317589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1080%2F17474086.2017.1317589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=28388244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXms1Wltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=383-392&author=M.+J.+Cejalvoauthor=J.+de+la+Rubia&title=Which+therapies+will+move+to+the+front+line+for+multiple+myeloma%3F&doi=10.1080%2F17474086.2017.1317589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Which therapies will move to the front line for multiple myeloma?</span></div><div class="casAuthors">Cejalvo, Maria J.; de la Rubia, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">383-392</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Despite substantial progress, multiple myeloma (MM) remains an incurable disease.  Recently the availability of several novel drugs with different and innovative mechanisms of action (daratumumab, elotuzumab, carfilzomib, ixazomib, and panobinostat) has increased the therapeutic options but has also increased complexity in the management of patients with MM.: The outstanding results obsd. in the relapsed setting with regimens including these new drugs has provided the investigators with several treatment options that are being tested also in patients with newly diagnosed MM.  Fully published phase 2 and randomized, phase 3 trials including new drugs in patients with relapsed and/or refractory MM have been reviewed.  In addn., the progressive incorporation of these new drugs in the front-line treatment of MM and the potential impact of these new therapies in the management of patients with newly diagnosed MM has also been addressed.: In the near future, several novel anti-MM drugs will move from the relapsed to the front-line setting.  While the increasing range of effective therapeutic agents is very encouraging it adds to the complexity of treatment decisions and prospective trials are needed to help clinicians to det. which could be the best therapeutic approaches for the different subgroups of patients with newly diagnosed MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ61n9yQUwbLVg90H21EOLACvtfcHk0lhCZGgf7MpwfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXms1Wltb8%253D&md5=37f31fddd140059dbb3063fdaab29f2b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F17474086.2017.1317589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2017.1317589%26sid%3Dliteratum%253Aachs%26aulast%3DCejalvo%26aufirst%3DM.%2BJ.%26aulast%3Dde%2Bla%2BRubia%26aufirst%3DJ.%26atitle%3DWhich%2520therapies%2520will%2520move%2520to%2520the%2520front%2520line%2520for%2520multiple%2520myeloma%253F%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2017%26volume%3D10%26spage%3D383%26epage%3D392%26doi%3D10.1080%2F17474086.2017.1317589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">List, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellamy, W.</span><span> </span><span class="NLM_article-title">Lenalidomide: targeted anemia therapy for myelodysplastic syndromes</span> <span class="citation_source-journal">Cancer Control</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=4-11&issue=Suppl&author=A.+F.+Listauthor=A.+F.+Bakerauthor=S.+Greenauthor=W.+Bellamy&title=Lenalidomide%3A+targeted+anemia+therapy+for+myelodysplastic+syndromes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DList%26aufirst%3DA.%2BF.%26aulast%3DBaker%26aufirst%3DA.%2BF.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DBellamy%26aufirst%3DW.%26atitle%3DLenalidomide%253A%2520targeted%2520anemia%2520therapy%2520for%2520myelodysplastic%2520syndromes%26jtitle%3DCancer%2520Control%26date%3D2006%26volume%3D13%26issue%3DSuppl%26spage%3D4%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Gras, J.</span><span> </span><span class="NLM_article-title">Pomalidomide for patients with multiple myeloma</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">555</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1358/dot.2013.49.09.2017031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1358%2Fdot.2013.49.09.2017031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252Flslyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=555-562&author=J.+Gras&title=Pomalidomide+for+patients+with+multiple+myeloma&doi=10.1358%2Fdot.2013.49.09.2017031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pomalidomide for patients with multiple myeloma</span></div><div class="casAuthors">Gras J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">555-62</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Multiple myeloma is a malignancy of plasma cells in the bone marrow.  Currently, multiple myeloma is not considered curable, but it is treatable with different strategies that can combine chemotherapy with autologous hematopoietic stem cell transplantation.  Pomalidomide is an orally active thalidomide analogue that has a pleiotropic mechanism of action involving oncolytic, antiangiogenic, immunomodulatory and anti-inflammatory activities.  Pomalidomide is extensively metabolized, mainly by the cytochrome P450 3A4 and 1A2 pathways.  The safety and efficacy of pomalidomide combined with dexamethasone has been demonstrated in a phase III trial for the treatment of multiple myeloma patients, relapsed/resistant to bortezomib and lenalidomide.  Adverse events that were mainly related to myelosuppression, were manageable.  Pomalidomide has orphan drug status both in the U.S. and Europe for multiple myeloma.  It was approved by the U.S.  Food and Drug Administration as Pomalyst® for the treatment of multiple myeloma last February, and recently approved in Europe in August.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSlb14qikVjeIJKJbLTgsvCfW6udTcc2eY8PtoobSsQ5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252Flslyluw%253D%253D&md5=062e9efce2fc76a61c6657c2c81f9050</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1358%2Fdot.2013.49.09.2017031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2013.49.09.2017031%26sid%3Dliteratum%253Aachs%26aulast%3DGras%26aufirst%3DJ.%26atitle%3DPomalidomide%2520for%2520patients%2520with%2520multiple%2520myeloma%26jtitle%3DDrugs%2520Today%26date%3D2013%26volume%3D49%26spage%3D555%26epage%3D562%26doi%3D10.1358%2Fdot.2013.49.09.2017031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Lu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naniong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaelin, W. G.,  Jr.</span><span> </span><span class="NLM_article-title">The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span><span class="refDoi"> DOI: 10.1126/science.1244917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1126%2Fscience.1244917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24292623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=305-309&author=G.+Luauthor=R.+E.+Middletonauthor=H.+Sunauthor=M.+Naniongauthor=C.+J.+Ottauthor=C.+S.+Mitsiadesauthor=K.+K.+Wongauthor=J.+E.+Bradnerauthor=W.+G.+Kaelin&title=The+myeloma+drug+lenalidomide+promotes+the+cereblon-dependent+destruction+of+Ikaros+proteins&doi=10.1126%2Fscience.1244917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins</span></div><div class="casAuthors">Lu, Gang; Middleton, Richard E.; Sun, Huahang; Naniong, MarkVic; Ott, Christopher J.; Mitsiades, Constantine S.; Wong, Kwok-Kin; Bradner, James E.; Kaelin, William G., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">305-309</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Thalidomide-like drugs such as lenalidomide are clin. important treatments for multiple myeloma and show promise for other B cell malignancies.  The biochem. mechanisms underlying their antitumor activity are unknown.  Thalidomide was recently shown to bind to, and inhibit, the cereblon ubiquitin ligase.  Cereblon loss in zebrafish causes fin defects reminiscent of the limb defects seen in children exposed to thalidomide in utero.  Here we show that lenalidomide-bound cereblon acquires the ability to target for proteasomal degrdn. two specific B cell transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3).  Anal. of myeloma cell lines revealed that loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect, suggesting that the antitumor and teratogenic activities of thalidomide-like drugs are dissociable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0froz4Kipu7Vg90H21EOLACvtfcHk0lgzlIRo3yGalQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D&md5=a9df5bbde0f676b92b1bec48fdbbb502</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244917%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DG.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DNaniong%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26atitle%3DThe%2520myeloma%2520drug%2520lenalidomide%2520promotes%2520the%2520cereblon-dependent%2520destruction%2520of%2520Ikaros%2520proteins%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D305%26epage%3D309%26doi%3D10.1126%2Fscience.1244917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Gandhi, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havens, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakurta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klippel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopra, R.</span><span> </span><span class="NLM_article-title">Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">821</span><span class="refDoi"> DOI: 10.1111/bjh.12708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1111%2Fbjh.12708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24328678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2014&pages=811-821&author=A.+K.+Gandhiauthor=J.+Kangauthor=C.+G.+Havensauthor=T.+Conklinauthor=Y.+Ningauthor=L.+Wuauthor=T.+Itoauthor=H.+Andoauthor=M.+F.+Waldmanauthor=A.+Thakurtaauthor=A.+Klippelauthor=H.+Handaauthor=T.+O.+Danielauthor=P.+H.+Schaferauthor=R.+Chopra&title=Immunomodulatory+agents+lenalidomide+and+pomalidomide+co-stimulate+T+cells+by+inducing+degradation+of+T+cell+repressors+Ikaros+and+Aiolos+via+modulation+of+the+E3+ubiquitin+ligase+complex+CRL4%28CRBN.%29&doi=10.1111%2Fbjh.12708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN</span></div><div class="casAuthors">Gandhi, Anita K.; Kang, Jian; Havens, Courtney G.; Conklin, Thomas; Ning, Yuhong; Wu, Lei; Ito, Takumi; Ando, Hideki; Waldman, Michelle F.; Thakurta, Anjan; Klippel, Anke; Handa, Hiroshi; Daniel, Thomas O.; Schafer, Peter H.; Chopra, Rajesh</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">811-821</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cereblon (CRBN), the mol. target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4CRBN.  T cell co-stimulation by lenalidomide or pomalidomide is cereblon dependent: however, the CRL4CRBN substrates responsible for T cell co-stimulation have yet to be identified.  Here we demonstrate that interaction of the transcription factors Ikaros (IKZF1, encoded by the IKZF1 gene) and Aiolos (IKZF3, encoded by the IKZF3 gene) with CRL4CRBN is induced by lenalidomide or pomalidomide.  Each agent promotes Aiolos and Ikaros binding to CRL4CRBN with enhanced ubiquitination leading to cereblon-dependent proteosomal degrdn. in T lymphocytes.  We confirm that Aiolos and Ikaros are transcriptional repressors of interleukin-2 expression.  The findings link lenalidomide- or pomalidomide-induced degrdn. of these transcriptional suppressors to well documented T cell activation.  Importantly, Aiolos could serve as a proximal pharmacodynamic marker for lenalidomide and pomalidomide, as healthy human subjects administered lenalidomide demonstrated Aiolos degrdn. in their peripheral T cells.  In conclusion, we present a mol. model in which drug binding to cereblon results in the interaction of Ikaros and Aiolos to CRL4CRBN, leading to their ubiquitination, subsequent proteasomal degrdn. and T cell activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNm80s9sQNeLVg90H21EOLACvtfcHk0lg_XLzEfO_PLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslWmu74%253D&md5=8ddf00ec1e3c1b1176603f22e8832f58</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12708%26sid%3Dliteratum%253Aachs%26aulast%3DGandhi%26aufirst%3DA.%2BK.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DHavens%26aufirst%3DC.%2BG.%26aulast%3DConklin%26aufirst%3DT.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DH.%26aulast%3DWaldman%26aufirst%3DM.%2BF.%26aulast%3DThakurta%26aufirst%3DA.%26aulast%3DKlippel%26aufirst%3DA.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DChopra%26aufirst%3DR.%26atitle%3DImmunomodulatory%2520agents%2520lenalidomide%2520and%2520pomalidomide%2520co-stimulate%2520T%2520cells%2520by%2520inducing%2520degradation%2520of%2520T%2520cell%2520repressors%2520Ikaros%2520and%2520Aiolos%2520via%2520modulation%2520of%2520the%2520E3%2520ubiquitin%2520ligase%2520complex%2520CRL4%2528CRBN.%2529%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2014%26volume%3D164%26spage%3D811%26epage%3D821%26doi%3D10.1111%2Fbjh.12708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hershko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciechanover, A.</span><span> </span><span class="NLM_article-title">The ubiquitin system</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span><span class="refDoi"> DOI: 10.1146/annurev.biochem.67.1.425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1146%2Fannurev.biochem.67.1.425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=9759494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADyaK1cXlsFOmsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1998&pages=425-479&author=A.+Hershkoauthor=A.+Ciechanover&title=The+ubiquitin+system&doi=10.1146%2Fannurev.biochem.67.1.425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitin system</span></div><div class="casAuthors">Hershko, Avram; Ciechanover, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">425-479</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with ∼298 refs.  The selective degrdn. of many short-lived proteins in eukaryotic cells is carried out by the ubiquitin system.  In this pathway, proteins are targeted for degrdn. by covalent ligation to ubiquitin, a highly conserved small protein.  Ubiquitin-mediated degrdn. of regulatory proteins plays important roles in the control of numerous processes, including cell-cycle progression, signal transduction, transcriptional regulation, receptor down-regulation, and endocytosis.  The ubiquitin system has been implicated in the immune response, development, and programmed cell death.  Abnormalities in ubiquitin-mediated processes have been shown to cause pathol. conditions, including malignant transformation.  In this review we discuss recent information on functions and mechanisms of the ubiquitin system.  Since the selectivity of protein degrdn. is detd. mainly at the stage of ligation to ubiquitin, special attention is focused on what we know, and would like to know, about the mode of action of ubiquitin-protein ligation systems and about signals in proteins recognized by these systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqo5VhDx0kSLVg90H21EOLACvtfcHk0lgnHpBhiOk3-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlsFOmsLc%253D&md5=7c3c0a6df9c07baf55b5000eae13ef49</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.67.1.425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.67.1.425%26sid%3Dliteratum%253Aachs%26aulast%3DHershko%26aufirst%3DA.%26aulast%3DCiechanover%26aufirst%3DA.%26atitle%3DThe%2520ubiquitin%2520system%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1998%26volume%3D67%26spage%3D425%26epage%3D479%26doi%3D10.1146%2Fannurev.biochem.67.1.425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ciechanover, A.</span><span> </span><span class="NLM_article-title">The unravelling of the ubiquitin system</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1038/nrm3982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrm3982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25907614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFCiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=322-324&author=A.+Ciechanover&title=The+unravelling+of+the+ubiquitin+system&doi=10.1038%2Fnrm3982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The unravelling of the ubiquitin system</span></div><div class="casAuthors">Ciechanover, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">322-324</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Today, many scientific discoveries are made using a top-down exptl. approach.  The ubiquitin system was discovered using a classic bottom-up approach to tackle the question: how are cellular proteins selectively degraded.  A simple proteolytic assay, which used a crude cell-ext., was all that was required to address this question; it was followed by fractionation and reconstitution expts. to decipher the role of the components in this multi-step process.  This biochem. at its best approach, which was published in a periodical that today would not be regarded as highly visible, provided magnificent findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHAT8iHvnR3LVg90H21EOLACvtfcHk0lhugkOjzayJYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFCiur4%253D&md5=9bddfc645a49922d90137156f0295aa3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrm3982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3982%26sid%3Dliteratum%253Aachs%26aulast%3DCiechanover%26aufirst%3DA.%26atitle%3DThe%2520unravelling%2520of%2520the%2520ubiquitin%2520system%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D322%26epage%3D324%26doi%3D10.1038%2Fnrm3982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goedert, M.</span><span> </span><span class="NLM_article-title">GSK3 inhibitors: development and therapeutic potential</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">487</span><span class="refDoi"> DOI: 10.1038/nrd1415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrd1415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=15173837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=479-487&author=P.+Cohenauthor=M.+Goedert&title=GSK3+inhibitors%3A+development+and+therapeutic+potential&doi=10.1038%2Fnrd1415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 inhibitors: development and therapeutic potential</span></div><div class="casAuthors">Cohen, Philip; Goedert, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metab.  In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics.  Here, we describe the biol. of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL3ua5xi0_qrVg90H21EOLACvtfcHk0lhugkOjzayJYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D&md5=165d1354bf11faa6021ac4dba797fda2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd1415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1415%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26atitle%3DGSK3%2520inhibitors%253A%2520development%2520and%2520therapeutic%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D479%26epage%3D487%26doi%3D10.1038%2Fnrd1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Isaacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbolsheimer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaviano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng-Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creswell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novielli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slack, R.</span><span> </span><span class="NLM_article-title">Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1007/s10549-010-1226-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs10549-010-1226-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20976541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWgtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2011&pages=137-143&author=C.+Isaacsauthor=P.+Herbolsheimerauthor=M.+C.+Liuauthor=M.+Wilkinsonauthor=Y.+Ottavianoauthor=G.+G.+Chungauthor=R.+Warrenauthor=J.+Eng-Wongauthor=P.+Cohenauthor=K.+L.+Smithauthor=K.+Creswellauthor=A.+Novielliauthor=R.+Slack&title=Phase+I%2FII+study+of+sorafenib+with+anastrozole+in+patients+with+hormone+receptor+positive+aromatase+inhibitor+resistant+metastatic+breast+cancer&doi=10.1007%2Fs10549-010-1226-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer</span></div><div class="casAuthors">Isaacs, Claudine; Herbolsheimer, Pia; Liu, Minetta C.; Wilkinson, Mary; Ottaviano, Yvonne; Chung, Gina G.; Warren, Robert; Eng-Wong, Jennifer; Cohen, Philip; Smith, Karen L.; Creswell, Karen; Novielli, Antonella; Slack, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-143</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We evaluated the use of sorafenib to overcome resistance to aromatase inhibitors (AIs) in patients with metastatic breast cancer who had disease recurrence or progression while on AIs.  We performed a multi-institution phase I/II study of sorafenib and anastrozole 1 mg daily in 35 postmenopausal females with hormone receptor pos. metastatic breast cancer resistant to AIs.  Primary objectives were to det. the dose of sorafenib in conjunction with anastrozole and the clin. benefit rate (CBR) (complete response [CR], partial response [PR], or stable disease [SD] ≥ 24 wk).  Secondary objectives were to det. toxicity and to evaluate if response was assocd. with change in no. of circulating endothelial cells or circulating endothelial progenitor cells.  Based on the phase I portion, sorafenib 400 mg twice daily was selected as the phase II dose.  Among 35 patients, 7 had SD ≥ 24 wk, 1 had PR ≥ 24 wk, and 14 had progressive disease (PD) ≤ 24 wk, corresponding to a CBR of 23%.  The most common adverse events (all; Grade 3/4) were fatigue (66%; 17%), diarrhea (63%; 6%), nausea (60%; 9%), and hand-foot syndrome (57%; 34%).  Dose redn. occurred in 77% of the patients and 31% came off study due to toxicity.  The combination of sorafenib and anastrozole demonstrated a 23% CBR in patients with hormone receptor pos., AI-resistant metastatic breast cancer, which may be attributable to the restoration of sensitivity to AIs.  Toxicities occurred frequently resulting in a high rate of discontinuation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpNHxpBnFn9bVg90H21EOLACvtfcHk0lhERPIkHrPrWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWgtLnN&md5=d45bd053969576e7534b0e553257d86d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs10549-010-1226-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-010-1226-z%26sid%3Dliteratum%253Aachs%26aulast%3DIsaacs%26aufirst%3DC.%26aulast%3DHerbolsheimer%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DM.%2BC.%26aulast%3DWilkinson%26aufirst%3DM.%26aulast%3DOttaviano%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DG.%2BG.%26aulast%3DWarren%26aufirst%3DR.%26aulast%3DEng-Wong%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DK.%2BL.%26aulast%3DCreswell%26aufirst%3DK.%26aulast%3DNovielli%26aufirst%3DA.%26aulast%3DSlack%26aufirst%3DR.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520sorafenib%2520with%2520anastrozole%2520in%2520patients%2520with%2520hormone%2520receptor%2520positive%2520aromatase%2520inhibitor%2520resistant%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D125%26spage%3D137%26epage%3D143%26doi%3D10.1007%2Fs10549-010-1226-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tcherpakov, M.</span><span> </span><span class="NLM_article-title">Will the ubiquitin system furnish as many drug targets as protein kinases?</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">143</span><span class="NLM_x">, </span> <span class="NLM_fpage">686</span><span class="NLM_x">–</span> <span class="NLM_lpage">693</span><span class="refDoi"> DOI: 10.1016/j.cell.2010.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.cell.2010.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21111230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygsLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2010&pages=686-693&author=P.+Cohenauthor=M.+Tcherpakov&title=Will+the+ubiquitin+system+furnish+as+many+drug+targets+as+protein+kinases%3F&doi=10.1016%2Fj.cell.2010.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?</span></div><div class="casAuthors">Cohen, Philip; Tcherpakov, Marianna</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">686-693</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation and protein ubiquitination regulate most aspects of cell life, and defects in these control mechanisms cause cancer and many other diseases.  In the past decade, protein kinases have become one of the most important classes of drug targets for the pharmaceutical industry.  In contrast, drug discovery programs that target components of the ubiquitin system have lagged behind.  In this Perspective, we discuss the reasons for the delay in this pipeline, the drugs targeting the ubiquitin system that have been developed, and new approaches that may popularize this area of drug discovery in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqocw2eBP5US7Vg90H21EOLACvtfcHk0lhERPIkHrPrWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygsLbI&md5=b273310afef9fd544a534d9f39b0afb2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DTcherpakov%26aufirst%3DM.%26atitle%3DWill%2520the%2520ubiquitin%2520system%2520furnish%2520as%2520many%2520drug%2520targets%2520as%2520protein%2520kinases%253F%26jtitle%3DCell%26date%3D2010%26volume%3D143%26spage%3D686%26epage%3D693%26doi%3D10.1016%2Fj.cell.2010.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Ciechanover, A.</span><span> </span><span class="NLM_article-title">The ubiquitin-proteasome pathway: on protein death and cell life</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7151</span><span class="NLM_x">–</span> <span class="NLM_lpage">7160</span><span class="refDoi"> DOI: 10.1093/emboj/17.24.7151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1093%2Femboj%2F17.24.7151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1998&pages=7151-7160&author=A.+Ciechanover&title=The+ubiquitin-proteasome+pathway%3A+on+protein+death+and+cell+life&doi=10.1093%2Femboj%2F17.24.7151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F17.24.7151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F17.24.7151%26sid%3Dliteratum%253Aachs%26aulast%3DCiechanover%26aufirst%3DA.%26atitle%3DThe%2520ubiquitin-proteasome%2520pathway%253A%2520on%2520protein%2520death%2520and%2520cell%2520life%26jtitle%3DEMBO%2520J.%26date%3D1998%26volume%3D17%26spage%3D7151%26epage%3D7160%26doi%3D10.1093%2Femboj%2F17.24.7151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hochstrasser, M.</span><span> </span><span class="NLM_article-title">Ubiquitin-dependent protein degradation</span> <span class="citation_source-journal">Annu. Rev. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1146/annurev.genet.30.1.405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1146%2Fannurev.genet.30.1.405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=8982460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADyaK2sXht1yk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1996&pages=405-439&author=M.+Hochstrasser&title=Ubiquitin-dependent+protein+degradation&doi=10.1146%2Fannurev.genet.30.1.405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-dependent protein degradation</span></div><div class="casAuthors">Hochstrasser, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Genetics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">405-439</span>CODEN:
                <span class="NLM_cas:coden">ARVGB7</span>;
        ISSN:<span class="NLM_cas:issn">0066-4197</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review with 115 refs.  A growing no. of cellular regulatory mechanisms are being linked to protein modification by the polypeptide ubiquitin.  These include key transitions in the cell cycle, class I antigen processing, signal transduction pathways, and receptor-mediated endocytosis.  In most, but not all, of these examples, ubiquitination of a protein leads to its degrdn. by the 26S proteasome.  Following attachment of ubiquitin to a substrate and binding of the ubiquitinated protein to the proteasome, the bound substrate must be unfolded (and eventually deubiquitinated) and translocated through a narrow set of channels that leads to the proteasome interior, where the polypeptide is cleaved into short peptides.  Protein ubiquitination and deubiquitination are both mediated by large enzyme families, and the proteasome itself comprises a family of related but functionally distinct particles.  This diversity underlies both the high substrate specificity of the ubiquitin system and the variety of regulatory mechanisms that it serves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8i3KZXfGSRrVg90H21EOLACvtfcHk0lj659DYUbWXNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1yk&md5=8b3d3ec0806e94afee1e0374fae69db2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1146%2Fannurev.genet.30.1.405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.genet.30.1.405%26sid%3Dliteratum%253Aachs%26aulast%3DHochstrasser%26aufirst%3DM.%26atitle%3DUbiquitin-dependent%2520protein%2520degradation%26jtitle%3DAnnu.%2520Rev.%2520Genet.%26date%3D1996%26volume%3D30%26spage%3D405%26epage%3D439%26doi%3D10.1146%2Fannurev.genet.30.1.405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Yamao, F.</span><span> </span><span class="NLM_article-title">Ubiquitin system: selectivity and timing of protein destruction</span> <span class="citation_source-journal">J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1093/oxfordjournals.jbchem.a022277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1093%2Foxfordjournals.jbchem.a022277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=9990117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADyaK1MXitFyktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=1999&pages=223-229&author=F.+Yamao&title=Ubiquitin+system%3A+selectivity+and+timing+of+protein+destruction&doi=10.1093%2Foxfordjournals.jbchem.a022277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin system: selectivity and timing of protein destruction</span></div><div class="casAuthors">Yamao, Fumiaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-229</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    
            (<span class="NLM_cas:orgname">Japanese Biochemical Society</span>)
        </div><div class="casAbstract">A review with 48 refs.  A growing no. of cellular functions have been shown to be regulated through protein degrdn.  The selective degrdn. of many short-lived proteins in eukaryotic cells is mediated by the ubiquitin system, by which proteins covalently ligated to ubiquitin are targeted for degrdn.  The selectivity of the destruction is ensured by the substrate specificity in the ubiquitination steps composed of a series of enzymic reactions.  Ubiquitin-ligase (E3), in conjunction with ubiquitin-conjugating enzyme (E2), has been implicated as playing an essential role in the substrate recognition.  The substantial character, however, of the ligase was not clear until several recent studies demonstrated ligases that exert key roles in irreversible steps of the cell-cycle control.  In this review, attention is focused on the mol. basis of target recognition of ubiquitination, particularly as exemplified in the ubiquitin-ligases in the cell-cycle control mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ_WqXwROGerVg90H21EOLACvtfcHk0lgw-SF98w2TpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFyktrs%253D&md5=be00de0dc5ee9d870e49d56d904b432e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Foxfordjournals.jbchem.a022277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Foxfordjournals.jbchem.a022277%26sid%3Dliteratum%253Aachs%26aulast%3DYamao%26aufirst%3DF.%26atitle%3DUbiquitin%2520system%253A%2520selectivity%2520and%2520timing%2520of%2520protein%2520destruction%26jtitle%3DJ.%2520Biochem.%26date%3D1999%26volume%3D125%26spage%3D223%26epage%3D229%26doi%3D10.1093%2Foxfordjournals.jbchem.a022277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Pickart, C. M.</span><span> </span><span class="NLM_article-title">Mechanisms underlying ubiquitination</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1146/annurev.biochem.70.1.503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1146%2Fannurev.biochem.70.1.503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=11395416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVehtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=503-533&author=C.+M.+Pickart&title=Mechanisms+underlying+ubiquitination&doi=10.1146%2Fannurev.biochem.70.1.503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms underlying ubiquitination</span></div><div class="casAuthors">Pickart, Cecile M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">503-533</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with 177 refs.  The conjugation of ubiquitin to other cellular proteins regulates a broad range of eukaryotic cell functions.  The high efficiency and exquisite selectivity of ubiquitination reactions reflect the properties of enzymes known as ubiquitin-protein ligases or E3s.  An E3 recognizes its substrates based on the presence of a specific ubiquitination signal, and catalyzes the formation of an isopeptide bond between a substrate (or ubiquitin) lysine residue and the C terminus of ubiquitin.  Although a great deal is known about the mol. basis of E3 specificity, much less is known about mol. mechanisms of catalysis by E3s.  Recent findings reveal that all known E3s utilize one of just two catalytic domains-a HECT domain or a RING finger-and crystal structures have provided the first detailed views of an active site of each type.  The new findings shed light on many aspects of E3 structure, function, and mechanism, but also emphasize that key features of E3 catalysis remain to be elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof8qQSvIayQbVg90H21EOLACvtfcHk0lgw-SF98w2TpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVehtLw%253D&md5=72e307d3cdb419853e4c611050429913</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.70.1.503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.70.1.503%26sid%3Dliteratum%253Aachs%26aulast%3DPickart%26aufirst%3DC.%2BM.%26atitle%3DMechanisms%2520underlying%2520ubiquitination%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2001%26volume%3D70%26spage%3D503%26epage%3D533%26doi%3D10.1146%2Fannurev.biochem.70.1.503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Komander, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes-Turcu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licchesi, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odenwaelder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span> </span><span class="NLM_article-title">Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains</span> <span class="citation_source-journal">EMBO Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1038/embor.2009.55</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fembor.2009.55" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=19373254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1ShsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=466-473&author=D.+Komanderauthor=F.+Reyes-Turcuauthor=J.+D.+Licchesiauthor=P.+Odenwaelderauthor=K.+D.+Wilkinsonauthor=D.+Barford&title=Molecular+discrimination+of+structurally+equivalent+Lys+63-linked+and+linear+polyubiquitin+chains&doi=10.1038%2Fembor.2009.55"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains</span></div><div class="casAuthors">Komander, David; Reyes-Turcu, Francisca; Licchesi, Julien D. F.; Odenwaelder, Peter; Wilkinson, Keith D.; Barford, David</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">466-473</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">At least eight types of ubiquitin (Ub) chain exist, and individual linkages affect distinct cellular processes.  The only distinguishing feature of differently linked ubiquitin chains is their structure, as polymers of the same unit are chem. identical.  Here, we have crystd. Lys 63-linked and linear ubiquitin dimers, revealing that both adopt equiv. open conformations, forming no contacts between ubiquitin mols. and thereby differing significantly from Lys 48-linked ubiquitin chains.  We also examd. the specificity of various deubiquitinases (DUBs) and ubiquitin-binding domains (UBDs).  All analyzed DUBs, except CYLD, cleave linear chains less efficiently compared with other chain types, or not at all.  Likewise, UBDs can show chain specificity, and are able to select distinct linkages from a ubiquitin chain mixt.  We found that the UBAN (ubiquitin binding in ABIN and NEMO) motif of NEMO (NF-κB essential modifier) binds to linear chains exclusively, whereas the NZF (Npl4 zinc finger) domain of TAB2 (TAK1 binding protein 2) is Lys 63 specific.  Our results highlight remarkable specificity determinants within the ubiquitin system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5UmdkgYjMU7Vg90H21EOLACvtfcHk0lgw-SF98w2TpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1ShsbY%253D&md5=e21e9b6a5e64116f7b594a001336104f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fembor.2009.55&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fembor.2009.55%26sid%3Dliteratum%253Aachs%26aulast%3DKomander%26aufirst%3DD.%26aulast%3DReyes-Turcu%26aufirst%3DF.%26aulast%3DLicchesi%26aufirst%3DJ.%2BD.%26aulast%3DOdenwaelder%26aufirst%3DP.%26aulast%3DWilkinson%26aufirst%3DK.%2BD.%26aulast%3DBarford%26aufirst%3DD.%26atitle%3DMolecular%2520discrimination%2520of%2520structurally%2520equivalent%2520Lys%252063-linked%2520and%2520linear%2520polyubiquitin%2520chains%26jtitle%3DEMBO%2520Rep.%26date%3D2009%26volume%3D10%26spage%3D466%26epage%3D473%26doi%3D10.1038%2Fembor.2009.55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Heideker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wertz, I. E.</span><span> </span><span class="NLM_article-title">DUBs, the regulation of cell identity and disease</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="refDoi"> DOI: 10.1042/bj4670191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1042%2Fbj4670191" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2015&pages=191&author=J.+Heidekerauthor=I.+E.+Wertz&title=DUBs%2C+the+regulation+of+cell+identity+and+disease&doi=10.1042%2Fbj4670191"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1042%2Fbj4670191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj4670191%26sid%3Dliteratum%253Aachs%26aulast%3DHeideker%26aufirst%3DJ.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26atitle%3DDUBs%252C%2520the%2520regulation%2520of%2520cell%2520identity%2520and%2520disease%26jtitle%3DBiochem.%2520J.%26date%3D2015%26volume%3D467%26spage%3D191%26doi%3D10.1042%2Fbj4670191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Adams, J.</span><span> </span><span class="NLM_article-title">The development of proteasome inhibitors as anticancer drugs</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span><span class="refDoi"> DOI: 10.1016/S1535-6108(04)00120-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2FS1535-6108%2804%2900120-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=15144949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=417-421&author=J.+Adams&title=The+development+of+proteasome+inhibitors+as+anticancer+drugs&doi=10.1016%2FS1535-6108%2804%2900120-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The development of proteasome inhibitors as anticancer drugs</span></div><div class="casAuthors">Adams, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">417-421</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular proteins, including cell cycle regulatory proteins.  Because these pathways are crit. for the proliferation and survival of all cells, and in particular cancerous cells, proteasome inhibition is a potentially attractive anticancer therapy.  Based on encouraging cytotoxic activity, bortezomib was the first proteasome inhibitor to be evaluated in clin. trials.  Efficacy and safety results from a phase 2 clin. trial contributed to approval of bortezomib for use in patients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies and have demonstrated disease progression on their last therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozXYZQ-zxJdbVg90H21EOLACvtfcHk0ljfBaQZ1IP56Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7s%253D&md5=9a070d342533a3b6108150c40852834e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2804%2900120-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252804%252900120-5%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DThe%2520development%2520of%2520proteasome%2520inhibitors%2520as%2520anticancer%2520drugs%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D417%26epage%3D421%26doi%3D10.1016%2FS1535-6108%2804%2900120-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Meister, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gramatzki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jack, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voll, R. E.</span><span> </span><span class="NLM_article-title">Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1792</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-2258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F0008-5472.CAN-06-2258" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=1783-1792&author=S.+Meisterauthor=U.+Schubertauthor=K.+Neubertauthor=K.+Herrmannauthor=R.+Burgerauthor=M.+Gramatzkiauthor=S.+Hahnauthor=S.+Schreiberauthor=S.+Wilhelmauthor=M.+Herrmannauthor=H.+M.+Jackauthor=R.+E.+Voll&title=Extensive+immunoglobulin+production+sensitizes+myeloma+cells+for+proteasome+inhibition&doi=10.1158%2F0008-5472.CAN-06-2258"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-2258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-2258%26sid%3Dliteratum%253Aachs%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DSchubert%26aufirst%3DU.%26aulast%3DNeubert%26aufirst%3DK.%26aulast%3DHerrmann%26aufirst%3DK.%26aulast%3DBurger%26aufirst%3DR.%26aulast%3DGramatzki%26aufirst%3DM.%26aulast%3DHahn%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DHerrmann%26aufirst%3DM.%26aulast%3DJack%26aufirst%3DH.%2BM.%26aulast%3DVoll%26aufirst%3DR.%2BE.%26atitle%3DExtensive%2520immunoglobulin%2520production%2520sensitizes%2520myeloma%2520cells%2520for%2520proteasome%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D1783%26epage%3D1792%26doi%3D10.1158%2F0008-5472.CAN-06-2258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Cenci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerruti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezghrani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasqualetto, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascio, P.</span><span> </span><span class="NLM_article-title">Pivotal advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">921</span><span class="NLM_x">–</span> <span class="NLM_lpage">931</span><span class="refDoi"> DOI: 10.1189/jlb.1011497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1189%2Fjlb.1011497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22685320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslerurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=921-931&author=S.+Cenciauthor=L.+Olivaauthor=F.+Cerrutiauthor=E.+Milanauthor=G.+Bianchiauthor=M.+Rauleauthor=A.+Mezghraniauthor=E.+Pasqualettoauthor=R.+Sitiaauthor=P.+Cascio&title=Pivotal+advance%3A+protein+synthesis+modulates+responsiveness+of+differentiating+and+malignant+plasma+cells+to+proteasome+inhibitors&doi=10.1189%2Fjlb.1011497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pivotal advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors</span></div><div class="casAuthors">Cenci, Simone; Oliva, Laura; Cerruti, Fulvia; Milan, Enrico; Bianchi, Giada; Raule, Mary; Mezghrani, Alexandre; Pasqualetto, Elena; Sitia, Roberto; Cascio, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">921-931</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Society for Leukocyte Biology</span>)
        </div><div class="casAbstract">A previously unsuspected, considerable proportion of newly synthesized polypeptides are hydrolyzed rapidly by proteasomes, possibly competing with endogenous substrates and altering proteostasis.  In view of the anti-cancer effects of PIs, we set out to achieve a quant. assessment of proteasome workload in cells hallmarked by different PI sensitivity, namely, a panel of MM cells, and in a dynamic model of plasma cell differentiation, a process that confers exquisite PI sensitivity.  Our results suggest that protein synthesis is a key determinant of proteasomal proteolytic burden and PI sensitivity.  In different MM cells and in differentiating plasma cells, the av. proteolytic work accomplished per proteasome ranges over different orders of magnitude, an unexpected degree of variability, with increased workload invariably assocd. to increased PI sensitivity.  The unfavorable load-vs.-capacity balance found in highly PI-sensitive MM lines is accounted for by a decreased total no. of immunoproteasomes/cell coupled to enhanced generation of RDPs.  Moreover, indicative of cause-effect relationships, attenuating general protein synthesis by the otherwise toxic agent CHX reduces PI sensitivity in activated B and in MM cells.  Our data support the view that in plasma cells protein synthesis contributes to det. PI sensitivity by satg. the proteasomal degradative capacity.  Quantitating protein synthesis and proteasome workload may thus prove crucial to design novel neg. proteostasis regulators against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzfLDlzFVvbVg90H21EOLACvtfcHk0ljfBaQZ1IP56Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslerurvM&md5=4573314c4f009333c5de968eaa890b26</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1011497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1011497%26sid%3Dliteratum%253Aachs%26aulast%3DCenci%26aufirst%3DS.%26aulast%3DOliva%26aufirst%3DL.%26aulast%3DCerruti%26aufirst%3DF.%26aulast%3DMilan%26aufirst%3DE.%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DRaule%26aufirst%3DM.%26aulast%3DMezghrani%26aufirst%3DA.%26aulast%3DPasqualetto%26aufirst%3DE.%26aulast%3DSitia%26aufirst%3DR.%26aulast%3DCascio%26aufirst%3DP.%26atitle%3DPivotal%2520advance%253A%2520protein%2520synthesis%2520modulates%2520responsiveness%2520of%2520differentiating%2520and%2520malignant%2520plasma%2520cells%2520to%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2012%26volume%3D92%26spage%3D921%26epage%3D931%26doi%3D10.1189%2Fjlb.1011497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Ratner, M.</span><span> </span><span class="NLM_article-title">FDA approves three different multiple myeloma drugs in one month</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">126</span><span class="refDoi"> DOI: 10.1038/nbt0216-126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnbt0216-126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=126&author=M.+Ratner&title=FDA+approves+three+different+multiple+myeloma+drugs+in+one+month&doi=10.1038%2Fnbt0216-126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt0216-126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0216-126%26sid%3Dliteratum%253Aachs%26aulast%3DRatner%26aufirst%3DM.%26atitle%3DFDA%2520approves%2520three%2520different%2520multiple%2520myeloma%2520drugs%2520in%2520one%2520month%26jtitle%3DNat.%2520Biotechnol.%26date%3D2016%26volume%3D34%26spage%3D126%26doi%3D10.1038%2Fnbt0216-126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span><span class="refDoi"> DOI: 10.1200/JCO.2011.37.8919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1200%2FJCO.2011.37.8919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22215754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=445-452&author=K.+C.+Anderson&title=The+39th+David+A.+Karnofsky+Lecture%3A+bench-to-bedside+translation+of+targeted+therapies+in+multiple+myeloma&doi=10.1200%2FJCO.2011.37.8919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The 39th David A. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma</span></div><div class="casAuthors">Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">445-452</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Multiple myeloma (MM) is a remarkable example of rapid bench-to-bedside translation in new drug development.  The proteasome inhibitor bortezomib and immunomodulatory drug lenalidomide targeted MM cells in the bone marrow (BM) microenvironment to overcome conventional drug resistance in lab. and animal models and were rapidly translated into clin. trials demonstrating their efficacy in patients with relapsed and then newly diagnosed MM, with a doubling of the median survival as a direct result.  The future is even brighter.  First, immune-based therapies are being developed (eg, elotuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell-dendritic cell vaccines; CD138, CS-1, and XBP-1 peptide vaccines; anti-17 MoAb; and other treatments to overcome causes of immune dysfunction).  Second, promising next-generation agents target the MM cell in its microenvironment (eg, deubiquitinating enzyme inhibitors; chymotryptic [carfilzomib, Onyx 0912, MLN 9708] and broader [NPI-0052] proteasome inhibitors; immunoproteasome inhibitors; and pomalidamide).  Moreover, agents targeting bone biol. (eg, zoledronic acid, anti-DKK-1 MoAb, anti-B-cell activating factor MoAb and bortezomib, Btk inhibitor) show promise not only in preserving bone integrity but also against MM.  Third, rationally based combination therapies, including bortezomib with Akt, mammalian target of rapamycin, or histone deacetylase inhibitors, are active even in bortezomib-refractory MM.  Finally, genomics is currently being used in the definition of MM heterogeneity, new target discovery, and development of personalized therapy.  Myeloma therefore represents a paradigm for targeting the tumor in its microenvironment, which has already markedly improved patient outcome in MM and has great potential in other hematol. malignancies and solid tumors as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonWQMjtpU4c7Vg90H21EOLACvtfcHk0lhY2EyRJBGbsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKgsrg%253D&md5=9d37e03ad2b6d8b4bed1607694aa45c4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.37.8919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.37.8919%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DThe%252039th%2520David%2520A.%2520Karnofsky%2520Lecture%253A%2520bench-to-bedside%2520translation%2520of%2520targeted%2520therapies%2520in%2520multiple%2520myeloma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D445%26epage%3D452%26doi%3D10.1200%2FJCO.2011.37.8919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Das, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oronsky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scicinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2187</span><span class="NLM_x">–</span> <span class="NLM_lpage">2197</span><span class="refDoi"> DOI: 10.1038/leu.2016.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fleu.2016.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27118403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=2187-2197&author=D.+S.+Dasauthor=A.+Rayauthor=A.+Dasauthor=Y.+Songauthor=Z.+Tianauthor=B.+Oronskyauthor=P.+Richardsonauthor=J.+Scicinskiauthor=D.+Chauhanauthor=K.+C.+Anderson&title=A+novel+hypoxia-selective+epigenetic+agent+RRx-001+triggers+apoptosis+and+overcomes+drug+resistance+in+multiple+myeloma+cells&doi=10.1038%2Fleu.2016.96"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells</span></div><div class="casAuthors">Sharma Das, D.; Ray, A.; Das, A.; Song, Y.; Tian, Z.; Oronsky, B.; Richardson, P.; Scicinski, J.; Chauhan, D.; Anderson, K. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2187-2197</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The hypoxic bone marrow (BM) microenvironment confers growth/survival and drug resistance in multiple myeloma (MM) cells.  Novel therapies targeting the MM cell in its hypoxic BM milieu may overcome drug resistance.  Recent studies led to the development of a novel mol. RRx-001 with hypoxia-selective epigenetic and nitric oxide-donating properties.  Here, we demonstrate that RRx-001 decreases the viability of MM cell lines and primary patient cells, as well as overcomes drug resistance.  RRx-001 inhibits MM cell growth in the presence of BM stromal cells.  RRx-001-induced apoptosis is assocd. with: (i) activation of caspases; (ii) release of ROS and nitrogen species; (iii) induction of DNA damage via ATM/γ-H2AX; and (iv) decrease in DNA methyltransferase (DNMT) and global methylation.  RNA interference study shows a predominant role of DNMT1 in MM cell survival vs. DNMT3a or DNMT3b.  The deubiquitylating enzyme USP7 stimulates DNMT1 activity, and conversely, USP7-siRNA reduced DNMT1 activity and decreased MM cell viability.  RRx-001 plus USP7 inhibitor P5091 triggered synergistic anti-MM activity.  MM xenograft studies show that RRx-001 is well tolerated, inhibits tumor growth and enhances survival.  Combining RRx-001 with pomalidomide, bortezomib or SAHA induces synergistic anti-MM activity.  Our results provide the rationale for translation of RRx-001, either alone or in combination, to clin. evaluation in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjV6OcM6-k8rVg90H21EOLACvtfcHk0lhY2EyRJBGbsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWjtL0%253D&md5=65ed426954f24c9b76b6a25c9e665d48</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.96%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DD.%2BS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DDas%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DOronsky%26aufirst%3DB.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DScicinski%26aufirst%3DJ.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520novel%2520hypoxia-selective%2520epigenetic%2520agent%2520RRx-001%2520triggers%2520apoptosis%2520and%2520overcomes%2520drug%2520resistance%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D2187%26epage%3D2197%26doi%3D10.1038%2Fleu.2016.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Lenalidomide in multiple myeloma</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1165</span><span class="NLM_x">–</span> <span class="NLM_lpage">1173</span><span class="refDoi"> DOI: 10.1586/14737140.6.8.1165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1586%2F14737140.6.8.1165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16925483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28XpslGhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=1165-1173&author=P.+G.+Richardsonauthor=C.+Mitsiadesauthor=T.+Hideshimaauthor=K.+C.+Anderson&title=Lenalidomide+in+multiple+myeloma&doi=10.1586%2F14737140.6.8.1165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide in multiple myeloma</span></div><div class="casAuthors">Richardson, Paul G.; Mitsiades, Constantine; Hideshima, Teru; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1165-1173</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Current therapies for multiple myeloma include steroids, alkylating agents and high-dose chemotherapy with autologous stem cell transplant.  These approaches are typically assocd. with initially good response rates, but they ultimately fail as a result of disease progression.  New therapies that overcome resistance, lower toxicity and maintain remission are needed.  Recent advances in the treatment of multiple myeloma include bortezomib and thalidomide.  Lenalidomide (Revlimid) is an immunomodulatory drug that has undergone rapid clin. development in multiple myeloma and was recently approved by the US FDA for use in patients with relapsed disease.  Clin. trials demonstrate that lenalidomide, particularly in combination with dexamethasone, produces durable clin. responses in patients with relapsed and refractory disease and is generally well tolerated, with manageable toxicities.  This review summarizes the profile of lenalidomide and the current evidence for its efficacy in multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK72GbiacBv7Vg90H21EOLACvtfcHk0lhY2EyRJBGbsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpslGhsLs%253D&md5=6c7ff6dc97a8fe5bda7c283e51a86c21</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1586%2F14737140.6.8.1165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.6.8.1165%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DLenalidomide%2520in%2520multiple%2520myeloma%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2006%26volume%3D6%26spage%3D1165%26epage%3D1173%26doi%3D10.1586%2F14737140.6.8.1165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Kojima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burks, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2545</span><span class="NLM_x">–</span> <span class="NLM_lpage">2557</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F1535-7163.MCT-10-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20736344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaqsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2545-2557&author=K.+Kojimaauthor=J.+K.+Burksauthor=J.+Artsauthor=M.+Andreeff&title=The+novel+tryptamine+derivative+JNJ-26854165+induces+wild-type+p53-+and+E2F1-mediated+apoptosis+in+acute+myeloid+and+lymphoid+leukemias&doi=10.1158%2F1535-7163.MCT-10-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias</span></div><div class="casAuthors">Kojima, Kensuke; Burks, Jared K.; Arts, Janine; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2545-2557</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The development of small-mol. activators of p53 is currently focused on malignancies contg. a wild-type p53 genotype, which is present in most leukemias.  JNJ-26854165 is one such p53-activating agent, but its mechanism of action remains to be elucidated.  Here, we report the effects of JNJ-26854165 in acute leukemias.  JNJ-26854165 treatment induced p53-mediated apoptosis in acute leukemia cells with wild-type p53, in which p53 rapidly drives transcription-independent apoptosis followed by activation of a transcription-dependent pathway.  JNJ-26854165 accelerated the proteasome-mediated degrdn. of p21 and antagonized the transcriptional induction of p21 by p53.  Interestingly, JNJ-26854165 induced S-phase delay and upregulated E2F1 expression in p53 mutant cells, resulting in apoptosis preferentially of S-phase cells.  E2F1 knockdown blocked apoptosis induced by JNJ-26854165 in p53 mutant cells.  Apoptotic activity of JNJ-26854165 against primary acute leukemia cells was maintained in leukemia/stroma cocultures, unlike doxorubicin, which has reduced cytotoxicity in coculture systems.  JNJ-26854165 synergizes with 1-β-arabinofuranosylcytosine or doxorubicin to induce p53-mediated apoptosis.  Our data suggest that JNJ-26854165 may provide a novel therapeutic approach for the treatment of acute leukemias.  The presence of p53-independent apoptotic activity in addn. to p53-mediated apoptosis induction, if operational in vivo, may prevent the selection of p53 mutant subclones during therapy.  Mol Cancer Ther; 9(9); 2545-57.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvjlM2mkfNWrVg90H21EOLACvtfcHk0ljTQmxqCOy20g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaqsrnJ&md5=046ba6911e9135ea180733a4c7451f77</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0337%26sid%3Dliteratum%253Aachs%26aulast%3DKojima%26aufirst%3DK.%26aulast%3DBurks%26aufirst%3DJ.%2BK.%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DThe%2520novel%2520tryptamine%2520derivative%2520JNJ-26854165%2520induces%2520wild-type%2520p53-%2520and%2520E2F1-mediated%2520apoptosis%2520in%2520acute%2520myeloid%2520and%2520lymphoid%2520leukemias%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2545%26epage%3D2557%26doi%3D10.1158%2F1535-7163.MCT-10-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Tabernero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirix, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Martin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdevila, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Beijsterveldt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platero, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoblauch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, S. H.</span><span> </span><span class="NLM_article-title">A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6313</span><span class="NLM_x">–</span> <span class="NLM_lpage">6321</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F1078-0432.CCR-11-1101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21831953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ggs7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6313-6321&author=J.+Taberneroauthor=L.+Dirixauthor=P.+Schoffskiauthor=A.+Cervantesauthor=J.+A.+Lopez-Martinauthor=J.+Capdevilaauthor=L.+van+Beijsterveldtauthor=S.+Plateroauthor=B.+Hallauthor=Z.+Yuanauthor=R.+Knoblauchauthor=S.+H.+Zhuang&title=A+phase+I+first-in-human+pharmacokinetic+and+pharmacodynamic+study+of+serdemetan+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-11-1101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Tabernero, Josep; Dirix, Luc; Schoffski, Patrick; Cervantes, Andres; Lopez-Martin, Jose Antonio; Capdevila, Jaume; van Beijsterveldt, Ludy; Platero, Suso; Hall, Brett; Yuan, Zhilong; Knoblauch, Roland; Zhuang, Sen Hong</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6313-6321</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Originally isolated on the basis of its ability to induce p53, serdemetan showed potent activity in various preclin. models, inducing S-phase arrest and apoptosis in TP53 wild-type and mutant tumors.  This study evaluated the safety and tolerability of serdemetan, detd. the pharmacokinetic and pharmacodynamic profiles, and identified a recommended phase II dose.  PATIENTS AND METHODS: Patients (71) with refractory solid tumors were allocated to dose-escalating cohorts (3+3 patients each) and received oral serdemetan once daily in 21-day cycles to det. the max. tolerated dose (MTD) and dose-limiting toxicities (DLT).  Plasma was collected for pharmacokinetic analyses.  Paired baseline and on-treatment skin and tumor biopsies were done; blood samples were collected for pharmacodynamic analyses, including p53 and macrophage inhibitory cytokine-1 induction.  RESULTS: The MTD of serdemetan was detd. to be 350 mg once daily.  During this study, grade 3 QTc prolongation was the most common DLT and nausea (66.2%) was the most frequent treatment-emergent adverse event.  Serdemetan was rapidly absorbed after oral administration and exhibited dose-proportional pharmacokinetics.  At steady state, mean max. plasma concn. (Cmax) was 2,330 ng/mL and mean area under plasma concn. curve (AUC0-24h) was 43.0 μg.h/mL, with serdemetan 300 mg/d.  There was a dose- and exposure-dependent p53 induction.  One patient with breast cancer showed a partial response; 22 (38.6%) patients had stable disease.  CONCLUSIONS: Serdemetan treatment was assocd. with p53 induction in both tumor and surrogate tissue pharmacodynamic studies and modest clin. activity.  Although serdemetan was well tolerated with dose-proportional pharmacokinetics, exposure-related QTc liability was obsd.  Clin Cancer Res; 17(19); 6313-21.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9duPLEjrFzbVg90H21EOLACvtfcHk0ljTQmxqCOy20g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ggs7bN&md5=4d7e41cda55e7acb50c2e52588804193</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1101%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DDirix%26aufirst%3DL.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DCervantes%26aufirst%3DA.%26aulast%3DLopez-Martin%26aufirst%3DJ.%2BA.%26aulast%3DCapdevila%26aufirst%3DJ.%26aulast%3Dvan%2BBeijsterveldt%26aufirst%3DL.%26aulast%3DPlatero%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DKnoblauch%26aufirst%3DR.%26aulast%3DZhuang%26aufirst%3DS.%2BH.%26atitle%3DA%2520phase%2520I%2520first-in-human%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520serdemetan%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6313%26epage%3D6321%26doi%3D10.1158%2F1078-0432.CCR-11-1101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">You, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, W.</span><span> </span><span class="NLM_article-title">The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">7777</span><span class="NLM_x">–</span> <span class="NLM_lpage">7790</span><span class="refDoi"> DOI: 10.18632/oncotarget.13951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.18632%2Foncotarget.13951" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=7777-7790&author=L.+Youauthor=H.+Liuauthor=J.+Huangauthor=W.+Xieauthor=J.+Weiauthor=X.+Yeauthor=W.+Qian&title=The+novel+anticancer+agent+JNJ-26854165+is+active+in+chronic+myeloid+leukemic+cells+with+unmutated+BCR%2FABL+and+T315I+mutant+BCR%2FABL+through+promoting+proteosomal+degradation+of+BCR%2FABL+proteins&doi=10.18632%2Foncotarget.13951"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13951%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DQian%26aufirst%3DW.%26atitle%3DThe%2520novel%2520anticancer%2520agent%2520JNJ-26854165%2520is%2520active%2520in%2520chronic%2520myeloid%2520leukemic%2520cells%2520with%2520unmutated%2520BCR%252FABL%2520and%2520T315I%2520mutant%2520BCR%252FABL%2520through%2520promoting%2520proteosomal%2520degradation%2520of%2520BCR%252FABL%2520proteins%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D7777%26epage%3D7790%26doi%3D10.18632%2Foncotarget.13951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Flygare, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budha, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheeti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshayes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisner, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazzard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plise, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Um, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varfolomeev, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vucic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ware, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zobel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairbrother, W. J.</span><span> </span><span class="NLM_article-title">Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4101</span><span class="NLM_x">–</span> <span class="NLM_lpage">4113</span><span class="refDoi"> DOI: 10.1021/jm300060k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300060k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Ois74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4101-4113&author=J.+A.+Flygareauthor=M.+Beresiniauthor=N.+Budhaauthor=H.+Chanauthor=I.+T.+Chanauthor=S.+Cheetiauthor=F.+Cohenauthor=K.+Deshayesauthor=K.+Doernerauthor=S.+G.+Eckhardtauthor=L.+O.+Elliottauthor=B.+Fengauthor=M.+C.+Franklinauthor=S.+F.+Reisnerauthor=L.+Gazzardauthor=J.+Halladayauthor=S.+G.+Hymowitzauthor=H.+Laauthor=P.+LoRussoauthor=B.+Maurerauthor=L.+Murrayauthor=E.+Pliseauthor=C.+Quanauthor=J.+P.+Stephanauthor=S.+G.+Youngauthor=J.+Tomauthor=V.+Tsuiauthor=J.+Umauthor=E.+Varfolomeevauthor=D.+Vucicauthor=A.+J.+Wagnerauthor=H.+J.+Wallweberauthor=L.+Wangauthor=J.+Wareauthor=Z.+Wenauthor=H.+Wongauthor=J.+M.+Wongauthor=M.+Wongauthor=S.+Wongauthor=R.+Yuauthor=K.+Zobelauthor=W.+J.+Fairbrother&title=Discovery+of+a+potent+small-molecule+antagonist+of+inhibitor+of+apoptosis+%28IAP%29+proteins+and+clinical+candidate+for+the+treatment+of+cancer+%28GDC-0152%29&doi=10.1021%2Fjm300060k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152)</span></div><div class="casAuthors">Flygare, John A.; Beresini, Maureen; Budha, Nageshwar; Chan, Helen; Chan, Iris T.; Cheeti, Sravanthi; Cohen, Frederick; Deshayes, Kurt; Doerner, Karl; Eckhardt, S. Gail; Elliott, Linda O.; Feng, Bainian; Franklin, Matthew C.; Reisner, Stacy Frankovitz; Gazzard, Lewis; Halladay, Jason; Hymowitz, Sarah G.; La, Hank; LoRusso, Patricia; Maurer, Brigitte; Murray, Lesley; Plise, Emile; Quan, Clifford; Stephan, Jean-Philippe; Young, Shin G.; Tom, Jeffrey; Tsui, Vickie; Um, Joanne; Varfolomeev, Eugene; Vucic, Domagoj; Wagner, Andrew J.; Wallweber, Heidi J. A.; Wang, Lan; Ware, Joseph; Wen, Zhaoyang; Wong, Harvey; Wong, Jonathan M.; Wong, Melisa; Wong, Susan; Yu, Ron; Zobel, Kerry; Fairbrother, Wayne J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4101-4113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of compds. were designed and synthesized as antagonists of cIAP1/2, ML-IAP, and XIAP based on the N-terminus, AVPI, of mature Smac.  Compd. (I) (GDC-0152) has the best profile of these compds.; it binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with Ki values of 28, 14, 17, and 43 nM, resp.  These compds. promote degrdn. of cIAP1, induce activation of caspase-3/7, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells.  Compd. I inhibits tumor growth when dosed orally in the MDA-MB-231 breast cancer xenograft model.  Compd. I was advanced to human clin. trials, and it exhibited linear pharmacokinetics over the dose range (0.049 to 1.48 mg/kg) tested.  Mean plasma clearance in humans was 9 ± 3 mL/min/kg, and the vol. of distribution was 0.6 ± 0.2 L/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZSPNVJ5gVWrVg90H21EOLACvtfcHk0lh2qIVMCaPMxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Ois74%253D&md5=19452878ea834d3c324d567b39a78fb2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm300060k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300060k%26sid%3Dliteratum%253Aachs%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBudha%26aufirst%3DN.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DI.%2BT.%26aulast%3DCheeti%26aufirst%3DS.%26aulast%3DCohen%26aufirst%3DF.%26aulast%3DDeshayes%26aufirst%3DK.%26aulast%3DDoerner%26aufirst%3DK.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DElliott%26aufirst%3DL.%2BO.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DFranklin%26aufirst%3DM.%2BC.%26aulast%3DReisner%26aufirst%3DS.%2BF.%26aulast%3DGazzard%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DPlise%26aufirst%3DE.%26aulast%3DQuan%26aufirst%3DC.%26aulast%3DStephan%26aufirst%3DJ.%2BP.%26aulast%3DYoung%26aufirst%3DS.%2BG.%26aulast%3DTom%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUm%26aufirst%3DJ.%26aulast%3DVarfolomeev%26aufirst%3DE.%26aulast%3DVucic%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWare%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DZobel%26aufirst%3DK.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520small-molecule%2520antagonist%2520of%2520inhibitor%2520of%2520apoptosis%2520%2528IAP%2529%2520proteins%2520and%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520cancer%2520%2528GDC-0152%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4101%26epage%3D4113%26doi%3D10.1021%2Fjm300060k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Andreeff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assouline, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strair, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popplewell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschbaum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruvolo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blotner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jukofsky, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, K.</span><span> </span><span class="NLM_article-title">Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">876</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F1078-0432.CCR-15-0481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26459177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFGmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=868-876&author=M.+Andreeffauthor=K.+R.+Kellyauthor=K.+Yeeauthor=S.+Assoulineauthor=R.+Strairauthor=L.+Popplewellauthor=D.+Bowenauthor=G.+Martinelliauthor=M.+W.+Drummondauthor=P.+Vyasauthor=M.+Kirschbaumauthor=S.+P.+Iyerauthor=V.+Ruvoloauthor=G.+M.+Gonzalezauthor=X.+Huangauthor=G.+Chenauthor=B.+Gravesauthor=S.+Blotnerauthor=P.+Bridgeauthor=L.+Jukofskyauthor=S.+Middletonauthor=M.+Recknerauthor=R.+Ruegerauthor=J.+Zhiauthor=G.+Nicholsauthor=K.+Kojima&title=Results+of+the+Phase+I+trial+of+RG7112%2C+a+small-molecule+MDM2+antagonist+in+leukemia&doi=10.1158%2F1078-0432.CCR-15-0481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia</span></div><div class="casAuthors">Andreeff, Michael; Kelly, Kevin R.; Yee, Karen; Assouline, Sarit; Strair, Roger; Popplewell, Leslie; Bowen, David; Martinelli, Giovanni; Drummond, Mark W.; Vyas, Paresh; Kirschbaum, Mark; Iyer, Swaminathan Padmanabhan; Ruvolo, Vivian; Gonzalez, Graciela M. Nogueras; Huang, Xuelin; Chen, Gong; Graves, Bradford; Blotner, Steven; Bridge, Peter; Jukofsky, Lori; Middleton, Steve; Reckner, Monica; Rueger, Ruediger; Zhi, Jianguo; Nichols, Gwen; Kojima, Kensuke</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">868-876</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: RG7112 is a small-mol. MDM2 antagonist.  MDM2 is a neg. regulator of the tumor suppressor p53 and frequently overexpressed in leukemias.  Thus, a phase I study of RG7112 in patients with hematol. malignancies was conducted.  Exptl. Design: Primary study objectives included detn. of the dose and safety profile of RG7112.  Secondary objectives included evaluation of pharmacokinetics; pharmacodynamics, such as TP53-mutation status and MDM2 expression; and preliminary clin. activity.  Patients were divided into two cohorts: Stratum A [relapsed/refractory acute myeloid leukemia (AML; except acute promyelocytic leukemia), acute lymphoblastic leukemia, and chronic myelogenous leukemia] and Stratum B (relapsed/refractory chronic lymphocytic leukemia/small cell lymphocytic leukemia; CLL/sCLL).  Some Stratum A patients were treated at the MTD to assess clin. activity.  Results: RG7112 was administered to 116 patients (96 patients in Stratum A and 20 patients in Stratum B).  All patients experienced at least 1 adverse event, and 3 dose-limiting toxicities were reported.  Pharmacokinetic anal. indicated that twice-daily dosing enhanced daily exposure.  Antileukemia activity was obsd. in the 30 patients with AML assessed at the MTD, including 5 patients who met International Working Group (IWG) criteria for response.  Exploratory anal. revealed TP53 mutations in 14% of Stratum A patients and in 40% of Stratum B patients.  Two patients with TP53 mutations exhibited clin. activity. p53 target genes were induced only in TP53 wild-type leukemic cells.  Baseline expression levels of MDM2 correlated pos. with clin. response.  Conclusions: RG7112 demonstrated clin. activity against relapsed/refractory AML and CLL/sCLL.  MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes.  We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clin. responses in hematol. malignancies.  Clin Cancer Res; 22(4); 868-76. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRuwfqK8jXXrVg90H21EOLACvtfcHk0liVjaCr60Ze3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFGmtrs%253D&md5=9fd607f309a6327c163738291413048a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0481%26sid%3Dliteratum%253Aachs%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DYee%26aufirst%3DK.%26aulast%3DAssouline%26aufirst%3DS.%26aulast%3DStrair%26aufirst%3DR.%26aulast%3DPopplewell%26aufirst%3DL.%26aulast%3DBowen%26aufirst%3DD.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DDrummond%26aufirst%3DM.%2BW.%26aulast%3DVyas%26aufirst%3DP.%26aulast%3DKirschbaum%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26aulast%3DRuvolo%26aufirst%3DV.%26aulast%3DGonzalez%26aufirst%3DG.%2BM.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DBlotner%26aufirst%3DS.%26aulast%3DBridge%26aufirst%3DP.%26aulast%3DJukofsky%26aufirst%3DL.%26aulast%3DMiddleton%26aufirst%3DS.%26aulast%3DReckner%26aufirst%3DM.%26aulast%3DRueger%26aufirst%3DR.%26aulast%3DZhi%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DG.%26aulast%3DKojima%26aufirst%3DK.%26atitle%3DResults%2520of%2520the%2520Phase%2520I%2520trial%2520of%2520RG7112%252C%2520a%2520small-molecule%2520MDM2%2520antagonist%2520in%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D868%26epage%3D876%26doi%3D10.1158%2F1078-0432.CCR-15-0481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemunaitis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beryozkina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarapa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhi, J.</span><span> </span><span class="NLM_article-title">Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">595</span><span class="refDoi"> DOI: 10.1007/s00280-015-2830-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs00280-015-2830-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26210682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1amtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2015&pages=587-595&author=A.+Patnaikauthor=A.+Tolcherauthor=M.+Beeramauthor=J.+Nemunaitisauthor=G.+J.+Weissauthor=K.+Bhallaauthor=M.+Agrawalauthor=G.+Nicholsauthor=S.+Middletonauthor=A.+Beryozkinaauthor=N.+Sarapaauthor=R.+Peckauthor=J.+Zhi&title=Clinical+pharmacology+characterization+of+RG7112%2C+an+MDM2+antagonist%2C+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-015-2830-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors</span></div><div class="casAuthors">Patnaik, Amita; Tolcher, Anthony; Beeram, Murali; Nemunaitis, John; Weiss, Glen J.; Bhalla, Kapil; Agrawal, Manish; Nichols, Gwen; Middleton, Steven; Beryozkina, Anna; Sarapa, Nenad; Peck, Richard; Zhi, Jianguo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-595</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: RG7112, the first selective small-mol. MDM2 antagonist in clin. testing, is a non-genotoxic oral p53 activator.  To optimize its dose and schedule, a no. of clin. pharmacol. characteristics were explored in this multicenter trial in patients with advanced solid tumors.  Method: In part 1, the impact of high-energy/high-fat meal and formulations (cryst. and amorphous) on relative bioavailability was examd. in single-dose crossover designs.  In part 2, schedule optimization (4 schedules of drug administration under fasting condition and 2 cohorts with liq. supplementation) was investigated in parallel, dose escalation designs.  Clin. endpoints were pharmacokinetics (PK), pharmacodynamics (PD) including MIC-1 elevation and platelet redn., and safety/tolerability.  Results: With a single-dose treatment, a high-fat/high-energy meal and a new formulation under fasting condition, resp., enhanced overall bioavailability of RG7112 slightly over twofold.  Following multiple-dose administrations, all four schedules yielded the comparable per-cycle (28-d) exposure (AUC), as designed; liq. supplements also enhanced bioavailability.  High-dose treatments of consecutive daily dosing for 5 and 3 days resulted in higher on-treatment-day exposure to RG7112 than both weekly and low-dose/long-duration (20-day) daily schedules.  Serum MIC-1 and blood platelet profiles showed similar patterns to those of PK when the clin. pharmacol. conditions were varied, suggesting the relative importance of treatment-day exposure than overall per-cycle AUC.  Conclusion: Food (both high-fat and low-fat meals) and new formulation enhanced bioavailability.  High-dose consecutive daily treatment for 3-5 days is superior to weekly and low-dose/long-duration (20-day) daily schedules in yielding the sufficiently high drug exposure and PD effects potentially required for cancer treatment efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob0X7kDb-ao7Vg90H21EOLACvtfcHk0liVjaCr60Ze3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1amtb%252FM&md5=1c6b7aff4b25e12c8e8b92ca966ed95f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs00280-015-2830-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-015-2830-8%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DTolcher%26aufirst%3DA.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DNemunaitis%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DBhalla%26aufirst%3DK.%26aulast%3DAgrawal%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DG.%26aulast%3DMiddleton%26aufirst%3DS.%26aulast%3DBeryozkina%26aufirst%3DA.%26aulast%3DSarapa%26aufirst%3DN.%26aulast%3DPeck%26aufirst%3DR.%26aulast%3DZhi%26aufirst%3DJ.%26atitle%3DClinical%2520pharmacology%2520characterization%2520of%2520RG7112%252C%2520an%2520MDM2%2520antagonist%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2015%26volume%3D76%26spage%3D587%26epage%3D595%26doi%3D10.1007%2Fs00280-015-2830-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Wong, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micel, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagby, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spreafico, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klauck, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blakemore, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tentler, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span> </span><span class="NLM_article-title">Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1007/s10637-016-0398-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs10637-016-0398-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=11-25&author=K.+M.+Wongauthor=L.+N.+Micelauthor=H.+M.+Selbyauthor=A.+C.+Tanauthor=T.+M.+Pittsauthor=S.+M.+Bagbyauthor=A.+Spreaficoauthor=P.+J.+Klauckauthor=S.+J.+Blakemoreauthor=P.+F.+Smithauthor=A.+McDonaldauthor=A.+Bergerauthor=J.+J.+Tentlerauthor=S.+G.+Eckhardt&title=Targeting+the+protein+ubiquitination+machinery+in+melanoma+by+the+NEDD8-activating+enzyme+inhibitor+pevonedistat+%28MLN4924%29&doi=10.1007%2Fs10637-016-0398-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs10637-016-0398-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-016-0398-8%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%2BM.%26aulast%3DMicel%26aufirst%3DL.%2BN.%26aulast%3DSelby%26aufirst%3DH.%2BM.%26aulast%3DTan%26aufirst%3DA.%2BC.%26aulast%3DPitts%26aufirst%3DT.%2BM.%26aulast%3DBagby%26aufirst%3DS.%2BM.%26aulast%3DSpreafico%26aufirst%3DA.%26aulast%3DKlauck%26aufirst%3DP.%2BJ.%26aulast%3DBlakemore%26aufirst%3DS.%2BJ.%26aulast%3DSmith%26aufirst%3DP.%2BF.%26aulast%3DMcDonald%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DTentler%26aufirst%3DJ.%2BJ.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26atitle%3DTargeting%2520the%2520protein%2520ubiquitination%2520machinery%2520in%2520melanoma%2520by%2520the%2520NEDD8-activating%2520enzyme%2520inhibitor%2520pevonedistat%2520%2528MLN4924%2529%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26spage%3D11%26epage%3D25%26doi%3D10.1007%2Fs10637-016-0398-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Shah, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubowiak, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebovic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diefenbach, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faessel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirrell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span> </span><span class="NLM_article-title">Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F1078-0432.CCR-15-1237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26561559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=34-43&author=J.+J.+Shahauthor=A.+J.+Jakubowiakauthor=O.+A.+O%E2%80%99Connorauthor=R.+Z.+Orlowskiauthor=R.+D.+Harveyauthor=M.+R.+Smithauthor=D.+Lebovicauthor=C.+Diefenbachauthor=K.+Kellyauthor=Z.+Huaauthor=A.+J.+Bergerauthor=G.+Mulliganauthor=H.+M.+Faesselauthor=S.+Tirrellauthor=B.+J.+Dezubeauthor=S.+Lonial&title=Phase+I+study+of+the+novel+investigational+NEDD8-activating+enzyme+inhibitor+pevonedistat+%28MLN4924%29+in+patients+with+relapsed%2Frefractory+multiple+myeloma+or+lymphoma&doi=10.1158%2F1078-0432.CCR-15-1237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma</span></div><div class="casAuthors">Shah, Jatin J.; Jakubowiak, Andrzej J.; O'Connor, Owen A.; Orlowski, Robert Z.; Harvey, R. Donald; Smith, Mitchell R.; Lebovic, Daniel; Diefenbach, Catherine; Kelly, Kevin; Hua, Zhaowei; Berger, Allison J.; Mulligan, George; Faessel, Helene M.; Tirrell, Stephen; Dezube, Bruce J.; Lonial, Sagar</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-43</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma.  Exptl. Design: Patients with relapsed/refractory myeloma (n = 17) or lymphoma (n = 27) received i.v. pevonedistat 25 to 147 mg/m2 on days 1, 2, 8, 9 (schedule A; n = 27) or 100 to 261 mg/m2 on days 1, 4, 8, 11 (schedule B; n = 17) of 21-day cycles.  Results: Maximum tolerated doses were 110 mg/m2 (schedule A) and 196 mg/m2 (schedule B).  Dose-limiting toxicities included febrile neutropenia, transaminase elevations, muscle cramps (schedule A), and thrombocytopenia (schedule B).  Common adverse events included fatigue and nausea.  Common grade ≥3 events were anemia (19%; schedule A), and neutropenia and pneumonia (12%; schedule B).  Clin. significant myelosuppression was uncommon.  There were no treatment-related deaths.  Pevonedistat pharmacokinetics exhibited a biphasic disposition phase and approx. dose-proportional increases in systemic exposure.  Consistent with the short mean elimination half-life of approx. 8.5 h, little-to-no drug accumulation in plasma was seen after multiple dosing.  Pharmacodynamic evidence of NAE inhibition included increased skin levels of CDT-1 and NRF-2 (substrates of NAE-dependent ubiquitin ligases), and increased NRF-2-regulated gene transcript levels in whole blood.  Pevonedistat-NEDD8 adduct was detected in bone marrow aspirates, indicating pevonedistat target engagement in the bone marrow compartment.  Three lymphoma patients had partial responses; 30 patients achieved stable disease.  Conclusions: Pevonedistat demonstrated anticipated pharmacodynamic effects in the clin. setting, a tolerable safety profile, and some preliminary evidence that may be suggestive of the potential for activity in relapsed/refractory lymphoma.  Clin Cancer Res; 22(1); 34-43. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrExZAI5ejiqrVg90H21EOLACvtfcHk0lhEgNKx1TMuzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGqsL8%253D&md5=601285c10bd3b286305dc5f052f02cfa</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1237%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DJ.%2BJ.%26aulast%3DJakubowiak%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DO.%2BA.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DHarvey%26aufirst%3DR.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BR.%26aulast%3DLebovic%26aufirst%3DD.%26aulast%3DDiefenbach%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DMulligan%26aufirst%3DG.%26aulast%3DFaessel%26aufirst%3DH.%2BM.%26aulast%3DTirrell%26aufirst%3DS.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DLonial%26aufirst%3DS.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520novel%2520investigational%2520NEDD8-activating%2520enzyme%2520inhibitor%2520pevonedistat%2520%2528MLN4924%2529%2520in%2520patients%2520with%2520relapsed%252Frefractory%2520multiple%2520myeloma%2520or%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D34%26epage%3D43%26doi%3D10.1158%2F1078-0432.CCR-15-1237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazurkiewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillert, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olofsson, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierrou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillertz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvaraju, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhtar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arcy, P.</span><span> </span><span class="NLM_article-title">The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">26979</span><span class="refDoi"> DOI: 10.1038/srep26979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fsrep26979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27264969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsF2qtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=26979&author=X.+Wangauthor=M.+Mazurkiewiczauthor=E.+K.+Hillertauthor=M.+H.+Olofssonauthor=S.+Pierrouauthor=P.+Hillertzauthor=J.+Gullboauthor=K.+Selvarajuauthor=A.+Paulusauthor=S.+Akhtarauthor=F.+Bosslerauthor=A.+C.+Khanauthor=S.+Linderauthor=P.+D%E2%80%99Arcy&title=The+proteasome+deubiquitinase+inhibitor+VLX1570+shows+selectivity+for+ubiquitin-specific+protease-14+and+induces+apoptosis+of+multiple+myeloma+cells&doi=10.1038%2Fsrep26979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells</span></div><div class="casAuthors">Wang, Xin; Mazurkiewicz, Magdalena; Hillert, Ellin-Kristina; Olofsson, Maria Haegg; Pierrou, Stefan; Hillertz, Per; Gullbo, Joachim; Selvaraju, Karthik; Paulus, Aneel; Akhtar, Sharoon; Bossler, Felicitas; Khan, Asher Chanan; Linder, Stig; D'Arcy, Padraig</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26979</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of deubiquitinase (DUB) activity is a promising strategy for cancer therapy.  VLX1570 is an inhibitor of proteasome DUB activity currently in clin. trials for relapsed multiple myeloma.  Here we show that VLX1570 binds to and inhibits the activity of ubiquitin-specific protease-14 (USP14) in vitro, with comparatively weaker inhibitory activity towards UCHL5 (ubiquitin-C-terminal hydrolase-5).  Exposure of multiple myeloma cells to VLX1570 resulted in thermostabilization of USP14 at therapeutically relevant concns.  Transient knockdown of USP14 or UCHL5 expression by electroporation of siRNA reduced the viability of multiple myeloma cells.  Treatment of multiple myeloma cells with VLX1570 induced the accumulation of proteasome-bound high mol. wt. polyubiquitin conjugates and an apoptotic response.  Sensitivity to VLX1570 was moderately affected by altered drug uptake, but was unaffected by overexpression of BCL2-family proteins or inhibitors of caspase activity.  Finally, treatment with VLX1570 was found to lead to extended survival in xenograft models of multiple myeloma.  Our findings demonstrate promising antiproliferative activity of VLX1570 in multiple myeloma, primarily assocd. with inhibition of USP14 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSyNNG3GPEDLVg90H21EOLACvtfcHk0lhEgNKx1TMuzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsF2qtLg%253D&md5=9826987b387c59f4fc10fa7c2d126011</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsrep26979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep26979%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMazurkiewicz%26aufirst%3DM.%26aulast%3DHillert%26aufirst%3DE.%2BK.%26aulast%3DOlofsson%26aufirst%3DM.%2BH.%26aulast%3DPierrou%26aufirst%3DS.%26aulast%3DHillertz%26aufirst%3DP.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DSelvaraju%26aufirst%3DK.%26aulast%3DPaulus%26aufirst%3DA.%26aulast%3DAkhtar%26aufirst%3DS.%26aulast%3DBossler%26aufirst%3DF.%26aulast%3DKhan%26aufirst%3DA.%2BC.%26aulast%3DLinder%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DP.%26atitle%3DThe%2520proteasome%2520deubiquitinase%2520inhibitor%2520VLX1570%2520shows%2520selectivity%2520for%2520ubiquitin-specific%2520protease-14%2520and%2520induces%2520apoptosis%2520of%2520multiple%2520myeloma%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D26979%26doi%3D10.1038%2Fsrep26979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arcy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulfield, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohanty, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linder, S.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">1036</span><span class="NLM_x">–</span> <span class="NLM_lpage">1048</span><span class="refDoi"> DOI: 10.1111/cbdd.12571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1111%2Fcbdd.12571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25854145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovV2qu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=1036-1048&author=X.+Wangauthor=P.+D%E2%80%99Arcyauthor=T.+R.+Caulfieldauthor=A.+Paulusauthor=K.+Chittaauthor=C.+Mohantyauthor=J.+Gullboauthor=A.+Chanan-Khanauthor=S.+Linder&title=Synthesis+and+evaluation+of+derivatives+of+the+proteasome+deubiquitinase+inhibitor+b-AP15&doi=10.1111%2Fcbdd.12571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15</span></div><div class="casAuthors">Wang, Xin; D'Arcy, Padraig; Caulfield, Thomas R.; Paulus, Aneel; Chitta, Kasyapa; Mohanty, Chitralekha; Gullbo, Joachim; Chanan-Khan, Asher; Linder, Stig</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1036-1048</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) is increasingly recognized as a therapeutic target for the development of anticancer therapies.  The success of the 20S proteasome core particle (20S CP) inhibitor bortezomib in the clin. management of multiple myeloma has raised the possibility of identifying other UPS components for therapeutic intervention.  We previously identified the small mol. b-AP15 as an inhibitor of 19S proteasome deubiquitinase (DUB) activity.  Building upon our previous data, we performed a structure-activity relation (SAR) study on b-AP15 and identified VLX1570 as an analog with promising properties, including enhanced potency and improved soly. in aq. soln.  In silico modeling was consistent with interaction of VLX1570 with key cysteine residues located at the active sites of the proteasome DUBs USP14 and UCHL5.  VLX1570 was found to inhibit proteasome deubiquitinase activity in vitro in a manner consistent with competitive inhibition.  Furthermore, using active-site-directed probes, VLX1570 also inhibited proteasome DUB activity in exposed cells.  Importantly, VLX1570 did not show inhibitory activity on a panel of recombinant non-proteasome DUBs, on recombinant kinases, or on caspase-3 activity, suggesting that VLX1570 is not an overtly reactive general enzyme inhibitor.  Taken together, our data shows the chem. and biol. properties of VLX1570 as an optimized proteasome DUB inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9jJ_S5YMId7Vg90H21EOLACvtfcHk0lhEgNKx1TMuzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovV2qu70%253D&md5=353bf1b03a5378ba70f0835a143516f1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12571%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DP.%26aulast%3DCaulfield%26aufirst%3DT.%2BR.%26aulast%3DPaulus%26aufirst%3DA.%26aulast%3DChitta%26aufirst%3DK.%26aulast%3DMohanty%26aufirst%3DC.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DChanan-Khan%26aufirst%3DA.%26aulast%3DLinder%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520derivatives%2520of%2520the%2520proteasome%2520deubiquitinase%2520inhibitor%2520b-AP15%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2015%26volume%3D86%26spage%3D1036%26epage%3D1048%26doi%3D10.1111%2Fcbdd.12571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Paiva, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Silva, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Araujo, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunning, P. T.</span><span> </span><span class="NLM_article-title">Regulating the master regulator: controlling ubiquitination by thinking outside the active site</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+L.+Paivaauthor=S.+R.+da+Silvaauthor=E.+D.+de+Araujoauthor=P.+T.+Gunning&title=Regulating+the+master+regulator%3A+controlling+ubiquitination+by+thinking+outside+the+active+site&doi=10.1021%2Facs.jmedchem.6b01346"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01346%26sid%3Dliteratum%253Aachs%26aulast%3DPaiva%26aufirst%3DS.%2BL.%26aulast%3Dda%2BSilva%26aufirst%3DS.%2BR.%26aulast%3Dde%2BAraujo%26aufirst%3DE.%2BD.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DRegulating%2520the%2520master%2520regulator%253A%2520controlling%2520ubiquitination%2520by%2520thinking%2520outside%2520the%2520active%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26doi%3D10.1021%2Facs.jmedchem.6b01346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Everett, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meredith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kathoria, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, J.</span><span> </span><span class="NLM_article-title">A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1519</span><span class="NLM_x">–</span> <span class="NLM_lpage">1530</span><span class="refDoi"> DOI: 10.1093/emboj/16.7.1519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1093%2Femboj%2F16.7.1519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=9130697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADyaK2sXislKmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=1519-1530&author=R.+D.+Everettauthor=M.+Meredithauthor=A.+Orrauthor=A.+Crossauthor=M.+Kathoriaauthor=J.+Parkinson&title=A+novel+ubiquitin-specific+protease+is+dynamically+associated+with+the+PML+nuclear+domain+and+binds+to+a+herpesvirus+regulatory+protein&doi=10.1093%2Femboj%2F16.7.1519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein</span></div><div class="casAuthors">Everett, Roger D.; Meredith, Michayla; Orr, Anne; Cross, Anne; Kathoria, Meeta; Parkinson, Jane</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1519-1530</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Herpes simplex virus type 1 immediate-early protein Vmw110 is a non-specific activator of gene expression and is required for efficient initiation of the viral lytic cycle.  Since Vmw110-deficient viruses reactivate inefficiently in mouse latency models it has been suggested that Vmw110 plays a role in the balance between the latent and lytic states of the virus.  The mechanisms by which Vmw110 achieves these functions are poorly understood.  Vmw110 migrates to discrete nuclear structures (ND10) which contain the cellular PML protein, and in consequence PML and other constituent proteins are dispersed.  In addn., Vmw110 binds to a cellular protein of ∼135 kDa, and its interactions with the 135-kDa protein and ND10 contribute to this ability to stimulate gene expression and viral lytic growth.  This report identifies the 135-kDa protein as a novel member of the ubiquitin-specific protease family.  The protease is distributed in the nucleus in a micropunctate pattern with a limited no. of larger discrete foci, some of which co-localize with PML in ND10.  At early times of virus infection, the presence of Vmw110 increases the proportion of ND10 which contain the ubiquitin-specific protease.  These results identify a novel, transitory component of ND10 and implicate a previously uncharacterized ubiquitin-dependent pathway in the control of viral gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYxp1O3Xh70LVg90H21EOLACvtfcHk0lhnTqXcCTSU7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislKmurk%253D&md5=43c11b7ec8a0c6ab764a16cc52035312</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.7.1519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.7.1519%26sid%3Dliteratum%253Aachs%26aulast%3DEverett%26aufirst%3DR.%2BD.%26aulast%3DMeredith%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DA.%26aulast%3DCross%26aufirst%3DA.%26aulast%3DKathoria%26aufirst%3DM.%26aulast%3DParkinson%26aufirst%3DJ.%26atitle%3DA%2520novel%2520ubiquitin-specific%2520protease%2520is%2520dynamically%2520associated%2520with%2520the%2520PML%2520nuclear%2520domain%2520and%2520binds%2520to%2520a%2520herpesvirus%2520regulatory%2520protein%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D1519%26epage%3D1530%26doi%3D10.1093%2Femboj%2F16.7.1519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suresh Kumar, K. G.</span><span> </span><span class="NLM_article-title">The multifaceted roles of USP7: new therapeutic opportunities</span> <span class="citation_source-journal">Cell Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1007/s12013-011-9185-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs12013-011-9185-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21468693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVGhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=61-68&author=B.+Nicholsonauthor=K.+G.+Suresh+Kumar&title=The+multifaceted+roles+of+USP7%3A+new+therapeutic+opportunities&doi=10.1007%2Fs12013-011-9185-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The Multifaceted Roles of USP7: New Therapeutic Opportunities</span></div><div class="casAuthors">Nicholson, Benjamin; Suresh Kumar, K. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">61-68</span>CODEN:
                <span class="NLM_cas:coden">CBBIFV</span>;
        ISSN:<span class="NLM_cas:issn">1085-9195</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The deubiquitylating enzyme USP7 (HAUSP) sits at a crit. node regulating the activities of numerous proteins broadly characterized as tumor suppressors, DNA repair proteins, immune responders, viral proteins, and epigenetic modulators.  Aberrant USP7 activity may promote oncogenesis and viral disease making it a compelling target for therapeutic intervention.  Disclosed drug discovery programs have identified inhibitors of USP7 such as P005091 with cellular proof of concept and anti-proliferative activity in cancer models.  Taken together, USP7 inhibitors hold promise as a new strategy for the treatment of disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW62HFUQNunrVg90H21EOLACvtfcHk0lhnTqXcCTSU7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVGhs7k%253D&md5=c84af523c76e0c756ef2cd37ae6d2a21</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs12013-011-9185-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12013-011-9185-5%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DSuresh%2BKumar%26aufirst%3DK.%2BG.%26atitle%3DThe%2520multifaceted%2520roles%2520of%2520USP7%253A%2520new%2520therapeutic%2520opportunities%26jtitle%3DCell%2520Biochem.%2520Biophys.%26date%3D2011%26volume%3D60%26spage%3D61%26epage%3D68%26doi%3D10.1007%2Fs12013-011-9185-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Kim, R. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sixma, T. K.</span><span> </span><span class="NLM_article-title">Regulation of USP7: a high incidence of E3 complexes</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1016/j.jmb.2017.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.jmb.2017.05.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=R.+Q.+Kimauthor=T.+K.+Sixma&title=Regulation+of+USP7%3A+a+high+incidence+of+E3+complexes&doi=10.1016%2Fj.jmb.2017.05.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2017.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2017.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DR.%2BQ.%26aulast%3DSixma%26aufirst%3DT.%2BK.%26atitle%3DRegulation%2520of%2520USP7%253A%2520a%2520high%2520incidence%2520of%2520E3%2520complexes%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2017%26doi%3D10.1016%2Fj.jmb.2017.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Kon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span> </span><span class="NLM_article-title">Inactivation of HAUSP in vivo modulates p53 function</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1270</span><span class="NLM_x">–</span> <span class="NLM_lpage">1279</span><span class="refDoi"> DOI: 10.1038/onc.2009.427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fonc.2009.427" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=1270-1279&author=N.+Konauthor=Y.+Kobayashiauthor=M.+Liauthor=C.+L.+Brooksauthor=T.+Ludwigauthor=W.+Gu&title=Inactivation+of+HAUSP+in+vivo+modulates+p53+function&doi=10.1038%2Fonc.2009.427"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.427%26sid%3Dliteratum%253Aachs%26aulast%3DKon%26aufirst%3DN.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DBrooks%26aufirst%3DC.%2BL.%26aulast%3DLudwig%26aufirst%3DT.%26aulast%3DGu%26aufirst%3DW.%26atitle%3DInactivation%2520of%2520HAUSP%2520in%2520vivo%2520modulates%2520p53%2520function%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D1270%26epage%3D1279%26doi%3D10.1038%2Fonc.2009.427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Kon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabolcs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canoll, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span> </span><span class="NLM_article-title">Roles of HAUSP-mediated p53 regulation in central nervous system development</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1366</span><span class="NLM_x">–</span> <span class="NLM_lpage">1375</span><span class="refDoi"> DOI: 10.1038/cdd.2011.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fcdd.2011.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21350561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Gku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1366-1375&author=N.+Konauthor=J.+Zhongauthor=Y.+Kobayashiauthor=M.+Liauthor=M.+Szabolcsauthor=T.+Ludwigauthor=P.+D.+Canollauthor=W.+Gu&title=Roles+of+HAUSP-mediated+p53+regulation+in+central+nervous+system+development&doi=10.1038%2Fcdd.2011.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of HAUSP-mediated p53 regulation in central nervous system development</span></div><div class="casAuthors">Kon, N.; Zhong, J.; Kobayashi, Y.; Li, M.; Szabolcs, M.; Ludwig, T.; Canoll, P. D.; Gu, W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1366-1375</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The deubiquitinase HAUSP (herpesvirus-assocd. ubiquitin-specific protease; also called USP7) has a crit. role in regulating the p53-Mdm2 (murine double minute 2) pathway.  By using the conventional knockout approach, we previously showed that hausp inactivation leads to early embryonic lethality.  To fully understand the physiol. functions of hausp, we have generated mice lacking hausp specifically in the brain and examd. the impacts of this manipulation on brain development.  We found that deletion of hausp in neural cells resulted in neonatal lethality.  The brains from these mice displayed hypoplasia and deficiencies in development, which were mainly caused by p53-mediated apoptosis.  Detailed anal. also showed an increase of both p53 levels and p53-dependent transcriptional activation in hausp knockout brains.  Notably, neural cell survival and brain development of hausp-mutant mice can largely be restored in the p53-null background.  Nevertheless, in contrast to the case of mdm2- and mdm4 (murine double minute 4)-mutant mice, inactivation of p53 failed to completely rescue the neonatal lethality of these hausp-mutant mice.  These results indicate that HAUSP-mediated p53 regulation is crucial for brain development, and also suggest that both the p53-dependent and the p53-independent functions of HAUSP contribute to the neonatal lethality of hausp-mutant mice.  Cell Death and Differentiation (2011) 18, 1366-1375; doi:10.1038/cdd.2011.12; published online 25 Feb. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJL6-JdtqU3LVg90H21EOLACvtfcHk0lgAK-CHeQJ-6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Gku74%253D&md5=a0c2dabcf8d472a88b8991d225df2512</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2011.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2011.12%26sid%3Dliteratum%253Aachs%26aulast%3DKon%26aufirst%3DN.%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSzabolcs%26aufirst%3DM.%26aulast%3DLudwig%26aufirst%3DT.%26aulast%3DCanoll%26aufirst%3DP.%2BD.%26aulast%3DGu%26aufirst%3DW.%26atitle%3DRoles%2520of%2520HAUSP-mediated%2520p53%2520regulation%2520in%2520central%2520nervous%2520system%2520development%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2011%26volume%3D18%26spage%3D1366%26epage%3D1375%26doi%3D10.1038%2Fcdd.2011.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Hao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fountain, M. D.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fon Tacer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeld, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Caignec, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isidor, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krantz, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noon, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfotenhauer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saenz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potts, P. R.</span><span> </span><span class="NLM_article-title">USP7 acts as a molecular rheostat to promote WASH-dependent endosomal protein recycling and is mutated in a human neurodevelopmental disorder</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">956</span><span class="NLM_x">–</span> <span class="NLM_lpage">969</span><span class="refDoi"> DOI: 10.1016/j.molcel.2015.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.molcel.2015.07.033" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=956-969&author=Y.+H.+Haoauthor=M.+D.+Fountainauthor=K.+Fon+Tacerauthor=F.+Xiaauthor=W.+Biauthor=S.+H.+Kangauthor=A.+Patelauthor=J.+A.+Rosenfeldauthor=C.+Le+Caignecauthor=B.+Isidorauthor=I.+D.+Krantzauthor=S.+E.+Noonauthor=J.+P.+Pfotenhauerauthor=T.+M.+Morganauthor=R.+Moranauthor=R.+C.+Pedersenauthor=M.+S.+Saenzauthor=C.+P.+Schaafauthor=P.+R.+Potts&title=USP7+acts+as+a+molecular+rheostat+to+promote+WASH-dependent+endosomal+protein+recycling+and+is+mutated+in+a+human+neurodevelopmental+disorder&doi=10.1016%2Fj.molcel.2015.07.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DY.%2BH.%26aulast%3DFountain%26aufirst%3DM.%2BD.%26aulast%3DFon%2BTacer%26aufirst%3DK.%26aulast%3DXia%26aufirst%3DF.%26aulast%3DBi%26aufirst%3DW.%26aulast%3DKang%26aufirst%3DS.%2BH.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DRosenfeld%26aufirst%3DJ.%2BA.%26aulast%3DLe%2BCaignec%26aufirst%3DC.%26aulast%3DIsidor%26aufirst%3DB.%26aulast%3DKrantz%26aufirst%3DI.%2BD.%26aulast%3DNoon%26aufirst%3DS.%2BE.%26aulast%3DPfotenhauer%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DT.%2BM.%26aulast%3DMoran%26aufirst%3DR.%26aulast%3DPedersen%26aufirst%3DR.%2BC.%26aulast%3DSaenz%26aufirst%3DM.%2BS.%26aulast%3DSchaaf%26aufirst%3DC.%2BP.%26aulast%3DPotts%26aufirst%3DP.%2BR.%26atitle%3DUSP7%2520acts%2520as%2520a%2520molecular%2520rheostat%2520to%2520promote%2520WASH-dependent%2520endosomal%2520protein%2520recycling%2520and%2520is%2520mutated%2520in%2520a%2520human%2520neurodevelopmental%2520disorder%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D59%26spage%3D956%26epage%3D969%26doi%3D10.1016%2Fj.molcel.2015.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Sanders, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan-Sencicek, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hus, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murtha, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-De-Luca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilguvar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celestino-Soper, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhodapkar, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiCola, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiLullo, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding-Singh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishman, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frahm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garagaloyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammela, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lund, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrew, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdoch, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Roak, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ober, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pottenger, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raubeson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaspan, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkiewicz, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaudet, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantor, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grice, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifton, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mane, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischfield, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledbetter, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fombonne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutcliffe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, E. H.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geschwind, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roeder, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devlin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">State, M. W.</span><span> </span><span class="NLM_article-title">Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams Syndrome region, are strongly associated with autism</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">863</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span><span class="refDoi"> DOI: 10.1016/j.neuron.2011.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.neuron.2011.05.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2011&pages=863-885&author=S.+J.+Sandersauthor=A.+G.+Ercan-Sencicekauthor=V.+Husauthor=R.+Luoauthor=M.+T.+Murthaauthor=D.+Moreno-De-Lucaauthor=S.+H.+Chuauthor=M.+P.+Moreauauthor=A.+R.+Guptaauthor=S.+A.+Thomsonauthor=C.+E.+Masonauthor=K.+Bilguvarauthor=P.+B.+Celestino-Soperauthor=M.+Choiauthor=E.+L.+Crawfordauthor=L.+Davisauthor=N.+R.+Wrightauthor=R.+M.+Dhodapkarauthor=M.+DiColaauthor=N.+M.+DiLulloauthor=T.+V.+Fernandezauthor=V.+Fielding-Singhauthor=D.+O.+Fishmanauthor=S.+Frahmauthor=R.+Garagaloyanauthor=G.+S.+Gohauthor=S.+Kammelaauthor=L.+Kleiauthor=J.+K.+Loweauthor=S.+C.+Lundauthor=A.+D.+McGrewauthor=K.+A.+Meyerauthor=W.+J.+Moffatauthor=J.+D.+Murdochauthor=B.+J.+O%E2%80%99Roakauthor=G.+T.+Oberauthor=R.+S.+Pottengerauthor=M.+J.+Raubesonauthor=Y.+Songauthor=Q.+Wangauthor=B.+L.+Yaspanauthor=T.+W.+Yuauthor=I.+R.+Yurkiewiczauthor=A.+L.+Beaudetauthor=R.+M.+Cantorauthor=M.+Curlandauthor=D.+E.+Griceauthor=M.+Gunelauthor=R.+P.+Liftonauthor=S.+M.+Maneauthor=D.+M.+Martinauthor=C.+A.+Shawauthor=M.+Sheldonauthor=J.+A.+Tischfieldauthor=C.+A.+Walshauthor=E.+M.+Morrowauthor=D.+H.+Ledbetterauthor=E.+Fombonneauthor=C.+Lordauthor=C.+L.+Martinauthor=A.+I.+Brooksauthor=J.+S.+Sutcliffeauthor=E.+H.+Cookauthor=D.+Geschwindauthor=K.+Roederauthor=B.+Devlinauthor=M.+W.+State&title=Multiple+recurrent+de+novo+CNVs%2C+including+duplications+of+the+7q11.23+Williams+Syndrome+region%2C+are+strongly+associated+with+autism&doi=10.1016%2Fj.neuron.2011.05.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2011.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2011.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DSanders%26aufirst%3DS.%2BJ.%26aulast%3DErcan-Sencicek%26aufirst%3DA.%2BG.%26aulast%3DHus%26aufirst%3DV.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DMurtha%26aufirst%3DM.%2BT.%26aulast%3DMoreno-De-Luca%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DS.%2BH.%26aulast%3DMoreau%26aufirst%3DM.%2BP.%26aulast%3DGupta%26aufirst%3DA.%2BR.%26aulast%3DThomson%26aufirst%3DS.%2BA.%26aulast%3DMason%26aufirst%3DC.%2BE.%26aulast%3DBilguvar%26aufirst%3DK.%26aulast%3DCelestino-Soper%26aufirst%3DP.%2BB.%26aulast%3DChoi%26aufirst%3DM.%26aulast%3DCrawford%26aufirst%3DE.%2BL.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DWright%26aufirst%3DN.%2BR.%26aulast%3DDhodapkar%26aufirst%3DR.%2BM.%26aulast%3DDiCola%26aufirst%3DM.%26aulast%3DDiLullo%26aufirst%3DN.%2BM.%26aulast%3DFernandez%26aufirst%3DT.%2BV.%26aulast%3DFielding-Singh%26aufirst%3DV.%26aulast%3DFishman%26aufirst%3DD.%2BO.%26aulast%3DFrahm%26aufirst%3DS.%26aulast%3DGaragaloyan%26aufirst%3DR.%26aulast%3DGoh%26aufirst%3DG.%2BS.%26aulast%3DKammela%26aufirst%3DS.%26aulast%3DKlei%26aufirst%3DL.%26aulast%3DLowe%26aufirst%3DJ.%2BK.%26aulast%3DLund%26aufirst%3DS.%2BC.%26aulast%3DMcGrew%26aufirst%3DA.%2BD.%26aulast%3DMeyer%26aufirst%3DK.%2BA.%26aulast%3DMoffat%26aufirst%3DW.%2BJ.%26aulast%3DMurdoch%26aufirst%3DJ.%2BD.%26aulast%3DO%25E2%2580%2599Roak%26aufirst%3DB.%2BJ.%26aulast%3DOber%26aufirst%3DG.%2BT.%26aulast%3DPottenger%26aufirst%3DR.%2BS.%26aulast%3DRaubeson%26aufirst%3DM.%2BJ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYaspan%26aufirst%3DB.%2BL.%26aulast%3DYu%26aufirst%3DT.%2BW.%26aulast%3DYurkiewicz%26aufirst%3DI.%2BR.%26aulast%3DBeaudet%26aufirst%3DA.%2BL.%26aulast%3DCantor%26aufirst%3DR.%2BM.%26aulast%3DCurland%26aufirst%3DM.%26aulast%3DGrice%26aufirst%3DD.%2BE.%26aulast%3DGunel%26aufirst%3DM.%26aulast%3DLifton%26aufirst%3DR.%2BP.%26aulast%3DMane%26aufirst%3DS.%2BM.%26aulast%3DMartin%26aufirst%3DD.%2BM.%26aulast%3DShaw%26aufirst%3DC.%2BA.%26aulast%3DSheldon%26aufirst%3DM.%26aulast%3DTischfield%26aufirst%3DJ.%2BA.%26aulast%3DWalsh%26aufirst%3DC.%2BA.%26aulast%3DMorrow%26aufirst%3DE.%2BM.%26aulast%3DLedbetter%26aufirst%3DD.%2BH.%26aulast%3DFombonne%26aufirst%3DE.%26aulast%3DLord%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DC.%2BL.%26aulast%3DBrooks%26aufirst%3DA.%2BI.%26aulast%3DSutcliffe%26aufirst%3DJ.%2BS.%26aulast%3DCook%26aufirst%3DE.%2BH.%26aulast%3DGeschwind%26aufirst%3DD.%26aulast%3DRoeder%26aufirst%3DK.%26aulast%3DDevlin%26aufirst%3DB.%26aulast%3DState%26aufirst%3DM.%2BW.%26atitle%3DMultiple%2520recurrent%2520de%2520novo%2520CNVs%252C%2520including%2520duplications%2520of%2520the%25207q11.23%2520Williams%2520Syndrome%2520region%252C%2520are%2520strongly%2520associated%2520with%2520autism%26jtitle%3DNeuron%26date%3D2011%26volume%3D70%26spage%3D863%26epage%3D885%26doi%3D10.1016%2Fj.neuron.2011.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Lecona, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Acebes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Contreras, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruppen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Capetillo, O.</span><span> </span><span class="NLM_article-title">USP7 is a SUMO deubiquitinase essential for DNA replication</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">277</span><span class="refDoi"> DOI: 10.1038/nsmb.3185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnsmb.3185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26950370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsVGmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=270-277&author=E.+Leconaauthor=S.+Rodriguez-Acebesauthor=J.+Specksauthor=A.+J.+Lopez-Contrerasauthor=I.+Ruppenauthor=M.+Murgaauthor=J.+Munozauthor=J.+Mendezauthor=O.+Fernandez-Capetillo&title=USP7+is+a+SUMO+deubiquitinase+essential+for+DNA+replication&doi=10.1038%2Fnsmb.3185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">USP7 is a SUMO deubiquitinase essential for DNA replication</span></div><div class="casAuthors">Lecona, Emilio; Rodriguez-Acebes, Sara; Specks, Julia; Lopez-Contreras, Andres J.; Ruppen, Isabel; Murga, Matilde; Munoz, Javier; Mendez, Juan; Fernandez-Capetillo, Oscar</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">270-277</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Post-translational modification of proteins by ubiquitin (Ub) and Ub-like modifiers regulates DNA replication.  We have previously shown that chromatin around replisomes is rich in SUMO and poor in Ub, whereas mature chromatin exhibits an opposite pattern.  How this SUMO-rich, Ub-poor environment is maintained at sites of DNA replication in mammalian cells remains unexplored.  Here we identify USP7 as a replisome-enriched SUMO deubiquitinase that is essential for DNA replication.  By acting on SUMO and SUMOylated proteins, USP7 counteracts their ubiquitination.  Inhibition or genetic deletion of USP7 leads to the accumulation of Ub on SUMOylated proteins, which are displaced away from replisomes.  Our findings provide a model explaining the differential accumulation of SUMO and Ub at replication forks and identify an essential role of USP7 in DNA replication that should be considered in the development of USP7 inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcwBs_aWMhurVg90H21EOLACvtfcHk0lgoaHZXCVTl5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsVGmsLk%253D&md5=0c1060d0b7dbae85a167a180c15f9741</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3185%26sid%3Dliteratum%253Aachs%26aulast%3DLecona%26aufirst%3DE.%26aulast%3DRodriguez-Acebes%26aufirst%3DS.%26aulast%3DSpecks%26aufirst%3DJ.%26aulast%3DLopez-Contreras%26aufirst%3DA.%2BJ.%26aulast%3DRuppen%26aufirst%3DI.%26aulast%3DMurga%26aufirst%3DM.%26aulast%3DMunoz%26aufirst%3DJ.%26aulast%3DMendez%26aufirst%3DJ.%26aulast%3DFernandez-Capetillo%26aufirst%3DO.%26atitle%3DUSP7%2520is%2520a%2520SUMO%2520deubiquitinase%2520essential%2520for%2520DNA%2520replication%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D270%26epage%3D277%26doi%3D10.1038%2Fnsmb.3185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, F. H.</span><span> </span><span class="NLM_article-title">USP7 promotes cell proliferation through the stabilization of Ki-67 protein in non-small cell lung cancer cells</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1016/j.biocel.2016.08.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.biocel.2016.08.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27590858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyiurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=209-221&author=C.+Zhangauthor=J.+Luauthor=Q.+W.+Zhangauthor=W.+Zhaoauthor=J.+H.+Guoauthor=S.+L.+Liuauthor=Y.+L.+Wuauthor=B.+Jiangauthor=F.+H.+Gao&title=USP7+promotes+cell+proliferation+through+the+stabilization+of+Ki-67+protein+in+non-small+cell+lung+cancer+cells&doi=10.1016%2Fj.biocel.2016.08.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">USP7 promotes cell proliferation through the stabilization of Ki-67 protein in non-small cell lung cancer cells</span></div><div class="casAuthors">Zhang, Chao; Lu, Jing; Zhang, Quan-Wu; Zhao, Wei; Guo, Jia-Hui; Liu, Shan-Ling; Wu, Ying-Li; Jiang, Bin; Gao, Feng-Hou</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Ki-67 antigen (Ki-67) is the most reliable immunohistochem. marker for evaluation of cell proliferation in non-small cell lung cancer.  However, the mechanisms underlying the regulation of protein levels of Ki-67 in non-small cell lung cancer have remained elusive.  In this study, we found that Ki-67 and ubiquitin-specific processing protease 7 (USP7) protein were highly expressed in the nucleus of non-small cell lung cancer cells.  Furthermore, statistical anal. uncovered the existence of a strong correlation between Ki-67 and USP7 levels.  We could also show that the protein levels of Ki-67 in non-small cell lung cancer cells significantly decreased after treatment with P22077, a selective chem. inhibitor of USP7, while the Ki-67 mRNA levels were unperturbed.  Similar results were obtained by knocking down USP7 using short hairpin RNA (shRNA) in lung cancer cells.  Interestingly, we noticed that ubiquitination levels of Ki-67 increased dramatically in USP7-silenced cells.  The tests in vitro and vivo showed a significant delay in tumor cell growth upon knockdown of USP7.  Addnl., drug sensitivity tests indicated that USP7-silenced A549 cells had enhanced sensitivity to paclitaxel and docetaxel, while there was no significant change in sensitivity toward carboplatin and cisplatin.  Taken together, these data strongly suggest that the overexpression of USP7 might promote cell proliferation by deubiquitinating Ki-67 protein, thereby maintaining its high levels in the non-small cell lung cancer.  Our study also hints potential for the development of deubiquitinase-based therapies, esp. those targeting USP7 to improve the condition of patients diagnosed with non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfCNqZdfSwJ7Vg90H21EOLACvtfcHk0lgoaHZXCVTl5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyiurnJ&md5=6c0125120978c298b4f2785b390ba51d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2016.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2016.08.025%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%2BW.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%2BH.%26aulast%3DLiu%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DF.%2BH.%26atitle%3DUSP7%2520promotes%2520cell%2520proliferation%2520through%2520the%2520stabilization%2520of%2520Ki-67%2520protein%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2016%26volume%3D79%26spage%3D209%26epage%3D221%26doi%3D10.1016%2Fj.biocel.2016.08.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Zhan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span> </span><span class="NLM_article-title">Usp7 promotes medulloblastoma cell survival and metastasis by activating Shh pathway</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">484</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2017.01.144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.bbrc.2017.01.144" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=484&publication_year=2017&pages=429-434&author=M.+Zhanauthor=X.+Sunauthor=J.+Liuauthor=Y.+Liauthor=Y.+Liauthor=X.+Heauthor=Z.+Zhouauthor=L.+Lu&title=Usp7+promotes+medulloblastoma+cell+survival+and+metastasis+by+activating+Shh+pathway&doi=10.1016%2Fj.bbrc.2017.01.144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.01.144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.01.144%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DL.%26atitle%3DUsp7%2520promotes%2520medulloblastoma%2520cell%2520survival%2520and%2520metastasis%2520by%2520activating%2520Shh%2520pathway%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D484%26spage%3D429%26epage%3D434%26doi%3D10.1016%2Fj.bbrc.2017.01.144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Tavana, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Califano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashiro, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span> </span><span class="NLM_article-title">HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1180</span><span class="NLM_x">–</span> <span class="NLM_lpage">1186</span><span class="refDoi"> DOI: 10.1038/nm.4180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnm.4180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27618649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2rtb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1180-1186&author=O.+Tavanaauthor=D.+Liauthor=C.+Daiauthor=G.+Lopezauthor=D.+Banerjeeauthor=N.+Konauthor=C.+Chenauthor=A.+Califanoauthor=D.+J.+Yamashiroauthor=H.+Sunauthor=W.+Gu&title=HAUSP+deubiquitinates+and+stabilizes+N-Myc+in+neuroblastoma&doi=10.1038%2Fnm.4180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma</span></div><div class="casAuthors">Tavana, Omid; Li, Dawei; Dai, Chao; Lopez, Gonzalo; Banerjee, Debarshi; Kon, Ning; Chen, Chao; Califano, Andrea; Yamashiro, Darrell J.; Sun, Hongbin; Gu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1180-1186</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The MYCN proto-oncogene is amplified in a no. of advanced-stage human tumors, such as neuroblastomas.  Similar to other members of the MYC family of oncoproteins, MYCN (also known as N-Myc) is a transcription factor, and its stability and activity are tightly controlled by ubiquitination-dependent proteasome degrdn.  Although numerous studies have demonstrated that N-Myc is a driver of neuroblastoma tumorigenesis, therapies that directly suppress N-Myc activity in human tumors are limited.  Here we have identified ubiquitin-specific protease 7 (USP7; also known as HAUSP) as a regulator of N-Myc function in neuroblastoma.  HAUSP interacts with N-Myc, and HAUSP expression induces deubiquitination and subsequent stabilization of N-Myc.  Conversely, RNA interference (RNAi)-mediated knockdown of USP7 in neuroblastoma cancer cell lines, or genetic ablation of Usp7 in the mouse brain, destabilizes N-Myc, which leads to inhibition of N-Myc function.  Notably, HAUSP is more abundant in patients with neuroblastoma who have poorer prognosis, and HAUSP expression substantially correlates with N-Myc transcriptional activity.  Furthermore, small-mol. inhibitors of HAUSP's deubiquitinase activity markedly suppress the growth of MYCN-amplified human neuroblastoma cell lines in xenograft mouse models.  Taken together, our findings demonstrate a crucial role of HAUSP in regulating N-Myc function in vivo and suggest that HAUSP inhibition is a potential therapy for MYCN-amplified tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC4ucMtC9h_7Vg90H21EOLACvtfcHk0lgs8ogjGUnf_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2rtb%252FE&md5=853ba98d5bd2dec31943b78765ed1f0f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnm.4180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4180%26sid%3Dliteratum%253Aachs%26aulast%3DTavana%26aufirst%3DO.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DC.%26aulast%3DLopez%26aufirst%3DG.%26aulast%3DBanerjee%26aufirst%3DD.%26aulast%3DKon%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCalifano%26aufirst%3DA.%26aulast%3DYamashiro%26aufirst%3DD.%2BJ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DW.%26atitle%3DHAUSP%2520deubiquitinates%2520and%2520stabilizes%2520N-Myc%2520in%2520neuroblastoma%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D1180%26epage%3D1186%26doi%3D10.1038%2Fnm.4180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span> </span><span class="NLM_article-title">Molecular mechanism for USP7-mediated DNMT1 stabilization by acetylation</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">7023</span><span class="refDoi"> DOI: 10.1038/ncomms8023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fncomms8023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25960197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2ktrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=7023&author=J.+Chengauthor=H.+Yangauthor=J.+Fangauthor=L.+Maauthor=R.+Gongauthor=P.+Wangauthor=Z.+Liauthor=Y.+Xu&title=Molecular+mechanism+for+USP7-mediated+DNMT1+stabilization+by+acetylation&doi=10.1038%2Fncomms8023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism for USP7-mediated DNMT1 stabilization by acetylation</span></div><div class="casAuthors">Cheng, Jingdong; Yang, Huirong; Fang, Jian; Ma, Lixiang; Gong, Rui; Wang, Ping; Li, Ze; Xu, Yanhui</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7023</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">DNMT1 is an important epigenetic regulator that plays a key role in the maintenance of DNA methylation.  Here we detd. the crystal structure of DNMT1 in complex with USP7 at 2.9 Å resoln.  The interaction between the two proteins is primarily mediated by an acidic pocket in USP7 and Lysine residues within DNMT1's KG linker.  This intermol. interaction is required for USP7-mediated stabilization of DNMT1.  Acetylation of the KG linker Lysine residues impair DNMT1-USP7 interaction and promote the degrdn. of DNMT1.  Treatment with HDAC inhibitors results in an increase in acetylated DNMT1 and decreased total DNMT1 protein.  This neg. correlation is obsd. in differentiated neuronal cells and pancreatic cancer cells.  Our studies reveal that USP7-mediated stabilization of DNMT1 is regulated by acetylation and provide a structural basis for the design of inhibitors, targeting the DNMT1-USP7 interaction surface for therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFGjRM0dWyxLVg90H21EOLACvtfcHk0lgs8ogjGUnf_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2ktrfP&md5=0375cf6c3f56cb4d8cbd2051750ee462</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fncomms8023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms8023%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DGong%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DMolecular%2520mechanism%2520for%2520USP7-mediated%2520DNMT1%2520stabilization%2520by%2520acetylation%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D7023%26doi%3D10.1038%2Fncomms8023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guryanova, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, S.</span><span> </span><span class="NLM_article-title">Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span><span class="refDoi"> DOI: 10.1038/ncb2153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fncb2153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21258371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlamtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=142-152&author=Z.+Huangauthor=Q.+Wuauthor=O.+A.+Guryanovaauthor=L.+Chengauthor=W.+Shouauthor=J.+N.+Richauthor=S.+Bao&title=Deubiquitylase+HAUSP+stabilizes+REST+and+promotes+maintenance+of+neural+progenitor+cells&doi=10.1038%2Fncb2153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells</span></div><div class="casAuthors">Huang, Zhi; Wu, Qiulian; Guryanova, Olga A.; Cheng, Lin; Shou, Weinian; Rich, Jeremy N.; Bao, Shideng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">142-152</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The repressor element 1-silencing transcription factor (REST) functions as a master regulator to maintain neural stem/progenitor cells (NPCs).  REST undergoes proteasomal degrdn. through β-TrCP-mediated ubiquitylation during neuronal differentiation.  However, reciprocal mechanisms that stabilize REST in NPCs are undefined.  Here we show that the deubiquitylase HAUSP counterbalances REST ubiquitylation and prevents NPC differentiation.  HAUSP expression declines concordantly with REST on neuronal differentiation and reciprocally with β-TrCP levels.  HAUSP knockdown in NPCs decreases REST and induces differentiation.  In contrast, HAUSP overexpression upregulates REST by overriding β-TrCP-mediated ubiquitylation.  A consensus site (310-PYSS-313) in human REST is required for HAUSP-mediated REST deubiquitylation.  Furthermore, REST overexpression in NPCs rescues the differentiation phenotype induced by HAUSP knockdown.  These data demonstrate that HAUSP stabilizes REST through deubiquitylation and antagonizes β-TrCP in regulating REST at the post-translational level.  Thus, HAUSP-mediated deubiquitylation represents a crit. regulatory mechanism involved in the maintenance of NPCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxgn5FrTahmrVg90H21EOLACvtfcHk0lgs8ogjGUnf_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlamtbo%253D&md5=2ffcdebf63a76ca32e3f5f5ed6f32204</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fncb2153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb2153%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DGuryanova%26aufirst%3DO.%2BA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShou%26aufirst%3DW.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26aulast%3DBao%26aufirst%3DS.%26atitle%3DDeubiquitylase%2520HAUSP%2520stabilizes%2520REST%2520and%2520promotes%2520maintenance%2520of%2520neural%2520progenitor%2520cells%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2011%26volume%3D13%26spage%3D142%26epage%3D152%26doi%3D10.1038%2Fncb2153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">An, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span> </span><span class="NLM_article-title">USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1016/j.bcp.2017.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.bcp.2017.02.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=29-39&author=T.+Anauthor=Y.+Gongauthor=X.+Liauthor=L.+Kongauthor=P.+Maauthor=L.+Gongauthor=H.+Zhuauthor=C.+Yuauthor=J.+Liuauthor=H.+Zhouauthor=B.+Maoauthor=Y.+Li&title=USP7+inhibitor+P5091+inhibits+Wnt+signaling+and+colorectal+tumor+growth&doi=10.1016%2Fj.bcp.2017.02.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DT.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DUSP7%2520inhibitor%2520P5091%2520inhibits%2520Wnt%2520signaling%2520and%2520colorectal%2520tumor%2520growth%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D131%26spage%3D29%26epage%3D39%26doi%3D10.1016%2Fj.bcp.2017.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Wade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, G. M.</span><span> </span><span class="NLM_article-title">MDM2, MDMX and p53 in oncogenesis and cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1038/nrc3430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrc3430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=23303139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvFKmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=83-96&author=M.+Wadeauthor=Y.+C.+Liauthor=G.+M.+Wahl&title=MDM2%2C+MDMX+and+p53+in+oncogenesis+and+cancer+therapy&doi=10.1038%2Fnrc3430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">MDM2, MDMX and p53 in oncogenesis and cancer therapy</span></div><div class="casAuthors">Wade, Mark; Li, Yao-Cheng; Wahl, Geoffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">83-96</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumor suppressor.  However, the MDM proteins modulate and respond to many other signalling networks in which they are embedded.  Recent mechanistic studies and animal models have demonstrated how functional interactions in these networks are crucial for maintaining normal tissue homeostasis, and for detg. responses to oncogenic and therapeutic challenges.  This Review highlights the progress made and pitfalls encountered as the field continues to search for MDM-targeted antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqETvNjDDuV_bVg90H21EOLACvtfcHk0lhhhyFl7En1hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvFKmtA%253D%253D&md5=58f901d95696dff8836ee9e7212b3478</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnrc3430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3430%26sid%3Dliteratum%253Aachs%26aulast%3DWade%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%2BC.%26aulast%3DWahl%26aufirst%3DG.%2BM.%26atitle%3DMDM2%252C%2520MDMX%2520and%2520p53%2520in%2520oncogenesis%2520and%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D83%26epage%3D96%26doi%3D10.1038%2Fnrc3430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span> </span><span class="NLM_article-title">A dynamic role of HAUSP in the p53-Mdm2 pathway</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">886</span><span class="refDoi"> DOI: 10.1016/S1097-2765(04)00157-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2FS1097-2765%2804%2900157-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=879-886&author=M.+Liauthor=C.+L.+Brooksauthor=N.+Konauthor=W.+Gu&title=A+dynamic+role+of+HAUSP+in+the+p53-Mdm2+pathway&doi=10.1016%2FS1097-2765%2804%2900157-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2804%2900157-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252804%252900157-1%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DBrooks%26aufirst%3DC.%2BL.%26aulast%3DKon%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DW.%26atitle%3DA%2520dynamic%2520role%2520of%2520HAUSP%2520in%2520the%2520p53-Mdm2%2520pathway%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D879%26epage%3D886%26doi%3D10.1016%2FS1097-2765%2804%2900157-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Meulmeester, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teunisse, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirks, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jochemsen, A. G.</span><span> </span><span class="NLM_article-title">Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">576</span><span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.molcel.2005.04.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=565-576&author=E.+Meulmeesterauthor=M.+M.+Mauriceauthor=C.+Boutellauthor=A.+F.+Teunisseauthor=H.+Ovaaauthor=T.+E.+Abrahamauthor=R.+W.+Dirksauthor=A.+G.+Jochemsen&title=Loss+of+HAUSP-mediated+deubiquitination+contributes+to+DNA+damage-induced+destabilization+of+Hdmx+and+Hdm2&doi=10.1016%2Fj.molcel.2005.04.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DMeulmeester%26aufirst%3DE.%26aulast%3DMaurice%26aufirst%3DM.%2BM.%26aulast%3DBoutell%26aufirst%3DC.%26aulast%3DTeunisse%26aufirst%3DA.%2BF.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DAbraham%26aufirst%3DT.%2BE.%26aulast%3DDirks%26aufirst%3DR.%2BW.%26aulast%3DJochemsen%26aufirst%3DA.%2BG.%26atitle%3DLoss%2520of%2520HAUSP-mediated%2520deubiquitination%2520contributes%2520to%2520DNA%2520damage-induced%2520destabilization%2520of%2520Hdmx%2520and%2520Hdm2%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26spage%3D565%26epage%3D576%26doi%3D10.1016%2Fj.molcel.2005.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Yi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span> </span><span class="NLM_article-title">Stabilization of LSD1 by deubiquitinating enzyme USP7 promotes glioblastoma cell tumorigenesis and metastasis through suppression of the p53 signaling pathway</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">2935</span><span class="NLM_x">–</span> <span class="NLM_lpage">2945</span><span class="refDoi"> DOI: 10.3892/or.2016.5099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.3892%2For.2016.5099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27632941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWksbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=2935-2945&author=L.+Yiauthor=Y.+Cuiauthor=Q.+Xuauthor=Y.+Jiang&title=Stabilization+of+LSD1+by+deubiquitinating+enzyme+USP7+promotes+glioblastoma+cell+tumorigenesis+and+metastasis+through+suppression+of+the+p53+signaling+pathway&doi=10.3892%2For.2016.5099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of LSD1 by deubiquitinating enzyme USP7 promotes glioblastoma cell tumorigenesis and metastasis through suppression of the p53 signaling pathway</span></div><div class="casAuthors">Yi, Lei; Cui, Yan; Xu, Qingfu; Jiang, Yugang</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2935-2945</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The substrates and mechanisms of ubiquitin specific peptidase 7 (USP7) in glioma remain unclear.  Lysine-specific demethylase 1 (LSD1) may undergo proteasomal degrdn.; however, a reciprocal mechanism that stabilizes LSD1 in glioma has not been dertermined.  Here co-immunopptn. and GST pull-down assays revealed that LSD1 is assocd. with USP7 in vivo and in vitro.  USP7 inhibited LSD1 ubiquitination and stabilized LSD1 in A172 and T98G cells.  MTT, EdU proliferation, flow cytometry and Transwell assays indicated that LSD1 played a crit. role in the proliferation and invasion of glioblastoma (GBM) cells.  We defined the mechanism of USP7 in GBM, through counterbalanced LSD1 ubiquitylation.  USP7 caused G0/G1 arrest, promoted tumorigenesis and invasion of A172 and T98G cells.  We also uncovered the suppression of the p53 signaling pathway that mediated the activity of USP7 and LSD1.  Furthermore, USP7 and LSD1 expression levels were higher in the 150 glioma patients than these levels in normal brain tissues and were correlated with glioma progression.  LSD1 was increased concurrently with USP7 during glioblastoma progression and both were predictors for worsened prognosis.  Collectively, our study suggested that USP7-LSD1 affects GBM cell proliferation and invasion and may be valuable as novel therapeutic targets and prognostic tools for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr89DZrK0dq67Vg90H21EOLACvtfcHk0lhhhyFl7En1hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWksbbN&md5=21358e5aff3d9678bc92f5ab952c7075</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.3892%2For.2016.5099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.5099%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DStabilization%2520of%2520LSD1%2520by%2520deubiquitinating%2520enzyme%2520USP7%2520promotes%2520glioblastoma%2520cell%2520tumorigenesis%2520and%2520metastasis%2520through%2520suppression%2520of%2520the%2520p53%2520signaling%2520pathway%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D36%26spage%3D2935%26epage%3D2945%26doi%3D10.3892%2For.2016.5099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Trotman, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alimonti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teruya-Feldstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carver, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordon-Cardo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdjument-Bromage, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tempst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misteli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span> </span><span class="NLM_article-title">Ubiquitination regulates PTEN nuclear import and tumor suppression</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.11.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.cell.2006.11.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=17218261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptl2hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=141-156&author=L.+C.+Trotmanauthor=X.+Wangauthor=A.+Alimontiauthor=Z.+Chenauthor=J.+Teruya-Feldsteinauthor=H.+Yangauthor=N.+P.+Pavletichauthor=B.+S.+Carverauthor=C.+Cordon-Cardoauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=S.+G.+Chiauthor=H.+J.+Kimauthor=T.+Misteliauthor=X.+Jiangauthor=P.+P.+Pandolfi&title=Ubiquitination+regulates+PTEN+nuclear+import+and+tumor+suppression&doi=10.1016%2Fj.cell.2006.11.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitination regulates PTEN nuclear import and tumor suppression</span></div><div class="casAuthors">Trotman, Lloyd C.; Wang, Xinjiang; Alimonti, Andrea; Chen, Zhenbang; Teruya-Feldstein, Julie; Yang, Haijuan; Pavletich, Nikola P.; Carver, Brett S.; Cordon-Cardo, Carlos; Erdjument-Bromage, Hediye; Tempst, Paul; Chi, Sung-Gil; Kim, Hyo-Jong; Misteli, Tom; Jiang, Xuejun; Pandolfi, Pier Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-156</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The PTEN tumor suppressor is frequently affected in cancer cells, and inherited PTEN mutation causes cancer-susceptibility conditions such as Cowden syndrome.  PTEN acts as a plasma-membrane lipid-phosphatase antagonizing the phosphoinositide 3-kinase/AKT cell survival pathway.  However, PTEN is also found in cell nuclei, but mechanism, function, and relevance of nuclear localization remain unclear.  We show that nuclear PTEN is essential for tumor suppression and that PTEN nuclear import is mediated by its mono-ubiquitination.  A lysine mutant of PTEN, K289E assocd. with Cowden syndrome, retains catalytic activity but fails to accumulate in nuclei of patient tissue due to an import defect.  We identify this and another lysine residue as major mono-ubiquitination sites essential for PTEN import.  While nuclear PTEN is stable, poly-ubiquitination leads to its degrdn. in the cytoplasm.  Thus, we identify cancer-assocd. mutations of PTEN that target its posttranslational modification and demonstrate how a discrete mol. mechanism dictates tumor progression by differentiating between degrdn. and protection of PTEN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzkJrjDyqRb7Vg90H21EOLACvtfcHk0lgE81zytsbg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptl2hug%253D%253D&md5=424ea5985c2e8040aeddf861ba23cd2c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.11.040%26sid%3Dliteratum%253Aachs%26aulast%3DTrotman%26aufirst%3DL.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DAlimonti%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DCarver%26aufirst%3DB.%2BS.%26aulast%3DCordon-Cardo%26aufirst%3DC.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DChi%26aufirst%3DS.%2BG.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DMisteli%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26atitle%3DUbiquitination%2520regulates%2520PTEN%2520nuclear%2520import%2520and%2520tumor%2520suppression%26jtitle%3DCell%26date%3D2007%26volume%3D128%26spage%3D141%26epage%3D156%26doi%3D10.1016%2Fj.cell.2006.11.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">van der Horst, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries-Smits, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenkman, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Triest, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Broek, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgering, B. M.</span><span> </span><span class="NLM_article-title">FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1064</span><span class="NLM_x">–</span> <span class="NLM_lpage">1073</span><span class="refDoi"> DOI: 10.1038/ncb1469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fncb1469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16964248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVWqsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=1064-1073&author=A.+van+der+Horstauthor=A.+M.+de+Vries-Smitsauthor=A.+B.+Brenkmanauthor=M.+H.+van+Triestauthor=N.+van+den+Broekauthor=F.+Collandauthor=M.+M.+Mauriceauthor=B.+M.+Burgering&title=FOXO4+transcriptional+activity+is+regulated+by+monoubiquitination+and+USP7%2FHAUSP&doi=10.1038%2Fncb1469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP</span></div><div class="casAuthors">van der Horst, Armando; de Vries-Smits, Alida M. M.; Brenkman, Arjan B.; van Triest, Miranda H.; van den Broek, Niels; Colland, Frederic; Maurice, Madelon M.; Burgering, Boudewijn M. T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1064-1073</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">FOXO (Forkhead box O) transcription factors are important regulators of cellular metab., cell-cycle progression and cell death.  FOXO activity is regulated by multiple post-translational modifications, including phosphorylation, acetylation and polyubiquitination.  Here, we show that FOXO becomes monoubiquitinated in response to increased cellular oxidative stress, resulting in its re-localization to the nucleus and an increase in its transcriptional activity.  Deubiquitination of FOXO requires the deubiquitinating enzyme USP7/HAUSP (herpesvirus-assocd. ubiquitin-specific protease), which interacts with and deubiquitinates FOXO in response to oxidative stress.  Oxidative stress-induced ubiquitination and deubiquitination by USP7 do not influence FOXO protein half-life.  However, USP7 does neg. regulate FOXO transcriptional activity towards endogenous promoters.  Our results demonstrate a novel mechanism of FOXO regulation and indicate that USP7 has an important role in regulating FOXO-mediated stress responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppc5cmFw8HVLVg90H21EOLACvtfcHk0lgE81zytsbg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVWqsLbM&md5=2b6a9c1e5a7f611a923c24b867c7cfb2</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fncb1469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1469%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHorst%26aufirst%3DA.%26aulast%3Dde%2BVries-Smits%26aufirst%3DA.%2BM.%26aulast%3DBrenkman%26aufirst%3DA.%2BB.%26aulast%3Dvan%2BTriest%26aufirst%3DM.%2BH.%26aulast%3Dvan%2Bden%2BBroek%26aufirst%3DN.%26aulast%3DColland%26aufirst%3DF.%26aulast%3DMaurice%26aufirst%3DM.%2BM.%26aulast%3DBurgering%26aufirst%3DB.%2BM.%26atitle%3DFOXO4%2520transcriptional%2520activity%2520is%2520regulated%2520by%2520monoubiquitination%2520and%2520USP7%252FHAUSP%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2006%26volume%3D8%26spage%3D1064%26epage%3D1073%26doi%3D10.1038%2Fncb1469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Song, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmena, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carracedo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo-Coco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teruya-Feldstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span> </span><span class="NLM_article-title">The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">817</span><span class="refDoi"> DOI: 10.1038/nature07290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnature07290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=18716620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1WktLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=813-817&author=M.+S.+Songauthor=L.+Salmenaauthor=A.+Carracedoauthor=A.+Egiaauthor=F.+Lo-Cocoauthor=J.+Teruya-Feldsteinauthor=P.+P.+Pandolfi&title=The+deubiquitinylation+and+localization+of+PTEN+are+regulated+by+a+HAUSP-PML+network&doi=10.1038%2Fnature07290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network</span></div><div class="casAuthors">Song, Min Sup; Salmena, Leonardo; Carracedo, Arkaitz; Egia, Ainara; Lo-Coco, Francesco; Teruya-Feldstein, Julie; Pandolfi, Pier Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7214</span>),
    <span class="NLM_cas:pages">813-817</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nuclear exclusion of the PTEN (phosphatase and tensin homolog deleted in chromosome 10) tumor suppressor has been assocd. with cancer progression.  However, the mechanisms leading to this aberrant PTEN localization in human cancers are currently unknown.  We have previously reported that ubiquitinylation of PTEN at specific lysine residues regulates its nuclear-cytoplasmic partitioning.  Here we show that functional promyelocytic leukemia protein (PML) nuclear bodies coordinate PTEN localization by opposing the action of a previously unknown PTEN-deubiquitinylating enzyme, herpesvirus-assocd. ubiquitin-specific protease (HAUSP, also known as USP7), and that the integrity of this mol. framework is required for PTEN to be able to enter the nucleus.  We find that PTEN is aberrantly localized in acute promyelocytic leukemia, in which PML function is disrupted by the PML-RARα fusion oncoprotein.  Remarkably, treatment with drugs that trigger PML-RARα degrdn., such as all-trans retinoic acid or arsenic trioxide, restore nuclear PTEN.  We demonstrate that PML opposes the activity of HAUSP towards PTEN through a mechanism involving the adaptor protein DAXX (death domain-assocd. protein).  In support of this paradigm, we show that HAUSP is overexpressed in human prostate cancer and is assocd. with PTEN nuclear exclusion.  Thus, our results delineate a previously unknown PML-DAXX-HAUSP mol. network controlling PTEN deubiquitinylation and trafficking, which is perturbed by oncogenic cues in human cancer, in turn defining a new deubiquitinylation-dependent model for PTEN subcellular compartmentalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfabOED4DeUbVg90H21EOLACvtfcHk0lgE81zytsbg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1WktLjL&md5=0f2f59360b366fb3c24a98f46d9e373a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature07290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07290%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DM.%2BS.%26aulast%3DSalmena%26aufirst%3DL.%26aulast%3DCarracedo%26aufirst%3DA.%26aulast%3DEgia%26aufirst%3DA.%26aulast%3DLo-Coco%26aufirst%3DF.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26atitle%3DThe%2520deubiquitinylation%2520and%2520localization%2520of%2520PTEN%2520are%2520regulated%2520by%2520a%2520HAUSP-PML%2520network%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D813%26epage%3D817%26doi%3D10.1038%2Fnature07290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Cai, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Z. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span> </span><span class="NLM_article-title">Ubiquitin-specific protease 7 accelerates p14(ARF) degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1603</span><span class="NLM_x">–</span> <span class="NLM_lpage">1614</span><span class="refDoi"> DOI: 10.1002/hep.27682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1002%2Fhep.27682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25557975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslWlsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1603-1614&author=J.+B.+Caiauthor=G.+M.+Shiauthor=Z.+R.+Dongauthor=A.+W.+Keauthor=H.+H.+Maauthor=Q.+Gaoauthor=Z.+Z.+Shenauthor=X.+Y.+Huangauthor=H.+Chenauthor=D.+D.+Yuauthor=L.+X.+Liuauthor=P.+F.+Zhangauthor=C.+Zhangauthor=M.+Y.+Huauthor=L.+X.+Yangauthor=Y.+H.+Shiauthor=X.+Y.+Wangauthor=Z.+B.+Dingauthor=S.+J.+Qiuauthor=H.+C.+Sunauthor=J.+Zhouauthor=Y.+G.+Shiauthor=J.+Fan&title=Ubiquitin-specific+protease+7+accelerates+p14%28ARF%29+degradation+by+deubiquitinating+thyroid+hormone+receptor-interacting+protein+12+and+promotes+hepatocellular+carcinoma+progression&doi=10.1002%2Fhep.27682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-specific protease 7 accelerates p14ARF degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression</span></div><div class="casAuthors">Cai, Jia-Bin; Shi, Guo-Ming; Dong, Zhao-Ru; Ke, Ai-Wu; Ma, Hong-Hui; Gao, Qiang; Shen, Zao-Zhuo; Huang, Xiao-Yong; Chen, Hao; Yu, Ding-Dang; Liu, Li-Xin; Zhang, Peng-Fei; Zhang, Chi; Hu, Mei-Yu; Yang, Liu-Xiao; Shi, Ying-Hong; Wang, Xiao-Ying; Ding, Zhen-Bin; Qiu, Shuang-Jian; Sun, Hui-Chuan; Zhou, Jian; Shi, Yujiang G.; Fan, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1603-1614</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The prognosis for hepatocellular carcinoma (HCC) remains dismal in terms of overall survival (OS), and its mol. pathogenesis has not been completely defined.  Here, we report that expression of deubiquitylase ubiquitin-specific protease 7 (USP7) is higher in human HCC tissues than in matched peritumoral tissues.  Ectopic USP7 expression promotes growth of HCC cells in vivo and in vitro.  Mechanistically, USP7 overexpression fosters HCC cell growth by forming a complex with and stabilizing thyroid hormone receptor-interacting protein 12 (TRIP12), which induces constitutive p14ARF ubiquitination.  Clin., USP7 overexpression is significantly correlated with a malignant phenotype, including larger tumor size, multiple tumor, poor differentiation, elevated alpha-fetoprotein, and microvascular invasion.  Moreover, overexpression of USP7 and/or TRIP12 correlates with shorter OS and higher cumulative recurrence rates of HCC.  Conclusion: USP7 stabilizes TRIP12 by deubiquitination, thus constitutively inactivating p14ARF and promoting HCC progression.  This represents a novel marker for predicting prognosis and a potential therapeutic target for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEXgZw-WH7ALVg90H21EOLACvtfcHk0ljTxc6xsJ742w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslWlsL0%253D&md5=c87ad1c5f0d2e6b22447e5b554f0b7a2</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fhep.27682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27682%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DJ.%2BB.%26aulast%3DShi%26aufirst%3DG.%2BM.%26aulast%3DDong%26aufirst%3DZ.%2BR.%26aulast%3DKe%26aufirst%3DA.%2BW.%26aulast%3DMa%26aufirst%3DH.%2BH.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DZ.%2BZ.%26aulast%3DHuang%26aufirst%3DX.%2BY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DD.%2BD.%26aulast%3DLiu%26aufirst%3DL.%2BX.%26aulast%3DZhang%26aufirst%3DP.%2BF.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DM.%2BY.%26aulast%3DYang%26aufirst%3DL.%2BX.%26aulast%3DShi%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DDing%26aufirst%3DZ.%2BB.%26aulast%3DQiu%26aufirst%3DS.%2BJ.%26aulast%3DSun%26aufirst%3DH.%2BC.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%2BG.%26aulast%3DFan%26aufirst%3DJ.%26atitle%3DUbiquitin-specific%2520protease%25207%2520accelerates%2520p14%2528ARF%2529%2520degradation%2520by%2520deubiquitinating%2520thyroid%2520hormone%2520receptor-interacting%2520protein%252012%2520and%2520promotes%2520hepatocellular%2520carcinoma%2520progression%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1603%26epage%3D1614%26doi%3D10.1002%2Fhep.27682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Gil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G.</span><span> </span><span class="NLM_article-title">Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span><span class="refDoi"> DOI: 10.1038/nrm1987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrm1987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16921403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot12ju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=667-677&author=J.+Gilauthor=G.+Peters&title=Regulation+of+the+INK4b-ARF-INK4a+tumour+suppressor+locus%3A+all+for+one+or+one+for+all&doi=10.1038%2Fnrm1987"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the INK4b-ARF-INK4a tumor suppressor locus: all for one or one for all</span></div><div class="casAuthors">Gil, Jesus; Peters, Gordon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">667-677</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The INK4b-ARF-INK4a locus encodes two members of the INK4 family of cyclin-dependent kinase inhibitors, p15INK4b and p16INK4a, and a completely unrelated protein, known as ARF.  All three products participate in major tumor suppressor networks that are disabled in human cancer and influence key physiol. processes such as replicative senescence, apoptosis and stem-cell self-renewal.  Transcription from the locus is therefore kept under strict control.  Mounting evidence suggests that although the individual genes can respond independently to pos. and neg. signals in different contexts, the entire locus might be coordinately suppressed by a cis-acting regulatory domain or by the action of Polycomb group repressor complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpReTaXF8IsJ7Vg90H21EOLACvtfcHk0ljTxc6xsJ742w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot12ju7o%253D&md5=b3fbf0f5ea86da57ced65ce9faf7f884</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fnrm1987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1987%26sid%3Dliteratum%253Aachs%26aulast%3DGil%26aufirst%3DJ.%26aulast%3DPeters%26aufirst%3DG.%26atitle%3DRegulation%2520of%2520the%2520INK4b-ARF-INK4a%2520tumour%2520suppressor%2520locus%253A%2520all%2520for%2520one%2520or%2520one%2520for%2520all%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2006%26volume%3D7%26spage%3D667%26epage%3D677%26doi%3D10.1038%2Fnrm1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Semenza, G. L.</span><span> </span><span class="NLM_article-title">Targeting HIF-1 for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">732</span><span class="refDoi"> DOI: 10.1038/nrc1187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrc1187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=13130303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFCiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=721-732&author=G.+L.+Semenza&title=Targeting+HIF-1+for+cancer+therapy&doi=10.1038%2Fnrc1187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HIF-1 for cancer therapy</span></div><div class="casAuthors">Semenza, Gregg L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">721-732</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes that are involved in crucial aspects of cancer biol., including angiogenesis, cell survival, glucose metab. and invasion.  Intratumoral hypoxia and genetic alterations can lead to HIF-1α overexpression, which has been assocd. with increased patient mortality in several cancer types.  In preclin. studies, inhibition of HIF-1 activity has marked effects on tumor growth.  Efforts are underway to identify inhibitors of HIF-1 and to test their efficacy as anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9RRo9WvLxN7Vg90H21EOLACvtfcHk0ljTxc6xsJ742w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFCiu70%253D&md5=099f0fe5908dc1aae0c177a8aa530047</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnrc1187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1187%26sid%3Dliteratum%253Aachs%26aulast%3DSemenza%26aufirst%3DG.%2BL.%26atitle%3DTargeting%2520HIF-1%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D721%26epage%3D732%26doi%3D10.1038%2Fnrc1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Wu, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teng, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K. J.</span><span> </span><span class="NLM_article-title">K63-polyubiquitinated HAUSP deubiquitinates HIF-1alpha and dictates H3K56 acetylation promoting hypoxia-induced tumour progression</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">13644</span><span class="refDoi"> DOI: 10.1038/ncomms13644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fncomms13644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27934968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFamsLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13644&author=H.+T.+Wuauthor=Y.+C.+Kuoauthor=J.+J.+Hungauthor=C.+H.+Huangauthor=W.+Y.+Chenauthor=T.+Y.+Chouauthor=Y.+Chenauthor=Y.+J.+Chenauthor=Y.+J.+Chenauthor=W.+C.+Chengauthor=S.+C.+Tengauthor=K.+J.+Wu&title=K63-polyubiquitinated+HAUSP+deubiquitinates+HIF-1alpha+and+dictates+H3K56+acetylation+promoting+hypoxia-induced+tumour+progression&doi=10.1038%2Fncomms13644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">K63-polyubiquitinated HAUSP deubiquitinates HIF-1α and dictates H3K56 acetylation promoting hypoxia-induced tumour progression</span></div><div class="casAuthors">Wu, Han-Tsang; Kuo, Yi-Chih; Hung, Jung-Jyh; Huang, Chi-Hung; Chen, Wei-Yi; Chou, Teh-Ying; Chen, Yeh; Chen, Yi-Ju; Chen, Yu-Ju; Cheng, Wei-Chung; Teng, Shu-Chun; Wu, Kou-Juey</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13644</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Intratumoral hypoxia induces HIF-1α and promotes tumor progression, metastasis and treatment resistance.  HIF-1α stability is regulated by VHL-E3 ligase-mediated ubiquitin-dependent degrdn.; however, the hypoxia-regulated deubiquitinase that stabilizes HIF-1α has not been identified.  Here we report that HAUSP (USP7) deubiquitinase deubiquitinates HIF-1α to increase its stability, induce epithelial-mesenchymal transition and promote metastasis.  Hypoxia induces K63-linked polyubiquitinated HAUSP at lysine 443 to enhance its functions.  Knockdown of HAUSP decreases acetylation of histone 3 lysine 56 (H3K56Ac).  K63-polyubiquitinated HAUSP interacts with a ubiquitin receptor CBP to specifically mediate H3K56 acetylation.  ChIP-seq anal. of HAUSP and HIF-1α binding reveals two motifs responsive to hypoxia.  HectH9 is the E3 ligase for HAUSP and a prognostic marker together with HIF-1α.  This report demonstrates that hypoxia-induced K63-polyubiquitinated HAUSP deubiquitinates HIF-1α and causes CBP-mediated H3K56 acetylation on HIF-1α target gene promoters to promote EMT/metastasis, further defining HAUSP as a therapeutic target in hypoxia-induced tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx_5DEryb7CbVg90H21EOLACvtfcHk0lgF5oRPIusryg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFamsLbL&md5=3d29d0076e11b871e37f79d1a18d742a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fncomms13644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13644%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%2BT.%26aulast%3DKuo%26aufirst%3DY.%2BC.%26aulast%3DHung%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DW.%2BY.%26aulast%3DChou%26aufirst%3DT.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DCheng%26aufirst%3DW.%2BC.%26aulast%3DTeng%26aufirst%3DS.%2BC.%26aulast%3DWu%26aufirst%3DK.%2BJ.%26atitle%3DK63-polyubiquitinated%2520HAUSP%2520deubiquitinates%2520HIF-1alpha%2520and%2520dictates%2520H3K56%2520acetylation%2520promoting%2520hypoxia-induced%2520tumour%2520progression%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13644%26doi%3D10.1038%2Fncomms13644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span> </span><span class="NLM_article-title">Deubiquitination of Ci/Gli by Usp7/HAUSP regulates hedgehog signaling</span> <span class="citation_source-journal">Dev. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1016/j.devcel.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.devcel.2015.05.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=58-72&author=Z.+Zhouauthor=X.+Yaoauthor=S.+Liauthor=Y.+Xiongauthor=X.+Dongauthor=Y.+Zhaoauthor=J.+Jiangauthor=Q.+Zhang&title=Deubiquitination+of+Ci%2FGli+by+Usp7%2FHAUSP+regulates+hedgehog+signaling&doi=10.1016%2Fj.devcel.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DDeubiquitination%2520of%2520Ci%252FGli%2520by%2520Usp7%252FHAUSP%2520regulates%2520hedgehog%2520signaling%26jtitle%3DDev.%2520Cell%26date%3D2015%26volume%3D34%26spage%3D58%26epage%3D72%26doi%3D10.1016%2Fj.devcel.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Liou, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storz, P.</span><span> </span><span class="NLM_article-title">Reactive oxygen species in cancer</span> <span class="citation_source-journal">Free Radical Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span><span class="refDoi"> DOI: 10.3109/10715761003667554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.3109%2F10715761003667554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20370557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVyhu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2010&pages=479-496&author=G.+Y.+Liouauthor=P.+Storz&title=Reactive+oxygen+species+in+cancer&doi=10.3109%2F10715761003667554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species in cancer</span></div><div class="casAuthors">Liou, Geou-Yarh; Storz, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">479-496</span>CODEN:
                <span class="NLM_cas:coden">FRARER</span>;
        ISSN:<span class="NLM_cas:issn">1071-5762</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Elevated rates of reactive oxygen species (ROS) have been detected in almost all cancers, where they promote many aspects of tumor development and progression.  However, tumor cells also express increased levels of antioxidant proteins to detoxify from ROS, suggesting that a delicate balance of intracellular ROS levels is required for cancer cell function.  Further, the radical generated, the location of its generation, as well as the local concn. is important for the cellular functions of ROS in cancer.  A challenge for novel therapeutic strategies will be the fine tuning of intracellular ROS signalling to effectively deprive cells from ROS-induced tumor promoting events, towards tipping the balance to ROS-induced apoptotic signalling.  Alternatively, therapeutic antioxidants may prevent early events in tumor development, where ROS are important.  However, to effectively target cancer cells specific ROS-sensing signalling pathways that mediate the diverse stress-regulated cellular functions need to be identified.  This review discusses the generation of ROS within tumor cells, their detoxification, their cellular effects, as well as the major signalling cascades they utilize, but also provides an outlook on their modulation in therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwtVSe56knA7Vg90H21EOLACvtfcHk0lgF5oRPIusryg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVyhu78%253D&md5=74d17b013387120ba165302bd7c282df</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.3109%2F10715761003667554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10715761003667554%26sid%3Dliteratum%253Aachs%26aulast%3DLiou%26aufirst%3DG.%2BY.%26aulast%3DStorz%26aufirst%3DP.%26atitle%3DReactive%2520oxygen%2520species%2520in%2520cancer%26jtitle%3DFree%2520Radical%2520Res.%26date%3D2010%26volume%3D44%26spage%3D479%26epage%3D496%26doi%3D10.3109%2F10715761003667554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Bouwman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span><span class="refDoi"> DOI: 10.1038/nrc3342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrc3342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22918414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GhsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=587-598&author=P.+Bouwmanauthor=J.+Jonkers&title=The+effects+of+deregulated+DNA+damage+signalling+on+cancer+chemotherapy+response+and+resistance&doi=10.1038%2Fnrc3342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance</span></div><div class="casAuthors">Bouwman, Peter; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">587-598</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumors with specific DNA repair defects can be completely dependent on back-up DNA repair pathways for their survival.  This dependence can be exploited therapeutically to induce synthetic lethality in tumor cells.  For instance, homologous recombination (HR)-deficient tumors can be effectively targeted by DNA double-strand break-inducing agents.  However, not all HR-defective tumors respond equally well to this type of therapy.  Tumor cells may acquire resistance by invoking biochem. mechanisms that reduce drug action or by acquiring addnl. alterations in DNA damage response pathways.  A thorough understanding of these processes is important for predicting treatment response and for the development of novel treatment strategies that prevent the emergence of therapy-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSTPQO2sEE7Vg90H21EOLACvtfcHk0ljd31TILbmAoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GhsLnN&md5=176b61bc1ce31c537067eae10417bf90</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnrc3342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3342%26sid%3Dliteratum%253Aachs%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DThe%2520effects%2520of%2520deregulated%2520DNA%2520damage%2520signalling%2520on%2520cancer%2520chemotherapy%2520response%2520and%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D587%26epage%3D598%26doi%3D10.1038%2Fnrc3342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majid, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brickner, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dango, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosammaparast, N.</span><span> </span><span class="NLM_article-title">Noncanonical regulation of alkylation damage resistance by the OTUD4 deubiquitinase</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1687</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span><span class="refDoi"> DOI: 10.15252/embj.201490497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.15252%2Fembj.201490497" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=1687-1703&author=Y.+Zhaoauthor=M.+C.+Majidauthor=J.+M.+Sollauthor=J.+R.+Bricknerauthor=S.+Dangoauthor=N.+Mosammaparast&title=Noncanonical+regulation+of+alkylation+damage+resistance+by+the+OTUD4+deubiquitinase&doi=10.15252%2Fembj.201490497"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.15252%2Fembj.201490497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201490497%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMajid%26aufirst%3DM.%2BC.%26aulast%3DSoll%26aufirst%3DJ.%2BM.%26aulast%3DBrickner%26aufirst%3DJ.%2BR.%26aulast%3DDango%26aufirst%3DS.%26aulast%3DMosammaparast%26aufirst%3DN.%26atitle%3DNoncanonical%2520regulation%2520of%2520alkylation%2520damage%2520resistance%2520by%2520the%2520OTUD4%2520deubiquitinase%26jtitle%3DEMBO%2520J.%26date%3D2015%26volume%3D34%26spage%3D1687%26epage%3D1703%26doi%3D10.15252%2Fembj.201490497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrasco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulcinniti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodrasov, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingsbury, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minvielle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">358</span><span class="refDoi"> DOI: 10.1016/j.ccr.2012.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.ccr.2012.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22975377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlCju77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=345-358&author=D.+Chauhanauthor=Z.+Tianauthor=B.+Nicholsonauthor=K.+G.+Kumarauthor=B.+Zhouauthor=R.+Carrascoauthor=J.+L.+McDermottauthor=C.+A.+Leachauthor=M.+Fulcinnitiauthor=M.+P.+Kodrasovauthor=J.+Weinstockauthor=W.+D.+Kingsburyauthor=T.+Hideshimaauthor=P.+K.+Shahauthor=S.+Minvielleauthor=M.+Altunauthor=B.+M.+Kesslerauthor=R.+Orlowskiauthor=P.+Richardsonauthor=N.+Munshiauthor=K.+C.+Anderson&title=A+small+molecule+inhibitor+of+ubiquitin-specific+protease-7+induces+apoptosis+in+multiple+myeloma+cells+and+overcomes+bortezomib+resistance&doi=10.1016%2Fj.ccr.2012.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance</span></div><div class="casAuthors">Chauhan, Dharminder; Tian, Ze; Nicholson, Benjamin; Kumar, K. G. Suresh; Zhou, Bin; Carrasco, Ruben; McDermott, Jeffrey L.; Leach, Craig A.; Fulcinniti, Mariaterresa; Kodrasov, Matthew P.; Weinstock, Joseph; Kingsbury, William D.; Hideshima, Teru; Shah, Parantu K.; Minvielle, Stephane; Altun, Mikael; Kessler, Benedikt M.; Orlowski, Robert; Richardson, Paul; Munshi, Nikhil; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-358</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility.  Here, we show that P5091 is an inhibitor of deubiquitylating enzyme USP7, which induces apoptosis in MM cells resistant to conventional and bortezomib therapies.  Biochem. and genetic studies show that blockade of HDM2 and p21 abrogates P5091-induced cytotoxicity.  In animal tumor model studies, P5091 is well tolerated, inhibits tumor growth, and prolongs survival.  Combining P5091 with lenalidomide, HDAC inhibitor SAHA, or dexamethasone triggers synergistic anti-MM activity.  Our preclin. study therefore supports clin. evaluation of USP7 inhibitor, alone or in combination, as a potential MM therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVKqojA-HcmLVg90H21EOLACvtfcHk0ljd31TILbmAoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlCju77F&md5=9c70da62de17591850c1e8195d5f97f7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DK.%2BG.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DCarrasco%26aufirst%3DR.%26aulast%3DMcDermott%26aufirst%3DJ.%2BL.%26aulast%3DLeach%26aufirst%3DC.%2BA.%26aulast%3DFulcinniti%26aufirst%3DM.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DWeinstock%26aufirst%3DJ.%26aulast%3DKingsbury%26aufirst%3DW.%2BD.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DShah%26aufirst%3DP.%2BK.%26aulast%3DMinvielle%26aufirst%3DS.%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26aulast%3DOrlowski%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520small%2520molecule%2520inhibitor%2520of%2520ubiquitin-specific%2520protease-7%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%2520and%2520overcomes%2520bortezomib%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D345%26epage%3D358%26doi%3D10.1016%2Fj.ccr.2012.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samanta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatti, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodrasov, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butt, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albelda, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Ubiquitin-specific Protease-7 inhibition impairs Tip60-dependent Foxp3+ T-regulatory cell function and promotes antitumor immunity</span> <span class="citation_source-journal">EBioMedicine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/j.ebiom.2016.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.ebiom.2016.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27769803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC2srltVWmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=99-112&author=L.+Wangauthor=S.+Kumarauthor=S.+Dahiyaauthor=F.+Wangauthor=J.+Wuauthor=K.+Newickauthor=R.+Hanauthor=A.+Samantaauthor=U.+H.+Beierauthor=T.+Akimovaauthor=T.+R.+Bhattiauthor=B.+Nicholsonauthor=M.+P.+Kodrasovauthor=S.+Agarwalauthor=D.+E.+Sternerauthor=W.+Guauthor=J.+Weinstockauthor=T.+R.+Buttauthor=S.+M.+Albeldaauthor=W.+W.+Hancock&title=Ubiquitin-specific+Protease-7+inhibition+impairs+Tip60-dependent+Foxp3%2B+T-regulatory+cell+function+and+promotes+antitumor+immunity&doi=10.1016%2Fj.ebiom.2016.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor Immunity</span></div><div class="casAuthors">Wang Liqing; Dahiya Satinder; Han Rongxiang; Samanta Arabinda; Akimova Tatiana; Bhatti Tricia R; Kumar Suresh; Wang Feng; Wu Jian; Nicholson Benjamin; Kodrasov Mathew P; Agarwal Saket; Sterner David E; Weinstock Joseph; Butt Tauseef R; Newick Kheng; Albelda Steven M; Beier Ulf H; Gu Wei; Hancock Wayne W</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">99-112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Foxp3+ T-regulatory (Treg) cells are known to suppress protective host immune responses to a wide variety of solid tumors, but their therapeutic targeting is largely restricted to their transient depletion or "secondary" modulation, e.g. using anti-CTLA-4 monoclonal antibody.  Our ongoing studies of the post-translational modifications that regulate Foxp3 demonstrated that the histone/protein acetyltransferase, Tip60, plays a dominant role in promoting acetylation, dimerization and function in Treg cells.  We now show that the ubiquitin-specific protease, Usp7, controls Treg function largely by stabilizing the expression and promoting the multimerization of Tip60 and Foxp3.  Genetic or pharmacologic targeting of Usp7 impairs Foxp3+ Treg suppressive functions, while conventional T cell responses remain intact.  As a result, pharmacologic inhibitors of Usp7 can limit tumor growth in immunocompetent mice, and promote the efficacy of antitumor vaccines and immune checkpoint therapy with anti-PD1 monoclonal antibody in murine models.  Hence, pharmacologic therapy with Usp7 inhibitors may have an important role in future cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRx7G_irn6DIPtos8R3JUhXfW6udTcc2ebBISwSfIcoYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srltVWmsQ%253D%253D&md5=f7456d0d7eddd4188ef4e6e2f3e8d691</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2016.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2016.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DDahiya%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DNewick%26aufirst%3DK.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DSamanta%26aufirst%3DA.%26aulast%3DBeier%26aufirst%3DU.%2BH.%26aulast%3DAkimova%26aufirst%3DT.%26aulast%3DBhatti%26aufirst%3DT.%2BR.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DSterner%26aufirst%3DD.%2BE.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DWeinstock%26aufirst%3DJ.%26aulast%3DButt%26aufirst%3DT.%2BR.%26aulast%3DAlbelda%26aufirst%3DS.%2BM.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DUbiquitin-specific%2520Protease-7%2520inhibition%2520impairs%2520Tip60-dependent%2520Foxp3%252B%2520T-regulatory%2520cell%2520function%2520and%2520promotes%2520antitumor%2520immunity%26jtitle%3DEBioMedicine%26date%3D2016%26volume%3D13%26spage%3D99%26epage%3D112%26doi%3D10.1016%2Fj.ebiom.2016.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Fan, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasudevan, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojas, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shohet, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuchtern, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span> </span><span class="NLM_article-title">USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis</span> <span class="citation_source-journal">Cell Death Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">e867</span><span class="refDoi"> DOI: 10.1038/cddis.2013.400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fcddis.2013.400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24136231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Olu77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=e867&author=Y.+H.+Fanauthor=J.+Chengauthor=S.+A.+Vasudevanauthor=J.+Douauthor=H.+Zhangauthor=R.+H.+Patelauthor=I.+T.+Maauthor=Y.+Rojasauthor=Y.+Zhaoauthor=Y.+Yuauthor=H.+Zhangauthor=J.+M.+Shohetauthor=J.+G.+Nuchternauthor=E.+S.+Kimauthor=J.+Yang&title=USP7+inhibitor+P22077+inhibits+neuroblastoma+growth+via+inducing+p53-mediated+apoptosis&doi=10.1038%2Fcddis.2013.400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis</span></div><div class="casAuthors">Fan, Y.-H.; Cheng, J.; Vasudevan, S. A.; Dou, J.; Zhang, H.; Patel, R. H.; Ma, I. T.; Rojas, Y.; Zhao, Y.; Yu, Y.; Zhang, H.; Shohet, J. M.; Nuchtern, J. G.; Kim, E. S.; Yang, J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">e867</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma (NB) is a common pediatric cancer and contributes to more than 15% of all pediatric cancer-related deaths.  Unlike adult tumors, recurrent somatic mutations in NB, such as tumor protein 53 (p53) mutations, occur with relative paucity.  In addn., p53 downstream function is intact in NB cells with wild-type p53, suggesting that reactivation of p53 may be a viable therapeutic strategy for NB treatment.  Herein, we report that the ubiquitin-specific protease 7 (USP7) inhibitor, P22077, potently induces apoptosis in NB cells with an intact USP7-HDM2-p53 axis but not in NB cells with mutant p53 or without human homolog of MDM2 (HDM2) expression.  In this study, we found that P22077 stabilized p53 by inducing HDM2 protein degrdn. in NB cells.  P22077 also significantly augmented the cytotoxic effects of doxorubicin (Dox) and etoposide (VP-16) in NB cells with an intact USP7-HDM2-p53 axis.  Moreover, P22077 was found to be able to sensitize chemoresistant LA-N-6 NB cells to chemotherapy.  In an in vivo orthotopic NB mouse model, P22077 significantly inhibited the xenograft growth of three NB cell lines.  Database anal. of NB patients shows that high expression of USP7 significantly predicts poor outcomes.  Together, our data strongly suggest that targeting USP7 is a novel concept in the treatment of NB.  USP7-specific inhibitors like P22077 may serve not only as a stand-alone therapy but also as an effective adjunct to current chemotherapeutic regimens for treating NB with an intact USP7-HDM2-p53 axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsoNqHcbJCuLVg90H21EOLACvtfcHk0lg46BBr4PX3ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Olu77J&md5=cd91e66041a54477fe081914da560a22</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.400%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DY.%2BH.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DVasudevan%26aufirst%3DS.%2BA.%26aulast%3DDou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPatel%26aufirst%3DR.%2BH.%26aulast%3DMa%26aufirst%3DI.%2BT.%26aulast%3DRojas%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DShohet%26aufirst%3DJ.%2BM.%26aulast%3DNuchtern%26aufirst%3DJ.%2BG.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DUSP7%2520inhibitor%2520P22077%2520inhibits%2520neuroblastoma%2520growth%2520via%2520inducing%2520p53-mediated%2520apoptosis%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26spage%3De867%26doi%3D10.1038%2Fcddis.2013.400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Qin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span> </span><span class="NLM_article-title">CDDO-Me reveals USP7 as a novel target in ovarian cancer cells</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">77096</span><span class="NLM_x">–</span> <span class="NLM_lpage">77109</span><span class="refDoi"> DOI: 10.18632/oncotarget.12801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.18632%2Foncotarget.12801" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=77096-77109&author=D.+Qinauthor=W.+Wangauthor=H.+Leiauthor=H.+Luoauthor=H.+Caiauthor=C.+Tangauthor=Y.+Wuauthor=Y.+Wangauthor=J.+Jinauthor=W.+Xiaoauthor=T.+Wangauthor=C.+Maauthor=H.+Xuauthor=J.+Zhangauthor=F.+Gaoauthor=Y.+L.+Wu&title=CDDO-Me+reveals+USP7+as+a+novel+target+in+ovarian+cancer+cells&doi=10.18632%2Foncotarget.12801"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12801%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DCDDO-Me%2520reveals%2520USP7%2520as%2520a%2520novel%2520target%2520in%2520ovarian%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D77096%26epage%3D77109%26doi%3D10.18632%2Foncotarget.12801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span> </span><span class="NLM_article-title">Expression of USP7 and MARCH7 is correlated with poor prognosis in epithelial ovarian cancer</span> <span class="citation_source-journal">Tohoku J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">239</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span><span class="refDoi"> DOI: 10.1620/tjem.239.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1620%2Ftjem.239.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27302477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC2s7gtlWhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=239&publication_year=2016&pages=165-175&author=L.+Zhangauthor=H.+Wangauthor=L.+Tianauthor=H.+Li&title=Expression+of+USP7+and+MARCH7+is+correlated+with+poor+prognosis+in+epithelial+ovarian+cancer&doi=10.1620%2Ftjem.239.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of USP7 and MARCH7 Is Correlated with Poor Prognosis in Epithelial Ovarian Cancer</span></div><div class="casAuthors">Zhang Li; Wang Hua; Tian Lin; Li Haixia</div><div class="citationInfo"><span class="NLM_cas:title">The Tohoku journal of experimental medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">239</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epithelial ovarian cancer (EOC) is one of the worst malignancies in females with poor overall survival due to the rapid metastasis and the absence of ideal biomarkers.  Ubiquitin-specific protease 7 (USP7), an important deubiquitinating enzyme, was reported to be upregulated in several cancers, including liver, prostate and colon cancers.  Membrane associated RING-CH protein 7 (MARCH7) belongs to the member of the E3 ubiquitin ligases.  In addition, MARCH7 regulates T cell proliferation and the neuronal development and participates in the membrane trafficking and protein degradation.  Importantly, MARCH7 itself is ubiquitinated and acts as a potential substrate of USP7.  However, the roles of USP7 and MARCH7 in EOC remain to be investigated.  We collected 121 EOC patients and analyzed the expression levels of USP7 and MARCH7 in tumor tissues with immunohistochemical staining.  We found that the high expression of the two proteins was correlated with lymph node metastasis in EOC patients.  Univariate and multivariate analyses revealed that the patients with high expression of the two proteins showed poorer prognosis compared with other patients.  Subsequently, using SKOV3 human ovarian adenocarcinoma cells, we showed that either USP7 or MARCH7 enhanced the proliferation and invasion abilities.  Moreover, USP7 could regulate the expression levels of E-cadherin and β-catenin through the MARCH7 signaling pathway.  Our findings indicate that USP7 and MARCH7 are involved in the progression of EOC.  In conclusion, analyzing the expression of USP7 and MARCH7 has high prognostic value in predicting EOC prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREyDgJgIFkExjv2lLSLOxFfW6udTcc2eZ-peITVo420Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7gtlWhtg%253D%253D&md5=e12b5798bb6d224a1a955b6d4e5fedff</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1620%2Ftjem.239.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1620%252Ftjem.239.165%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DExpression%2520of%2520USP7%2520and%2520MARCH7%2520is%2520correlated%2520with%2520poor%2520prognosis%2520in%2520epithelial%2520ovarian%2520cancer%26jtitle%3DTohoku%2520J.%2520Exp.%2520Med.%26date%3D2016%26volume%3D239%26spage%3D165%26epage%3D175%26doi%3D10.1620%2Ftjem.239.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span> </span><span class="NLM_article-title">Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">2205</span><span class="NLM_x">–</span> <span class="NLM_lpage">2220</span><span class="refDoi"> DOI: 10.1172/JCI85747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1172%2FJCI85747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27183383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FgtVChuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2016&pages=2205-2220&author=Q.+Wangauthor=S.+Maauthor=N.+Songauthor=X.+Liauthor=L.+Liuauthor=S.+Yangauthor=X.+Dingauthor=L.+Shanauthor=X.+Zhouauthor=D.+Suauthor=Y.+Wangauthor=Q.+Zhangauthor=X.+Liuauthor=N.+Yuauthor=K.+Zhangauthor=Y.+Shangauthor=Z.+Yaoauthor=L.+Shi&title=Stabilization+of+histone+demethylase+PHF8+by+USP7+promotes+breast+carcinogenesis&doi=10.1172%2FJCI85747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis</span></div><div class="casAuthors">Wang Qian; Ma Shuai; Song Nan; Li Xin; Liu Ling; Yang Shangda; Ding Xiang; Shan Lin; Zhou Xing; Su Dongxue; Wang Yue; Zhang Qi; Liu Xinhua; Yu Na; Zhang Kai; Shang Yongfeng; Yao Zhi; Shi Lei</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2205-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The histone demethylase PHF8 has been implicated in multiple pathological disorders, including X-linked mental retardation and tumorigenesis.  However, it is not clear how the abundance and function of PHF8 are regulated.  Here, we report that PHF8 physically associates with the deubiquitinase USP7.  Specifically, we demonstrated that USP7 promotes deubiquitination and stabilization of PHF8, leading to the upregulation of a group of genes, including cyclin A2, that are critical for cell growth and proliferation.  The USP7-encoding gene was also transcriptionally regulated by PHF8, via positive feedback.  USP7 was overexpressed in breast carcinomas, and the level of expression positively correlated with expression of PHF8 and cyclin A2 and with the histological grade of breast cancer.  We showed that USP7 promotes breast carcinogenesis by stabilizing PHF8 and upregulating cyclin A2 and that the interaction between USP7 and PHF8 is augmented during DNA damage.  Moreover, USP7-promoted PHF8 stabilization conferred cellular resistance to genotoxic insults and was required for the recruitment of BLM and KU70, which are both essential for DNA double-strand break repair.  Our study mechanistically links USP7 to epigenetic regulation and DNA repair.  Moreover, these data support the pursuit of USP7 and PHF8 as potential targets for breast cancer intervention, especially in combination with chemo- or radiotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcuqLndLpKaOLt9HypzAgQfW6udTcc2eaCZR0UIMVFkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FgtVChuw%253D%253D&md5=b4704b72507d1926c48b5c6da8d868bf</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1172%2FJCI85747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI85747%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DShan%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DShang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DStabilization%2520of%2520histone%2520demethylase%2520PHF8%2520by%2520USP7%2520promotes%2520breast%2520carcinogenesis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2016%26volume%3D126%26spage%3D2205%26epage%3D2220%26doi%3D10.1172%2FJCI85747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Zhao, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, F. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J. Y.</span><span> </span><span class="NLM_article-title">USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1721</span><span class="NLM_x">–</span> <span class="NLM_lpage">1729</span><span class="refDoi"> DOI: 10.1007/s13277-014-2773-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs13277-014-2773-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25519684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOrs7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=1721-1729&author=G.+Y.+Zhaoauthor=Z.+W.+Linauthor=C.+L.+Luauthor=J.+Guauthor=Y.+F.+Yuanauthor=F.+K.+Xuauthor=R.+H.+Liuauthor=D.+Geauthor=J.+Y.+Ding&title=USP7+overexpression+predicts+a+poor+prognosis+in+lung+squamous+cell+carcinoma+and+large+cell+carcinoma&doi=10.1007%2Fs13277-014-2773-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma</span></div><div class="casAuthors">Zhao, Guang-Yin; Lin, Zong-Wu; Lu, Chun-Lai; Gu, Jie; Yuan, Yun-Feng; Xu, Feng-Kai; Liu, Rong-Hua; Ge, Di; Ding, Jian-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1721-1729</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In non-small cell lung cancer (NSCLC), both USP7 expression and p53 gene status were reported to be an indicator of poor prognosis in adenocarcinoma patients; however, its roles and mechanisms in lung squamous cell carcinoma and large cell carcinoma need to be clarified.  The USP7 expression was examd. in NSCLC tumors (excluding adenocarcinoma), their corresponding non-tumorous tissues, and NSCLC cells.  Then, the prognostic role of USP7 was analyzed in 110 NSCLC samples (excluding the adenocarcinoma).  Finally, the roles and mechanisms of USP7 in the proliferation, metastasis, and invasion of a NSCLC cell were assessed using a specific vshRNA.  The USP7 expression was higher in NSCLC tissues compared to non-tumorous samples, accordingly, the high level of USP7 was detected in NSCLC cell lines compared with HBE cell.  After the USP7 downregulation, the H460 cells exhibited decreased metastasis/invasion in vitro and in vivo.  The preliminary mechanism study indicated overexpression of USP7 might regulate the p53-MDM2 pathway by inducing the MDM2 de-ubiquitination and subsequent stabilization, which resulted in the upregulation of the Bad phosphorylation.  Addnl., we also found that USP7 might induce cell epithelial-mesenchymal transition to enhance the cell invasive ability.  Clin., USP7 overexpression significantly correlated with malignant phenotype.  Furthermore, the 5-yr overall survival in patients with USP7low was higher than that of USP7high.  Multivariate anal. showed USP7 overexpression was an independent prognostic marker for these cancers.  USP7 overexpression may regulate the survival and invasive properties of squamous cell carcinoma and large cell carcinoma cells, and may serve as a mol. target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF7saboNrUWrVg90H21EOLACvtfcHk0lj1KaLuwlzjFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOrs7fI&md5=4bd47ff37c19acbaddb3c0b6940a71e6</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs13277-014-2773-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-014-2773-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%2BY.%26aulast%3DLin%26aufirst%3DZ.%2BW.%26aulast%3DLu%26aufirst%3DC.%2BL.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DY.%2BF.%26aulast%3DXu%26aufirst%3DF.%2BK.%26aulast%3DLiu%26aufirst%3DR.%2BH.%26aulast%3DGe%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DJ.%2BY.%26atitle%3DUSP7%2520overexpression%2520predicts%2520a%2520poor%2520prognosis%2520in%2520lung%2520squamous%2520cell%2520carcinoma%2520and%2520large%2520cell%2520carcinoma%26jtitle%3DTumor%2520Biol.%26date%3D2015%26volume%3D36%26spage%3D1721%26epage%3D1729%26doi%3D10.1007%2Fs13277-014-2773-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Samkari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packer, R.</span><span> </span><span class="NLM_article-title">Shh inhibitors for the treatment of medulloblastoma</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">763</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span><span class="refDoi"> DOI: 10.1586/14737175.2015.1052796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1586%2F14737175.2015.1052796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26027634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKntbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=763-770&author=A.+Samkariauthor=J.+Whiteauthor=R.+Packer&title=Shh+inhibitors+for+the+treatment+of+medulloblastoma&doi=10.1586%2F14737175.2015.1052796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">SHH inhibitors for the treatment of medulloblastoma</span></div><div class="casAuthors">Samkari, Ayman; White, Jason; Packer, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">763-770</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Medulloblastoma is the most common malignant brain tumor of childhood.  It is currently stratified into four mol. variants through the advances in transcriptional profiling.  They include: wingless, sonic hedgehog (SHH), Group III, and Group IV.  The SHH group is characterized by constitutive activation of the SHH signaling pathway, and genetically characterized by mutations in patched homolog 1 (PTCH1) or other downstream pathway mutations.  SHH inhibitors have become of great clin. interest in treating SHH-driven medulloblastoma.  Many inhibitors are currently in different stages of development, some already approved for other SHH-driven cancers, such as basal cell carcinoma.  In vitro and in vivo medulloblastoma studies have shown efficacy and these findings have been translated into Phase I and II clin. trials.  In this review, we present an overview of SHH medulloblastoma, as well as a discussion of currently available SHH inhibitors, and the challenges assocd. with their use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ9NSFcovDXbVg90H21EOLACvtfcHk0lj1KaLuwlzjFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKntbfO&md5=3a5af11e9f2cb451e84908bbf4e25bf8</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1586%2F14737175.2015.1052796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2015.1052796%26sid%3Dliteratum%253Aachs%26aulast%3DSamkari%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DPacker%26aufirst%3DR.%26atitle%3DShh%2520inhibitors%2520for%2520the%2520treatment%2520of%2520medulloblastoma%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2015%26volume%3D15%26spage%3D763%26epage%3D770%26doi%3D10.1586%2F14737175.2015.1052796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Woo, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goletz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlienger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coukos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">June, C. H.</span><span> </span><span class="NLM_article-title">Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">4766</span><span class="NLM_x">–</span> <span class="NLM_lpage">4772</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4766-4772&author=E.+Y.+Wooauthor=C.+S.+Chuauthor=T.+J.+Goletzauthor=K.+Schliengerauthor=H.+Yehauthor=G.+Coukosauthor=S.+C.+Rubinauthor=L.+R.+Kaiserauthor=C.+H.+June&title=Regulatory+CD4%28%2B%29CD25%28%2B%29+T+cells+in+tumors+from+patients+with+early-stage+non-small+cell+lung+cancer+and+late-stage+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DE.%2BY.%26aulast%3DChu%26aufirst%3DC.%2BS.%26aulast%3DGoletz%26aufirst%3DT.%2BJ.%26aulast%3DSchlienger%26aufirst%3DK.%26aulast%3DYeh%26aufirst%3DH.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DRubin%26aufirst%3DS.%2BC.%26aulast%3DKaiser%26aufirst%3DL.%2BR.%26aulast%3DJune%26aufirst%3DC.%2BH.%26atitle%3DRegulatory%2520CD4%2528%252B%2529CD25%2528%252B%2529%2520T%2520cells%2520in%2520tumors%2520from%2520patients%2520with%2520early-stage%2520non-small%2520cell%2520lung%2520cancer%2520and%2520late-stage%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4766%26epage%3D4772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Petersen, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campa, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperlazza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conlon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpole, D. H.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patz, E. F.,  Jr.</span><span> </span><span class="NLM_article-title">Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">2866</span><span class="NLM_x">–</span> <span class="NLM_lpage">2872</span><span class="refDoi"> DOI: 10.1002/cncr.22282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1002%2Fcncr.22282" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=2866-2872&author=R.+P.+Petersenauthor=M.+J.+Campaauthor=J.+Sperlazzaauthor=D.+Conlonauthor=M.+B.+Joshiauthor=D.+H.+Harpoleauthor=E.+F.+Patz&title=Tumor+infiltrating+Foxp3%2B+regulatory+T-cells+are+associated+with+recurrence+in+pathologic+stage+I+NSCLC+patients&doi=10.1002%2Fcncr.22282"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fcncr.22282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.22282%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DR.%2BP.%26aulast%3DCampa%26aufirst%3DM.%2BJ.%26aulast%3DSperlazza%26aufirst%3DJ.%26aulast%3DConlon%26aufirst%3DD.%26aulast%3DJoshi%26aufirst%3DM.%2BB.%26aulast%3DHarpole%26aufirst%3DD.%2BH.%26aulast%3DPatz%26aufirst%3DE.%2BF.%26atitle%3DTumor%2520infiltrating%2520Foxp3%252B%2520regulatory%2520T-cells%2520are%2520associated%2520with%2520recurrence%2520in%2520pathologic%2520stage%2520I%2520NSCLC%2520patients%26jtitle%3DCancer%26date%3D2006%26volume%3D107%26spage%3D2866%26epage%3D2872%26doi%3D10.1002%2Fcncr.22282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">O’Callaghan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rexhepaj, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gately, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coate, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K. J.</span><span> </span><span class="NLM_article-title">Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1762</span><span class="NLM_x">–</span> <span class="NLM_lpage">1772</span><span class="refDoi"> DOI: 10.1183/13993003.00176-2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1183%2F13993003.00176-2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26541534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVWhtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=1762-1772&author=D.+S.+O%E2%80%99Callaghanauthor=E.+Rexhepajauthor=K.+Gatelyauthor=L.+Coateauthor=D.+Delaneyauthor=D.+M.+O%E2%80%99Donnellauthor=E.+Kayauthor=F.+O%E2%80%99Connellauthor=W.+M.+Gallagherauthor=K.+J.+O%E2%80%99Byrne&title=Tumour+islet+Foxp3%2B+T-cell+infiltration+predicts+poor+outcome+in+nonsmall+cell+lung+cancer&doi=10.1183%2F13993003.00176-2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer</span></div><div class="casAuthors">O'Callaghan, Dermot S.; Rexhepaj, Elton; Gately, Kathy; Coate, Linda; Delaney, David; O'Donnell, Dearbhaile. M.; Kay, Elaine; O'Connell, Finbarr; Gallagher, William. M.; O'Byrne, Kenneth J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1762-1772</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">The impact of host immunity on outcome in nonsmall cell lung cancer (NSCLC) is controversial.  We examd. the relationship between lymphoid infiltration patterns in NSCLC and prognosis.Tumor- and stroma-infiltrating CD3+, CD8+ and forkhead box P3 (Foxp3)+ T-lymphocytes were identified using immunohistochem. and a novel image anal. algorithm to assess total, cytotoxic and regulatory T-lymphocyte counts, resp., in 196 NSCLC cases.  The median cell count was selected as a cut-point to define patient subgroups and the ratio of the corresponding tumor islet:stroma (TI/S) counts was detd.  There was a pos. assocn. between overall survival and increased CD8+ TI/S ratio (hazard ratio (HR) for death 0.44, p<0.001) but an inverse relationship between Foxp3+ TI/S ratio and overall survival (HR 4.86, p<0.001).  Patients with high CD8+ islet (HR 0.48, p<0.001) and Foxp3+ stromal (HR 0.23, p<0.001) counts had better survival, whereas high CD3+ and CD8+ stromal counts and high Foxp3+ islet infiltration conferred a worse survival (HR 1.55, 2.19 and 3.14, resp.).  By multivariate anal., a high CD8+ TI/S ratio conferred an improved survival (HR 0.48, p=0.002) but a high Foxp3+ TI/S ratio was assocd. with worse survival (HR 3.91, p<0.001).  Microlocalisation of infiltrating T-lymphocytes is a powerful predictor of outcome in resected NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ULB0eO97ALVg90H21EOLACvtfcHk0ljDTokZg42Miw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVWhtbw%253D&md5=aa9d82dc27b34752d108e3213e04ac90</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1183%2F13993003.00176-2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.00176-2014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DD.%2BS.%26aulast%3DRexhepaj%26aufirst%3DE.%26aulast%3DGately%26aufirst%3DK.%26aulast%3DCoate%26aufirst%3DL.%26aulast%3DDelaney%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DD.%2BM.%26aulast%3DKay%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DF.%26aulast%3DGallagher%26aufirst%3DW.%2BM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26atitle%3DTumour%2520islet%2520Foxp3%252B%2520T-cell%2520infiltration%2520predicts%2520poor%2520outcome%2520in%2520nonsmall%2520cell%2520lung%2520cancer%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3D1762%26epage%3D1772%26doi%3D10.1183%2F13993003.00176-2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Z.</span><span> </span><span class="NLM_article-title">Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients</span> <span class="citation_source-journal">Digestion</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1159/000342801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1159%2F000342801" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=329-337&author=Y.+Huangauthor=F.+M.+Wangauthor=T.+Wangauthor=Y.+J.+Wangauthor=Z.+Y.+Zhuauthor=Y.+T.+Gaoauthor=Z.+Du&title=Tumor-infiltrating+FoxP3%2B+Tregs+and+CD8%2B+T+cells+affect+the+prognosis+of+hepatocellular+carcinoma+patients&doi=10.1159%2F000342801"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1159%2F000342801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000342801%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%2BM.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DZhu%26aufirst%3DZ.%2BY.%26aulast%3DGao%26aufirst%3DY.%2BT.%26aulast%3DDu%26aufirst%3DZ.%26atitle%3DTumor-infiltrating%2520FoxP3%252B%2520Tregs%2520and%2520CD8%252B%2520T%2520cells%2520affect%2520the%2520prognosis%2520of%2520hepatocellular%2520carcinoma%2520patients%26jtitle%3DDigestion%26date%3D2012%26volume%3D86%26spage%3D329%26epage%3D337%26doi%3D10.1159%2F000342801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Shou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span> </span><span class="NLM_article-title">Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs: a systematic review and meta-analysis</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">687</span><span class="refDoi"> DOI: 10.1186/s12885-016-2732-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1186%2Fs12885-016-2732-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=687&author=J.+Shouauthor=Z.+Zhangauthor=Y.+Laiauthor=Z.+Chenauthor=J.+Huang&title=Worse+outcome+in+breast+cancer+with+higher+tumor-infiltrating+FOXP3%2B+Tregs%3A+a+systematic+review+and+meta-analysis&doi=10.1186%2Fs12885-016-2732-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1186%2Fs12885-016-2732-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-016-2732-0%26sid%3Dliteratum%253Aachs%26aulast%3DShou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DWorse%2520outcome%2520in%2520breast%2520cancer%2520with%2520higher%2520tumor-infiltrating%2520FOXP3%252B%2520Tregs%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DBMC%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D687%26doi%3D10.1186%2Fs12885-016-2732-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Golovina, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonderheide, R. H.</span><span> </span><span class="NLM_article-title">Regulatory T cells: overcoming suppression of T-cell immunity</span> <span class="citation_source-journal">Cancer J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span><span class="refDoi"> DOI: 10.1097/PPO.0b013e3181eb336d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1097%2FPPO.0b013e3181eb336d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20693845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGnurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=342-347&author=T.+N.+Golovinaauthor=R.+H.+Vonderheide&title=Regulatory+T+cells%3A+overcoming+suppression+of+T-cell+immunity&doi=10.1097%2FPPO.0b013e3181eb336d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory cells: overcoming suppression of T-cell immunity</span></div><div class="casAuthors">Golovina, Tatiana N.; Vonderheide, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">342-347</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Regulatory T cells inhibit cellular immunity and represent an obstacle for the development of cancer immunotherapy.  The understanding of Treg cellular biol. has exponentially increased during the last 10 years, driven primarily by elegant in vivo studies of mouse models systems and in vitro studies of human cells.  Numerous clin. strategies are under active investigation to achieve Treg depletion or inhibition in patients with cancer, including low-dose cyclophosphamide and interleukin-2 or anti-interleukin-2R immunotoxins.  To date, only modest results have been reported in patients.  Our preliminary data suggest that the antihuman CD25 monoclonal daclizumab may be useful as an alternative approach for in vivo Treg depletion, but the mechanism of action of this effect remains to be elucidated.  Certain immune modulatory agents may indirectly affect Tregs in patients with cancer but not necessarily in the desired direction for the therapeutic setting.  More sophisticated techniques that have become available for Treg anal. in patients will assist in this important translational effort.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreGroQIxmYLrVg90H21EOLACvtfcHk0ljDTokZg42Miw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGnurvF&md5=0adf2d5310765517a86ad50685f0811c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1097%2FPPO.0b013e3181eb336d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0b013e3181eb336d%26sid%3Dliteratum%253Aachs%26aulast%3DGolovina%26aufirst%3DT.%2BN.%26aulast%3DVonderheide%26aufirst%3DR.%2BH.%26atitle%3DRegulatory%2520T%2520cells%253A%2520overcoming%2520suppression%2520of%2520T-cell%2520immunity%26jtitle%3DCancer%2520J.%26date%3D2010%26volume%3D16%26spage%3D342%26epage%3D347%26doi%3D10.1097%2FPPO.0b013e3181eb336d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Ireland, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissick, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beilharz, M. W.</span><span> </span><span class="NLM_article-title">The role of regulatory T Cells in mesothelioma</span> <span class="citation_source-journal">Cancer Microenviron.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span><span class="refDoi"> DOI: 10.1007/s12307-012-0100-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs12307-012-0100-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22302659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=165-172&author=D.+J.+Irelandauthor=H.+T.+Kissickauthor=M.+W.+Beilharz&title=The+role+of+regulatory+T+Cells+in+mesothelioma&doi=10.1007%2Fs12307-012-0100-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Regulatory T Cells in Mesothelioma</span></div><div class="casAuthors">Ireland, Demelza J.; Kissick, Haydn T.; Beilharz, Manfred W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Microenvironment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-172</span>CODEN:
                <span class="NLM_cas:coden">CMAICW</span>;
        ISSN:<span class="NLM_cas:issn">1875-2284</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Malignant mesothelioma (MM) appears to be responsive to immunotherapy.  The lack of complete tumor cure as a result of many immunotherapies tested to date suggests that the immune response to MM is complex and multi-parametric.  Regulatory T (Treg) cells are prevalent within murine and human mesotheliomas with their removal shown to result in tumor growth inhibition and the release of anti-tumor effector T cells from immunosuppression.  The targeting of immune checkpoints as treatments for various solid tumors has recently shown promise in clin. settings.  In addn., synergy between chemotherapy and immunotherapy has been demonstrated for many cancers, including mesothelioma.  Here we demonstrate Treg cells as crit. mediators of the anti-tumor immune response to MM and potential targets for anti-tumor immunotherapy; though the timing and dosage of Treg cell manipulating immunotherapies need to be optimized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQefJT95tQJ7Vg90H21EOLACvtfcHk0ljDTokZg42Miw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7nL&md5=b7a1e85b818d9d4f16184969538910fc</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs12307-012-0100-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12307-012-0100-4%26sid%3Dliteratum%253Aachs%26aulast%3DIreland%26aufirst%3DD.%2BJ.%26aulast%3DKissick%26aufirst%3DH.%2BT.%26aulast%3DBeilharz%26aufirst%3DM.%2BW.%26atitle%3DThe%2520role%2520of%2520regulatory%2520T%2520Cells%2520in%2520mesothelioma%26jtitle%3DCancer%2520Microenviron.%26date%3D2012%26volume%3D5%26spage%3D165%26epage%3D172%26doi%3D10.1007%2Fs12307-012-0100-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Schabowsky, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madireddi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yolcu, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirwan, H.</span><span> </span><span class="NLM_article-title">Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1002</span><span class="NLM_x">–</span> <span class="NLM_lpage">1008</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=1002-1008&author=R.+H.+Schabowskyauthor=S.+Madireddiauthor=R.+Sharmaauthor=E.+S.+Yolcuauthor=H.+Shirwan&title=Targeting+CD4%2BCD25%2BFoxP3%2B+regulatory+T-cells+for+the+augmentation+of+cancer+immunotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchabowsky%26aufirst%3DR.%2BH.%26aulast%3DMadireddi%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DYolcu%26aufirst%3DE.%2BS.%26aulast%3DShirwan%26aufirst%3DH.%26atitle%3DTargeting%2520CD4%252BCD25%252BFoxP3%252B%2520regulatory%2520T-cells%2520for%2520the%2520augmentation%2520of%2520cancer%2520immunotherapy%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D8%26spage%3D1002%26epage%3D1008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Wang, R. F.</span><span> </span><span class="NLM_article-title">Functional control of regulatory T cells and cancer immunotherapy</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1016/j.semcancer.2005.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.semcancer.2005.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16423537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVGisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=106-114&author=R.+F.+Wang&title=Functional+control+of+regulatory+T+cells+and+cancer+immunotherapy&doi=10.1016%2Fj.semcancer.2005.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Functional control of regulatory T cells and cancer immunotherapy</span></div><div class="casAuthors">Wang, Rong-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">106-114</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Regulatory T (Treg) cells induce immune tolerance by suppressing host immune responses against self- or non-self-antigens.  Hence, they not only play crit. roles in preventing autoimmune diseases, but also may have detrimental effects on vaccines directed to cancer and infectious diseases.  Understanding the antigen specificity and functional control of Treg cells will be crucial to the development of effective cancer immunotherapy.  This review will discuss different subsets of Treg cells, the factors that contribute to Treg cell generation and suppressive function, and the ability of signaling through Toll-like receptor 8 to reverse the suppressive function of Treg cells.  Importantly, this TLR pathway does not depend on interaction with dendritic cells, but operates independently in Treg cells, relying on TLR8 (with MyD88 as its sole receptor-proximal adaptor) to transduce signals generated by TLR8 ligands.  Linking TLR signaling to the functional control of Treg cells opens intriguing opportunities to shift the balance between CD4+ T-helper and Treg cells, in ways that may improve the outcome of cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSr0A_aJetF7Vg90H21EOLACvtfcHk0liXmRUet8HbYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVGisrg%253D&md5=817b48162077cb82b4b5033e3f7f57f7</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2005.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2005.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%2BF.%26atitle%3DFunctional%2520control%2520of%2520regulatory%2520T%2520cells%2520and%2520cancer%2520immunotherapy%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D106%26epage%3D114%26doi%3D10.1016%2Fj.semcancer.2005.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Williams, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudensky, A. Y.</span><span> </span><span class="NLM_article-title">Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1038/ni1437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fni1437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=17220892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslWmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=277-284&author=L.+M.+Williamsauthor=A.+Y.+Rudensky&title=Maintenance+of+the+Foxp3-dependent+developmental+program+in+mature+regulatory+T+cells+requires+continued+expression+of+Foxp3&doi=10.1038%2Fni1437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3</span></div><div class="casAuthors">Williams, Luke M.; Rudensky, Alexander Y.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-284</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The transcription factor Foxp3 is required for the development of regulatory T cells (Treg cell).  Here the authors report that induced ablation of a loxP-flanked Foxp3 allele in mature Treg cells resulted in the loss of their suppressive function in vivo and acquisition of the ability to produce interleukin 2 and T helper type 1 cytokines.  Furthermore, after adoptive transfer in the absence of functional Treg cells into lymphopenic hosts, Treg cells with deletion of Foxp3 proliferated and were predominant among tissue-infiltrating T cells.  In agreement with those results, the authors found deregulation of Foxp3 target gene expression after Foxp3 deletion.  Thus, continued Foxp3 expression in mature Treg cells is needed to maintain the transcriptional and functional program established during Treg cell development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrne9sUBpH4FLVg90H21EOLACvtfcHk0liXmRUet8HbYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslWmsrk%253D&md5=bfbc7deccecf86e6a04a808e91cb023f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fni1437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1437%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DL.%2BM.%26aulast%3DRudensky%26aufirst%3DA.%2BY.%26atitle%3DMaintenance%2520of%2520the%2520Foxp3-dependent%2520developmental%2520program%2520in%2520mature%2520regulatory%2520T%2520cells%2520requires%2520continued%2520expression%2520of%2520Foxp3%26jtitle%3DNat.%2520Immunol.%26date%3D2007%26volume%3D8%26spage%3D277%26epage%3D284%26doi%3D10.1038%2Fni1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Fontenot, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudensky, A. Y.</span><span> </span><span class="NLM_article-title">Foxp3 programs the development and function of CD4+CD25+ regulatory T cells</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">330</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/ni904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fni904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=12612578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlyqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=330-336&author=J.+D.+Fontenotauthor=M.+A.+Gavinauthor=A.+Y.+Rudensky&title=Foxp3+programs+the+development+and+function+of+CD4%2BCD25%2B+regulatory+T+cells&doi=10.1038%2Fni904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Foxp3 programs the development and function of CD4+CD25+ regulatory T cells</span></div><div class="casAuthors">Fontenot, Jason D.; Gavin, Marc A.; Rudensky, Alexander Y.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">330-336</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CD4+CD25+ regulatory T cells are essential for the active suppression of autoimmunity.  Here the authors report that the forkhead transcription factor Foxp3 is specifically expressed in CD4+CD25+ regulatory T cells and is required for their development.  The lethal autoimmune syndrome obsd. in Foxp3-mutant scurfy mice and Foxp3-null mice results from a CD4+CD25+ regulatory T cell deficiency and not from a cell-intrinsic defect of CD4+CD25- T cells.  CD4+CD25+ regulatory T cells rescue disease development and preferentially expand when transferred into neonatal Foxp3-deficient mice.  Furthermore, ectopic expression of Foxp3 confers suppressor function on peripheral CD4+CD25- T cells.  Thus, Foxp3 is a crit. regulator of CD4+CD25+ regulatory T cell development and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriHBlgR28euLVg90H21EOLACvtfcHk0liXmRUet8HbYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlyqs74%253D&md5=e923b4054210b2902140bd155e8a7daf</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fni904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni904%26sid%3Dliteratum%253Aachs%26aulast%3DFontenot%26aufirst%3DJ.%2BD.%26aulast%3DGavin%26aufirst%3DM.%2BA.%26aulast%3DRudensky%26aufirst%3DA.%2BY.%26atitle%3DFoxp3%2520programs%2520the%2520development%2520and%2520function%2520of%2520CD4%252BCD25%252B%2520regulatory%2520T%2520cells%26jtitle%3DNat.%2520Immunol.%26date%3D2003%26volume%3D4%26spage%3D330%26epage%3D336%26doi%3D10.1038%2Fni904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Chatila, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaeser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voulgaropoulos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helms, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowcock, A. M.</span><span> </span><span class="NLM_article-title">JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">R75</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1172/JCI11679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1172%2FJCI11679" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2000&pages=R75-81&author=T.+A.+Chatilaauthor=F.+Blaeserauthor=N.+Hoauthor=H.+M.+Ledermanauthor=C.+Voulgaropoulosauthor=C.+Helmsauthor=A.+M.+Bowcock&title=JM2%2C+encoding+a+fork+head-related+protein%2C+is+mutated+in+X-linked+autoimmunity-allergic+disregulation+syndrome&doi=10.1172%2FJCI11679"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1172%2FJCI11679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI11679%26sid%3Dliteratum%253Aachs%26aulast%3DChatila%26aufirst%3DT.%2BA.%26aulast%3DBlaeser%26aufirst%3DF.%26aulast%3DHo%26aufirst%3DN.%26aulast%3DLederman%26aufirst%3DH.%2BM.%26aulast%3DVoulgaropoulos%26aufirst%3DC.%26aulast%3DHelms%26aufirst%3DC.%26aulast%3DBowcock%26aufirst%3DA.%2BM.%26atitle%3DJM2%252C%2520encoding%2520a%2520fork%2520head-related%2520protein%252C%2520is%2520mutated%2520in%2520X-linked%2520autoimmunity-allergic%2520disregulation%2520syndrome%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2000%26volume%3D106%26spage%3DR75%26epage%3D81%26doi%3D10.1172%2FJCI11679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lough, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samanta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, M. I.</span><span> </span><span class="NLM_article-title">Dynamic interactions between TIP60 and p300 regulate FOXP3 function through a structural switch defined by a single lysine on TIP60</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1471</span><span class="NLM_x">–</span> <span class="NLM_lpage">1480</span><span class="refDoi"> DOI: 10.1016/j.celrep.2014.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.celrep.2014.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24835996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFGlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=1471-1480&author=Y.+Xiaoauthor=Y.+Nagaiauthor=G.+Dengauthor=T.+Ohtaniauthor=Z.+Zhuauthor=Z.+Zhouauthor=H.+Zhangauthor=M.+Q.+Jiauthor=J.+W.+Loughauthor=A.+Samantaauthor=W.+W.+Hancockauthor=M.+I.+Greene&title=Dynamic+interactions+between+TIP60+and+p300+regulate+FOXP3+function+through+a+structural+switch+defined+by+a+single+lysine+on+TIP60&doi=10.1016%2Fj.celrep.2014.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic Interactions between TIP60 and p300 Regulate FOXP3 Function through a Structural Switch Defined by a Single Lysine on TIP60</span></div><div class="casAuthors">Xiao, Yan; Nagai, Yasuhiro; Deng, Guoping; Ohtani, Takuya; Zhu, Zhiqiang; Zhou, Zhaocai; Zhang, Hongtao; Ji, Mei Q.; Lough, John W.; Samanta, Arabinda; Hancock, Wayne W.; Greene, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1471-1480</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The human FOXP3 mol. is an oligomeric transcriptional factor able to mediate activities that characterize T regulatory cells, a class of lymphocytes central to the regulation of immune responses.  The activity of FOXP3 is regulated at the posttranslational level, in part by two histone acetyltransferases (HATs): TIP60 and p300.  TIP60 and p300 work cooperatively to regulate FOXP3 activity.  Initially, p300 and TIP60 interactions lead to the activation of TIP60 and facilitate acetylation of K327 of TIP60, which functions as a mol. switch to allow TIP60 to change binding partners.  Subsequently, p300 is released from this complex, and TIP60 interacts with and acetylates FOXP3.  Maximal induction of FOXP3 activities is obsd. when both p300 and TIP60 are able to undergo cooperative interactions.  Conditional knockout of TIP60 in Treg cells significantly decreases the Treg population in the peripheral immune organs, leading to a scurfy-like fatal autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoisEBghRHaSrVg90H21EOLACvtfcHk0ljau61I5AxrRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFGlsbw%253D&md5=4d3ed5d4713140bd2e17e6288ad9f1af</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2014.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2014.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DG.%26aulast%3DOhtani%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DM.%2BQ.%26aulast%3DLough%26aufirst%3DJ.%2BW.%26aulast%3DSamanta%26aufirst%3DA.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26aulast%3DGreene%26aufirst%3DM.%2BI.%26atitle%3DDynamic%2520interactions%2520between%2520TIP60%2520and%2520p300%2520regulate%2520FOXP3%2520function%2520through%2520a%2520structural%2520switch%2520defined%2520by%2520a%2520single%2520lysine%2520on%2520TIP60%26jtitle%3DCell%2520Rep.%26date%3D2014%26volume%3D7%26spage%3D1471%26epage%3D1480%26doi%3D10.1016%2Fj.celrep.2014.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">van Loosdregt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleskens, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenkman, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekker, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pals, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meerding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sijts, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalkhoven, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakken, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaiss, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffer, P. J.</span><span> </span><span class="NLM_article-title">Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span><span class="refDoi"> DOI: 10.1016/j.immuni.2013.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.immuni.2013.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=23973222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCgtr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=259-271&author=J.+van+Loosdregtauthor=V.+Fleskensauthor=J.+Fuauthor=A.+B.+Brenkmanauthor=C.+P.+Bekkerauthor=C.+E.+Palsauthor=J.+Meerdingauthor=C.+R.+Berkersauthor=J.+Barbiauthor=A.+Groneauthor=A.+J.+Sijtsauthor=M.+M.+Mauriceauthor=E.+Kalkhovenauthor=B.+J.+Prakkenauthor=H.+Ovaaauthor=F.+Panauthor=D.+M.+Zaissauthor=P.+J.+Coffer&title=Stabilization+of+the+transcription+factor+Foxp3+by+the+deubiquitinase+USP7+increases+Treg-cell-suppressive+capacity&doi=10.1016%2Fj.immuni.2013.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of the Transcription Factor Foxp3 by the Deubiquitinase USP7 Increases Treg-Cell-Suppressive Capacity</span></div><div class="casAuthors">van Loosdregt, Jorg; Fleskens, Veerle; Fu, Juan; Brenkman, Arjan B.; Bekker, Cornelis P. J.; Pals, Cornelieke E. G. M.; Meerding, Jenny; Berkers, Celia R.; Barbi, Joseph; Grone, Andrea; Sijts, Alice J. A. M.; Maurice, Madelon M.; Kalkhoven, Eric; Prakken, Berent J.; Ovaa, Huib; Pan, Fan; Zaiss, Dietmar M. W.; Coffer, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-271</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Stable Foxp3 expression is required for the development of functional regulatory T (Treg) cells.  Here, we demonstrate that the expression of the transcription factor Foxp3 can be regulated through the polyubiquitination of multiple lysine residues, resulting in proteasome-mediated degrdn.  Expression of the deubiquitinase (DUB) USP7 was found to be upregulated and active in Treg cells, being assocd. with Foxp3 in the nucleus.  Ectopic expression of USP7 decreased Foxp3 polyubiquitination and increased Foxp3 expression.  Conversely, either treatment with DUB inhibitor or USP7 knockdown decreased endogenous Foxp3 protein expression and decreased Treg-cell-mediated suppression in vitro.  Furthermore, in a murine adoptive-transfer-induced colitis model, either inhibition of DUB activity or USP7 knockdown in Treg cells abrogated their ability to resolve inflammation in vivo.  Our data reveal a mol. mechanism in which rapid temporal control of Foxp3 expression in Treg cells can be regulated by USP7, thereby modulating Treg cell nos. and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Zpb6_zouu7Vg90H21EOLACvtfcHk0ljau61I5AxrRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCgtr3F&md5=78bd3e51a661ecac49461a3811d2e768</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2013.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2013.05.018%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BLoosdregt%26aufirst%3DJ.%26aulast%3DFleskens%26aufirst%3DV.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DBrenkman%26aufirst%3DA.%2BB.%26aulast%3DBekker%26aufirst%3DC.%2BP.%26aulast%3DPals%26aufirst%3DC.%2BE.%26aulast%3DMeerding%26aufirst%3DJ.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DBarbi%26aufirst%3DJ.%26aulast%3DGrone%26aufirst%3DA.%26aulast%3DSijts%26aufirst%3DA.%2BJ.%26aulast%3DMaurice%26aufirst%3DM.%2BM.%26aulast%3DKalkhoven%26aufirst%3DE.%26aulast%3DPrakken%26aufirst%3DB.%2BJ.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DZaiss%26aufirst%3DD.%2BM.%26aulast%3DCoffer%26aufirst%3DP.%2BJ.%26atitle%3DStabilization%2520of%2520the%2520transcription%2520factor%2520Foxp3%2520by%2520the%2520deubiquitinase%2520USP7%2520increases%2520Treg-cell-suppressive%2520capacity%26jtitle%3DImmunity%26date%3D2013%26volume%3D39%26spage%3D259%26epage%3D271%26doi%3D10.1016%2Fj.immuni.2013.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatti, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Foxp3+ T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">3631</span><span class="NLM_x">–</span> <span class="NLM_lpage">3639</span><span class="refDoi"> DOI: 10.1182/blood-2012-08-451765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1182%2Fblood-2012-08-451765" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=3631-3639&author=L.+Wangauthor=Y.+Liuauthor=U.+H.+Beierauthor=R.+Hanauthor=T.+R.+Bhattiauthor=T.+Akimovaauthor=W.+W.+Hancock&title=Foxp3%2B+T-regulatory+cells+require+DNA+methyltransferase+1+expression+to+prevent+development+of+lethal+autoimmunity&doi=10.1182%2Fblood-2012-08-451765"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-08-451765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-08-451765%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBeier%26aufirst%3DU.%2BH.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DBhatti%26aufirst%3DT.%2BR.%26aulast%3DAkimova%26aufirst%3DT.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DFoxp3%252B%2520T-regulatory%2520cells%2520require%2520DNA%2520methyltransferase%25201%2520expression%2520to%2520prevent%2520development%2520of%2520lethal%2520autoimmunity%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26spage%3D3631%26epage%3D3639%26doi%3D10.1182%2Fblood-2012-08-451765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group">Obata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furusawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atarashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otsubo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamura, Y. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masumoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohara, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koseki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hase, K.</span><span> </span><span class="NLM_article-title">The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">571</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span><span class="refDoi"> DOI: 10.1038/ni.2886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fni.2886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24777532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvFSjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=571-579&author=Y.+Obataauthor=Y.+Furusawaauthor=T.+A.+Endoauthor=J.+Sharifauthor=D.+Takahashiauthor=K.+Atarashiauthor=M.+Nakayamaauthor=S.+Onawaauthor=Y.+Fujimuraauthor=M.+Takahashiauthor=T.+Ikawaauthor=T.+Otsuboauthor=Y.+I.+Kawamuraauthor=T.+Dohiauthor=S.+Tajimaauthor=H.+Masumotoauthor=O.+Oharaauthor=K.+Hondaauthor=S.+Horiauthor=H.+Ohnoauthor=H.+Kosekiauthor=K.+Hase&title=The+epigenetic+regulator+Uhrf1+facilitates+the+proliferation+and+maturation+of+colonic+regulatory+T+cells&doi=10.1038%2Fni.2886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells</span></div><div class="casAuthors">Obata, Yuuki; Furusawa, Yukihiro; Endo, Takaho A.; Sharif, Jafar; Takahashi, Daisuke; Atarashi, Koji; Nakayama, Manabu; Onawa, Satoshi; Fujimura, Yumiko; Takahashi, Masumi; Ikawa, Tomokatsu; Otsubo, Takeshi; Kawamura, Yuki I.; Dohi, Taeko; Tajima, Shoji; Masumoto, Hiroshi; Ohara, Osamu; Honda, Kenya; Hori, Shohei; Ohno, Hiroshi; Koseki, Haruhiko; Hase, Koji</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">571-579</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Intestinal regulatory T cells (Treg cells) are necessary for the suppression of excessive immune responses to commensal bacteria.  However, the mol. machinery that controls the homeostasis of intestinal Treg cells has remained largely unknown.  Here we report that colonization of germ-free mice with gut microbiota upregulated expression of the DNA-methylation adaptor Uhrf1 in Treg cells.  Mice with T cell-specific deficiency in Uhrf1 (Uhrf1fl/flCd4-Cre mice) showed defective proliferation and functional maturation of colonic Treg cells.  Uhrf1 deficiency resulted in derepression of the gene (Cdkn1a) that encodes the cyclin-dependent kinase inhibitor p21 due to hypomethylation of its promoter region, which resulted in cell-cycle arrest of Treg cells.  As a consequence, Uhrf1fl/flCd4-Cre mice spontaneously developed severe colitis.  Thus, Uhrf1-dependent epigenetic silencing of Cdkn1a was required for the maintenance of gut immunol. homeostasis.  This mechanism enforces symbiotic host-microbe interactions without an inflammatory response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9DFM1a_urd7Vg90H21EOLACvtfcHk0liJXsXuMSyk_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvFSjt7s%253D&md5=667da544031f317df47c8f8a777838ef</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1038%2Fni.2886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2886%26sid%3Dliteratum%253Aachs%26aulast%3DObata%26aufirst%3DY.%26aulast%3DFurusawa%26aufirst%3DY.%26aulast%3DEndo%26aufirst%3DT.%2BA.%26aulast%3DSharif%26aufirst%3DJ.%26aulast%3DTakahashi%26aufirst%3DD.%26aulast%3DAtarashi%26aufirst%3DK.%26aulast%3DNakayama%26aufirst%3DM.%26aulast%3DOnawa%26aufirst%3DS.%26aulast%3DFujimura%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DIkawa%26aufirst%3DT.%26aulast%3DOtsubo%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DY.%2BI.%26aulast%3DDohi%26aufirst%3DT.%26aulast%3DTajima%26aufirst%3DS.%26aulast%3DMasumoto%26aufirst%3DH.%26aulast%3DOhara%26aufirst%3DO.%26aulast%3DHonda%26aufirst%3DK.%26aulast%3DHori%26aufirst%3DS.%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DKoseki%26aufirst%3DH.%26aulast%3DHase%26aufirst%3DK.%26atitle%3DThe%2520epigenetic%2520regulator%2520Uhrf1%2520facilitates%2520the%2520proliferation%2520and%2520maturation%2520of%2520colonic%2520regulatory%2520T%2520cells%26jtitle%3DNat.%2520Immunol.%26date%3D2014%26volume%3D15%26spage%3D571%26epage%3D579%26doi%3D10.1038%2Fni.2886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Pacholczyk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kern, J.</span><span> </span><span class="NLM_article-title">The T-cell receptor repertoire of regulatory T cells</span> <span class="citation_source-journal">Immunology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">450</span><span class="NLM_x">–</span> <span class="NLM_lpage">458</span><span class="refDoi"> DOI: 10.1111/j.1365-2567.2008.02992.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1111%2Fj.1365-2567.2008.02992.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2008&pages=450-458&author=R.+Pacholczykauthor=J.+Kern&title=The+T-cell+receptor+repertoire+of+regulatory+T+cells&doi=10.1111%2Fj.1365-2567.2008.02992.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2567.2008.02992.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2567.2008.02992.x%26sid%3Dliteratum%253Aachs%26aulast%3DPacholczyk%26aufirst%3DR.%26aulast%3DKern%26aufirst%3DJ.%26atitle%3DThe%2520T-cell%2520receptor%2520repertoire%2520of%2520regulatory%2520T%2520cells%26jtitle%3DImmunology%26date%3D2008%26volume%3D125%26spage%3D450%26epage%3D458%26doi%3D10.1111%2Fj.1365-2567.2008.02992.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Pfoh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacdao, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georges, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frappier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saridakis, V.</span><span> </span><span class="NLM_article-title">Crystal structure of USP7 ubiquitin-like domains with an ICP0 peptide reveals a novel mechanism used by viral and cellular proteins to target USP7</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1004950</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1004950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1371%2Fjournal.ppat.1004950" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1004950&author=R.+Pfohauthor=I.+K.+Lacdaoauthor=A.+A.+Georgesauthor=A.+Caparauthor=H.+Zhengauthor=L.+Frappierauthor=V.+Saridakis&title=Crystal+structure+of+USP7+ubiquitin-like+domains+with+an+ICP0+peptide+reveals+a+novel+mechanism+used+by+viral+and+cellular+proteins+to+target+USP7&doi=10.1371%2Fjournal.ppat.1004950"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004950%26sid%3Dliteratum%253Aachs%26aulast%3DPfoh%26aufirst%3DR.%26aulast%3DLacdao%26aufirst%3DI.%2BK.%26aulast%3DGeorges%26aufirst%3DA.%2BA.%26aulast%3DCapar%26aufirst%3DA.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DFrappier%26aufirst%3DL.%26aulast%3DSaridakis%26aufirst%3DV.%26atitle%3DCrystal%2520structure%2520of%2520USP7%2520ubiquitin-like%2520domains%2520with%2520an%2520ICP0%2520peptide%2520reveals%2520a%2520novel%2520mechanism%2520used%2520by%2520viral%2520and%2520cellular%2520proteins%2520to%2520target%2520USP7%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26spage%3De1004950%26doi%3D10.1371%2Fjournal.ppat.1004950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Reddy, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Knaap, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bot, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohd-Sarip, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekkers, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmermans, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martens, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demmers, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verrijzer, C. P.</span><span> </span><span class="NLM_article-title">Nucleotide biosynthetic enzyme GMP synthase is a TRIM21-controlled relay of p53 stabilization</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">458</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span><span class="refDoi"> DOI: 10.1016/j.molcel.2013.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.molcel.2013.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24462112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=458-470&author=B.+A.+Reddyauthor=J.+A.+van+der+Knaapauthor=A.+G.+Botauthor=A.+Mohd-Saripauthor=D.+H.+Dekkersauthor=M.+A.+Timmermansauthor=J.+W.+Martensauthor=J.+A.+Demmersauthor=C.+P.+Verrijzer&title=Nucleotide+biosynthetic+enzyme+GMP+synthase+is+a+TRIM21-controlled+relay+of+p53+stabilization&doi=10.1016%2Fj.molcel.2013.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleotide Biosynthetic Enzyme GMP Synthase Is a TRIM21-Controlled Relay of p53 Stabilization</span></div><div class="casAuthors">Reddy, B. Ashok; van der Knaap, Jan A.; Bot, Alice G. M.; Mohd-Sarip, Adone; Dekkers, Dick H. W.; Timmermans, Mieke A.; Martens, John W. M.; Demmers, Jeroen A. A.; Verrijzer, C. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">458-470</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Nucleotide biosynthesis is fundamental to normal cell proliferation as well as to oncogenesis.  Tumor suppressor p53, which prevents aberrant cell proliferation, is destabilized through ubiquitylation by MDM2.  Ubiquitin-specific protease 7 (USP7) plays a dualistic role in p53 regulation and has been proposed to deubiquitylate either p53 or MDM2.  Here, we show that GMP synthase (GMPS) is required for USP7-mediated stabilization of p53.  Normally, most GMPS is sequestered in the cytoplasm, sepd. from nuclear USP7 and p53.  In response to genotoxic stress or nucleotide deprivation, GMPS becomes nuclear and facilitates p53 stabilization by promoting its transfer from MDM2 to a GMPS-USP7 deubiquitylation complex.  Intriguingly, cytoplasmic sequestration of GMPS requires ubiquitylation by TRIM21, a ubiquitin ligase assocd. with autoimmune disease.  These results implicate a classic nucleotide biosynthetic enzyme and a ubiquitin ligase, better known for its role in autoimmune disease, in p53 control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6TeSvWWHlkrVg90H21EOLACvtfcHk0lj4Ya1D7D3mSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GnsrY%253D&md5=dce70456374b51d74254766bb0867cec</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DB.%2BA.%26aulast%3Dvan%2Bder%2BKnaap%26aufirst%3DJ.%2BA.%26aulast%3DBot%26aufirst%3DA.%2BG.%26aulast%3DMohd-Sarip%26aufirst%3DA.%26aulast%3DDekkers%26aufirst%3DD.%2BH.%26aulast%3DTimmermans%26aufirst%3DM.%2BA.%26aulast%3DMartens%26aufirst%3DJ.%2BW.%26aulast%3DDemmers%26aufirst%3DJ.%2BA.%26aulast%3DVerrijzer%26aufirst%3DC.%2BP.%26atitle%3DNucleotide%2520biosynthetic%2520enzyme%2520GMP%2520synthase%2520is%2520a%2520TRIM21-controlled%2520relay%2520of%2520p53%2520stabilization%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D53%26spage%3D458%26epage%3D470%26doi%3D10.1016%2Fj.molcel.2013.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Faesen, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirac, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanmugham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrakis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sixma, T. K.</span><span> </span><span class="NLM_article-title">Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.molcel.2011.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.molcel.2011.06.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21981925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12gtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2011&pages=147-159&author=A.+C.+Faesenauthor=A.+M.+Diracauthor=A.+Shanmughamauthor=H.+Ovaaauthor=A.+Perrakisauthor=T.+K.+Sixma&title=Mechanism+of+USP7%2FHAUSP+activation+by+its+C-terminal+ubiquitin-like+domain+and+allosteric+regulation+by+GMP-synthetase&doi=10.1016%2Fj.molcel.2011.06.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of USP7/HAUSP Activation by Its C-Terminal Ubiquitin-like Domain and Allosteric Regulation by GMP-Synthetase</span></div><div class="casAuthors">Faesen, Alex C.; Dirac, Annette M. G.; Shanmugham, Anitha; Ovaa, Huib; Perrakis, Anastassis; Sixma, Titia K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-159</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The ubiquitin-specific protease USP7/HAUSP regulates p53 and MDM2 levels and cellular localization of FOXO4 and PTEN, and hence is critically important for their role in cellular processes.  Here we show how the 64 kDa C-terminal region of USP7 can pos. regulate deubiquitinating activity.  We present the crystal structure of this USP7/HAUSP ubiquitin-like domain (HUBL) comprised of five ubiquitin-like (Ubl) domains organized in 2-1-2 Ubl units.  The last di-Ubl unit, HUBL-45, is sufficient to activate USP7 through binding to a "switching" loop in the catalytic domain, which promotes ubiquitin binding and increases activity 100-fold.  This activation can be enhanced allosterically by the metabolic enzyme GMPS.  It binds to the first three Ubl domains (HUBL-123) and hyperactivates USP7 by stabilization of the HUBL-45-dependent active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYdH4sjakohbVg90H21EOLACvtfcHk0lj4Ya1D7D3mSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12gtrrE&md5=ec58186e658876ab9e2b83f9fde82fb9</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2011.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2011.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DFaesen%26aufirst%3DA.%2BC.%26aulast%3DDirac%26aufirst%3DA.%2BM.%26aulast%3DShanmugham%26aufirst%3DA.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DPerrakis%26aufirst%3DA.%26aulast%3DSixma%26aufirst%3DT.%2BK.%26atitle%3DMechanism%2520of%2520USP7%252FHAUSP%2520activation%2520by%2520its%2520C-terminal%2520ubiquitin-like%2520domain%2520and%2520allosteric%2520regulation%2520by%2520GMP-synthetase%26jtitle%3DMol.%2520Cell%26date%3D2011%26volume%3D44%26spage%3D147%26epage%3D159%26doi%3D10.1016%2Fj.molcel.2011.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Sheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saridakis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkari, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frappier, L.</span><span> </span><span class="NLM_article-title">Molecular recognition of p53 and MDM2 by USP7/HAUSP</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span><span class="refDoi"> DOI: 10.1038/nsmb1067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnsmb1067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16474402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=285-291&author=Y.+Shengauthor=V.+Saridakisauthor=F.+Sarkariauthor=S.+Duanauthor=T.+Wuauthor=C.+H.+Arrowsmithauthor=L.+Frappier&title=Molecular+recognition+of+p53+and+MDM2+by+USP7%2FHAUSP&doi=10.1038%2Fnsmb1067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular recognition of p53 and MDM2 by USP7/HAUSP</span></div><div class="casAuthors">Sheng, Yi; Saridakis, Vivian; Sarkari, Feroz; Duan, Shili; Wu, Tianne; Arrowsmith, Cheryl H.; Frappier, Lori</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-291</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ubiquitin-specific protease, USP7, has key roles in the p53 pathway whereby it stabilizes both p53 and MDM2.  We show that the N-terminal domain of USP7 binds two closely spaced 4-residue sites in both p53 and MDM2, falling between p53 residues 359-367 and MDM2 residues 147-159.  Cocrystal structures with USP7 were detd. for both p53 peptides and for one MDM2 peptide.  These peptides bind the same surface of USP7 as Epstein-Barr nuclear antigen-1, explaining the competitive nature of the interactions.  The structures and mutagenesis data indicate a preference for a P/AXXS motif in peptides that bind USP7.  Contacts made by serine are identical and crucial for all peptides, and Trp165 in the peptide-binding pocket of USP7 is also crucial.  These results help to elucidate the mechanism of substrate recognition by USP7 and the regulation of the p53 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppxsEZ-TJFZrVg90H21EOLACvtfcHk0lgbb4KmgcnLVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOltr8%253D&md5=09d2f534fbd4fdb60bbc27a99d01e781</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fnsmb1067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb1067%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DY.%26aulast%3DSaridakis%26aufirst%3DV.%26aulast%3DSarkari%26aufirst%3DF.%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DFrappier%26aufirst%3DL.%26atitle%3DMolecular%2520recognition%2520of%2520p53%2520and%2520MDM2%2520by%2520USP7%252FHAUSP%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D285%26epage%3D291%26doi%3D10.1038%2Fnsmb1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span> </span><span class="NLM_article-title">Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">e27</span><span class="refDoi"> DOI: 10.1371/journal.pbio.0040027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1371%2Fjournal.pbio.0040027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=e27&author=M.+Huauthor=L.+Guauthor=M.+Liauthor=P.+D.+Jeffreyauthor=W.+Guauthor=Y.+Shi&title=Structural+basis+of+competitive+recognition+of+p53+and+MDM2+by+HAUSP%2FUSP7%3A+implications+for+the+regulation+of+the+p53-MDM2+pathway&doi=10.1371%2Fjournal.pbio.0040027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.0040027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.0040027%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520basis%2520of%2520competitive%2520recognition%2520of%2520p53%2520and%2520MDM2%2520by%2520HAUSP%252FUSP7%253A%2520implications%2520for%2520the%2520regulation%2520of%2520the%2520p53-MDM2%2520pathway%26jtitle%3DPLoS%2520Biol.%26date%3D2006%26volume%3D4%26spage%3De27%26doi%3D10.1371%2Fjournal.pbio.0040027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lor, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy-Wilson, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinnamon, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span> </span><span class="NLM_article-title">C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site</span> <span class="citation_source-journal">Arch. Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">503</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1016/j.abb.2010.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.abb.2010.08.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2010&pages=207-212&author=J.+Maauthor=J.+D.+Martinauthor=Y.+Xueauthor=L.+A.+Lorauthor=K.+M.+Kennedy-Wilsonauthor=R.+H.+Sinnamonauthor=T.+F.+Hoauthor=G.+Zhangauthor=B.+Schwartzauthor=P.+J.+Tumminoauthor=Z.+Lai&title=C-terminal+region+of+USP7%2FHAUSP+is+critical+for+deubiquitination+activity+and+contains+a+second+mdm2%2Fp53+binding+site&doi=10.1016%2Fj.abb.2010.08.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2010.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2010.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DJ.%2BD.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DLor%26aufirst%3DL.%2BA.%26aulast%3DKennedy-Wilson%26aufirst%3DK.%2BM.%26aulast%3DSinnamon%26aufirst%3DR.%2BH.%26aulast%3DHo%26aufirst%3DT.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DLai%26aufirst%3DZ.%26atitle%3DC-terminal%2520region%2520of%2520USP7%252FHAUSP%2520is%2520critical%2520for%2520deubiquitination%2520activity%2520and%2520contains%2520a%2520second%2520mdm2%252Fp53%2520binding%2520site%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2010%26volume%3D503%26spage%3D207%26epage%3D212%26doi%3D10.1016%2Fj.abb.2010.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Ndubaku, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span> </span><span class="NLM_article-title">Inhibiting the deubiquitinating enzymes (DUBs)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1581</span><span class="NLM_x">–</span> <span class="NLM_lpage">1595</span><span class="refDoi"> DOI: 10.1021/jm501061a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501061a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1581-1595&author=C.+Ndubakuauthor=V.+Tsui&title=Inhibiting+the+deubiquitinating+enzymes+%28DUBs%29&doi=10.1021%2Fjm501061a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the Deubiquitinating Enzymes (DUBs)</span></div><div class="casAuthors">Ndubaku, Chudi; Tsui, Vickie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1581-1595</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The diverse roles of deubiquitinating enzymes, or DUBs, in detg. the fate of specific proteins continue to unfold.  Concurrent with the revelation of DUBs as potential therapeutic targets are publications of small mol. inhibitors of these enzymes.  In this review, we summarize these mols. and their assocd. data and suggest addnl. expts. to further validate and characterize these compds.  We believe the field of drug discovery against DUBs is still in its infancy, but advances in assay development, biophys. techniques, and screening libraries hold promise for identifying suitable agents that could advance into the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsiPtPfBsxNrVg90H21EOLACvtfcHk0lgbb4KmgcnLVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLrL&md5=8ec54b033ba6fd8acb3187e4fc004296</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm501061a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501061a%26sid%3Dliteratum%253Aachs%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DTsui%26aufirst%3DV.%26atitle%3DInhibiting%2520the%2520deubiquitinating%2520enzymes%2520%2528DUBs%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1581%26epage%3D1595%26doi%3D10.1021%2Fjm501061a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Kemp, M.</span><span> </span><span class="NLM_article-title">Recent advances in the discovery of deubiquitinating enzyme inhibitors</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1016/bs.pmch.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fbs.pmch.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26852935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC28nos1KmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=149-192&author=M.+Kemp&title=Recent+advances+in+the+discovery+of+deubiquitinating+enzyme+inhibitors&doi=10.1016%2Fbs.pmch.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors</span></div><div class="casAuthors">Kemp Mark</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">149-92</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOLsGcWRMxs691pGlMMoT5fW6udTcc2eYOt7Dw2cC3zrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nos1KmsQ%253D%253D&md5=e2e3691b281395ca076f4ac93b577f75</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DKemp%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520deubiquitinating%2520enzyme%2520inhibitors%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D55%26spage%3D149%26epage%3D192%26doi%3D10.1016%2Fbs.pmch.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span> </span><span class="NLM_article-title">Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1041</span><span class="NLM_x">–</span> <span class="NLM_lpage">1054</span><span class="refDoi"> DOI: 10.1016/S0092-8674(02)01199-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2FS0092-8674%2802%2901199-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=12507430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1Kiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2002&pages=1041-1054&author=M.+Huauthor=P.+Liauthor=M.+Liauthor=W.+Liauthor=T.+Yaoauthor=J.+W.+Wuauthor=W.+Guauthor=R.+E.+Cohenauthor=Y.+Shi&title=Crystal+structure+of+a+UBP-family+deubiquitinating+enzyme+in+isolation+and+in+complex+with+ubiquitin+aldehyde&doi=10.1016%2FS0092-8674%2802%2901199-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde</span></div><div class="casAuthors">Hu, Min; Li, Pingwei; Li, Muyang; Li, Wenyu; Yao, Tingting; Wu, Jia-Wei; Gu, Wei; Cohen, Robert E.; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1041-1054</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The ubiquitin-specific processing protease (UBP) family of deubiquitinating enzymes plays an essential role in numerous cellular processes.  HAUSP, a representative UBP, specifically deubiquitinates and hence stabilizes the tumor suppressor protein p53.  Here, we report the crystal structures of the 40 kDa catalytic core domain of HAUSP in isolation and in complex with ubiquitin aldehyde.  These studies reveal that the UBP deubiquitinating enzymes exhibit a conserved three-domain architecture, comprising Fingers, Palm, and Thumb.  The leaving ubiquitin moiety is specifically coordinated by the Fingers, with its C terminus placed in the active site between the Palm and the Thumb.  Binding by ubiquitin aldehyde induces a drastic conformational change in the active site that realigns the catalytic triad residues for catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqIQcIuHlub7Vg90H21EOLACvtfcHk0ljqGeTP5vfCzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1Kiug%253D%253D&md5=5f781c94cc2e89f6776533ae0ca3df03</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2901199-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252901199-6%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%2BW.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DCohen%26aufirst%3DR.%2BE.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DCrystal%2520structure%2520of%2520a%2520UBP-family%2520deubiquitinating%2520enzyme%2520in%2520isolation%2520and%2520in%2520complex%2520with%2520ubiquitin%2520aldehyde%26jtitle%3DCell%26date%3D2002%26volume%3D111%26spage%3D1041%26epage%3D1054%26doi%3D10.1016%2FS0092-8674%2802%2901199-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Komander, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clague, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbe, S.</span><span> </span><span class="NLM_article-title">Breaking the chains: structure and function of the deubiquitinases</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">563</span><span class="refDoi"> DOI: 10.1038/nrm2731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrm2731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=19626045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFSru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=550-563&author=D.+Komanderauthor=M.+J.+Clagueauthor=S.+Urbe&title=Breaking+the+chains%3A+structure+and+function+of+the+deubiquitinases&doi=10.1038%2Fnrm2731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Breaking the chains: structure and function of the deubiquitinases</span></div><div class="casAuthors">Komander, David; Clague, Michael J.; Urbe, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">550-563</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ubiquitination is a reversible protein modification that is implicated in many cellular functions.  Recently, much progress has been made in the characterization of a superfamily of isopeptidases that remove ubiquitin: the deubiquitinases (DUBs; also known as deubiquitinating enzymes).  Far from being uniform in structure and function, these enzymes display a myriad of distinct mechanistic features.  The small no. (<100) of DUBs might at 1st suggest a low degree of selectivity; however, DUBs are subject to multiple layers of regulation that modulate both their activity and their specificity.  Due to their wide-ranging involvement in key regulatory processes, these enzymes might provide new therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8Woj6hOAP5rVg90H21EOLACvtfcHk0ljqGeTP5vfCzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFSru74%253D&md5=9268e6c24101ff8137937a5c851d5bb8</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnrm2731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2731%26sid%3Dliteratum%253Aachs%26aulast%3DKomander%26aufirst%3DD.%26aulast%3DClague%26aufirst%3DM.%2BJ.%26aulast%3DUrbe%26aufirst%3DS.%26atitle%3DBreaking%2520the%2520chains%253A%2520structure%2520and%2520function%2520of%2520the%2520deubiquitinases%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2009%26volume%3D10%26spage%3D550%26epage%3D563%26doi%3D10.1038%2Fnrm2731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Dang, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melandri, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R. L.</span><span> </span><span class="NLM_article-title">Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1868</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span><span class="refDoi"> DOI: 10.1021/bi9723360</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi9723360" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADyaK1cXms1OjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=1868-1879&author=L.+C.+Dangauthor=F.+D.+Melandriauthor=R.+L.+Stein&title=Kinetic+and+mechanistic+studies+on+the+hydrolysis+of+ubiquitin+C-terminal+7-amido-4-methylcoumarin+by+deubiquitinating+enzymes&doi=10.1021%2Fbi9723360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic and Mechanistic Studies on the Hydrolysis of Ubiquitin C-Terminal 7-Amido-4-Methylcoumarin by Deubiquitinating Enzymes</span></div><div class="casAuthors">Dang, Luan C.; Melandri, Francesco D.; Stein, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1868-1879</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Deubiquitinating enzymes constitute a family of cysteine hydrolases that specifically cleave ubiquitin-derived substrates of general structure Ub-X, where X can be any no. of leaving groups ranging from small thiols and amines to Ub and other proteins (Ub, ubiquitin).  We have developed a general assay for deubiquitinating enzymes based on the substrate ubiquitin C-terminal 7-amido-4-methylcoumarin (Ub-AMC).  Ub-AMC is efficiently hydrolyzed with liberation of highly fluorescent AMC by two rabbit reticulocyte deubiquitinating enzymes: isopeptidase T (IPaseT), a member of the gene family of ubiquitin-specific processing enzymes, and UCH-L3, a member of the family of ubiquitin C-terminal hydrolases.  We used this new assay to probe kinetic and mechanistic aspects of catalysis by IPaseT and UCH-L3.  Results from four series of expts. are discussed: (1) For UCH-L3, we detd. steady-state kinetic parameters that suggest a diffusion-limited reaction of UCH-L3 with Ub-AMC.  To probe this, we detd. the viscosity dependence of kc/Km, as well as kc.  We found complex viscosity dependencies and interpreted these in the context of a model in which assocn. and acylation are viscosity-dependent but deacylation is viscosity-independent.  (2) The kinetics of inhibition of UCH-L3 by ubiquitin C-terminal aldehyde (Ub-H) were detd. and reveal a Ki that is less than 10-14 M.  Several mechanisms are considered to account for the extreme inhibition.  (3) The IPaseT-catalyzed hydrolysis of Ub-AMC is modulated by Ub with activation at low [Ub] and inhibition at high [Ub].  (4) Finally, we compare kc/Km values for deubiquitinating enzyme-catalyzed hydrolysis of Ub-AMC and Z-Leu-Arg-Gly-Gly-AMC.  For IPaseT, the ratio of rate consts. is 104, while for UCH-L3 this ratio is >107.  These results suggest the following: (i) Deubiquitinating enzymes are able to utilize the free energy that is released from remote interactions with Ub-contg. substrates for stabilization of catalytic transition states, and (ii) UCHs are more efficient at utilizing the energy from these interactions, presumably because they do not possess a binding domain for a Ub "leaving group".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpMDRjOWV2LVg90H21EOLACvtfcHk0lgwMzHa-0QBbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms1OjsA%253D%253D&md5=078fe0b916c22ef4ea7d4fc77aca75c1</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fbi9723360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9723360%26sid%3Dliteratum%253Aachs%26aulast%3DDang%26aufirst%3DL.%2BC.%26aulast%3DMelandri%26aufirst%3DF.%2BD.%26aulast%3DStein%26aufirst%3DR.%2BL.%26atitle%3DKinetic%2520and%2520mechanistic%2520studies%2520on%2520the%2520hydrolysis%2520of%2520ubiquitin%2520C-terminal%25207-amido-4-methylcoumarin%2520by%2520deubiquitinating%2520enzymes%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D1868%26epage%3D1879%26doi%3D10.1021%2Fbi9723360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Hassiepen, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eidhoff, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meder, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulber, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodendorf, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorthiois, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martoglio, B.</span><span> </span><span class="NLM_article-title">A sensitive fluorescence intensity assay for deubiquitinating proteases using ubiquitin-rhodamine110-glycine as substrate</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span><span class="refDoi"> DOI: 10.1016/j.ab.2007.07.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.ab.2007.07.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=17869210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1GlurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2007&pages=201-207&author=U.+Hassiepenauthor=U.+Eidhoffauthor=G.+Mederauthor=J.+F.+Bulberauthor=A.+Heinauthor=U.+Bodendorfauthor=E.+Lorthioisauthor=B.+Martoglio&title=A+sensitive+fluorescence+intensity+assay+for+deubiquitinating+proteases+using+ubiquitin-rhodamine110-glycine+as+substrate&doi=10.1016%2Fj.ab.2007.07.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">A sensitive fluorescence intensity assay for deubiquitinating proteases using ubiquitin-rhodamine110-glycine as substrate</span></div><div class="casAuthors">Hassiepen, Ulrich; Eidhoff, Ulf; Meder, Gabriele; Bulber, Jean-Francois; Hein, Andreas; Bodendorf, Ursula; Lorthiois, Edwige; Martoglio, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-207</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The dynamic modification of proteins with ubiquitin is a key regulation paradigm in eukaryotic cells that controls stability, localization, and function of the vast majority of intracellular proteins.  Here we describe a robust fluorescence intensity assay for monitoring the enzymic activity of deubiquitinating proteases, which reverse ubiquitin modifications and comprise over 100 members in humans.  The assay was developed for the catalytic domain of human ubiquitin-specific protease 2 (USP2) and human ubiquitin carboxyterminal hydrolase L3 (UCH-L3), and makes use of the novel substrate ubiquitin-rhodamine110-glycine.  The latter combines the advantages of a high dynamic range and beneficial optical properties.  Its enzymic behavior is characterized by the kinetic consts. Km = 1.5 μM, kcat = 0.53 s-1 and kcat/Km = 3.5×105 M-1 s-1 for USP2 and Km = 34 nM, kcat = 4.72 s-1, and kcat/Km = 1.4×108 M-1 s-1 for UCH-L3.  This new assay is suitable for inhibitor screening and characterizations, and has been established for the 384-well plate format using protease concns. of 120 pM for USP2 and 1 pM for UCH-L3 and substrate concns. of 100 nM for both enzymes.  Due to the low protease concns. and high sensitivity, this assay would allow the detn. of inhibitory consts. in the subnanomolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2_cU_l6AT7Vg90H21EOLACvtfcHk0lgwMzHa-0QBbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1GlurjK&md5=e9a430d206d99d4b8bef17030139e61a</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2007.07.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2007.07.034%26sid%3Dliteratum%253Aachs%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DEidhoff%26aufirst%3DU.%26aulast%3DMeder%26aufirst%3DG.%26aulast%3DBulber%26aufirst%3DJ.%2BF.%26aulast%3DHein%26aufirst%3DA.%26aulast%3DBodendorf%26aufirst%3DU.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DMartoglio%26aufirst%3DB.%26atitle%3DA%2520sensitive%2520fluorescence%2520intensity%2520assay%2520for%2520deubiquitinating%2520proteases%2520using%2520ubiquitin-rhodamine110-glycine%2520as%2520substrate%26jtitle%3DAnal.%2520Biochem.%26date%3D2007%26volume%3D371%26spage%3D201%26epage%3D207%26doi%3D10.1016%2Fj.ab.2007.07.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Orcutt, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eddins, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickler, J. E.</span><span> </span><span class="NLM_article-title">Bioluminescence assay platform for selective and sensitive detection of Ub/Ubl proteases</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1823</span><span class="NLM_x">, </span> <span class="NLM_fpage">2079</span><span class="NLM_x">–</span> <span class="NLM_lpage">2086</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2012.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.bbamcr.2012.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22705352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVOrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1823&publication_year=2012&pages=2079-2086&author=S.+J.+Orcuttauthor=J.+Wuauthor=M.+J.+Eddinsauthor=C.+A.+Leachauthor=J.+E.+Strickler&title=Bioluminescence+assay+platform+for+selective+and+sensitive+detection+of+Ub%2FUbl+proteases&doi=10.1016%2Fj.bbamcr.2012.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Bioluminescence assay platform for selective and sensitive detection of Ub/Ubl proteases</span></div><div class="casAuthors">Orcutt, Steven J.; Wu, Jian; Eddins, Michael J.; Leach, Craig A.; Strickler, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1823</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2079-2086</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As the importance of ubiquitylation in certain disease states becomes increasingly apparent, the enzymes responsible for removal of ubiquitin (Ub) from target proteins, deubiquitylases (DUBs), are becoming attractive targets for drug discovery.  For rapid identification of compds. that alter DUB function, in vitro assays must be able to provide statistically robust data over a wide dynamic range of both substrate and enzyme concns. during high throughput screening HTS.  The most established reagents for HTS are Ubs with a quenched fluorophore conjugated to the C-terminus; however, a luciferase-based strategy for detecting DUB activity (DUB-Glo, Promega) provides a wider dynamic range than traditional fluorogenic reagents.  Unfortunately, this assay requires high enzyme concns. and lacks specificity for DUBs over other isopeptidases, e.g., desumoylases, as it is based on an aminoluciferin AML deriv. of a peptide derived from the C-terminus of Ub (Z-RLRGG-).  Conjugation of aminoluciferin to a full-length Ub, Ub-AML yields a substrate that has a wide dynamic range, yet displays detection limits for DUBs 100- to 1000-fold lower than obsd. with DUB-Glo.  Ub-AML was even a sensitive substrate for DUBs (e.g., JosD1 and USP14) that do not show appreciable activity with DUB-Glo.  Aminoluciferin derivs. of hSUMO2 and NEDD8 were also shown to be sensitive substrates for desumoylases and deneddylases, resp.  Ub/Ubl-AML substrates are amenable to HTS (Z' = 0.67) yielding robust signal, and providing an alternative drug discovery platform for Ub/Ubl isopeptidases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0tLNzEwt2ubVg90H21EOLACvtfcHk0lgwMzHa-0QBbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVOrsbc%253D&md5=4b1e6e9a2e44f49e121c03bb8081842d</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2012.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2012.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DOrcutt%26aufirst%3DS.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DEddins%26aufirst%3DM.%2BJ.%26aulast%3DLeach%26aufirst%3DC.%2BA.%26aulast%3DStrickler%26aufirst%3DJ.%2BE.%26atitle%3DBioluminescence%2520assay%2520platform%2520for%2520selective%2520and%2520sensitive%2520detection%2520of%2520Ub%252FUbl%2520proteases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2012%26volume%3D1823%26spage%3D2079%26epage%3D2086%26doi%3D10.1016%2Fj.bbamcr.2012.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodrasov, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattern, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butt, T. R.</span><span> </span><span class="NLM_article-title">Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span><span class="refDoi"> DOI: 10.1110/ps.083450408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1110%2Fps.083450408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=18424514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvFKhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1035-1043&author=B.+Nicholsonauthor=C.+A.+Leachauthor=S.+J.+Goldenbergauthor=D.+M.+Francisauthor=M.+P.+Kodrasovauthor=X.+Tianauthor=J.+Shanksauthor=D.+E.+Sternerauthor=A.+Bernalauthor=M.+R.+Matternauthor=K.+D.+Wilkinsonauthor=T.+R.+Butt&title=Characterization+of+ubiquitin+and+ubiquitin-like-protein+isopeptidase+activities&doi=10.1110%2Fps.083450408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities</span></div><div class="casAuthors">Nicholson, Benjamin; Leach, Craig A.; Goldenberg, Seth J.; Francis, Dana M.; Kodrasov, Matthew P.; Tian, Xufan; Shanks, John; Sterner, David E.; Bernal, Alejandro; Mattern, Michael R.; Wilkinson, Keith D.; Butt, Tauseef R.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1035-1043</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Conjugation or deconjugation of ubiquitin (Ub) or ubiquitin-like proteins (UBLs) to or from cellular proteins is a multifaceted and universal means of regulating cellular physiol., controlling the lifetime, localization, and activity of many crit. proteins.  Deconjugation of Ub or UBL from proteins is performed by a class of proteases called isopeptidases.  Herein is described a readily quantifiable novel isopeptidase assay platform consisting of Ub or UBL fused to the reporter enzyme phospholipase A2 (PLA2).  Isopeptidase activity releases PLA2, which cleaves its substrate, generating a signal that is linear with deubiquitylase (DUB) concn. and is able to discriminate DUB, deSUMOylase, deNEDDylase, and deISGylase activities.  The power and sensitivity of the UBL-PLA2 assay are demonstrated by its ability to differentiate the contrasting deISGylase and DUB activities of two coronavirus proteases: severe acute respiratory syndrome papain-like protease (SARS-CoV PLpro) and NL63 CoV papain-like protease 2 (PLP2).  Furthermore, direct comparisons with the current Ub-7-amino-4-methylcoumarin (Ub-AMC) assay demonstrated that the Ub-PLA2 assay is an effective tool for characterizing modulators of isopeptidase activity.  This observation was expanded by profiling the inhibitory activity of the nonselective isopeptidase inhibitor NSC 632839 against DUBs and deSUMOylases.  Taken together, these studies illustrate the utility of the reporter-based approach to measuring isopeptidase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8B_bxI25uwbVg90H21EOLACvtfcHk0liETdEtw2eCcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvFKhtLo%253D&md5=eae8fac2cc0e3c82aa7a75c982c635cd</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1110%2Fps.083450408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.083450408%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DLeach%26aufirst%3DC.%2BA.%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DFrancis%26aufirst%3DD.%2BM.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DShanks%26aufirst%3DJ.%26aulast%3DSterner%26aufirst%3DD.%2BE.%26aulast%3DBernal%26aufirst%3DA.%26aulast%3DMattern%26aufirst%3DM.%2BR.%26aulast%3DWilkinson%26aufirst%3DK.%2BD.%26aulast%3DButt%26aufirst%3DT.%2BR.%26atitle%3DCharacterization%2520of%2520ubiquitin%2520and%2520ubiquitin-like-protein%2520isopeptidase%2520activities%26jtitle%3DProtein%2520Sci.%26date%3D2008%26volume%3D17%26spage%3D1035%26epage%3D1043%26doi%3D10.1110%2Fps.083450408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Tian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isamiddinova, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peroutka, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattern, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C.</span><span> </span><span class="NLM_article-title">Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span><span class="refDoi"> DOI: 10.1089/adt.2010.0317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1089%2Fadt.2010.0317" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=165-173&author=X.+Tianauthor=N.+S.+Isamiddinovaauthor=R.+J.+Peroutkaauthor=S.+J.+Goldenbergauthor=M.+R.+Matternauthor=B.+Nicholsonauthor=C.+Leach&title=Characterization+of+selective+ubiquitin+and+ubiquitin-like+protease+inhibitors+using+a+fluorescence-based+multiplex+assay+format&doi=10.1089%2Fadt.2010.0317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1089%2Fadt.2010.0317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2010.0317%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DX.%26aulast%3DIsamiddinova%26aufirst%3DN.%2BS.%26aulast%3DPeroutka%26aufirst%3DR.%2BJ.%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DMattern%26aufirst%3DM.%2BR.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DLeach%26aufirst%3DC.%26atitle%3DCharacterization%2520of%2520selective%2520ubiquitin%2520and%2520ubiquitin-like%2520protease%2520inhibitors%2520using%2520a%2520fluorescence-based%2520multiplex%2520assay%2520format%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2011%26volume%3D9%26spage%3D165%26epage%3D173%26doi%3D10.1089%2Fadt.2010.0317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Geurink, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Oualid, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hameed, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span> </span><span class="NLM_article-title">A general chemical ligation approach towards isopeptide-linked ubiquitin and ubiquitin-like assay reagents</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span><span class="refDoi"> DOI: 10.1002/cbic.201100706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1002%2Fcbic.201100706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22213387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1OiurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=293-297&author=P.+P.+Geurinkauthor=F.+El+Oualidauthor=A.+Jonkerauthor=D.+S.+Hameedauthor=H.+Ovaa&title=A+general+chemical+ligation+approach+towards+isopeptide-linked+ubiquitin+and+ubiquitin-like+assay+reagents&doi=10.1002%2Fcbic.201100706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">A General Chemical Ligation Approach Towards Isopeptide-Linked Ubiquitin and Ubiquitin-Like Assay Reagents</span></div><div class="casAuthors">Geurink, Paul P.; El Oualid, Farid; Jonker, Anika; Hameed, Dharjath S.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-297</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The 5-thiolysine-mediated ligation can be used to generate a wide range of isopeptide-linked ubiquitin Ub(I)-based FP (fluorescence anisotropy/flourescence polarization) assay reagents.  These are powerful tools for measuring Ub(I) deconjugating activity.  The methodol. can be adapted to any ubiquitin-like proteins (Ubl) for which the E1 enzyme is available.  In contrast to any other reagent, it is possible to incorporate substrate-based peptide sequences.  This is a major advantage, as it offers the possibility of more physiol. relevant assay reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqou4rjkVgI1rVg90H21EOLACvtfcHk0liETdEtw2eCcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1OiurrJ&md5=4c7d4048b95b1218a340123dd71d9716</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201100706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201100706%26sid%3Dliteratum%253Aachs%26aulast%3DGeurink%26aufirst%3DP.%2BP.%26aulast%3DEl%2BOualid%26aufirst%3DF.%26aulast%3DJonker%26aufirst%3DA.%26aulast%3DHameed%26aufirst%3DD.%2BS.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DA%2520general%2520chemical%2520ligation%2520approach%2520towards%2520isopeptide-linked%2520ubiquitin%2520and%2520ubiquitin-like%2520assay%2520reagents%26jtitle%3DChemBioChem%26date%3D2012%26volume%3D13%26spage%3D293%26epage%3D297%26doi%3D10.1002%2Fcbic.201100706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Bozza, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, Z.</span><span> </span><span class="NLM_article-title">Transient kinetic analysis of USP2-catalyzed deubiquitination reveals a conformational rearrangement in the K48-linked diubiquitin substrate</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">10075</span><span class="NLM_x">–</span> <span class="NLM_lpage">10086</span><span class="refDoi"> DOI: 10.1021/bi3009104</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi3009104" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=10075-10086&author=W.+P.+Bozzaauthor=Q.+Liangauthor=P.+Gongauthor=Z.+Zhuang&title=Transient+kinetic+analysis+of+USP2-catalyzed+deubiquitination+reveals+a+conformational+rearrangement+in+the+K48-linked+diubiquitin+substrate&doi=10.1021%2Fbi3009104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fbi3009104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi3009104%26sid%3Dliteratum%253Aachs%26aulast%3DBozza%26aufirst%3DW.%2BP.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DZhuang%26aufirst%3DZ.%26atitle%3DTransient%2520kinetic%2520analysis%2520of%2520USP2-catalyzed%2520deubiquitination%2520reveals%2520a%2520conformational%2520rearrangement%2520in%2520the%2520K48-linked%2520diubiquitin%2520substrate%26jtitle%3DBiochemistry%26date%3D2012%26volume%3D51%26spage%3D10075%26epage%3D10086%26doi%3D10.1021%2Fbi3009104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Ritorto, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Oliva, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knebel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wightman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virdee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrice, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trost, M.</span><span> </span><span class="NLM_article-title">Screening of DUB activity and specificity by MALDI-TOF mass spectrometry</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">4763</span><span class="refDoi"> DOI: 10.1038/ncomms5763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fncomms5763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25159004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFentro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4763&author=M.+S.+Ritortoauthor=R.+Ewanauthor=A.+B.+Perez-Olivaauthor=A.+Knebelauthor=S.+J.+Buhrlageauthor=M.+Wightmanauthor=S.+M.+Kellyauthor=N.+T.+Woodauthor=S.+Virdeeauthor=N.+S.+Grayauthor=N.+A.+Morriceauthor=D.+R.+Alessiauthor=M.+Trost&title=Screening+of+DUB+activity+and+specificity+by+MALDI-TOF+mass+spectrometry&doi=10.1038%2Fncomms5763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Screening of DUB activity and specificity by MALDI-TOF mass spectrometry</span></div><div class="casAuthors">Ritorto, Maria Stella; Ewan, Richard; Perez-Oliva, Ana B.; Knebel, Axel; Buhrlage, Sara J.; Wightman, Melanie; Kelly, Sharon M.; Wood, Nicola T.; Virdee, Satpal; Gray, Nathanael S.; Morrice, Nicholas A.; Alessi, Dario R.; Trost, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4763</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Deubiquitylases (DUBs) are key regulators of the ubiquitin system which cleave ubiquitin moieties from proteins and polyubiquitin chains.  Several DUBs have been implicated in various diseases and are attractive drug targets.  We have developed a sensitive and fast assay to quantify in vitro DUB enzyme activity using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.  Unlike other current assays, this method uses unmodified substrates, such as diubiquitin topoisomers.  By analyzing 42 human DUBs against all diubiquitin topoisomers we provide an extensive characterization of DUB activity and specificity.  Our results confirm the high specificity of many members of the OTU and JAB/MPN/Mov34 metalloenzyme DUB families and highlight that all USPs tested display low linkage selectivity.  We also demonstrate that this assay can be deployed to assess the potency and specificity of DUB inhibitors by profiling 11 compds. against a panel of 32 DUBs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf9lg-hgw78rVg90H21EOLACvtfcHk0liga1wnCrcxSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFentro%253D&md5=614edc01e83206811d3e27a2ca11ae3b</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fncomms5763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms5763%26sid%3Dliteratum%253Aachs%26aulast%3DRitorto%26aufirst%3DM.%2BS.%26aulast%3DEwan%26aufirst%3DR.%26aulast%3DPerez-Oliva%26aufirst%3DA.%2BB.%26aulast%3DKnebel%26aufirst%3DA.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DWightman%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DS.%2BM.%26aulast%3DWood%26aufirst%3DN.%2BT.%26aulast%3DVirdee%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DMorrice%26aufirst%3DN.%2BA.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DTrost%26aufirst%3DM.%26atitle%3DScreening%2520of%2520DUB%2520activity%2520and%2520specificity%2520by%2520MALDI-TOF%2520mass%2520spectrometry%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D4763%26doi%3D10.1038%2Fncomms5763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Altun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willems, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konietzny, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackeen, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGouran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoronenkova, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dianov, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, B. M.</span><span> </span><span class="NLM_article-title">Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1412</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2011.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.chembiol.2011.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22118674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFeqs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1401-1412&author=M.+Altunauthor=H.+B.+Kramerauthor=L.+I.+Willemsauthor=J.+L.+McDermottauthor=C.+A.+Leachauthor=S.+J.+Goldenbergauthor=K.+G.+Kumarauthor=R.+Konietznyauthor=R.+Fischerauthor=E.+Koganauthor=M.+M.+Mackeenauthor=J.+McGouranauthor=S.+V.+Khoronenkovaauthor=J.+L.+Parsonsauthor=G.+L.+Dianovauthor=B.+Nicholsonauthor=B.+M.+Kessler&title=Activity-based+chemical+proteomics+accelerates+inhibitor+development+for+deubiquitylating+enzymes&doi=10.1016%2Fj.chembiol.2011.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes</span></div><div class="casAuthors">Altun, Mikael; Kramer, Holger B.; Willems, Lianne I.; McDermott, Jeffrey L.; Leach, Craig A.; Goldenberg, Seth J.; Kumar, K. G. Suresh; Konietzny, Rebecca; Fischer, Roman; Kogan, Edward; Mackeen, Mukram M.; McGouran, Joanna; Khoronenkova, Svetlana V.; Parsons, Jason L.; Dianov, Grigory L.; Nicholson, Benjamin; Kessler, Benedikt M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1401-1412</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Converting lead compds. into drug candidates is a crucial step in drug development, requiring early assessment of potency, selectivity, and off-target effects.  We have utilized activity-based chem. proteomics to det. the potency and selectivity of deubiquitylating enzyme (DUB) inhibitors in cell culture models.  Importantly, we characterized the small mol. PR-619 as a broad-range DUB inhibitor, and P22077 as a USP7 inhibitor with potential for further development as a chemotherapeutic agent in cancer therapy.  A striking accumulation of polyubiquitylated proteins was obsd. after both selective and general inhibition of cellular DUB activity without direct impairment of proteasomal proteolysis.  The repertoire of ubiquitylated substrates was analyzed by tandem mass spectrometry, identifying distinct subsets for general or specific inhibition of DUBs.  This enabled identification of previously unknown functional links between USP7 and enzymes involved in DNA repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK4Gf8r60zILVg90H21EOLACvtfcHk0liga1wnCrcxSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFeqs7nP&md5=6988660c27e71f2e92d021de887b720d</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DH.%2BB.%26aulast%3DWillems%26aufirst%3DL.%2BI.%26aulast%3DMcDermott%26aufirst%3DJ.%2BL.%26aulast%3DLeach%26aufirst%3DC.%2BA.%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DKumar%26aufirst%3DK.%2BG.%26aulast%3DKonietzny%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DR.%26aulast%3DKogan%26aufirst%3DE.%26aulast%3DMackeen%26aufirst%3DM.%2BM.%26aulast%3DMcGouran%26aufirst%3DJ.%26aulast%3DKhoronenkova%26aufirst%3DS.%2BV.%26aulast%3DParsons%26aufirst%3DJ.%2BL.%26aulast%3DDianov%26aufirst%3DG.%2BL.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26atitle%3DActivity-based%2520chemical%2520proteomics%2520accelerates%2520inhibitor%2520development%2520for%2520deubiquitylating%2520enzymes%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D1401%26epage%3D1412%26doi%3D10.1016%2Fj.chembiol.2011.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Jafari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almqvist, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelsson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ignatushchenko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundback, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordlund, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez Molina, D.</span><span> </span><span class="NLM_article-title">The cellular thermal shift assay for evaluating drug target interactions in cells</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2100</span><span class="NLM_x">–</span> <span class="NLM_lpage">2122</span><span class="refDoi"> DOI: 10.1038/nprot.2014.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnprot.2014.138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25101824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2100-2122&author=R.+Jafariauthor=H.+Almqvistauthor=H.+Axelssonauthor=M.+Ignatushchenkoauthor=T.+Lundbackauthor=P.+Nordlundauthor=D.+Martinez+Molina&title=The+cellular+thermal+shift+assay+for+evaluating+drug+target+interactions+in+cells&doi=10.1038%2Fnprot.2014.138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">The cellular thermal shift assay for evaluating drug target interactions in cells</span></div><div class="casAuthors">Jafari, Rozbeh; Almqvist, Helena; Axelsson, Hanna; Ignatushchenko, Marina; Lundbaeck, Thomas; Nordlund, Paer; Molina, Daniel Martinez</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2100-2122</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thermal shift assays are used to study thermal stabilization of proteins upon ligand binding.  Such assays have been used extensively on purified proteins in the drug discovery industry and in academia to detect interactions.  Recently, we published a proof-of-principle study describing the implementation of thermal shift assays in a cellular format, which we call the cellular thermal shift assay (CETSA).  The method allows studies of target engagement of drug candidates in a cellular context, herein exemplified with exptl. data on the human kinases p38α and ERK1/2.  The assay involves treatment of cells with a compd. of interest, heating to denature and ppt. proteins, cell lysis, and the sepn. of cell debris and aggregates from the sol. protein fraction.  Whereas unbound proteins denature and ppt. at elevated temps., ligand-bound proteins remain in soln.  We describe two procedures for detecting the stabilized protein in the sol. fraction of the samples.  One approach involves sample workup and detection using quant. western blotting, whereas the second is performed directly in soln. and relies on the induced proximity of two target-directed antibodies upon binding to sol. protein.  The latter protocol has been optimized to allow an increased throughput, as potential applications require large nos. of samples.  Both approaches can be completed in a day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzarqomAK6eLVg90H21EOLACvtfcHk0liYlasVl6EJuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ&md5=e7852e1a306bca1698a8e8463ae566b1</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2014.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2014.138%26sid%3Dliteratum%253Aachs%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DAlmqvist%26aufirst%3DH.%26aulast%3DAxelsson%26aufirst%3DH.%26aulast%3DIgnatushchenko%26aufirst%3DM.%26aulast%3DLundback%26aufirst%3DT.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DMartinez%2BMolina%26aufirst%3DD.%26atitle%3DThe%2520cellular%2520thermal%2520shift%2520assay%2520for%2520evaluating%2520drug%2520target%2520interactions%2520in%2520cells%26jtitle%3DNat.%2520Protoc.%26date%3D2014%26volume%3D9%26spage%3D2100%26epage%3D2122%26doi%3D10.1038%2Fnprot.2014.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Colland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Formstecher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacq, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reverdy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planquette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trouplin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aushev, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camonis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg-Capra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sippl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boissy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedat, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delansorne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daviet, L.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2286</span><span class="NLM_x">–</span> <span class="NLM_lpage">2295</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F1535-7163.MCT-09-0097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=19671755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2286-2295&author=F.+Collandauthor=E.+Formstecherauthor=X.+Jacqauthor=C.+Reverdyauthor=C.+Planquetteauthor=S.+Conrathauthor=V.+Trouplinauthor=J.+Bianchiauthor=V.+N.+Aushevauthor=J.+Camonisauthor=A.+Calabreseauthor=C.+Borg-Capraauthor=W.+Sipplauthor=V.+Colluraauthor=G.+Boissyauthor=J.+C.+Rainauthor=P.+Guedatauthor=R.+Delansorneauthor=L.+Daviet&title=Small-molecule+inhibitor+of+USP7%2FHAUSP+ubiquitin+protease+stabilizes+and+activates+p53+in+cells&doi=10.1158%2F1535-7163.MCT-09-0097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells</span></div><div class="casAuthors">Colland, Frederic; Formstecher, Etienne; Jacq, Xavier; Reverdy, Celine; Planquette, Cecile; Conrath, Susan; Trouplin, Virginie; Bianchi, Julie; Aushev, Vasily N.; Camonis, Jacques; Calabrese, Alessandra; Borg-Capra, Catherine; Sippl, Wolfgang; Collura, Vincent; Boissy, Guillaume; Rain, Jean-Christophe; Guedat, Philippe; Delansorne, Remi; Daviet, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2286-2295</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulation of the ubiquitin/proteasome system has been implicated in the pathogenesis of many human diseases, including cancer.  Ubiquitin-specific proteases (USP) are cysteine proteases involved in the deubiquitination of protein substrates.  Functional connections between USP7 and essential viral proteins and oncogenic pathways, such as the p53/Mdm2 and phosphatidylinositol 3-kinase/protein kinase B networks, strongly suggest that the targeting of USP7 with small-mol. inhibitors may be useful for the treatment of cancers and viral diseases.  Using high-throughput screening, we have discovered HBX 41,108, a small-mol. compd. that inhibits USP7 deubiquitinating activity with an IC50 in the submicromolar range.  Kinetics data indicate an uncompetitive reversible inhibition mechanism.  HBX 41,108 was shown to affect USP7-mediated p53 deubiquitination in vitro and in cells.  As RNA interference-mediated USP7 silencing in cancer cells, HBX 41,108 treatment stabilized p53, activated the transcription of a p53 target gene without inducing genotoxic stress, and inhibited cancer cell growth.  Finally, HBX 41,108 induced p53-dependent apoptosis as shown in p53 wild-type and null isogenic cancer cell lines.  We thus report the identification of the first lead-like inhibitor against USP7, providing a structural basis for the development of new anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN5f2O-cNWmbVg90H21EOLACvtfcHk0liYlasVl6EJuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCmsrw%253D&md5=bb84e2bd3cf54d0a6842b39e2784eea9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0097%26sid%3Dliteratum%253Aachs%26aulast%3DColland%26aufirst%3DF.%26aulast%3DFormstecher%26aufirst%3DE.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DReverdy%26aufirst%3DC.%26aulast%3DPlanquette%26aufirst%3DC.%26aulast%3DConrath%26aufirst%3DS.%26aulast%3DTrouplin%26aufirst%3DV.%26aulast%3DBianchi%26aufirst%3DJ.%26aulast%3DAushev%26aufirst%3DV.%2BN.%26aulast%3DCamonis%26aufirst%3DJ.%26aulast%3DCalabrese%26aufirst%3DA.%26aulast%3DBorg-Capra%26aufirst%3DC.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DCollura%26aufirst%3DV.%26aulast%3DBoissy%26aufirst%3DG.%26aulast%3DRain%26aufirst%3DJ.%2BC.%26aulast%3DGuedat%26aufirst%3DP.%26aulast%3DDelansorne%26aufirst%3DR.%26aulast%3DDaviet%26aufirst%3DL.%26atitle%3DSmall-molecule%2520inhibitor%2520of%2520USP7%252FHAUSP%2520ubiquitin%2520protease%2520stabilizes%2520and%2520activates%2520p53%2520in%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2286%26epage%3D2295%26doi%3D10.1158%2F1535-7163.MCT-09-0097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peretto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacq, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedat, P.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">552</span><span class="NLM_x">–</span> <span class="NLM_lpage">558</span><span class="refDoi"> DOI: 10.1002/cmdc.200900409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1002%2Fcmdc.200900409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20186914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFyqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=552-558&author=M.+Colomboauthor=S.+Valleseauthor=I.+Perettoauthor=X.+Jacqauthor=J.+C.+Rainauthor=F.+Collandauthor=P.+Guedat&title=Synthesis+and+biological+evaluation+of+9-oxo-9H-indeno%5B1%2C2-b%5Dpyrazine-2%2C3-dicarbonitrile+analogues+as+potential+inhibitors+of+deubiquitinating+enzymes&doi=10.1002%2Fcmdc.200900409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile Analogues as Potential Inhibitors of Deubiquitinating Enzymes</span></div><div class="casAuthors">Colombo, Matteo; Vallese, Stefania; Peretto, Ilaria; Jacq, Xavier; Rain, Jean-Christophe; Colland, Frederic; Guedat, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">552-558</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">High-throughput screening highlighted 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile (1) as an active inhibitor of ubiquitin-specific proteases (USPs), a family of hydrolytic enzymes involved in the removal of ubiquitin from protein substrates.  The chem. behavior of compd. 1 was examd.  Moreover, the synthesis and in vitro evaluation of new compds., analogs of 1, led to the identification of potent and selective inhibitors of the deubiquitinating enzyme USP8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG5ve4XfTip7Vg90H21EOLACvtfcHk0liYlasVl6EJuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFyqt7k%253D&md5=b30b6569922a1eac1ab8b5d011ea0d21</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900409%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DVallese%26aufirst%3DS.%26aulast%3DPeretto%26aufirst%3DI.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DRain%26aufirst%3DJ.%2BC.%26aulast%3DColland%26aufirst%3DF.%26aulast%3DGuedat%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25209-oxo-9H-indeno%255B1%252C2-b%255Dpyrazine-2%252C3-dicarbonitrile%2520analogues%2520as%2520potential%2520inhibitors%2520of%2520deubiquitinating%2520enzymes%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D552%26epage%3D558%26doi%3D10.1002%2Fcmdc.200900409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Lopez, R.; Collura, V.; Wolfgang, S.; Colland, F.</span><span> </span><span class="NLM_article-title">Novel Specific Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions thereof and their Therapeutic Applications</span>. International Patent WO2010081783,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=R.+Lopez&author=V.+Collura&author=S.+Wolfgang&author=F.+Colland&title=Novel+Specific+Inhibitors+of+Ubiquitin+Specific+Protease+7%2C+the+Pharmaceutical+Compositions+thereof+and+their+Therapeutic+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DR.%26atitle%3DNovel%2520Specific%2520Inhibitors%2520of%2520Ubiquitin%2520Specific%2520Protease%25207%252C%2520the%2520Pharmaceutical%2520Compositions%2520thereof%2520and%2520their%2520Therapeutic%2520Applications%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Reverdy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planquette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atmanene, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivat, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sippl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colland, F.</span><span> </span><span class="NLM_article-title">Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.chembiol.2012.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22520753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFyruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=467-477&author=C.+Reverdyauthor=S.+Conrathauthor=R.+Lopezauthor=C.+Planquetteauthor=C.+Atmaneneauthor=V.+Colluraauthor=J.+Harponauthor=V.+Battagliaauthor=V.+Vivatauthor=W.+Sipplauthor=F.+Colland&title=Discovery+of+specific+inhibitors+of+human+USP7%2FHAUSP+deubiquitinating+enzyme&doi=10.1016%2Fj.chembiol.2012.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Specific Inhibitors of Human USP7/HAUSP Deubiquitinating Enzyme</span></div><div class="casAuthors">Reverdy, Celine; Conrath, Susan; Lopez, Roman; Planquette, Cecile; Atmanene, Cedric; Collura, Vincent; Harpon, Jane; Battaglia, Veronique; Vivat, Valerie; Sippl, Wolfgang; Colland, Frederic</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">467-477</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The human USP7 deubiquitinating enzyme was shown to regulate many proteins involved in the cell cycle, as well as tumor suppressors and oncogenes.  Thus, USP7 offers a promising, strategic target for cancer therapy.  Using biochem. assays and activity-based protein profiling in living systems, we identified small-mol. antagonists of USP7 and demonstrated USP7 inhibitor occupancy and selectivity in cancer cell lines.  These compds. bind USP7 in the active site through a covalent mechanism.  In cancer cells, these active-site-targeting inhibitors were shown to regulate the level of several USP7 substrates and thus recapitulated the USP7 knockdown phenotype that leads to G1 arrest in colon cancer cells.  The data presented in this report provide proof of principle that USP7 inhibitors may be a valuable therapeutic for cancer.  In addn., the discovery of such mols. offers interesting tools for studying deubiquitination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt0GVteDWstbVg90H21EOLACvtfcHk0lgBd4oZq9jU1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFyruro%253D&md5=f5e3497c9893342571e3c97ae85d1361</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DReverdy%26aufirst%3DC.%26aulast%3DConrath%26aufirst%3DS.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DPlanquette%26aufirst%3DC.%26aulast%3DAtmanene%26aufirst%3DC.%26aulast%3DCollura%26aufirst%3DV.%26aulast%3DHarpon%26aufirst%3DJ.%26aulast%3DBattaglia%26aufirst%3DV.%26aulast%3DVivat%26aufirst%3DV.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DColland%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520specific%2520inhibitors%2520of%2520human%2520USP7%252FHAUSP%2520deubiquitinating%2520enzyme%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D467%26epage%3D477%26doi%3D10.1016%2Fj.chembiol.2012.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Menard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulea, T.</span><span> </span><span class="NLM_article-title">Selective inhibition of USP7</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">438</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.chembiol.2012.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22520747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFylurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=437-438&author=R.+Menardauthor=T.+Sulea&title=Selective+inhibition+of+USP7&doi=10.1016%2Fj.chembiol.2012.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of USP7</span></div><div class="casAuthors">Menard, Robert; Sulea, Traian</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-438</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The deubiquitinating enzyme USP7 is an emerging oncol. and antiviral target.  Reverdy et al., in this issue of Chem. & Biol., disclose the first small-mol. inhibitor selective for USP7, which recapitulates its knockdown in cancer cells and hence demonstrates the therapeutic feasibility of USP7 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPZVMDrXlaYLVg90H21EOLACvtfcHk0lgBd4oZq9jU1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFylurs%253D&md5=46a1a0aa80568e64f60814d3184b370d</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DMenard%26aufirst%3DR.%26aulast%3DSulea%26aufirst%3DT.%26atitle%3DSelective%2520inhibition%2520of%2520USP7%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D437%26epage%3D438%26doi%3D10.1016%2Fj.chembiol.2012.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Colland, F.; Gourdel, M.-E.</span><span> </span><span class="NLM_article-title">Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7</span>. International Patent WO2013030218,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Colland&author=M.-E.+Gourdel&title=Selective+and+Reversible+Inhibitors+of+Ubiquitin+Specific+Protease+7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DColland%26aufirst%3DF.%26atitle%3DSelective%2520and%2520Reversible%2520Inhibitors%2520of%2520Ubiquitin%2520Specific%2520Protease%25207%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Kessler, B. M.</span><span> </span><span class="NLM_article-title">Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span><span class="refDoi"> DOI: 10.1517/13543776.2014.882320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1517%2F13543776.2014.882320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24456106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=597-602&author=B.+M.+Kessler&title=Selective+and+reversible+inhibitors+of+ubiquitin-specific+protease+7%3A+a+patent+evaluation+%28WO2013030218%29&doi=10.1517%2F13543776.2014.882320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218)</span></div><div class="casAuthors">Kessler, Benedikt M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">597-602</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The invention described in this review (WO2013030218) relates to compds. based on the quinazolin-4-one scaffold, their process of prepn. and applications to inhibit the ubiquitin-specific protease 7 (USP7), a deubiquitinating enzyme (DUB), which is considered a potentially important new drug target for treating cancer and immunol. disorders.  Data are presented indicating that these small-mol. compds. are useful as selective and reversible inhibitors of USP7 in vitro and also in a cellular context, although the panel of other enzymes tested was limited.  The synthesis strategy allows for the generation of a considerable variety of compds., although similar properties of selective USP7 inhibition were reported for other related compd. classes, thereby increasing the complexity of the patenting process.  However, structural patterns that contribute to the selectivity of USP7 and other DUB enzyme inhibition are starting to emerge.  Practical implications involve the treatment of cancer, neurodegenerative diseases, immunol. disorders, diabetes, bone and joint diseases, cardiovascular diseases and viral and bacterial infections.  The quality of these findings and a comparison to other compd. classes with similar properties, as well as the potential for further development toward clin. exploitation are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCEfdSzsMM37Vg90H21EOLACvtfcHk0lgBd4oZq9jU1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu7c%253D&md5=a1dec5801ef0354471f799a8869fbfc4</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.882320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.882320%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DB.%2BM.%26atitle%3DSelective%2520and%2520reversible%2520inhibitors%2520of%2520ubiquitin-specific%2520protease%25207%253A%2520a%2520patent%2520evaluation%2520%2528WO2013030218%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D597%26epage%3D602%26doi%3D10.1517%2F13543776.2014.882320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Zaman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, S.</span><span> </span><span class="NLM_article-title">Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor necrosis factor alpha-induced apoptosis</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">4971</span><span class="NLM_x">–</span> <span class="NLM_lpage">4984</span><span class="refDoi"> DOI: 10.1128/MCB.00465-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1128%2FMCB.00465-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24144979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FosVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=4971-4984&author=M.+M.+Zamanauthor=T.+Nomuraauthor=T.+Takagiauthor=T.+Okamuraauthor=W.+Jinauthor=T.+Shinagawaauthor=Y.+Tanakaauthor=S.+Ishii&title=Ubiquitination-deubiquitination+by+the+TRIM27-USP7+complex+regulates+tumor+necrosis+factor+alpha-induced+apoptosis&doi=10.1128%2FMCB.00465-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor necrosis factor alpha-induced apoptosis</span></div><div class="casAuthors">Zaman Mohammad Mahabub-Uz; Nomura Teruaki; Takagi Tsuyoshi; Okamura Tomoo; Jin Wanzhu; Shinagawa Toshie; Tanaka Yasunori; Ishii Shunsuke</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and cellular biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4971-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tumor necrosis factor alpha (TNF-α) plays a role in apoptosis and proliferation in multiple types of cells, and defects in TNF-α-induced apoptosis are associated with various autoimmune diseases.  Here, we show that TRIM27, a tripartite motif (TRIM) protein containing RING finger, B-box, and coiled-coil domains, positively regulates TNF-α-induced apoptosis.  Trim27-deficient mice are resistant to TNF-α-d-galactosamine-induced hepatocyte apoptosis.  Trim27-deficient mouse embryonic fibroblasts (MEFs) are also resistant to TNF-α-cycloheximide-induced apoptosis.  TRIM27 forms a complex with and ubiquitinates the ubiquitin-specific protease USP7, which deubiquitinates receptor-interacting protein 1 (RIP1), resulting in the positive regulation of TNF-α-induced apoptosis.  Our findings indicate that the ubiquitination-deubiquitination cascade mediated by the TRIM27-USP7 complex plays an important role in TNF-α-induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpTLZW3DBytnWEEzDrymxmfW6udTcc2easXLLA6r-ukbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FosVKgtQ%253D%253D&md5=cdd23694f3168c85be13d6cc58a7e087</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1128%2FMCB.00465-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00465-13%26sid%3Dliteratum%253Aachs%26aulast%3DZaman%26aufirst%3DM.%2BM.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DOkamura%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DShinagawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DS.%26atitle%3DUbiquitination-deubiquitination%2520by%2520the%2520TRIM27-USP7%2520complex%2520regulates%2520tumor%2520necrosis%2520factor%2520alpha-induced%2520apoptosis%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2013%26volume%3D33%26spage%3D4971%26epage%3D4984%26doi%3D10.1128%2FMCB.00465-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, A. A.</span><span> </span><span class="NLM_article-title">Ubiquitin-specific protease 7 regulates nucleotide excision repair through deubiquitinating XPC protein and preventing XPC protein from undergoing ultraviolet light-induced and VCP/p97 protein-regulated proteolysis</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">27278</span><span class="NLM_x">–</span> <span class="NLM_lpage">27289</span><span class="refDoi"> DOI: 10.1074/jbc.M114.589812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1074%2Fjbc.M114.589812" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=27278-27289&author=J.+Heauthor=Q.+Zhuauthor=G.+Waniauthor=N.+Sharmaauthor=C.+Hanauthor=J.+Qianauthor=K.+Pentzauthor=Q.+E.+Wangauthor=A.+A.+Wani&title=Ubiquitin-specific+protease+7+regulates+nucleotide+excision+repair+through+deubiquitinating+XPC+protein+and+preventing+XPC+protein+from+undergoing+ultraviolet+light-induced+and+VCP%2Fp97+protein-regulated+proteolysis&doi=10.1074%2Fjbc.M114.589812"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.589812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.589812%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DWani%26aufirst%3DG.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DPentz%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DQ.%2BE.%26aulast%3DWani%26aufirst%3DA.%2BA.%26atitle%3DUbiquitin-specific%2520protease%25207%2520regulates%2520nucleotide%2520excision%2520repair%2520through%2520deubiquitinating%2520XPC%2520protein%2520and%2520preventing%2520XPC%2520protein%2520from%2520undergoing%2520ultraviolet%2520light-induced%2520and%2520VCP%252Fp97%2520protein-regulated%2520proteolysis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D27278%26epage%3D27289%26doi%3D10.1074%2Fjbc.M114.589812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, A. A.</span><span> </span><span class="NLM_article-title">USP7 modulates UV-induced PCNA monoubiquitination by regulating DNA polymerase eta stability</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">4791</span><span class="NLM_x">–</span> <span class="NLM_lpage">4796</span><span class="refDoi"> DOI: 10.1038/onc.2014.394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fonc.2014.394" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=4791-4796&author=J.+Qianauthor=K.+Pentzauthor=Q.+Zhuauthor=Q.+Wangauthor=J.+Heauthor=A.+K.+Srivastavaauthor=A.+A.+Wani&title=USP7+modulates+UV-induced+PCNA+monoubiquitination+by+regulating+DNA+polymerase+eta+stability&doi=10.1038%2Fonc.2014.394"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.394%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DPentz%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DSrivastava%26aufirst%3DA.%2BK.%26aulast%3DWani%26aufirst%3DA.%2BA.%26atitle%3DUSP7%2520modulates%2520UV-induced%2520PCNA%2520monoubiquitination%2520by%2520regulating%2520DNA%2520polymerase%2520eta%2520stability%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26spage%3D4791%26epage%3D4796%26doi%3D10.1038%2Fonc.2014.394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, A. A.</span><span> </span><span class="NLM_article-title">USP7 deubiquitinase promotes ubiquitin-dependent DNA damage signaling by stabilizing RNF168</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1413</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span><span class="refDoi"> DOI: 10.1080/15384101.2015.1007785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1080%2F15384101.2015.1007785" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1413-1425&author=Q.+Zhuauthor=N.+Sharmaauthor=J.+Heauthor=G.+Waniauthor=A.+A.+Wani&title=USP7+deubiquitinase+promotes+ubiquitin-dependent+DNA+damage+signaling+by+stabilizing+RNF168&doi=10.1080%2F15384101.2015.1007785"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1007785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1007785%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DWani%26aufirst%3DG.%26aulast%3DWani%26aufirst%3DA.%2BA.%26atitle%3DUSP7%2520deubiquitinase%2520promotes%2520ubiquitin-dependent%2520DNA%2520damage%2520signaling%2520by%2520stabilizing%2520RNF168%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26spage%3D1413%26epage%3D1425%26doi%3D10.1080%2F15384101.2015.1007785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Hirano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshitane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozuka-Hata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanjakornsiripan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukada, Y.</span><span> </span><span class="NLM_article-title">USP7 and TDP-43: pleiotropic regulation of cryptochrome protein stability paces the oscillation of the mammalian circadian clock</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0154263</span><span class="refDoi"> DOI: 10.1371/journal.pone.0154263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1371%2Fjournal.pone.0154263" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0154263&author=A.+Hiranoauthor=T.+Nakagawaauthor=H.+Yoshitaneauthor=M.+Oyamaauthor=H.+Kozuka-Hataauthor=D.+Lanjakornsiripanauthor=Y.+Fukada&title=USP7+and+TDP-43%3A+pleiotropic+regulation+of+cryptochrome+protein+stability+paces+the+oscillation+of+the+mammalian+circadian+clock&doi=10.1371%2Fjournal.pone.0154263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0154263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0154263%26sid%3Dliteratum%253Aachs%26aulast%3DHirano%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DYoshitane%26aufirst%3DH.%26aulast%3DOyama%26aufirst%3DM.%26aulast%3DKozuka-Hata%26aufirst%3DH.%26aulast%3DLanjakornsiripan%26aufirst%3DD.%26aulast%3DFukada%26aufirst%3DY.%26atitle%3DUSP7%2520and%2520TDP-43%253A%2520pleiotropic%2520regulation%2520of%2520cryptochrome%2520protein%2520stability%2520paces%2520the%2520oscillation%2520of%2520the%2520mammalian%2520circadian%2520clock%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0154263%26doi%3D10.1371%2Fjournal.pone.0154263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Lee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baek, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. G.</span><span> </span><span class="NLM_article-title">Herpesvirus-associated ubiquitin-specific protease (HAUSP) modulates peroxisome proliferator-activated receptor gamma (PPARgamma) stability through its deubiquitinating activity</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">32886</span><span class="NLM_x">–</span> <span class="NLM_lpage">32896</span><span class="refDoi"> DOI: 10.1074/jbc.M113.496331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1074%2Fjbc.M113.496331" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=32886-32896&author=K.+W.+Leeauthor=J.+G.+Choauthor=C.+M.+Kimauthor=A.+Y.+Kangauthor=M.+Kimauthor=B.+Y.+Ahnauthor=S.+S.+Chungauthor=K.+H.+Limauthor=K.+H.+Baekauthor=J.+H.+Sungauthor=K.+S.+Parkauthor=S.+G.+Park&title=Herpesvirus-associated+ubiquitin-specific+protease+%28HAUSP%29+modulates+peroxisome+proliferator-activated+receptor+gamma+%28PPARgamma%29+stability+through+its+deubiquitinating+activity&doi=10.1074%2Fjbc.M113.496331"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.496331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.496331%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DCho%26aufirst%3DJ.%2BG.%26aulast%3DKim%26aufirst%3DC.%2BM.%26aulast%3DKang%26aufirst%3DA.%2BY.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DB.%2BY.%26aulast%3DChung%26aufirst%3DS.%2BS.%26aulast%3DLim%26aufirst%3DK.%2BH.%26aulast%3DBaek%26aufirst%3DK.%2BH.%26aulast%3DSung%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DK.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BG.%26atitle%3DHerpesvirus-associated%2520ubiquitin-specific%2520protease%2520%2528HAUSP%2529%2520modulates%2520peroxisome%2520proliferator-activated%2520receptor%2520gamma%2520%2528PPARgamma%2529%2520stability%2520through%2520its%2520deubiquitinating%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D32886%26epage%3D32896%26doi%3D10.1074%2Fjbc.M113.496331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Lecona, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narendra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinberg, D.</span><span> </span><span class="NLM_article-title">USP7 cooperates with SCML2 to regulate the activity of PRC1</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1168</span><span class="refDoi"> DOI: 10.1128/MCB.01197-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1128%2FMCB.01197-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25605328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvFKgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1157-1168&author=E.+Leconaauthor=V.+Narendraauthor=D.+Reinberg&title=USP7+cooperates+with+SCML2+to+regulate+the+activity+of+PRC1&doi=10.1128%2FMCB.01197-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">USP7 cooperates with SCML2 to regulate the activity of PRC1</span></div><div class="casAuthors">Lecona, Emilio; Narendra, Varun; Reinberg, Danny</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1157-1168</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">USP7 is a protein deubiquitinase with an essential role in development.  Here, we provide evidence that USP7 regulates the activity of Polycomb repressive complex 1 (PRC1) in coordination with SCML2.  There are six versions of PRC1 defined by the assocn. of one of the PCGF homologues (PCGF1 to PCGF6) with the common catalytic subunit RING1B.  First, we show that SCML2, a Polycomb group protein that assocs. with PRC1.2 (contg. PCGF2/MEL18) and PRC1.4 (contg. PCGF4/ BMI1), modulates the localization of USP7 and bridges USP7 with PRC1.4, allowing for the stabilization of BMI1.  Chromatin immunopptn. (ChIP) expts. demonstrate that USP7 is found at SCML2 and BMI1 target genes.  Second, inhibition of USP7 leads to a redn. in the level of ubiquitinated histone H2A (H2Aub), the catalytic product of PRC1 and key for its repressive activity.  USP7 regulates the posttranslational status of RING1B and BMI1, a specific component of PRC1.4.  Thus, not only does USP7 stabilize PRC1 components, its catalytic activity is also necessary to maintain a functional PRC1, thereby ensuring appropriate levels of repressive H2Aub.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXtU7vBWEzwbVg90H21EOLACvtfcHk0lgctlQtDBsdwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvFKgs7Y%253D&md5=5a0e624eb19f2228ab39ea5ab545a9bd</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1128%2FMCB.01197-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01197-14%26sid%3Dliteratum%253Aachs%26aulast%3DLecona%26aufirst%3DE.%26aulast%3DNarendra%26aufirst%3DV.%26aulast%3DReinberg%26aufirst%3DD.%26atitle%3DUSP7%2520cooperates%2520with%2520SCML2%2520to%2520regulate%2520the%2520activity%2520of%2520PRC1%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D1157%26epage%3D1168%26doi%3D10.1128%2FMCB.01197-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Weinstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingsbury, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodrasov, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKelvey, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suresh Kumar, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattern, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span> </span><span class="NLM_article-title">Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1021/ml200276j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200276j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=789-792&author=J.+Weinstockauthor=J.+Wuauthor=P.+Caoauthor=W.+D.+Kingsburyauthor=J.+L.+McDermottauthor=M.+P.+Kodrasovauthor=D.+M.+McKelveyauthor=K.+G.+Suresh+Kumarauthor=S.+J.+Goldenbergauthor=M.+R.+Matternauthor=B.+Nicholson&title=Selective+dual+inhibitors+of+the+cancer-related+deubiquitylating+proteases+USP7+and+USP47&doi=10.1021%2Fml200276j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fml200276j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200276j%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstock%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DKingsbury%26aufirst%3DW.%2BD.%26aulast%3DMcDermott%26aufirst%3DJ.%2BL.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DMcKelvey%26aufirst%3DD.%2BM.%26aulast%3DSuresh%2BKumar%26aufirst%3DK.%2BG.%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DMattern%26aufirst%3DM.%2BR.%26aulast%3DNicholson%26aufirst%3DB.%26atitle%3DSelective%2520dual%2520inhibitors%2520of%2520the%2520cancer-related%2520deubiquitylating%2520proteases%2520USP7%2520and%2520USP47%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D789%26epage%3D792%26doi%3D10.1021%2Fml200276j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Weinstock, J.; Wu, J.; Kumar, K. G. S.; Wang, F.; Kodrasov, M. P.; Agarwal, S.</span><span> </span><span class="NLM_article-title">Covalent Irreversible Inhibitors of USP7 as Anti-Cancer Agents</span>. International Patent WO2017023684,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+Weinstock&author=J.+Wu&author=K.+G.+S.+Kumar&author=F.+Wang&author=M.+P.+Kodrasov&author=S.+Agarwal&title=Covalent+Irreversible+Inhibitors+of+USP7+as+Anti-Cancer+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstock%26aufirst%3DJ.%26atitle%3DCovalent%2520Irreversible%2520Inhibitors%2520of%2520USP7%2520as%2520Anti-Cancer%2520Agents%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Ioannidis, S.; Talbot, A. C.; Follows, B.; Buckmelter, A. J.; Wang, M.; Campbell, A.-M.; Schmidt, D. R.; Guerin, D. J.; Caravella, J. A.; Diebold, R. B.; Ericsson, A.; Lancia, D.,  Jr.</span><span> </span><span class="NLM_article-title">Preparation of Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors</span>. International Patent WO2016109515,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ioannidis&author=A.+C.+Talbot&author=B.+Follows&author=A.+J.+Buckmelter&author=M.+Wang&author=A.-M.+Campbell&author=D.+R.+Schmidt&author=D.+J.+Guerin&author=J.+A.+Caravella&author=R.+B.+Diebold&author=A.+Ericsson&author=D.+Lancia&title=Preparation+of+Pyrrolo+and+Pyrazolopyrimidines+as+Ubiquitin-Specific+Protease+7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Pyrrolo%2520and%2520Pyrazolopyrimidines%2520as%2520Ubiquitin-Specific%2520Protease%25207%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Ioannidis, S.; Talbot, A. C.; Follows, B.; Buckmelter, A. J.; Wang, M.; Campbell, A.-M.; Schmidt, D. R.; Guerin, D. J.; Caravella, J. A.; Diebold, R. B.; Ericsson, A.; Lancia, D.,  Jr.</span><span> </span><span class="NLM_article-title">Preparation of Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors</span>. International Patent WO2016109480,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ioannidis&author=A.+C.+Talbot&author=B.+Follows&author=A.+J.+Buckmelter&author=M.+Wang&author=A.-M.+Campbell&author=D.+R.+Schmidt&author=D.+J.+Guerin&author=J.+A.+Caravella&author=R.+B.+Diebold&author=A.+Ericsson&author=D.+Lancia&title=Preparation+of+Pyrrolotriazinones+and+Imidazotriazinones+as+Ubiquitin-Specific+Protease+7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Pyrrolotriazinones%2520and%2520Imidazotriazinones%2520as%2520Ubiquitin-Specific%2520Protease%25207%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Ioannidis, S.; Talbot, A. C.; Follows, B.; Buckmelter, A. J.; Wang, M.; Campbell, A.-M.; Lancia, D.,  Jr.</span><span> </span><span class="NLM_article-title">Preparation of (Aza)quinazolinones as Ubiquitin-Specific Protease 7 Inhibitors</span>. International Patent WO2016126926,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ioannidis&author=A.+C.+Talbot&author=B.+Follows&author=A.+J.+Buckmelter&author=M.+Wang&author=A.-M.+Campbell&author=D.+Lancia&title=Preparation+of+%28Aza%29quinazolinones+as+Ubiquitin-Specific+Protease+7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520%2528Aza%2529quinazolinones%2520as%2520Ubiquitin-Specific%2520Protease%25207%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Ioannidis, S.; Talbot, A. C.; Follows, B.; Buckmelter, A. J.; Wang, M.; Campbell, A.-M.; Lancia, D.,  Jr.</span><span> </span><span class="NLM_article-title">Preparation of Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors</span>. International Patent WO2016126929,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ioannidis&author=A.+C.+Talbot&author=B.+Follows&author=A.+J.+Buckmelter&author=M.+Wang&author=A.-M.+Campbell&author=D.+Lancia&title=Preparation+of+Thienopyrimidinones+as+Ubiquitin-Specific+Protease+7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Thienopyrimidinones%2520as%2520Ubiquitin-Specific%2520Protease%25207%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Ioannidis, S.; Talbot, A. C.; Follows, B.; Buckmelter, A. J.; Wang, M.; Campbell, A.-M.</span><span> </span><span class="NLM_article-title">Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors</span>. International Patent WO2016126935,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ioannidis&author=A.+C.+Talbot&author=B.+Follows&author=A.+J.+Buckmelter&author=M.+Wang&author=A.-M.+Campbell&title=Isothiazolopyrimidinones%2C+Pyrazolopyrimidinones%2C+and+Pyrrolopyrimidinones+as+Ubiquitin-Specific+Protease+7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DIsothiazolopyrimidinones%252C%2520Pyrazolopyrimidinones%252C%2520and%2520Pyrrolopyrimidinones%2520as%2520Ubiquitin-Specific%2520Protease%25207%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Blake, R.; Di, L. P.; Drummond, J.; Heideker, C. J.; Kategaya, L.; Maurer, T.; Murray, J. M.; Ndubaku, C.; Pastor, R.; Rouge, L.; Tsui, V.; Wertz, I. E.; Yu, K.</span><span> </span><span class="NLM_article-title">Arylpyridinamines as USP7 Inhibitor Compounds and their Preparation</span>. U.S. Patent US20160272588,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=R.+Blake&author=L.+P.+Di&author=J.+Drummond&author=C.+J.+Heideker&author=L.+Kategaya&author=T.+Maurer&author=J.+M.+Murray&author=C.+Ndubaku&author=R.+Pastor&author=L.+Rouge&author=V.+Tsui&author=I.+E.+Wertz&author=K.+Yu&title=Arylpyridinamines+as+USP7+Inhibitor+Compounds+and+their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DR.%26atitle%3DArylpyridinamines%2520as%2520USP7%2520Inhibitor%2520Compounds%2520and%2520their%2520Preparation%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">845</span><span class="NLM_x">–</span> <span class="NLM_lpage">849</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.bmcl.2017.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=28108249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlamurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=845-849&author=C.+Chenauthor=J.+Songauthor=J.+Wangauthor=C.+Xuauthor=C.+Chenauthor=W.+Guauthor=H.+Sunauthor=X.+Wen&title=Synthesis+and+biological+evaluation+of+thiazole+derivatives+as+novel+USP7+inhibitors&doi=10.1016%2Fj.bmcl.2017.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors</span></div><div class="casAuthors">Chen, Chao; Song, Jiemei; Wang, Jinzheng; Xu, Chang; Chen, Caiping; Gu, Wei; Sun, Hongbin; Wen, Xiaoan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">845-849</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herpesvirus-assocd. Ubiquitin-Specific Protease (HAUSP, also called USP7) interacts with and stabilizes Mdm2, and represents one of the first examples that deubiquitinases oncogenic proteins.  USP7 has been regarded as a potential drug target for cancer therapy.  Inhibitors of USP7 have been recently shown to suppress tumor cell growth in vitro and in vivo.  Based on leading USP7 inhibitors P5091 and P22077, we designed and synthesized a series of thiazole derivs.  The results of in vitro assays showed that the thiazole compds., e.g., I, exhibited low micromolar inhibition activity against both USP7 enzyme and cancer cell lines.  The compds. induced cell death in a p53-dependent and p53-independent manner.  Taken together, this study may provide thiazole compds. as a new class of USP7 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDDE4EusDZFbVg90H21EOLACvtfcHk0lj1EGIt23lJJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlamurY%253D&md5=ff5533266d3634bc921c39cab4a76820</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DWen%26aufirst%3DX.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520thiazole%2520derivatives%2520as%2520novel%2520USP7%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D845%26epage%3D849%26doi%3D10.1016%2Fj.bmcl.2017.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Sun, H.; Song, J.; Chen, C.; Wang, J.; Xu, C.; Wen, X.; Gu, W.</span><span> </span><span class="NLM_article-title">Thiazole Compounds as Antitumor Agents and their Preparation, Pharmaceutical Compositions and Use in the Treatment of Cancer</span>. International Patent WO2015127797,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+Sun&author=J.+Song&author=C.+Chen&author=J.+Wang&author=C.+Xu&author=X.+Wen&author=W.+Gu&title=Thiazole+Compounds+as+Antitumor+Agents+and+their+Preparation%2C+Pharmaceutical+Compositions+and+Use+in+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26atitle%3DThiazole%2520Compounds%2520as%2520Antitumor%2520Agents%2520and%2520their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Cancer%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Yamaguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodrasov, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotinsulu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Losung, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangindaan, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Voogd, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokosawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span> </span><span class="NLM_article-title">Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3884</span><span class="NLM_x">–</span> <span class="NLM_lpage">3886</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.04.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.bmcl.2013.04.066" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3884-3886&author=M.+Yamaguchiauthor=M.+Miyazakiauthor=M.+P.+Kodrasovauthor=H.+Rotinsuluauthor=F.+Losungauthor=R.+E.+Mangindaanauthor=N.+J.+de+Voogdauthor=H.+Yokosawaauthor=B.+Nicholsonauthor=S.+Tsukamoto&title=Spongiacidin+C%2C+a+pyrrole+alkaloid+from+the+marine+sponge+Stylissa+massa%2C+functions+as+a+USP7+inhibitor&doi=10.1016%2Fj.bmcl.2013.04.066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.04.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.04.066%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DRotinsulu%26aufirst%3DH.%26aulast%3DLosung%26aufirst%3DF.%26aulast%3DMangindaan%26aufirst%3DR.%2BE.%26aulast%3Dde%2BVoogd%26aufirst%3DN.%2BJ.%26aulast%3DYokosawa%26aufirst%3DH.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DTsukamoto%26aufirst%3DS.%26atitle%3DSpongiacidin%2520C%252C%2520a%2520pyrrole%2520alkaloid%2520from%2520the%2520marine%2520sponge%2520Stylissa%2520massa%252C%2520functions%2520as%2520a%2520USP7%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3884%26epage%3D3886%26doi%3D10.1016%2Fj.bmcl.2013.04.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thunnissen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleverley, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salinas, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biernat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelkow, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span> </span><span class="NLM_article-title">Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1016/S1074-5521(00)00063-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2FS1074-5521%2800%2900063-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10662688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFertA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=51-63&author=L.+Meijerauthor=A.+M.+Thunnissenauthor=A.+W.+Whiteauthor=M.+Garnierauthor=M.+Nikolicauthor=L.+H.+Tsaiauthor=J.+Walterauthor=K.+E.+Cleverleyauthor=P.+C.+Salinasauthor=Y.+Z.+Wuauthor=J.+Biernatauthor=E.+M.+Mandelkowauthor=S.+H.+Kimauthor=G.+R.+Pettit&title=Inhibition+of+cyclin-dependent+kinases%2C+GSK-3beta+and+CK1+by+hymenialdisine%2C+a+marine+sponge+constituent&doi=10.1016%2FS1074-5521%2800%2900063-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent</span></div><div class="casAuthors">Meijer, L.; Thunnissen, A. M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S. H.; Pettit, G. R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-63</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Over 2000 protein kinases regulate cellular functions.  Screening for inhibitors of some of these kinases has already yielded some potent and selective compds. with promising potential for the treatment of human diseases.  Here, the marine sponge constituent, hymenialdisine (I), was found to be a potent inhibitor of cyclin-dependent kinases (CDKs), glycogen synthase kinase-3β (GSK-3β), and casein kinase 1 (CK1).  I was found to compete with ATP for binding to these kinases.  A CDK2-I complex crystal structure showed that 3 H-bonds linked I to the Glu-81 and Leu-83 residues of CDK2, as obsd. with other inhibitors.  I inhibited CDK5/p35 in vivo as demonstrated by the lack of phosphorylation/down-regulation of Pak1 kinase in E18 rat cortical neurons, and also inhibited GSK-3 in vivo as shown by the inhibition of microtubule-assocd. protein-1B phosphorylation.  I also blocked the in vivo phosphorylation of the microtubule-binding protein, tau, at sites that were hyperphosphorylated by GSK-3 and CDK5/p35 in Alzheimer's disease (cross-reacting with Alzheimer's-specific AT100 antibodies) and blocked presenilin-2 phosphorylation in vitro.  Thus, the natural product, I, is a new kinase inhibitor with promising potential applications for treating neurodegenerative disorders such as Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp80sKXSk6kF7Vg90H21EOLACvtfcHk0lj1EGIt23lJJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFertA%253D%253D&md5=62a4e11bc0d13980751cadd2d1ec723a</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2800%2900063-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252800%252900063-6%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DThunnissen%26aufirst%3DA.%2BM.%26aulast%3DWhite%26aufirst%3DA.%2BW.%26aulast%3DGarnier%26aufirst%3DM.%26aulast%3DNikolic%26aufirst%3DM.%26aulast%3DTsai%26aufirst%3DL.%2BH.%26aulast%3DWalter%26aufirst%3DJ.%26aulast%3DCleverley%26aufirst%3DK.%2BE.%26aulast%3DSalinas%26aufirst%3DP.%2BC.%26aulast%3DWu%26aufirst%3DY.%2BZ.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3DMandelkow%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26atitle%3DInhibition%2520of%2520cyclin-dependent%2520kinases%252C%2520GSK-3beta%2520and%2520CK1%2520by%2520hymenialdisine%252C%2520a%2520marine%2520sponge%2520constituent%26jtitle%3DChem.%2520Biol.%26date%3D2000%26volume%3D7%26spage%3D51%26epage%3D63%26doi%3D10.1016%2FS1074-5521%2800%2900063-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Tanokashira, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nehira, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angkouw, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangindaan, R. E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Voogd, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span> </span><span class="NLM_article-title">Petroquinones: trimeric and dimeric Xestoquinone derivatives isolated from the marine sponge Petrosia alfiani</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5530</span><span class="NLM_x">–</span> <span class="NLM_lpage">5540</span><span class="refDoi"> DOI: 10.1016/j.tet.2016.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.tet.2016.07.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=5530-5540&author=N.+Tanokashiraauthor=S.+Kukitaauthor=H.+Katoauthor=T.+Nehiraauthor=E.+D.+Angkouwauthor=R.+E.+P.+Mangindaanauthor=N.+J.+de+Voogdauthor=S.+Tsukamoto&title=Petroquinones%3A+trimeric+and+dimeric+Xestoquinone+derivatives+isolated+from+the+marine+sponge+Petrosia+alfiani&doi=10.1016%2Fj.tet.2016.07.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2016.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2016.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DTanokashira%26aufirst%3DN.%26aulast%3DKukita%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DNehira%26aufirst%3DT.%26aulast%3DAngkouw%26aufirst%3DE.%2BD.%26aulast%3DMangindaan%26aufirst%3DR.%2BE.%2BP.%26aulast%3Dde%2BVoogd%26aufirst%3DN.%2BJ.%26aulast%3DTsukamoto%26aufirst%3DS.%26atitle%3DPetroquinones%253A%2520trimeric%2520and%2520dimeric%2520Xestoquinone%2520derivatives%2520isolated%2520from%2520the%2520marine%2520sponge%2520Petrosia%2520alfiani%26jtitle%3DTetrahedron%26date%3D2016%26volume%3D72%26spage%3D5530%26epage%3D5540%26doi%3D10.1016%2Fj.tet.2016.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Wang, W.; Wu, Y.; Liu, M.; Jing, B.</span><span> </span><span class="NLM_article-title">Application of Pentacyclic Triterpenoid in Preparation of USP7 Inhibitor</span>. China Patent CN105534991A,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=W.+Wang&author=Y.+Wu&author=M.+Liu&author=B.+Jing&title=Application+of+Pentacyclic+Triterpenoid+in+Preparation+of+USP7+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26atitle%3DApplication%2520of%2520Pentacyclic%2520Triterpenoid%2520in%2520Preparation%2520of%2520USP7%2520Inhibitor%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Wang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S. F.</span><span> </span><span class="NLM_article-title">Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2075</span><span class="NLM_x">–</span> <span class="NLM_lpage">2088</span><span class="refDoi"> DOI: 10.2147/DDDT.S68872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.2147%2FDDDT.S68872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25364233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOlsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=2075-2088&author=Y.+Y.+Wangauthor=Y.+X.+Yangauthor=H.+Zheauthor=Z.+X.+Heauthor=S.+F.+Zhou&title=Bardoxolone+methyl+%28CDDO-Me%29+as+a+therapeutic+agent%3A+an+update+on+its+pharmacokinetic+and+pharmacodynamic+properties&doi=10.2147%2FDDDT.S68872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties</span></div><div class="casAuthors">Wang, Yan-Yang; Yang, Yin-Xue; Zhe, Hong; He, Zhi-Xu; Zhou, Shu-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2075-2088, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Triterpenoids have been used for medicinal purposes in many Asian countries because of their anti-inflammatory, antioxidant, antiproliferative, anticancer, and anticarcinogenic properties.  Bardoxolone Me, the C-28 Me ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) known as CDDO-Me or RTA 402, is one of the derivs. of synthetic triterpenoids.  CDDO-Me has been used for the treatment of chronic kidney disease, cancer (including leukemia and solid tumors), and other diseases.  In this review, we will update our knowledge of the clin. pharmacokinetics and pharmacodynamics of CDDO-Me, highlighting its clin. benefits and the underlying mechanisms involved.  The role of the Kelch-like erythroid cell-derived protein with CNC homol.-assocd. protein 1 (Keap1)/the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in the therapeutic activities of CDDO-Me will be discussed.  CDDO-Me contains α,β-unsatd. carbonyl groups on rings A and C that can generate reversible adducts with the thiol groups of Cys residues in target proteins such as Keap1 and IκB kinase.  At low nanomolar concns., CDDO-Me protects the cells against oxidative stress via inhibition of reactive oxygen species generation, while CDDO-Me at low micromolar concns. induces apoptosis by increasing reactive oxygen species and decreasinging intracellular glutathione levels.  Through Keap1/Nrf2 and nuclear factor-κB pathways, this agent can modulate the activities of a no. of important proteins that regulate inflammation, redox balance, cell proliferation and programmed cell death.  In a Phase I trial in cancer patients, CDDO-Me was found to have a slow and saturable oral absorption, a relatively long terminal phase half-life (39 h at 900 mg/day), nonlinearity (dose-dependent) at high doses (600-1,300 mg/day), and high interpatient variability.  As a multifunctional agent, CDDO-Me has improved the renal function in patients with chronic kidney disease assocd. with type 2 diabetes.  CDDO-Me has shown a promising anticancer effect in a Phase I trial.  This agent is generally well tolerated, but it may increase adverse cardiovascular events.  Presently, it is being further tested for the treatment of patients with chronic kidney disease, cancer, and pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBzXblYw_T8bVg90H21EOLACvtfcHk0lh_Q55rwHVsEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOlsLvI&md5=75feb541785ab658bee232d7e5a6f073</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S68872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S68872%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BY.%26aulast%3DYang%26aufirst%3DY.%2BX.%26aulast%3DZhe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DZ.%2BX.%26aulast%3DZhou%26aufirst%3DS.%2BF.%26atitle%3DBardoxolone%2520methyl%2520%2528CDDO-Me%2529%2520as%2520a%2520therapeutic%2520agent%253A%2520an%2520update%2520on%2520its%2520pharmacokinetic%2520and%2520pharmacodynamic%2520properties%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D2075%26epage%3D2088%26doi%3D10.2147%2FDDDT.S68872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span><span class="refDoi"> DOI: 10.1038/nrd2130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrd2130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=17016424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+a+multikinase+inhibitor+for+treating+cancer&doi=10.1038%2Fnrd2130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span></div><div class="casAuthors">Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways.  The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process.  Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature.  The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compd. to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WjjfgNSCtbVg90H21EOLACvtfcHk0lh_Q55rwHVsEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM&md5=490d4995170f3a7270ae9bbdd24b12e5</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1038%2Fnrd2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2130%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520a%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D835%26epage%3D844%26doi%3D10.1038%2Fnrd2130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Broekman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannetti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: multi-targeted or single-targeted?</span> <span class="citation_source-journal">World J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.5306/wjco.v2.i2.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.5306%2Fwjco.v2.i2.80" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21603317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC3Mrkt1arsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=80-93&author=F.+Broekmanauthor=E.+Giovannettiauthor=G.+J.+Peters&title=Tyrosine+kinase+inhibitors%3A+multi-targeted+or+single-targeted%3F&doi=10.5306%2Fwjco.v2.i2.80"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors: Multi-targeted or single-targeted?</span></div><div class="casAuthors">Broekman Fleur; Giovannetti Elisa; Peters Godefridus J</div><div class="citationInfo"><span class="NLM_cas:title">World journal of clinical oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">80-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since in most tumors multiple signaling pathways are involved, many of the inhibitors in clinical development are designed to affect a wide range of targeted kinases.  The most important tyrosine kinase families in the development of tyrosine kinase inhibitors are the ABL, SCR, platelet derived growth factor, vascular endothelial growth factor receptor and epidermal growth factor receptor families.  Both multi-kinase inhibitors and single-kinase inhibitors have advantages and disadvantages, which are related to potential resistance mechanisms, pharmacokinetics, selectivity and tumor environment.  In different malignancies various tyrosine kinases are mutated or overexpressed and several resistance mechanisms exist.  Pharmacokinetics is influenced by interindividual differences and differs for two single targeted inhibitors or between patients treated by the same tyrosine kinase inhibitor.  Different tyrosine kinase inhibitors have various mechanisms to achieve selectivity, while differences in gene expression exist between tumor and stromal cells.  Considering these aspects, one type of inhibitor can generally not be preferred above the other, but will depend on the specific genetic constitution of the patient and the tumor, allowing personalized therapy.  The most effective way of cancer treatment by using tyrosine kinase inhibitors is to consider each patient/tumor individually and to determine the strategy that specifically targets the consequences of altered (epi)genetics of the tumor.  This strategy might result in treatment by a single multi kinase inhibitor for one patient, but in treatment by a couple of single kinase inhibitors for other patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUsa5qqJaBY_csfMJQC1ZdfW6udTcc2eaBwwWfgCK2VLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mrkt1arsw%253D%253D&md5=683eaad679244b5efc5813d1ffaaaf57</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.5306%2Fwjco.v2.i2.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5306%252Fwjco.v2.i2.80%26sid%3Dliteratum%253Aachs%26aulast%3DBroekman%26aufirst%3DF.%26aulast%3DGiovannetti%26aufirst%3DE.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520multi-targeted%2520or%2520single-targeted%253F%26jtitle%3DWorld%2520J.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D2%26spage%3D80%26epage%3D93%26doi%3D10.5306%2Fwjco.v2.i2.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Goldenberg, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butt, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattern, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span> </span><span class="NLM_article-title">Strategies for the identification of novel inhibitors of deubiquitinating enzymes</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">828</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1042/BST0360828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1042%2FBST0360828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=18793145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSrt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=828-832&author=S.+J.+Goldenbergauthor=J.+L.+McDermottauthor=T.+R.+Buttauthor=M.+R.+Matternauthor=B.+Nicholson&title=Strategies+for+the+identification+of+novel+inhibitors+of+deubiquitinating+enzymes&doi=10.1042%2FBST0360828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for the identification of novel inhibitors of deubiquitinating enzymes</span></div><div class="casAuthors">Goldenberg, Seth J.; McDermott, Jeffrey L.; Butt, Tauseef R.; Mattern, Michael R.; Nicholson, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">828-832</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Dysregulation of the UPS (ubiquitin-proteasome system) has been implicated in a wide range of pathologies including cancer, neurodegeneration and viral infection.  Inhibiting the proteasome has been shown to be an effective therapeutic strategy in humans; yet toxicity with this target remains high.  DUBs (deubiquitinating enzymes) represent an alternative target in the UPS with low predicted toxicity.  Currently, there are no DUB inhibitors that have been used clin.  To address this situation, Progenra has developed a novel assay to measure the proteolytic cleavage of Ub (ubiquitin) or UBL (Ub-like protein) conjugates such as SUMO (small Ub-related modifier), NEDD8 (neural-precursor-cell-expressed, developmentally down-regulated 8) or ISG15 (interferon-stimulated gene 15) by isopeptidases.  In this review, current platforms for detecting DUB inhibitors are discussed and the advantages and disadvantages of the approaches are underlined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-0x67KYwgCbVg90H21EOLACvtfcHk0ljGs9e2Xzm2fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSrt77J&md5=b8ec5a0826d6b233130156418afc1b2e</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1042%2FBST0360828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0360828%26sid%3Dliteratum%253Aachs%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DMcDermott%26aufirst%3DJ.%2BL.%26aulast%3DButt%26aufirst%3DT.%2BR.%26aulast%3DMattern%26aufirst%3DM.%2BR.%26aulast%3DNicholson%26aufirst%3DB.%26atitle%3DStrategies%2520for%2520the%2520identification%2520of%2520novel%2520inhibitors%2520of%2520deubiquitinating%2520enzymes%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2008%26volume%3D36%26spage%3D828%26epage%3D832%26doi%3D10.1042%2FBST0360828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0ljGs9e2Xzm2fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Burger, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedeschi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robak, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bairey, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillmen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosicki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devereux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quach, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaidano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maslyak, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polliack, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clow, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Styles, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipps, T. J.</span><span> </span><span class="NLM_article-title">Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">2425</span><span class="NLM_x">–</span> <span class="NLM_lpage">2437</span><span class="refDoi"> DOI: 10.1056/NEJMoa1509388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1056%2FNEJMoa1509388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26639149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit10%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2425-2437&author=J.+A.+Burgerauthor=A.+Tedeschiauthor=P.+M.+Barrauthor=T.+Robakauthor=C.+Owenauthor=P.+Ghiaauthor=O.+Baireyauthor=P.+Hillmenauthor=N.+L.+Bartlettauthor=J.+Liauthor=D.+Simpsonauthor=S.+Grosickiauthor=S.+Devereuxauthor=H.+McCarthyauthor=S.+Coutreauthor=H.+Quachauthor=G.+Gaidanoauthor=Z.+Maslyakauthor=D.+A.+Stevensauthor=A.+Janssensauthor=F.+Offnerauthor=J.+Mayerauthor=M.+O%E2%80%99Dwyerauthor=A.+Hellmannauthor=A.+Schuhauthor=T.+Siddiqiauthor=A.+Polliackauthor=C.+S.+Tamauthor=D.+Suriauthor=M.+Chengauthor=F.+Clowauthor=L.+Stylesauthor=D.+F.+Jamesauthor=T.+J.+Kipps&title=Ibrutinib+as+initial+therapy+for+patients+with+chronic+lymphocytic+leukemia&doi=10.1056%2FNEJMoa1509388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia</span></div><div class="casAuthors">Burger, J. A.; Tedeschi, A.; Barr, P. M.; Robak, T.; Owen, C.; Ghia, P.; Bairey, O.; Hillmen, P.; Bartlett, N. L.; Li, J.; Simpson, D.; Grosicki, S.; Devereux, S.; McCarthy, H.; Coutre, S.; Quach, H.; Gaidano, G.; Maslyak, Z.; Stevens, D. A.; Janssens, A.; Offner, F.; Mayer, J.; O'Dwyer, M.; Hellmann, A.; Schuh, A.; Siddiqi, T.; Polliack, A.; Tam, C. S.; Suri, D.; Cheng, M.; Clow, F.; Styles, L.; James, D. F.; Kipps, T. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2425-2437</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addn. to disease-related immunosuppression and myelosuppression.  We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma.  Methods We randomly assigned 269 previously untreated patients who were 65 years of age or older and had CLL or small lymphocytic lymphoma to receive ibrutinib or chlorambucil.  The primary end point was progression-free survival as assessed by an independent review committee. results The median age of the patients was 73 years.  During a median follow-up period of 18.4 mo, ibrutinib resulted in significantly longer progression-free survival than did chlorambucil (median, not reached vs. 18.9 mo), with a risk of progression or death that was 84% lower with ibrutinib than that with chlorambucil (hazard ratio, 0.16; P<0.001).  Ibrutinib significantly prolonged overall survival; the estd. survival rate at 24 mo was 98% with ibrutinib vs. 85% with chlorambucil, with a relative risk of death that was 84% lower in the ibrutinib group than in the chlorambucil group (hazard ratio, 0.16; P = 0.001).  The overall response rate was higher with ibrutinib than with chlorambucil (86% vs. 35%, P<0.001).  The rates of sustained increases from baseline values in the Hb and platelet levels were higher with ibrutinib.  Adverse events of any grade that occurred in at least 20% of the patients receiving ibrutinib included diarrhea, fatigue, cough, and nausea; adverse events occurring in at least 20% of those receiving chlorambucil included nausea, fatigue, neutropenia, anemia, and vomiting.  In the ibrutinib group, four patients had a grade 3 hemorrhage and one had a grade 4 hemorrhage.  A total of 87% of the patients in the ibrutinib group are continuing to take ibrutinib. conclusions Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematol. variables.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMCNq9IoqJj7Vg90H21EOLACvtfcHk0lhJplQilr6Uiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit10%253D&md5=7f6c13e398a31d067951c094abb84e65</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509388%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DTedeschi%26aufirst%3DA.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DOwen%26aufirst%3DC.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBairey%26aufirst%3DO.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DBartlett%26aufirst%3DN.%2BL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSimpson%26aufirst%3DD.%26aulast%3DGrosicki%26aufirst%3DS.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DMcCarthy%26aufirst%3DH.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DQuach%26aufirst%3DH.%26aulast%3DGaidano%26aufirst%3DG.%26aulast%3DMaslyak%26aufirst%3DZ.%26aulast%3DStevens%26aufirst%3DD.%2BA.%26aulast%3DJanssens%26aufirst%3DA.%26aulast%3DOffner%26aufirst%3DF.%26aulast%3DMayer%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DM.%26aulast%3DHellmann%26aufirst%3DA.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3DSiddiqi%26aufirst%3DT.%26aulast%3DPolliack%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DSuri%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DStyles%26aufirst%3DL.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26atitle%3DIbrutinib%2520as%2520initial%2520therapy%2520for%2520patients%2520with%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2425%26epage%3D2437%26doi%3D10.1056%2FNEJMoa1509388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span><span class="refDoi"> DOI: 10.1016/j.phrs.2015.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.phrs.2015.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26529477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2016&pages=26-48&author=R.+Roskoski&title=Classification+of+small+molecule+protein+kinase+inhibitors+based+upon+the+structures+of+their+drug-enzyme+complexes&doi=10.1016%2Fj.phrs.2015.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-48</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Because dysregulation and mutations of protein kinases play causal roles in human disease, this family of enzymes has become one of the most important drug targets over the past two decades.  The X-ray crystal structures of 21 of the 27 FDA-approved small mol. inhibitors bound to their target protein kinases are depicted in this paper.  The structure of the enzyme-bound antagonist complex is used in the classification of these inhibitors.  Type I inhibitors bind to the active protein kinase conformation (DFG-Asp in, αC-helix in).  Type I1/2 inhibitors bind to a DFG-Asp in inactive conformation while Type II inhibitors bind to a DFG-Asp out inactive conformation.  Type I, I1/2, and type II inhibitors occupy part of the adenine binding pocket and form hydrogen bonds with the hinge region connecting the small and large lobes of the enzyme.  Type III inhibitors bind next to the ATP-binding pocket and type IV inhibitors do not bind to the ATP or peptide substrate binding sites.  Type III and IV inhibitors are allosteric in nature.  Type V inhibitors bind to two different regions of the protein kinase domain and are therefore bivalent inhibitors.  The type I-V inhibitors are reversible.  In contrast, type VI inhibitors bind covalently to their target enzyme.  Type I, I1/2, and II inhibitors are divided into A and B subtypes.  The type A inhibitors bind in the front cleft, the back cleft, and near the gatekeeper residue, all of which occur within the region sepg. the small and large lobes of the protein kinase.  The type B inhibitors bind in the front cleft and gate area but do not extend into the back cleft.  An anal. of the limited available data indicates that type A inhibitors have a long residence time (minutes to hours) while the type B inhibitors have a short residence time (seconds to minutes).  The catalytic spine includes residues from the small and large lobes and interacts with the adenine ring of ATP.  Nearly all of the approved protein kinase inhibitors occupy the adenine-binding pocket; thus it is not surprising that these inhibitors interact with nearby catalytic spine (CS) residues.  Moreover, a significant no. of approved drugs also interact with regulatory spine (RS) residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0COwqC0CabVg90H21EOLACvtfcHk0lhJplQilr6Uiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN&md5=e6b45c8644e322f30f898e763780c64b</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DClassification%2520of%2520small%2520molecule%2520protein%2520kinase%2520inhibitors%2520based%2520upon%2520the%2520structures%2520of%2520their%2520drug-enzyme%2520complexes%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D103%26spage%3D26%26epage%3D48%26doi%3D10.1016%2Fj.phrs.2015.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Johnson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerapana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span><span class="refDoi"> DOI: 10.4155/fmc.10.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.+S.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors&doi=10.4155%2Ffmc.10.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0lhJplQilr6Uiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964%26doi%3D10.4155%2Ffmc.10.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref189':['cit189'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Paul R. Leger, Dennis X. Hu, Berenger Biannic, Minna Bui, Xinping Han, Emily Karbarz, Jack Maung, Akinori Okano, Maksim Osipov, Grant M. Shibuya, Kyle Young, Christopher Higgs, Betty Abraham, Delia Bradford, Cynthia Cho, Christophe Colas, Scott Jacobson, Yamini M. Ohol, Deepa Pookot, Payal Rana, Jerick Sanchez, Niket Shah, Michael Sun, Steve Wong, Dirk G. Brockstedt, Paul D. Kassner, Jacob B. Schwarz, <span class="NLM_string-name hlFld-ContribAuthor">David J. Wustrow</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5398-5420. <a href="https://doi.org/10.1021/acs.jmedchem.0c00245" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00245%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BBioavailable%252BInhibitors%252Bof%252BUSP7%252Bwith%252BIn%252BVivo%252BAntitumor%252BActivity%26aulast%3DLeger%26aufirst%3DPaul%2BR.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20022020%26date%3D06052020%26date%3D17042020%26volume%3D63%26issue%3D10%26spage%3D5398%26epage%3D5420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Colin R. O’Dowd, Matthew D. Helm, J. S. Shane Rountree, Jakub T. Flasz, Elias Arkoudis, Hugues Miel, Peter R. Hewitt, Linda Jordan, Oliver Barker, Caroline Hughes, Ewelina Rozycka, Eamon Cassidy, Keeva McClelland, Ewa Odrzywol, Natalie Page, Stephanie Feutren-Burton, Scarlett Dvorkin, Gerald Gavory, <span class="NLM_string-name hlFld-ContribAuthor">Timothy Harrison</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (3)
                                     , 238-243. <a href="https://doi.org/10.1021/acsmedchemlett.7b00512" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00512</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00512%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Band%252BStructure-Guided%252BDevelopment%252Bof%252BPyrimidinone%252BBased%252BUSP7%252BInhibitors%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DColin%2BR.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D08122017%26date%3D12022018%26date%3D21022018%26volume%3D9%26issue%3D3%26spage%3D238%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fan  Zhang</span>, <span class="hlFld-ContribAuthor ">Baoguo  Zhang</span>, <span class="hlFld-ContribAuthor ">Rong  Tang</span>, <span class="hlFld-ContribAuthor ">Haiping  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhimin  Ji</span>, <span class="hlFld-ContribAuthor ">Yongjian  Chen</span>, <span class="hlFld-ContribAuthor ">Hao  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">The occurrence of lupus nephritis is regulated by USP7-mediated JMJD3 stabilization. </span><span class="cited-content_cbyCitation_journal-name">Immunology Letters</span><span> <strong>2021,</strong> <em>235 </em>, 41-50. <a href="https://doi.org/10.1016/j.imlet.2021.04.006" title="DOI URL">https://doi.org/10.1016/j.imlet.2021.04.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.imlet.2021.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.imlet.2021.04.006%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunology%2520Letters%26atitle%3DThe%252Boccurrence%252Bof%252Blupus%252Bnephritis%252Bis%252Bregulated%252Bby%252BUSP7-mediated%252BJMJD3%252Bstabilization%26aulast%3DZhang%26aufirst%3DFan%26date%3D2021%26volume%3D235%26spage%3D41%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji  Sun</span>, <span class="hlFld-ContribAuthor ">Lan  Lin</span>, <span class="hlFld-ContribAuthor ">Jiahao  Zhang</span>, <span class="hlFld-ContribAuthor ">Chunyan  Hu</span>, <span class="hlFld-ContribAuthor ">Jie  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">The prognostic value of USP7 and p53 in advanced hypopharyngeal carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Annals of Diagnostic Pathology</span><span> <strong>2021,</strong> <em>51 </em>, 151695. <a href="https://doi.org/10.1016/j.anndiagpath.2020.151695" title="DOI URL">https://doi.org/10.1016/j.anndiagpath.2020.151695</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.anndiagpath.2020.151695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.anndiagpath.2020.151695%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Diagnostic%2520Pathology%26atitle%3DThe%252Bprognostic%252Bvalue%252Bof%252BUSP7%252Band%252Bp53%252Bin%252Badvanced%252Bhypopharyngeal%252Bcarcinoma%26aulast%3DSun%26aufirst%3DJi%26date%3D2021%26volume%3D51%26spage%3D151695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lauraine  Nininahazwe</span>, <span class="hlFld-ContribAuthor ">Bingrui  Liu</span>, <span class="hlFld-ContribAuthor ">Chenghua  He</span>, <span class="hlFld-ContribAuthor ">Hang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhe-Sheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (2)
                                     , 490-502. <a href="https://doi.org/10.1016/j.drudis.2020.10.028" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.10.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.10.028%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DThe%252Bemerging%252Bnature%252Bof%252BUbiquitin-specific%252Bprotease%252B7%252B%252528USP7%252529%25253A%252Ba%252Bnew%252Btarget%252Bin%252Bcancer%252Btherapy%26aulast%3DNininahazwe%26aufirst%3DLauraine%26date%3D2021%26volume%3D26%26issue%3D2%26spage%3D490%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yamini M.  Ohol</span>, <span class="hlFld-ContribAuthor ">Michael T.  Sun</span>, <span class="hlFld-ContribAuthor ">Gene  Cutler</span>, <span class="hlFld-ContribAuthor ">Paul R.  Leger</span>, <span class="hlFld-ContribAuthor ">Dennis X.  Hu</span>, <span class="hlFld-ContribAuthor ">Berenger  Biannic</span>, <span class="hlFld-ContribAuthor ">Payal  Rana</span>, <span class="hlFld-ContribAuthor ">Cynthia  Cho</span>, <span class="hlFld-ContribAuthor ">Scott  Jacobson</span>, <span class="hlFld-ContribAuthor ">Steve T.  Wong</span>, <span class="hlFld-ContribAuthor ">Jerick  Sanchez</span>, <span class="hlFld-ContribAuthor ">Niket  Shah</span>, <span class="hlFld-ContribAuthor ">Deepa  Pookot</span>, <span class="hlFld-ContribAuthor ">Betty  Abraham</span>, <span class="hlFld-ContribAuthor ">Kyle  Young</span>, <span class="hlFld-ContribAuthor ">Silpa  Suthram</span>, <span class="hlFld-ContribAuthor ">Lisa A.  Marshall</span>, <span class="hlFld-ContribAuthor ">Delia  Bradford</span>, <span class="hlFld-ContribAuthor ">Nathan  Kozon</span>, <span class="hlFld-ContribAuthor ">Xinping  Han</span>, <span class="hlFld-ContribAuthor ">Akinori  Okano</span>, <span class="hlFld-ContribAuthor ">Jack  Maung</span>, <span class="hlFld-ContribAuthor ">Christophe  Colas</span>, <span class="hlFld-ContribAuthor ">Jacob  Schwarz</span>, <span class="hlFld-ContribAuthor ">David  Wustrow</span>, <span class="hlFld-ContribAuthor ">Dirk G.  Brockstedt</span>, <span class="hlFld-ContribAuthor ">Paul D.  Kassner</span>. </span><span class="cited-content_cbyCitation_article-title">Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity
              In Vitro
              and
              In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (10)
                                     , 1970-1980. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0184" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0184</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0184%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DNovel%25252C%252BSelective%252BInhibitors%252Bof%252BUSP7%252BUncover%252BMultiple%252BMechanisms%252Bof%252BAntitumor%252BActivity%252BIn%252BVitro%252Band%252BIn%252BVivo%26aulast%3DOhol%26aufirst%3DYamini%2BM.%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D10%26spage%3D1970%26epage%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Si-Min  Qi</span>, <span class="hlFld-ContribAuthor ">Gang  Cheng</span>, <span class="hlFld-ContribAuthor ">Xiang-Dong  Cheng</span>, <span class="hlFld-ContribAuthor ">Zhiyuan  Xu</span>, <span class="hlFld-ContribAuthor ">Beihua  Xu</span>, <span class="hlFld-ContribAuthor ">Wei-Dong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiang-Jiang  Qin</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fcell.2020.00233" title="DOI URL">https://doi.org/10.3389/fcell.2020.00233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2020.00233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2020.00233%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DTargeting%252BUSP7-Mediated%252BDeubiquitination%252Bof%252BMDM2%25252FMDMX-p53%252BPathway%252Bfor%252BCancer%252BTherapy%25253A%252BAre%252BWe%252BThere%252BYet%25253F%26aulast%3DQi%26aufirst%3DSi-Min%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhe  Wang</span>, <span class="hlFld-ContribAuthor ">Xuwen  Wang</span>, <span class="hlFld-ContribAuthor ">Yu  Kang</span>, <span class="hlFld-ContribAuthor ">Haiyang  Zhong</span>, <span class="hlFld-ContribAuthor ">Chao  Shen</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Yao</span>, <span class="hlFld-ContribAuthor ">Dongsheng  Cao</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Binding affinity and dissociation pathway predictions for a series of USP7 inhibitors with pyrimidinone scaffold by multiple computational methods. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2020,</strong> <em>22 </em>
                                    (10)
                                     , 5487-5499. <a href="https://doi.org/10.1039/D0CP00370K" title="DOI URL">https://doi.org/10.1039/D0CP00370K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CP00370K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CP00370K%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DBinding%252Baffinity%252Band%252Bdissociation%252Bpathway%252Bpredictions%252Bfor%252Ba%252Bseries%252Bof%252BUSP7%252Binhibitors%252Bwith%252Bpyrimidinone%252Bscaffold%252Bby%252Bmultiple%252Bcomputational%252Bmethods%26aulast%3DWang%26aufirst%3DZhe%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D10%26spage%3D5487%26epage%3D5499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yukang  Yuan</span>, <span class="hlFld-ContribAuthor ">Ying  Miao</span>, <span class="hlFld-ContribAuthor ">Chenhua  Zeng</span>, <span class="hlFld-ContribAuthor ">Jin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiangjie  Chen</span>, <span class="hlFld-ContribAuthor ">Liping  Qian</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Wang</span>, <span class="hlFld-ContribAuthor ">Feng  Qian</span>, <span class="hlFld-ContribAuthor ">Zhengyuan  Yu</span>, <span class="hlFld-ContribAuthor ">Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Guanghui  Qian</span>, <span class="hlFld-ContribAuthor ">Qian  Fu</span>, <span class="hlFld-ContribAuthor ">Haitao  Lv</span>, <span class="hlFld-ContribAuthor ">Hui  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Small‐molecule inhibitors of ubiquitin‐specific protease 7 enhance type‐I interferon antiviral efficacy by destabilizing SOCS1. </span><span class="cited-content_cbyCitation_journal-name">Immunology</span><span> <strong>2020,</strong> <em>159 </em>
                                    (3)
                                     , 309-321. <a href="https://doi.org/10.1111/imm.13147" title="DOI URL">https://doi.org/10.1111/imm.13147</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/imm.13147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fimm.13147%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunology%26atitle%3DSmall%2525E2%252580%252590molecule%252Binhibitors%252Bof%252Bubiquitin%2525E2%252580%252590specific%252Bprotease%252B7%252Benhance%252Btype%2525E2%252580%252590I%252Binterferon%252Bantiviral%252Befficacy%252Bby%252Bdestabilizing%252BSOCS1%26aulast%3DYuan%26aufirst%3DYukang%26date%3D2020%26date%3D2019%26volume%3D159%26issue%3D3%26spage%3D309%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xue  Li</span>, <span class="hlFld-ContribAuthor ">Lingmei  Kong</span>, <span class="hlFld-ContribAuthor ">Qihong  Yang</span>, <span class="hlFld-ContribAuthor ">Aizhu  Duan</span>, <span class="hlFld-ContribAuthor ">Xiaoman  Ju</span>, <span class="hlFld-ContribAuthor ">Bicheng  Cai</span>, <span class="hlFld-ContribAuthor ">Lin  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  An</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2020,</strong> <em>295 </em>
                                    (11)
                                     , 3576-3589. <a href="https://doi.org/10.1074/jbc.RA119.011396" title="DOI URL">https://doi.org/10.1074/jbc.RA119.011396</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA119.011396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA119.011396%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DParthenolide%252Binhibits%252Bubiquitin-specific%252Bpeptidase%252B7%252B%252528USP7%252529%25252C%252BWnt%252Bsignaling%25252C%252Band%252Bcolorectal%252Bcancer%252Bcell%252Bgrowth%26aulast%3DLi%26aufirst%3DXue%26date%3D2020%26volume%3D295%26issue%3D11%26spage%3D3576%26epage%3D3589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lining  Lu</span>, <span class="hlFld-ContribAuthor ">Yu  Guo</span>, <span class="hlFld-ContribAuthor ">Tian  Wang</span>, <span class="hlFld-ContribAuthor ">Lujun  Liang</span>, <span class="hlFld-ContribAuthor ">Suwen  Zhao</span>, <span class="hlFld-ContribAuthor ">Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Inactivity of YGL082W in vitro due to impairment of conformational change in the catalytic center loop. </span><span class="cited-content_cbyCitation_journal-name">Science China Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 237-243. <a href="https://doi.org/10.1007/s11426-019-9623-0" title="DOI URL">https://doi.org/10.1007/s11426-019-9623-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11426-019-9623-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11426-019-9623-0%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520China%2520Chemistry%26atitle%3DInactivity%252Bof%252BYGL082W%252Bin%252Bvitro%252Bdue%252Bto%252Bimpairment%252Bof%252Bconformational%252Bchange%252Bin%252Bthe%252Bcatalytic%252Bcenter%252Bloop%26aulast%3DLu%26aufirst%3DLining%26date%3D2020%26date%3D2019%26volume%3D63%26issue%3D2%26spage%3D237%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah  Zachariah</span>, <span class="hlFld-ContribAuthor ">Douglas A.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Deubiquitinating Enzymes in Model Systems and Therapy: Redundancy and Compensation Have Implications. </span><span class="cited-content_cbyCitation_journal-name">BioEssays</span><span> <strong>2019,</strong> <em>41 </em>
                                    (11)
                                     , 1900112. <a href="https://doi.org/10.1002/bies.201900112" title="DOI URL">https://doi.org/10.1002/bies.201900112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bies.201900112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbies.201900112%26sid%3Dliteratum%253Aachs%26jtitle%3DBioEssays%26atitle%3DDeubiquitinating%252BEnzymes%252Bin%252BModel%252BSystems%252Band%252BTherapy%25253A%252BRedundancy%252Band%252BCompensation%252BHave%252BImplications%26aulast%3DZachariah%26aufirst%3DSarah%26date%3D2019%26date%3D2019%26volume%3D41%26issue%3D11%26spage%3D1900112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kifayat  Ullah</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Zubia</span>, <span class="hlFld-ContribAuthor ">Mahesh  Narayan</span>, <span class="hlFld-ContribAuthor ">Jing  Yang</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Diverse roles of the E2/E3 hybrid enzyme
              UBE
              2O in the regulation of protein ubiquitination, cellular functions, and disease onset. </span><span class="cited-content_cbyCitation_journal-name">The FEBS Journal</span><span> <strong>2019,</strong> <em>286 </em>
                                    (11)
                                     , 2018-2034. <a href="https://doi.org/10.1111/febs.14708" title="DOI URL">https://doi.org/10.1111/febs.14708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/febs.14708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Ffebs.14708%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FEBS%2520Journal%26atitle%3DDiverse%252Broles%252Bof%252Bthe%252BE2%25252FE3%252Bhybrid%252Benzyme%252BUBE%252B2O%252Bin%252Bthe%252Bregulation%252Bof%252Bprotein%252Bubiquitination%25252C%252Bcellular%252Bfunctions%25252C%252Band%252Bdisease%252Bonset%26aulast%3DUllah%26aufirst%3DKifayat%26date%3D2019%26date%3D2018%26volume%3D286%26issue%3D11%26spage%3D2018%26epage%3D2034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saumitra  Sengupta</span>, <span class="hlFld-ContribAuthor ">Goverdhan  Mehta</span>. </span><span class="cited-content_cbyCitation_article-title">Non-peptidic natural products as ubiquitin-proteasome inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2019,</strong> <em>75 </em>
                                    (7)
                                     , 817-853. <a href="https://doi.org/10.1016/j.tet.2018.12.012" title="DOI URL">https://doi.org/10.1016/j.tet.2018.12.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2018.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2018.12.012%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DNon-peptidic%252Bnatural%252Bproducts%252Bas%252Bubiquitin-proteasome%252Binhibitors%26aulast%3DSengupta%26aufirst%3DSaumitra%26date%3D2019%26volume%3D75%26issue%3D7%26spage%3D817%26epage%3D853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Gao</span>, <span class="hlFld-ContribAuthor ">Yaqin  Wang</span>, <span class="hlFld-ContribAuthor ">Chan  Zhou</span>, <span class="hlFld-ContribAuthor ">Shuangbo  Kong</span>, <span class="hlFld-ContribAuthor ">Jinhua  Lu</span>, <span class="hlFld-ContribAuthor ">Haibin  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Ubiquitin-specific protease 7 (USP7) is essential for endometrial stromal cell decidualization in mice. </span><span class="cited-content_cbyCitation_journal-name">Development, Growth & Differentiation</span><span> <strong>2019,</strong> <em>61 </em>
                                    (2)
                                     , 176-185. <a href="https://doi.org/10.1111/dgd.12594" title="DOI URL">https://doi.org/10.1111/dgd.12594</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/dgd.12594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fdgd.12594%26sid%3Dliteratum%253Aachs%26jtitle%3DDevelopment%252C%2520Growth%2520%2526%2520Differentiation%26atitle%3DUbiquitin-specific%252Bprotease%252B7%252B%252528USP7%252529%252Bis%252Bessential%252Bfor%252Bendometrial%252Bstromal%252Bcell%252Bdecidualization%252Bin%252Bmice%26aulast%3DGao%26aufirst%3DYue%26date%3D2019%26date%3D2019%26volume%3D61%26issue%3D2%26spage%3D176%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gerald  Gavory</span>, <span class="hlFld-ContribAuthor ">Colin R  O'Dowd</span>, <span class="hlFld-ContribAuthor ">Matthew D  Helm</span>, <span class="hlFld-ContribAuthor ">Jakub  Flasz</span>, <span class="hlFld-ContribAuthor ">Elias  Arkoudis</span>, <span class="hlFld-ContribAuthor ">Anthony  Dossang</span>, <span class="hlFld-ContribAuthor ">Caroline  Hughes</span>, <span class="hlFld-ContribAuthor ">Eamon  Cassidy</span>, <span class="hlFld-ContribAuthor ">Keeva  McClelland</span>, <span class="hlFld-ContribAuthor ">Ewa  Odrzywol</span>, <span class="hlFld-ContribAuthor ">Natalie  Page</span>, <span class="hlFld-ContribAuthor ">Oliver  Barker</span>, <span class="hlFld-ContribAuthor ">Hugues  Miel</span>, <span class="hlFld-ContribAuthor ">Timothy  Harrison</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2018,</strong> <em>14 </em>
                                    (2)
                                     , 118-125. <a href="https://doi.org/10.1038/nchembio.2528" title="DOI URL">https://doi.org/10.1038/nchembio.2528</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nchembio.2528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnchembio.2528%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DDiscovery%252Band%252Bcharacterization%252Bof%252Bhighly%252Bpotent%252Band%252Bselective%252Ballosteric%252BUSP7%252Binhibitors%26aulast%3DGavory%26aufirst%3DGerald%26date%3D2018%26date%3D2017%26volume%3D14%26issue%3D2%26spage%3D118%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Ubiquitin pathway and inhibitors: Ubiquitin is activated by E1 in an ATP dependent adenylation reaction forming E1–Ub thioester. Activated Ub is transferred to the active site cysteine of an E2 enzyme in a transthiolation reaction to generate E2–Ub thioester, which is subsequently transferred in an E3 ligase dependent manner to the ε-amino group of lysine in a substrate. Substrates modified with lysine 48-linked polyubiquitin chains are degraded by the proteasome. Alternately, ubiquitin can be removed from the substrate by deubiquitinating enzymes called DUBs. Representative examples of small molecule inhibitors that perturb E2, E3, and DUBs are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Multimodal antitumor activities of USP7 inhibitors. USP7 inhibitors exhibit intrinsic antitumor activities by downregulating protumorigenic proteins and extrinsic immune mediated antitumor activities by attenuating T<sub>reg</sub> functions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Cocrystal structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WPI">4WPI</a>) of ICP0 peptide (green) with USP7 C-terminal UBL-123 domain (gray); (B) key interactions between ICP0 peptide (green) and USP7 UBL-2 domain (gray).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Superimposed cocrystal structures (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FOO">2FOO</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FOP">2FOP</a>) of p53 peptide (green), MDM2 peptide (orange), and USP7 N-terminal TRAF domain (gray); (B) key interactions between substrate peptides (green and orange) and USP7 TRAF pocket (gray).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Overlay of Apo-USP7 (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4M5X">4M5X</a>) with Ub-bound USP7 (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JTV">5JTV</a>). Ub-bound USP7 catalytic domain flexible loops are colored in green, Apo-USP7 catalytic domain flexible loops are colored in red, and ubiquitin is colored in cyan. (B) Shift of catalytic trial residues (C223, H464, and D481) upon the binding of ubiquitin. Inactive conformation is shown in gray, while the active conformation is shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Catalytic mechanism of USP7.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Various DUB substrates: (A) C-terminal fusion of ubiquitin with fluorophore resulting in Ub-AMC and Ub-Rh110 substrates. (B) Ubiquitin fusion to the amino-terminus of reporter enzymes PLA2 and EKL to generate coupled reporter substrates. (C) Internally quenched fluorescent diubiquitins. (D) Fluorescently labeled substrate derived peptide containing isopeptide linked ubiquitin as substrate for fluorescence polarization assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of reported USP7 inhibitors from Hybrigenics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of USP7 inhibitors from Progenra.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of USP7 inhibitors from FORMA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of USP7 inhibitors from Genentech.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of USP7 inhibitors from China Pharmaceutical University.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/medium/jm-2017-00498c_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of USP7 inhibitors from natural sources.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-2/acs.jmedchem.7b00498/20180119/images/large/jm-2017-00498c_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00498&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77102" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77102" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 146 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Giles, J.</span><span> </span><span class="NLM_article-title">Chemistry Nobel for trio who revealed molecular death-tag</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">431</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="refDoi"> DOI: 10.1038/431729a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2F431729a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2004&pages=729&author=J.+Giles&title=Chemistry+Nobel+for+trio+who+revealed+molecular+death-tag&doi=10.1038%2F431729a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F431729a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F431729a%26sid%3Dliteratum%253Aachs%26aulast%3DGiles%26aufirst%3DJ.%26atitle%3DChemistry%2520Nobel%2520for%2520trio%2520who%2520revealed%2520molecular%2520death-tag%26jtitle%3DNature%26date%3D2004%26volume%3D431%26spage%3D729%26doi%3D10.1038%2F431729a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Bortezomib: a novel therapy approved for multiple myeloma</span> <span class="citation_source-journal">Clin. Adv. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16258456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BD2MrnvVCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=596-600&author=P.+G.+Richardsonauthor=K.+C.+Anderson&title=Bortezomib%3A+a+novel+therapy+approved+for+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib: a novel therapy approved for multiple myeloma</span></div><div class="casAuthors">Richardson Paul G; Anderson Kenneth C</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">596-600</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">Cellular homeostasis requires routine degradation of key regulatory proteins, including tumor suppressor gene products, transcription factors, cell-cycle proteins and their inhibitors, as well as damaged and misfolded proteins.  A critical part of this process is mediated by the 26S proteasome, a multi-subunit enzyme found in the nucleus and cytoplasm of all eukaryotic cells.  Because of its essential role in many cellular processes controlling growth and survival, the proteasome has been identified as a potential target for cancer therapy.  Drugs known to inhibit proteasome activity have been shown to induce cell-cycle arrest and programmed cell death (apoptosis).  The impact of this finding is heightened by research showing that cancer cells are more sensitive to the proapoptotic effects of proteasome inhibition than normal cells.  Preclinical evidence using bortezomib, the only proteasome inhibitor to enter clinical trials, suggests that proteasome inhibition may be effective in the treatment of hematologic and solid malignancies by promoting apoptosis, retarding angiogenesis, and inhibiting tumor cell adhesion and production of growth factors by acting on molecules such as nuclear factor-kappaB.  Further preclinical evidence suggests that the antitumor effects of cytotoxic chemotherapy or radiotherapy may be enhanced by the addition of a proteasome inhibitor.  Bortezomib was recently approved for the treatment of multiple myeloma.  It is currently being investigated, both as a single agent and in combination, in phase I and II trials in a variety of tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOfAcXvzm18T0SWnHPWbmmfW6udTcc2eb8ZF89FKcvWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrnvVCqsQ%253D%253D&md5=1f5722a7647672435cb2c72096f6b71a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DBortezomib%253A%2520a%2520novel%2520therapy%2520approved%2520for%2520multiple%2520myeloma%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2003%26volume%3D1%26spage%3D596%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Cejalvo, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Rubia, J.</span><span> </span><span class="NLM_article-title">Which therapies will move to the front line for multiple myeloma?</span> <span class="citation_source-journal">Expert Rev. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span><span class="refDoi"> DOI: 10.1080/17474086.2017.1317589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1080%2F17474086.2017.1317589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=28388244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXms1Wltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=383-392&author=M.+J.+Cejalvoauthor=J.+de+la+Rubia&title=Which+therapies+will+move+to+the+front+line+for+multiple+myeloma%3F&doi=10.1080%2F17474086.2017.1317589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Which therapies will move to the front line for multiple myeloma?</span></div><div class="casAuthors">Cejalvo, Maria J.; de la Rubia, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">383-392</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Despite substantial progress, multiple myeloma (MM) remains an incurable disease.  Recently the availability of several novel drugs with different and innovative mechanisms of action (daratumumab, elotuzumab, carfilzomib, ixazomib, and panobinostat) has increased the therapeutic options but has also increased complexity in the management of patients with MM.: The outstanding results obsd. in the relapsed setting with regimens including these new drugs has provided the investigators with several treatment options that are being tested also in patients with newly diagnosed MM.  Fully published phase 2 and randomized, phase 3 trials including new drugs in patients with relapsed and/or refractory MM have been reviewed.  In addn., the progressive incorporation of these new drugs in the front-line treatment of MM and the potential impact of these new therapies in the management of patients with newly diagnosed MM has also been addressed.: In the near future, several novel anti-MM drugs will move from the relapsed to the front-line setting.  While the increasing range of effective therapeutic agents is very encouraging it adds to the complexity of treatment decisions and prospective trials are needed to help clinicians to det. which could be the best therapeutic approaches for the different subgroups of patients with newly diagnosed MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ61n9yQUwbLVg90H21EOLACvtfcHk0liFrd2xV38XAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXms1Wltb8%253D&md5=37f31fddd140059dbb3063fdaab29f2b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F17474086.2017.1317589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2017.1317589%26sid%3Dliteratum%253Aachs%26aulast%3DCejalvo%26aufirst%3DM.%2BJ.%26aulast%3Dde%2Bla%2BRubia%26aufirst%3DJ.%26atitle%3DWhich%2520therapies%2520will%2520move%2520to%2520the%2520front%2520line%2520for%2520multiple%2520myeloma%253F%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2017%26volume%3D10%26spage%3D383%26epage%3D392%26doi%3D10.1080%2F17474086.2017.1317589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">List, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellamy, W.</span><span> </span><span class="NLM_article-title">Lenalidomide: targeted anemia therapy for myelodysplastic syndromes</span> <span class="citation_source-journal">Cancer Control</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=4-11&issue=Suppl&author=A.+F.+Listauthor=A.+F.+Bakerauthor=S.+Greenauthor=W.+Bellamy&title=Lenalidomide%3A+targeted+anemia+therapy+for+myelodysplastic+syndromes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DList%26aufirst%3DA.%2BF.%26aulast%3DBaker%26aufirst%3DA.%2BF.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DBellamy%26aufirst%3DW.%26atitle%3DLenalidomide%253A%2520targeted%2520anemia%2520therapy%2520for%2520myelodysplastic%2520syndromes%26jtitle%3DCancer%2520Control%26date%3D2006%26volume%3D13%26issue%3DSuppl%26spage%3D4%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Gras, J.</span><span> </span><span class="NLM_article-title">Pomalidomide for patients with multiple myeloma</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">555</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1358/dot.2013.49.09.2017031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1358%2Fdot.2013.49.09.2017031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252Flslyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=555-562&author=J.+Gras&title=Pomalidomide+for+patients+with+multiple+myeloma&doi=10.1358%2Fdot.2013.49.09.2017031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pomalidomide for patients with multiple myeloma</span></div><div class="casAuthors">Gras J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">555-62</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Multiple myeloma is a malignancy of plasma cells in the bone marrow.  Currently, multiple myeloma is not considered curable, but it is treatable with different strategies that can combine chemotherapy with autologous hematopoietic stem cell transplantation.  Pomalidomide is an orally active thalidomide analogue that has a pleiotropic mechanism of action involving oncolytic, antiangiogenic, immunomodulatory and anti-inflammatory activities.  Pomalidomide is extensively metabolized, mainly by the cytochrome P450 3A4 and 1A2 pathways.  The safety and efficacy of pomalidomide combined with dexamethasone has been demonstrated in a phase III trial for the treatment of multiple myeloma patients, relapsed/resistant to bortezomib and lenalidomide.  Adverse events that were mainly related to myelosuppression, were manageable.  Pomalidomide has orphan drug status both in the U.S. and Europe for multiple myeloma.  It was approved by the U.S.  Food and Drug Administration as Pomalyst® for the treatment of multiple myeloma last February, and recently approved in Europe in August.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSlb14qikVjeIJKJbLTgsvCfW6udTcc2eYU7kxuXuV_0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252Flslyluw%253D%253D&md5=062e9efce2fc76a61c6657c2c81f9050</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1358%2Fdot.2013.49.09.2017031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2013.49.09.2017031%26sid%3Dliteratum%253Aachs%26aulast%3DGras%26aufirst%3DJ.%26atitle%3DPomalidomide%2520for%2520patients%2520with%2520multiple%2520myeloma%26jtitle%3DDrugs%2520Today%26date%3D2013%26volume%3D49%26spage%3D555%26epage%3D562%26doi%3D10.1358%2Fdot.2013.49.09.2017031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Lu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naniong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaelin, W. G.,  Jr.</span><span> </span><span class="NLM_article-title">The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span><span class="refDoi"> DOI: 10.1126/science.1244917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1126%2Fscience.1244917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24292623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=305-309&author=G.+Luauthor=R.+E.+Middletonauthor=H.+Sunauthor=M.+Naniongauthor=C.+J.+Ottauthor=C.+S.+Mitsiadesauthor=K.+K.+Wongauthor=J.+E.+Bradnerauthor=W.+G.+Kaelin&title=The+myeloma+drug+lenalidomide+promotes+the+cereblon-dependent+destruction+of+Ikaros+proteins&doi=10.1126%2Fscience.1244917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins</span></div><div class="casAuthors">Lu, Gang; Middleton, Richard E.; Sun, Huahang; Naniong, MarkVic; Ott, Christopher J.; Mitsiades, Constantine S.; Wong, Kwok-Kin; Bradner, James E.; Kaelin, William G., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">305-309</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Thalidomide-like drugs such as lenalidomide are clin. important treatments for multiple myeloma and show promise for other B cell malignancies.  The biochem. mechanisms underlying their antitumor activity are unknown.  Thalidomide was recently shown to bind to, and inhibit, the cereblon ubiquitin ligase.  Cereblon loss in zebrafish causes fin defects reminiscent of the limb defects seen in children exposed to thalidomide in utero.  Here we show that lenalidomide-bound cereblon acquires the ability to target for proteasomal degrdn. two specific B cell transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3).  Anal. of myeloma cell lines revealed that loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect, suggesting that the antitumor and teratogenic activities of thalidomide-like drugs are dissociable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0froz4Kipu7Vg90H21EOLACvtfcHk0lg6ga8LC3Wt6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D&md5=a9df5bbde0f676b92b1bec48fdbbb502</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244917%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DG.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DNaniong%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26atitle%3DThe%2520myeloma%2520drug%2520lenalidomide%2520promotes%2520the%2520cereblon-dependent%2520destruction%2520of%2520Ikaros%2520proteins%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D305%26epage%3D309%26doi%3D10.1126%2Fscience.1244917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Gandhi, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havens, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakurta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klippel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopra, R.</span><span> </span><span class="NLM_article-title">Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">821</span><span class="refDoi"> DOI: 10.1111/bjh.12708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1111%2Fbjh.12708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24328678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2014&pages=811-821&author=A.+K.+Gandhiauthor=J.+Kangauthor=C.+G.+Havensauthor=T.+Conklinauthor=Y.+Ningauthor=L.+Wuauthor=T.+Itoauthor=H.+Andoauthor=M.+F.+Waldmanauthor=A.+Thakurtaauthor=A.+Klippelauthor=H.+Handaauthor=T.+O.+Danielauthor=P.+H.+Schaferauthor=R.+Chopra&title=Immunomodulatory+agents+lenalidomide+and+pomalidomide+co-stimulate+T+cells+by+inducing+degradation+of+T+cell+repressors+Ikaros+and+Aiolos+via+modulation+of+the+E3+ubiquitin+ligase+complex+CRL4%28CRBN.%29&doi=10.1111%2Fbjh.12708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN</span></div><div class="casAuthors">Gandhi, Anita K.; Kang, Jian; Havens, Courtney G.; Conklin, Thomas; Ning, Yuhong; Wu, Lei; Ito, Takumi; Ando, Hideki; Waldman, Michelle F.; Thakurta, Anjan; Klippel, Anke; Handa, Hiroshi; Daniel, Thomas O.; Schafer, Peter H.; Chopra, Rajesh</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">811-821</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cereblon (CRBN), the mol. target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4CRBN.  T cell co-stimulation by lenalidomide or pomalidomide is cereblon dependent: however, the CRL4CRBN substrates responsible for T cell co-stimulation have yet to be identified.  Here we demonstrate that interaction of the transcription factors Ikaros (IKZF1, encoded by the IKZF1 gene) and Aiolos (IKZF3, encoded by the IKZF3 gene) with CRL4CRBN is induced by lenalidomide or pomalidomide.  Each agent promotes Aiolos and Ikaros binding to CRL4CRBN with enhanced ubiquitination leading to cereblon-dependent proteosomal degrdn. in T lymphocytes.  We confirm that Aiolos and Ikaros are transcriptional repressors of interleukin-2 expression.  The findings link lenalidomide- or pomalidomide-induced degrdn. of these transcriptional suppressors to well documented T cell activation.  Importantly, Aiolos could serve as a proximal pharmacodynamic marker for lenalidomide and pomalidomide, as healthy human subjects administered lenalidomide demonstrated Aiolos degrdn. in their peripheral T cells.  In conclusion, we present a mol. model in which drug binding to cereblon results in the interaction of Ikaros and Aiolos to CRL4CRBN, leading to their ubiquitination, subsequent proteasomal degrdn. and T cell activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNm80s9sQNeLVg90H21EOLACvtfcHk0lghLV-O84J7JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslWmu74%253D&md5=8ddf00ec1e3c1b1176603f22e8832f58</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12708%26sid%3Dliteratum%253Aachs%26aulast%3DGandhi%26aufirst%3DA.%2BK.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DHavens%26aufirst%3DC.%2BG.%26aulast%3DConklin%26aufirst%3DT.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DH.%26aulast%3DWaldman%26aufirst%3DM.%2BF.%26aulast%3DThakurta%26aufirst%3DA.%26aulast%3DKlippel%26aufirst%3DA.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DChopra%26aufirst%3DR.%26atitle%3DImmunomodulatory%2520agents%2520lenalidomide%2520and%2520pomalidomide%2520co-stimulate%2520T%2520cells%2520by%2520inducing%2520degradation%2520of%2520T%2520cell%2520repressors%2520Ikaros%2520and%2520Aiolos%2520via%2520modulation%2520of%2520the%2520E3%2520ubiquitin%2520ligase%2520complex%2520CRL4%2528CRBN.%2529%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2014%26volume%3D164%26spage%3D811%26epage%3D821%26doi%3D10.1111%2Fbjh.12708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hershko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciechanover, A.</span><span> </span><span class="NLM_article-title">The ubiquitin system</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span><span class="refDoi"> DOI: 10.1146/annurev.biochem.67.1.425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1146%2Fannurev.biochem.67.1.425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=9759494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADyaK1cXlsFOmsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1998&pages=425-479&author=A.+Hershkoauthor=A.+Ciechanover&title=The+ubiquitin+system&doi=10.1146%2Fannurev.biochem.67.1.425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitin system</span></div><div class="casAuthors">Hershko, Avram; Ciechanover, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">425-479</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with ∼298 refs.  The selective degrdn. of many short-lived proteins in eukaryotic cells is carried out by the ubiquitin system.  In this pathway, proteins are targeted for degrdn. by covalent ligation to ubiquitin, a highly conserved small protein.  Ubiquitin-mediated degrdn. of regulatory proteins plays important roles in the control of numerous processes, including cell-cycle progression, signal transduction, transcriptional regulation, receptor down-regulation, and endocytosis.  The ubiquitin system has been implicated in the immune response, development, and programmed cell death.  Abnormalities in ubiquitin-mediated processes have been shown to cause pathol. conditions, including malignant transformation.  In this review we discuss recent information on functions and mechanisms of the ubiquitin system.  Since the selectivity of protein degrdn. is detd. mainly at the stage of ligation to ubiquitin, special attention is focused on what we know, and would like to know, about the mode of action of ubiquitin-protein ligation systems and about signals in proteins recognized by these systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqo5VhDx0kSLVg90H21EOLACvtfcHk0lghLV-O84J7JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlsFOmsLc%253D&md5=7c3c0a6df9c07baf55b5000eae13ef49</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.67.1.425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.67.1.425%26sid%3Dliteratum%253Aachs%26aulast%3DHershko%26aufirst%3DA.%26aulast%3DCiechanover%26aufirst%3DA.%26atitle%3DThe%2520ubiquitin%2520system%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1998%26volume%3D67%26spage%3D425%26epage%3D479%26doi%3D10.1146%2Fannurev.biochem.67.1.425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ciechanover, A.</span><span> </span><span class="NLM_article-title">The unravelling of the ubiquitin system</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1038/nrm3982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrm3982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25907614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFCiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=322-324&author=A.+Ciechanover&title=The+unravelling+of+the+ubiquitin+system&doi=10.1038%2Fnrm3982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The unravelling of the ubiquitin system</span></div><div class="casAuthors">Ciechanover, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">322-324</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Today, many scientific discoveries are made using a top-down exptl. approach.  The ubiquitin system was discovered using a classic bottom-up approach to tackle the question: how are cellular proteins selectively degraded.  A simple proteolytic assay, which used a crude cell-ext., was all that was required to address this question; it was followed by fractionation and reconstitution expts. to decipher the role of the components in this multi-step process.  This biochem. at its best approach, which was published in a periodical that today would not be regarded as highly visible, provided magnificent findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHAT8iHvnR3LVg90H21EOLACvtfcHk0lghLV-O84J7JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFCiur4%253D&md5=9bddfc645a49922d90137156f0295aa3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrm3982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3982%26sid%3Dliteratum%253Aachs%26aulast%3DCiechanover%26aufirst%3DA.%26atitle%3DThe%2520unravelling%2520of%2520the%2520ubiquitin%2520system%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D322%26epage%3D324%26doi%3D10.1038%2Fnrm3982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goedert, M.</span><span> </span><span class="NLM_article-title">GSK3 inhibitors: development and therapeutic potential</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">487</span><span class="refDoi"> DOI: 10.1038/nrd1415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrd1415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=15173837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=479-487&author=P.+Cohenauthor=M.+Goedert&title=GSK3+inhibitors%3A+development+and+therapeutic+potential&doi=10.1038%2Fnrd1415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 inhibitors: development and therapeutic potential</span></div><div class="casAuthors">Cohen, Philip; Goedert, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metab.  In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics.  Here, we describe the biol. of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL3ua5xi0_qrVg90H21EOLACvtfcHk0liOFwLJNomnRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D&md5=165d1354bf11faa6021ac4dba797fda2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd1415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1415%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26atitle%3DGSK3%2520inhibitors%253A%2520development%2520and%2520therapeutic%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D479%26epage%3D487%26doi%3D10.1038%2Fnrd1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Isaacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbolsheimer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaviano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng-Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creswell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novielli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slack, R.</span><span> </span><span class="NLM_article-title">Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1007/s10549-010-1226-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs10549-010-1226-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20976541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWgtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2011&pages=137-143&author=C.+Isaacsauthor=P.+Herbolsheimerauthor=M.+C.+Liuauthor=M.+Wilkinsonauthor=Y.+Ottavianoauthor=G.+G.+Chungauthor=R.+Warrenauthor=J.+Eng-Wongauthor=P.+Cohenauthor=K.+L.+Smithauthor=K.+Creswellauthor=A.+Novielliauthor=R.+Slack&title=Phase+I%2FII+study+of+sorafenib+with+anastrozole+in+patients+with+hormone+receptor+positive+aromatase+inhibitor+resistant+metastatic+breast+cancer&doi=10.1007%2Fs10549-010-1226-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer</span></div><div class="casAuthors">Isaacs, Claudine; Herbolsheimer, Pia; Liu, Minetta C.; Wilkinson, Mary; Ottaviano, Yvonne; Chung, Gina G.; Warren, Robert; Eng-Wong, Jennifer; Cohen, Philip; Smith, Karen L.; Creswell, Karen; Novielli, Antonella; Slack, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-143</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We evaluated the use of sorafenib to overcome resistance to aromatase inhibitors (AIs) in patients with metastatic breast cancer who had disease recurrence or progression while on AIs.  We performed a multi-institution phase I/II study of sorafenib and anastrozole 1 mg daily in 35 postmenopausal females with hormone receptor pos. metastatic breast cancer resistant to AIs.  Primary objectives were to det. the dose of sorafenib in conjunction with anastrozole and the clin. benefit rate (CBR) (complete response [CR], partial response [PR], or stable disease [SD] ≥ 24 wk).  Secondary objectives were to det. toxicity and to evaluate if response was assocd. with change in no. of circulating endothelial cells or circulating endothelial progenitor cells.  Based on the phase I portion, sorafenib 400 mg twice daily was selected as the phase II dose.  Among 35 patients, 7 had SD ≥ 24 wk, 1 had PR ≥ 24 wk, and 14 had progressive disease (PD) ≤ 24 wk, corresponding to a CBR of 23%.  The most common adverse events (all; Grade 3/4) were fatigue (66%; 17%), diarrhea (63%; 6%), nausea (60%; 9%), and hand-foot syndrome (57%; 34%).  Dose redn. occurred in 77% of the patients and 31% came off study due to toxicity.  The combination of sorafenib and anastrozole demonstrated a 23% CBR in patients with hormone receptor pos., AI-resistant metastatic breast cancer, which may be attributable to the restoration of sensitivity to AIs.  Toxicities occurred frequently resulting in a high rate of discontinuation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpNHxpBnFn9bVg90H21EOLACvtfcHk0liOFwLJNomnRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWgtLnN&md5=d45bd053969576e7534b0e553257d86d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs10549-010-1226-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-010-1226-z%26sid%3Dliteratum%253Aachs%26aulast%3DIsaacs%26aufirst%3DC.%26aulast%3DHerbolsheimer%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DM.%2BC.%26aulast%3DWilkinson%26aufirst%3DM.%26aulast%3DOttaviano%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DG.%2BG.%26aulast%3DWarren%26aufirst%3DR.%26aulast%3DEng-Wong%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DK.%2BL.%26aulast%3DCreswell%26aufirst%3DK.%26aulast%3DNovielli%26aufirst%3DA.%26aulast%3DSlack%26aufirst%3DR.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520sorafenib%2520with%2520anastrozole%2520in%2520patients%2520with%2520hormone%2520receptor%2520positive%2520aromatase%2520inhibitor%2520resistant%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D125%26spage%3D137%26epage%3D143%26doi%3D10.1007%2Fs10549-010-1226-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tcherpakov, M.</span><span> </span><span class="NLM_article-title">Will the ubiquitin system furnish as many drug targets as protein kinases?</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">143</span><span class="NLM_x">, </span> <span class="NLM_fpage">686</span><span class="NLM_x">–</span> <span class="NLM_lpage">693</span><span class="refDoi"> DOI: 10.1016/j.cell.2010.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.cell.2010.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21111230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygsLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2010&pages=686-693&author=P.+Cohenauthor=M.+Tcherpakov&title=Will+the+ubiquitin+system+furnish+as+many+drug+targets+as+protein+kinases%3F&doi=10.1016%2Fj.cell.2010.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?</span></div><div class="casAuthors">Cohen, Philip; Tcherpakov, Marianna</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">686-693</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation and protein ubiquitination regulate most aspects of cell life, and defects in these control mechanisms cause cancer and many other diseases.  In the past decade, protein kinases have become one of the most important classes of drug targets for the pharmaceutical industry.  In contrast, drug discovery programs that target components of the ubiquitin system have lagged behind.  In this Perspective, we discuss the reasons for the delay in this pipeline, the drugs targeting the ubiquitin system that have been developed, and new approaches that may popularize this area of drug discovery in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqocw2eBP5US7Vg90H21EOLACvtfcHk0liOFwLJNomnRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygsLbI&md5=b273310afef9fd544a534d9f39b0afb2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DTcherpakov%26aufirst%3DM.%26atitle%3DWill%2520the%2520ubiquitin%2520system%2520furnish%2520as%2520many%2520drug%2520targets%2520as%2520protein%2520kinases%253F%26jtitle%3DCell%26date%3D2010%26volume%3D143%26spage%3D686%26epage%3D693%26doi%3D10.1016%2Fj.cell.2010.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Ciechanover, A.</span><span> </span><span class="NLM_article-title">The ubiquitin-proteasome pathway: on protein death and cell life</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7151</span><span class="NLM_x">–</span> <span class="NLM_lpage">7160</span><span class="refDoi"> DOI: 10.1093/emboj/17.24.7151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1093%2Femboj%2F17.24.7151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1998&pages=7151-7160&author=A.+Ciechanover&title=The+ubiquitin-proteasome+pathway%3A+on+protein+death+and+cell+life&doi=10.1093%2Femboj%2F17.24.7151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F17.24.7151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F17.24.7151%26sid%3Dliteratum%253Aachs%26aulast%3DCiechanover%26aufirst%3DA.%26atitle%3DThe%2520ubiquitin-proteasome%2520pathway%253A%2520on%2520protein%2520death%2520and%2520cell%2520life%26jtitle%3DEMBO%2520J.%26date%3D1998%26volume%3D17%26spage%3D7151%26epage%3D7160%26doi%3D10.1093%2Femboj%2F17.24.7151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hochstrasser, M.</span><span> </span><span class="NLM_article-title">Ubiquitin-dependent protein degradation</span> <span class="citation_source-journal">Annu. Rev. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1146/annurev.genet.30.1.405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1146%2Fannurev.genet.30.1.405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=8982460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADyaK2sXht1yk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1996&pages=405-439&author=M.+Hochstrasser&title=Ubiquitin-dependent+protein+degradation&doi=10.1146%2Fannurev.genet.30.1.405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-dependent protein degradation</span></div><div class="casAuthors">Hochstrasser, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Genetics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">405-439</span>CODEN:
                <span class="NLM_cas:coden">ARVGB7</span>;
        ISSN:<span class="NLM_cas:issn">0066-4197</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review with 115 refs.  A growing no. of cellular regulatory mechanisms are being linked to protein modification by the polypeptide ubiquitin.  These include key transitions in the cell cycle, class I antigen processing, signal transduction pathways, and receptor-mediated endocytosis.  In most, but not all, of these examples, ubiquitination of a protein leads to its degrdn. by the 26S proteasome.  Following attachment of ubiquitin to a substrate and binding of the ubiquitinated protein to the proteasome, the bound substrate must be unfolded (and eventually deubiquitinated) and translocated through a narrow set of channels that leads to the proteasome interior, where the polypeptide is cleaved into short peptides.  Protein ubiquitination and deubiquitination are both mediated by large enzyme families, and the proteasome itself comprises a family of related but functionally distinct particles.  This diversity underlies both the high substrate specificity of the ubiquitin system and the variety of regulatory mechanisms that it serves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8i3KZXfGSRrVg90H21EOLACvtfcHk0lhzcbnX3kgauQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1yk&md5=8b3d3ec0806e94afee1e0374fae69db2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1146%2Fannurev.genet.30.1.405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.genet.30.1.405%26sid%3Dliteratum%253Aachs%26aulast%3DHochstrasser%26aufirst%3DM.%26atitle%3DUbiquitin-dependent%2520protein%2520degradation%26jtitle%3DAnnu.%2520Rev.%2520Genet.%26date%3D1996%26volume%3D30%26spage%3D405%26epage%3D439%26doi%3D10.1146%2Fannurev.genet.30.1.405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Yamao, F.</span><span> </span><span class="NLM_article-title">Ubiquitin system: selectivity and timing of protein destruction</span> <span class="citation_source-journal">J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1093/oxfordjournals.jbchem.a022277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1093%2Foxfordjournals.jbchem.a022277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=9990117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADyaK1MXitFyktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=1999&pages=223-229&author=F.+Yamao&title=Ubiquitin+system%3A+selectivity+and+timing+of+protein+destruction&doi=10.1093%2Foxfordjournals.jbchem.a022277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin system: selectivity and timing of protein destruction</span></div><div class="casAuthors">Yamao, Fumiaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-229</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    
            (<span class="NLM_cas:orgname">Japanese Biochemical Society</span>)
        </div><div class="casAbstract">A review with 48 refs.  A growing no. of cellular functions have been shown to be regulated through protein degrdn.  The selective degrdn. of many short-lived proteins in eukaryotic cells is mediated by the ubiquitin system, by which proteins covalently ligated to ubiquitin are targeted for degrdn.  The selectivity of the destruction is ensured by the substrate specificity in the ubiquitination steps composed of a series of enzymic reactions.  Ubiquitin-ligase (E3), in conjunction with ubiquitin-conjugating enzyme (E2), has been implicated as playing an essential role in the substrate recognition.  The substantial character, however, of the ligase was not clear until several recent studies demonstrated ligases that exert key roles in irreversible steps of the cell-cycle control.  In this review, attention is focused on the mol. basis of target recognition of ubiquitination, particularly as exemplified in the ubiquitin-ligases in the cell-cycle control mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ_WqXwROGerVg90H21EOLACvtfcHk0lhzcbnX3kgauQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFyktrs%253D&md5=be00de0dc5ee9d870e49d56d904b432e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Foxfordjournals.jbchem.a022277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Foxfordjournals.jbchem.a022277%26sid%3Dliteratum%253Aachs%26aulast%3DYamao%26aufirst%3DF.%26atitle%3DUbiquitin%2520system%253A%2520selectivity%2520and%2520timing%2520of%2520protein%2520destruction%26jtitle%3DJ.%2520Biochem.%26date%3D1999%26volume%3D125%26spage%3D223%26epage%3D229%26doi%3D10.1093%2Foxfordjournals.jbchem.a022277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Pickart, C. M.</span><span> </span><span class="NLM_article-title">Mechanisms underlying ubiquitination</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1146/annurev.biochem.70.1.503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1146%2Fannurev.biochem.70.1.503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=11395416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVehtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=503-533&author=C.+M.+Pickart&title=Mechanisms+underlying+ubiquitination&doi=10.1146%2Fannurev.biochem.70.1.503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms underlying ubiquitination</span></div><div class="casAuthors">Pickart, Cecile M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">503-533</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with 177 refs.  The conjugation of ubiquitin to other cellular proteins regulates a broad range of eukaryotic cell functions.  The high efficiency and exquisite selectivity of ubiquitination reactions reflect the properties of enzymes known as ubiquitin-protein ligases or E3s.  An E3 recognizes its substrates based on the presence of a specific ubiquitination signal, and catalyzes the formation of an isopeptide bond between a substrate (or ubiquitin) lysine residue and the C terminus of ubiquitin.  Although a great deal is known about the mol. basis of E3 specificity, much less is known about mol. mechanisms of catalysis by E3s.  Recent findings reveal that all known E3s utilize one of just two catalytic domains-a HECT domain or a RING finger-and crystal structures have provided the first detailed views of an active site of each type.  The new findings shed light on many aspects of E3 structure, function, and mechanism, but also emphasize that key features of E3 catalysis remain to be elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof8qQSvIayQbVg90H21EOLACvtfcHk0lhzcbnX3kgauQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVehtLw%253D&md5=72e307d3cdb419853e4c611050429913</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.70.1.503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.70.1.503%26sid%3Dliteratum%253Aachs%26aulast%3DPickart%26aufirst%3DC.%2BM.%26atitle%3DMechanisms%2520underlying%2520ubiquitination%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2001%26volume%3D70%26spage%3D503%26epage%3D533%26doi%3D10.1146%2Fannurev.biochem.70.1.503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Komander, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes-Turcu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licchesi, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odenwaelder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span> </span><span class="NLM_article-title">Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains</span> <span class="citation_source-journal">EMBO Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1038/embor.2009.55</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fembor.2009.55" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=19373254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1ShsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=466-473&author=D.+Komanderauthor=F.+Reyes-Turcuauthor=J.+D.+Licchesiauthor=P.+Odenwaelderauthor=K.+D.+Wilkinsonauthor=D.+Barford&title=Molecular+discrimination+of+structurally+equivalent+Lys+63-linked+and+linear+polyubiquitin+chains&doi=10.1038%2Fembor.2009.55"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains</span></div><div class="casAuthors">Komander, David; Reyes-Turcu, Francisca; Licchesi, Julien D. F.; Odenwaelder, Peter; Wilkinson, Keith D.; Barford, David</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">466-473</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">At least eight types of ubiquitin (Ub) chain exist, and individual linkages affect distinct cellular processes.  The only distinguishing feature of differently linked ubiquitin chains is their structure, as polymers of the same unit are chem. identical.  Here, we have crystd. Lys 63-linked and linear ubiquitin dimers, revealing that both adopt equiv. open conformations, forming no contacts between ubiquitin mols. and thereby differing significantly from Lys 48-linked ubiquitin chains.  We also examd. the specificity of various deubiquitinases (DUBs) and ubiquitin-binding domains (UBDs).  All analyzed DUBs, except CYLD, cleave linear chains less efficiently compared with other chain types, or not at all.  Likewise, UBDs can show chain specificity, and are able to select distinct linkages from a ubiquitin chain mixt.  We found that the UBAN (ubiquitin binding in ABIN and NEMO) motif of NEMO (NF-κB essential modifier) binds to linear chains exclusively, whereas the NZF (Npl4 zinc finger) domain of TAB2 (TAK1 binding protein 2) is Lys 63 specific.  Our results highlight remarkable specificity determinants within the ubiquitin system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5UmdkgYjMU7Vg90H21EOLACvtfcHk0lhzcbnX3kgauQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1ShsbY%253D&md5=e21e9b6a5e64116f7b594a001336104f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fembor.2009.55&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fembor.2009.55%26sid%3Dliteratum%253Aachs%26aulast%3DKomander%26aufirst%3DD.%26aulast%3DReyes-Turcu%26aufirst%3DF.%26aulast%3DLicchesi%26aufirst%3DJ.%2BD.%26aulast%3DOdenwaelder%26aufirst%3DP.%26aulast%3DWilkinson%26aufirst%3DK.%2BD.%26aulast%3DBarford%26aufirst%3DD.%26atitle%3DMolecular%2520discrimination%2520of%2520structurally%2520equivalent%2520Lys%252063-linked%2520and%2520linear%2520polyubiquitin%2520chains%26jtitle%3DEMBO%2520Rep.%26date%3D2009%26volume%3D10%26spage%3D466%26epage%3D473%26doi%3D10.1038%2Fembor.2009.55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Heideker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wertz, I. E.</span><span> </span><span class="NLM_article-title">DUBs, the regulation of cell identity and disease</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="refDoi"> DOI: 10.1042/bj4670191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1042%2Fbj4670191" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2015&pages=191&author=J.+Heidekerauthor=I.+E.+Wertz&title=DUBs%2C+the+regulation+of+cell+identity+and+disease&doi=10.1042%2Fbj4670191"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1042%2Fbj4670191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj4670191%26sid%3Dliteratum%253Aachs%26aulast%3DHeideker%26aufirst%3DJ.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26atitle%3DDUBs%252C%2520the%2520regulation%2520of%2520cell%2520identity%2520and%2520disease%26jtitle%3DBiochem.%2520J.%26date%3D2015%26volume%3D467%26spage%3D191%26doi%3D10.1042%2Fbj4670191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Adams, J.</span><span> </span><span class="NLM_article-title">The development of proteasome inhibitors as anticancer drugs</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span><span class="refDoi"> DOI: 10.1016/S1535-6108(04)00120-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2FS1535-6108%2804%2900120-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=15144949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=417-421&author=J.+Adams&title=The+development+of+proteasome+inhibitors+as+anticancer+drugs&doi=10.1016%2FS1535-6108%2804%2900120-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The development of proteasome inhibitors as anticancer drugs</span></div><div class="casAuthors">Adams, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">417-421</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular proteins, including cell cycle regulatory proteins.  Because these pathways are crit. for the proliferation and survival of all cells, and in particular cancerous cells, proteasome inhibition is a potentially attractive anticancer therapy.  Based on encouraging cytotoxic activity, bortezomib was the first proteasome inhibitor to be evaluated in clin. trials.  Efficacy and safety results from a phase 2 clin. trial contributed to approval of bortezomib for use in patients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies and have demonstrated disease progression on their last therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozXYZQ-zxJdbVg90H21EOLACvtfcHk0lhDVUhJ2fx5uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFCmt7s%253D&md5=9a070d342533a3b6108150c40852834e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2804%2900120-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252804%252900120-5%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DThe%2520development%2520of%2520proteasome%2520inhibitors%2520as%2520anticancer%2520drugs%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D417%26epage%3D421%26doi%3D10.1016%2FS1535-6108%2804%2900120-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Meister, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gramatzki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jack, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voll, R. E.</span><span> </span><span class="NLM_article-title">Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1792</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-2258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F0008-5472.CAN-06-2258" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=1783-1792&author=S.+Meisterauthor=U.+Schubertauthor=K.+Neubertauthor=K.+Herrmannauthor=R.+Burgerauthor=M.+Gramatzkiauthor=S.+Hahnauthor=S.+Schreiberauthor=S.+Wilhelmauthor=M.+Herrmannauthor=H.+M.+Jackauthor=R.+E.+Voll&title=Extensive+immunoglobulin+production+sensitizes+myeloma+cells+for+proteasome+inhibition&doi=10.1158%2F0008-5472.CAN-06-2258"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-2258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-2258%26sid%3Dliteratum%253Aachs%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DSchubert%26aufirst%3DU.%26aulast%3DNeubert%26aufirst%3DK.%26aulast%3DHerrmann%26aufirst%3DK.%26aulast%3DBurger%26aufirst%3DR.%26aulast%3DGramatzki%26aufirst%3DM.%26aulast%3DHahn%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DHerrmann%26aufirst%3DM.%26aulast%3DJack%26aufirst%3DH.%2BM.%26aulast%3DVoll%26aufirst%3DR.%2BE.%26atitle%3DExtensive%2520immunoglobulin%2520production%2520sensitizes%2520myeloma%2520cells%2520for%2520proteasome%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D1783%26epage%3D1792%26doi%3D10.1158%2F0008-5472.CAN-06-2258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Cenci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerruti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezghrani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasqualetto, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascio, P.</span><span> </span><span class="NLM_article-title">Pivotal advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">921</span><span class="NLM_x">–</span> <span class="NLM_lpage">931</span><span class="refDoi"> DOI: 10.1189/jlb.1011497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1189%2Fjlb.1011497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22685320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslerurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=921-931&author=S.+Cenciauthor=L.+Olivaauthor=F.+Cerrutiauthor=E.+Milanauthor=G.+Bianchiauthor=M.+Rauleauthor=A.+Mezghraniauthor=E.+Pasqualettoauthor=R.+Sitiaauthor=P.+Cascio&title=Pivotal+advance%3A+protein+synthesis+modulates+responsiveness+of+differentiating+and+malignant+plasma+cells+to+proteasome+inhibitors&doi=10.1189%2Fjlb.1011497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pivotal advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors</span></div><div class="casAuthors">Cenci, Simone; Oliva, Laura; Cerruti, Fulvia; Milan, Enrico; Bianchi, Giada; Raule, Mary; Mezghrani, Alexandre; Pasqualetto, Elena; Sitia, Roberto; Cascio, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">921-931</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Society for Leukocyte Biology</span>)
        </div><div class="casAbstract">A previously unsuspected, considerable proportion of newly synthesized polypeptides are hydrolyzed rapidly by proteasomes, possibly competing with endogenous substrates and altering proteostasis.  In view of the anti-cancer effects of PIs, we set out to achieve a quant. assessment of proteasome workload in cells hallmarked by different PI sensitivity, namely, a panel of MM cells, and in a dynamic model of plasma cell differentiation, a process that confers exquisite PI sensitivity.  Our results suggest that protein synthesis is a key determinant of proteasomal proteolytic burden and PI sensitivity.  In different MM cells and in differentiating plasma cells, the av. proteolytic work accomplished per proteasome ranges over different orders of magnitude, an unexpected degree of variability, with increased workload invariably assocd. to increased PI sensitivity.  The unfavorable load-vs.-capacity balance found in highly PI-sensitive MM lines is accounted for by a decreased total no. of immunoproteasomes/cell coupled to enhanced generation of RDPs.  Moreover, indicative of cause-effect relationships, attenuating general protein synthesis by the otherwise toxic agent CHX reduces PI sensitivity in activated B and in MM cells.  Our data support the view that in plasma cells protein synthesis contributes to det. PI sensitivity by satg. the proteasomal degradative capacity.  Quantitating protein synthesis and proteasome workload may thus prove crucial to design novel neg. proteostasis regulators against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzfLDlzFVvbVg90H21EOLACvtfcHk0lhDVUhJ2fx5uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslerurvM&md5=4573314c4f009333c5de968eaa890b26</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1011497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1011497%26sid%3Dliteratum%253Aachs%26aulast%3DCenci%26aufirst%3DS.%26aulast%3DOliva%26aufirst%3DL.%26aulast%3DCerruti%26aufirst%3DF.%26aulast%3DMilan%26aufirst%3DE.%26aulast%3DBianchi%26aufirst%3DG.%26aulast%3DRaule%26aufirst%3DM.%26aulast%3DMezghrani%26aufirst%3DA.%26aulast%3DPasqualetto%26aufirst%3DE.%26aulast%3DSitia%26aufirst%3DR.%26aulast%3DCascio%26aufirst%3DP.%26atitle%3DPivotal%2520advance%253A%2520protein%2520synthesis%2520modulates%2520responsiveness%2520of%2520differentiating%2520and%2520malignant%2520plasma%2520cells%2520to%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2012%26volume%3D92%26spage%3D921%26epage%3D931%26doi%3D10.1189%2Fjlb.1011497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Ratner, M.</span><span> </span><span class="NLM_article-title">FDA approves three different multiple myeloma drugs in one month</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">126</span><span class="refDoi"> DOI: 10.1038/nbt0216-126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnbt0216-126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=126&author=M.+Ratner&title=FDA+approves+three+different+multiple+myeloma+drugs+in+one+month&doi=10.1038%2Fnbt0216-126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt0216-126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0216-126%26sid%3Dliteratum%253Aachs%26aulast%3DRatner%26aufirst%3DM.%26atitle%3DFDA%2520approves%2520three%2520different%2520multiple%2520myeloma%2520drugs%2520in%2520one%2520month%26jtitle%3DNat.%2520Biotechnol.%26date%3D2016%26volume%3D34%26spage%3D126%26doi%3D10.1038%2Fnbt0216-126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span><span class="refDoi"> DOI: 10.1200/JCO.2011.37.8919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1200%2FJCO.2011.37.8919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22215754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=445-452&author=K.+C.+Anderson&title=The+39th+David+A.+Karnofsky+Lecture%3A+bench-to-bedside+translation+of+targeted+therapies+in+multiple+myeloma&doi=10.1200%2FJCO.2011.37.8919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The 39th David A. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma</span></div><div class="casAuthors">Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">445-452</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Multiple myeloma (MM) is a remarkable example of rapid bench-to-bedside translation in new drug development.  The proteasome inhibitor bortezomib and immunomodulatory drug lenalidomide targeted MM cells in the bone marrow (BM) microenvironment to overcome conventional drug resistance in lab. and animal models and were rapidly translated into clin. trials demonstrating their efficacy in patients with relapsed and then newly diagnosed MM, with a doubling of the median survival as a direct result.  The future is even brighter.  First, immune-based therapies are being developed (eg, elotuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell-dendritic cell vaccines; CD138, CS-1, and XBP-1 peptide vaccines; anti-17 MoAb; and other treatments to overcome causes of immune dysfunction).  Second, promising next-generation agents target the MM cell in its microenvironment (eg, deubiquitinating enzyme inhibitors; chymotryptic [carfilzomib, Onyx 0912, MLN 9708] and broader [NPI-0052] proteasome inhibitors; immunoproteasome inhibitors; and pomalidamide).  Moreover, agents targeting bone biol. (eg, zoledronic acid, anti-DKK-1 MoAb, anti-B-cell activating factor MoAb and bortezomib, Btk inhibitor) show promise not only in preserving bone integrity but also against MM.  Third, rationally based combination therapies, including bortezomib with Akt, mammalian target of rapamycin, or histone deacetylase inhibitors, are active even in bortezomib-refractory MM.  Finally, genomics is currently being used in the definition of MM heterogeneity, new target discovery, and development of personalized therapy.  Myeloma therefore represents a paradigm for targeting the tumor in its microenvironment, which has already markedly improved patient outcome in MM and has great potential in other hematol. malignancies and solid tumors as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonWQMjtpU4c7Vg90H21EOLACvtfcHk0lhroM7J7IDOjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKgsrg%253D&md5=9d37e03ad2b6d8b4bed1607694aa45c4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.37.8919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.37.8919%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DThe%252039th%2520David%2520A.%2520Karnofsky%2520Lecture%253A%2520bench-to-bedside%2520translation%2520of%2520targeted%2520therapies%2520in%2520multiple%2520myeloma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D445%26epage%3D452%26doi%3D10.1200%2FJCO.2011.37.8919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Das, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oronsky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scicinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2187</span><span class="NLM_x">–</span> <span class="NLM_lpage">2197</span><span class="refDoi"> DOI: 10.1038/leu.2016.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fleu.2016.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27118403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=2187-2197&author=D.+S.+Dasauthor=A.+Rayauthor=A.+Dasauthor=Y.+Songauthor=Z.+Tianauthor=B.+Oronskyauthor=P.+Richardsonauthor=J.+Scicinskiauthor=D.+Chauhanauthor=K.+C.+Anderson&title=A+novel+hypoxia-selective+epigenetic+agent+RRx-001+triggers+apoptosis+and+overcomes+drug+resistance+in+multiple+myeloma+cells&doi=10.1038%2Fleu.2016.96"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells</span></div><div class="casAuthors">Sharma Das, D.; Ray, A.; Das, A.; Song, Y.; Tian, Z.; Oronsky, B.; Richardson, P.; Scicinski, J.; Chauhan, D.; Anderson, K. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2187-2197</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The hypoxic bone marrow (BM) microenvironment confers growth/survival and drug resistance in multiple myeloma (MM) cells.  Novel therapies targeting the MM cell in its hypoxic BM milieu may overcome drug resistance.  Recent studies led to the development of a novel mol. RRx-001 with hypoxia-selective epigenetic and nitric oxide-donating properties.  Here, we demonstrate that RRx-001 decreases the viability of MM cell lines and primary patient cells, as well as overcomes drug resistance.  RRx-001 inhibits MM cell growth in the presence of BM stromal cells.  RRx-001-induced apoptosis is assocd. with: (i) activation of caspases; (ii) release of ROS and nitrogen species; (iii) induction of DNA damage via ATM/γ-H2AX; and (iv) decrease in DNA methyltransferase (DNMT) and global methylation.  RNA interference study shows a predominant role of DNMT1 in MM cell survival vs. DNMT3a or DNMT3b.  The deubiquitylating enzyme USP7 stimulates DNMT1 activity, and conversely, USP7-siRNA reduced DNMT1 activity and decreased MM cell viability.  RRx-001 plus USP7 inhibitor P5091 triggered synergistic anti-MM activity.  MM xenograft studies show that RRx-001 is well tolerated, inhibits tumor growth and enhances survival.  Combining RRx-001 with pomalidomide, bortezomib or SAHA induces synergistic anti-MM activity.  Our results provide the rationale for translation of RRx-001, either alone or in combination, to clin. evaluation in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjV6OcM6-k8rVg90H21EOLACvtfcHk0lhroM7J7IDOjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWjtL0%253D&md5=65ed426954f24c9b76b6a25c9e665d48</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.96%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DD.%2BS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DDas%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DOronsky%26aufirst%3DB.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DScicinski%26aufirst%3DJ.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520novel%2520hypoxia-selective%2520epigenetic%2520agent%2520RRx-001%2520triggers%2520apoptosis%2520and%2520overcomes%2520drug%2520resistance%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D2187%26epage%3D2197%26doi%3D10.1038%2Fleu.2016.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Lenalidomide in multiple myeloma</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1165</span><span class="NLM_x">–</span> <span class="NLM_lpage">1173</span><span class="refDoi"> DOI: 10.1586/14737140.6.8.1165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1586%2F14737140.6.8.1165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16925483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28XpslGhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=1165-1173&author=P.+G.+Richardsonauthor=C.+Mitsiadesauthor=T.+Hideshimaauthor=K.+C.+Anderson&title=Lenalidomide+in+multiple+myeloma&doi=10.1586%2F14737140.6.8.1165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide in multiple myeloma</span></div><div class="casAuthors">Richardson, Paul G.; Mitsiades, Constantine; Hideshima, Teru; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1165-1173</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Current therapies for multiple myeloma include steroids, alkylating agents and high-dose chemotherapy with autologous stem cell transplant.  These approaches are typically assocd. with initially good response rates, but they ultimately fail as a result of disease progression.  New therapies that overcome resistance, lower toxicity and maintain remission are needed.  Recent advances in the treatment of multiple myeloma include bortezomib and thalidomide.  Lenalidomide (Revlimid) is an immunomodulatory drug that has undergone rapid clin. development in multiple myeloma and was recently approved by the US FDA for use in patients with relapsed disease.  Clin. trials demonstrate that lenalidomide, particularly in combination with dexamethasone, produces durable clin. responses in patients with relapsed and refractory disease and is generally well tolerated, with manageable toxicities.  This review summarizes the profile of lenalidomide and the current evidence for its efficacy in multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK72GbiacBv7Vg90H21EOLACvtfcHk0lhroM7J7IDOjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpslGhsLs%253D&md5=6c7ff6dc97a8fe5bda7c283e51a86c21</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1586%2F14737140.6.8.1165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.6.8.1165%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DLenalidomide%2520in%2520multiple%2520myeloma%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2006%26volume%3D6%26spage%3D1165%26epage%3D1173%26doi%3D10.1586%2F14737140.6.8.1165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Kojima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burks, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2545</span><span class="NLM_x">–</span> <span class="NLM_lpage">2557</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F1535-7163.MCT-10-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20736344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaqsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2545-2557&author=K.+Kojimaauthor=J.+K.+Burksauthor=J.+Artsauthor=M.+Andreeff&title=The+novel+tryptamine+derivative+JNJ-26854165+induces+wild-type+p53-+and+E2F1-mediated+apoptosis+in+acute+myeloid+and+lymphoid+leukemias&doi=10.1158%2F1535-7163.MCT-10-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias</span></div><div class="casAuthors">Kojima, Kensuke; Burks, Jared K.; Arts, Janine; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2545-2557</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The development of small-mol. activators of p53 is currently focused on malignancies contg. a wild-type p53 genotype, which is present in most leukemias.  JNJ-26854165 is one such p53-activating agent, but its mechanism of action remains to be elucidated.  Here, we report the effects of JNJ-26854165 in acute leukemias.  JNJ-26854165 treatment induced p53-mediated apoptosis in acute leukemia cells with wild-type p53, in which p53 rapidly drives transcription-independent apoptosis followed by activation of a transcription-dependent pathway.  JNJ-26854165 accelerated the proteasome-mediated degrdn. of p21 and antagonized the transcriptional induction of p21 by p53.  Interestingly, JNJ-26854165 induced S-phase delay and upregulated E2F1 expression in p53 mutant cells, resulting in apoptosis preferentially of S-phase cells.  E2F1 knockdown blocked apoptosis induced by JNJ-26854165 in p53 mutant cells.  Apoptotic activity of JNJ-26854165 against primary acute leukemia cells was maintained in leukemia/stroma cocultures, unlike doxorubicin, which has reduced cytotoxicity in coculture systems.  JNJ-26854165 synergizes with 1-β-arabinofuranosylcytosine or doxorubicin to induce p53-mediated apoptosis.  Our data suggest that JNJ-26854165 may provide a novel therapeutic approach for the treatment of acute leukemias.  The presence of p53-independent apoptotic activity in addn. to p53-mediated apoptosis induction, if operational in vivo, may prevent the selection of p53 mutant subclones during therapy.  Mol Cancer Ther; 9(9); 2545-57.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvjlM2mkfNWrVg90H21EOLACvtfcHk0ljtFbwxvcgA6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaqsrnJ&md5=046ba6911e9135ea180733a4c7451f77</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0337%26sid%3Dliteratum%253Aachs%26aulast%3DKojima%26aufirst%3DK.%26aulast%3DBurks%26aufirst%3DJ.%2BK.%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DThe%2520novel%2520tryptamine%2520derivative%2520JNJ-26854165%2520induces%2520wild-type%2520p53-%2520and%2520E2F1-mediated%2520apoptosis%2520in%2520acute%2520myeloid%2520and%2520lymphoid%2520leukemias%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2545%26epage%3D2557%26doi%3D10.1158%2F1535-7163.MCT-10-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Tabernero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirix, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Martin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdevila, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Beijsterveldt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platero, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoblauch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, S. H.</span><span> </span><span class="NLM_article-title">A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6313</span><span class="NLM_x">–</span> <span class="NLM_lpage">6321</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F1078-0432.CCR-11-1101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21831953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ggs7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6313-6321&author=J.+Taberneroauthor=L.+Dirixauthor=P.+Schoffskiauthor=A.+Cervantesauthor=J.+A.+Lopez-Martinauthor=J.+Capdevilaauthor=L.+van+Beijsterveldtauthor=S.+Plateroauthor=B.+Hallauthor=Z.+Yuanauthor=R.+Knoblauchauthor=S.+H.+Zhuang&title=A+phase+I+first-in-human+pharmacokinetic+and+pharmacodynamic+study+of+serdemetan+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-11-1101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Tabernero, Josep; Dirix, Luc; Schoffski, Patrick; Cervantes, Andres; Lopez-Martin, Jose Antonio; Capdevila, Jaume; van Beijsterveldt, Ludy; Platero, Suso; Hall, Brett; Yuan, Zhilong; Knoblauch, Roland; Zhuang, Sen Hong</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6313-6321</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Originally isolated on the basis of its ability to induce p53, serdemetan showed potent activity in various preclin. models, inducing S-phase arrest and apoptosis in TP53 wild-type and mutant tumors.  This study evaluated the safety and tolerability of serdemetan, detd. the pharmacokinetic and pharmacodynamic profiles, and identified a recommended phase II dose.  PATIENTS AND METHODS: Patients (71) with refractory solid tumors were allocated to dose-escalating cohorts (3+3 patients each) and received oral serdemetan once daily in 21-day cycles to det. the max. tolerated dose (MTD) and dose-limiting toxicities (DLT).  Plasma was collected for pharmacokinetic analyses.  Paired baseline and on-treatment skin and tumor biopsies were done; blood samples were collected for pharmacodynamic analyses, including p53 and macrophage inhibitory cytokine-1 induction.  RESULTS: The MTD of serdemetan was detd. to be 350 mg once daily.  During this study, grade 3 QTc prolongation was the most common DLT and nausea (66.2%) was the most frequent treatment-emergent adverse event.  Serdemetan was rapidly absorbed after oral administration and exhibited dose-proportional pharmacokinetics.  At steady state, mean max. plasma concn. (Cmax) was 2,330 ng/mL and mean area under plasma concn. curve (AUC0-24h) was 43.0 μg.h/mL, with serdemetan 300 mg/d.  There was a dose- and exposure-dependent p53 induction.  One patient with breast cancer showed a partial response; 22 (38.6%) patients had stable disease.  CONCLUSIONS: Serdemetan treatment was assocd. with p53 induction in both tumor and surrogate tissue pharmacodynamic studies and modest clin. activity.  Although serdemetan was well tolerated with dose-proportional pharmacokinetics, exposure-related QTc liability was obsd.  Clin Cancer Res; 17(19); 6313-21.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9duPLEjrFzbVg90H21EOLACvtfcHk0ljtFbwxvcgA6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ggs7bN&md5=4d7e41cda55e7acb50c2e52588804193</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1101%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DDirix%26aufirst%3DL.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DCervantes%26aufirst%3DA.%26aulast%3DLopez-Martin%26aufirst%3DJ.%2BA.%26aulast%3DCapdevila%26aufirst%3DJ.%26aulast%3Dvan%2BBeijsterveldt%26aufirst%3DL.%26aulast%3DPlatero%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DKnoblauch%26aufirst%3DR.%26aulast%3DZhuang%26aufirst%3DS.%2BH.%26atitle%3DA%2520phase%2520I%2520first-in-human%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520serdemetan%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6313%26epage%3D6321%26doi%3D10.1158%2F1078-0432.CCR-11-1101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">You, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, W.</span><span> </span><span class="NLM_article-title">The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">7777</span><span class="NLM_x">–</span> <span class="NLM_lpage">7790</span><span class="refDoi"> DOI: 10.18632/oncotarget.13951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.18632%2Foncotarget.13951" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=7777-7790&author=L.+Youauthor=H.+Liuauthor=J.+Huangauthor=W.+Xieauthor=J.+Weiauthor=X.+Yeauthor=W.+Qian&title=The+novel+anticancer+agent+JNJ-26854165+is+active+in+chronic+myeloid+leukemic+cells+with+unmutated+BCR%2FABL+and+T315I+mutant+BCR%2FABL+through+promoting+proteosomal+degradation+of+BCR%2FABL+proteins&doi=10.18632%2Foncotarget.13951"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13951%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DQian%26aufirst%3DW.%26atitle%3DThe%2520novel%2520anticancer%2520agent%2520JNJ-26854165%2520is%2520active%2520in%2520chronic%2520myeloid%2520leukemic%2520cells%2520with%2520unmutated%2520BCR%252FABL%2520and%2520T315I%2520mutant%2520BCR%252FABL%2520through%2520promoting%2520proteosomal%2520degradation%2520of%2520BCR%252FABL%2520proteins%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D7777%26epage%3D7790%26doi%3D10.18632%2Foncotarget.13951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Flygare, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budha, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheeti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshayes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisner, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazzard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plise, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Um, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varfolomeev, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vucic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ware, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zobel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairbrother, W. J.</span><span> </span><span class="NLM_article-title">Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4101</span><span class="NLM_x">–</span> <span class="NLM_lpage">4113</span><span class="refDoi"> DOI: 10.1021/jm300060k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300060k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Ois74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4101-4113&author=J.+A.+Flygareauthor=M.+Beresiniauthor=N.+Budhaauthor=H.+Chanauthor=I.+T.+Chanauthor=S.+Cheetiauthor=F.+Cohenauthor=K.+Deshayesauthor=K.+Doernerauthor=S.+G.+Eckhardtauthor=L.+O.+Elliottauthor=B.+Fengauthor=M.+C.+Franklinauthor=S.+F.+Reisnerauthor=L.+Gazzardauthor=J.+Halladayauthor=S.+G.+Hymowitzauthor=H.+Laauthor=P.+LoRussoauthor=B.+Maurerauthor=L.+Murrayauthor=E.+Pliseauthor=C.+Quanauthor=J.+P.+Stephanauthor=S.+G.+Youngauthor=J.+Tomauthor=V.+Tsuiauthor=J.+Umauthor=E.+Varfolomeevauthor=D.+Vucicauthor=A.+J.+Wagnerauthor=H.+J.+Wallweberauthor=L.+Wangauthor=J.+Wareauthor=Z.+Wenauthor=H.+Wongauthor=J.+M.+Wongauthor=M.+Wongauthor=S.+Wongauthor=R.+Yuauthor=K.+Zobelauthor=W.+J.+Fairbrother&title=Discovery+of+a+potent+small-molecule+antagonist+of+inhibitor+of+apoptosis+%28IAP%29+proteins+and+clinical+candidate+for+the+treatment+of+cancer+%28GDC-0152%29&doi=10.1021%2Fjm300060k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152)</span></div><div class="casAuthors">Flygare, John A.; Beresini, Maureen; Budha, Nageshwar; Chan, Helen; Chan, Iris T.; Cheeti, Sravanthi; Cohen, Frederick; Deshayes, Kurt; Doerner, Karl; Eckhardt, S. Gail; Elliott, Linda O.; Feng, Bainian; Franklin, Matthew C.; Reisner, Stacy Frankovitz; Gazzard, Lewis; Halladay, Jason; Hymowitz, Sarah G.; La, Hank; LoRusso, Patricia; Maurer, Brigitte; Murray, Lesley; Plise, Emile; Quan, Clifford; Stephan, Jean-Philippe; Young, Shin G.; Tom, Jeffrey; Tsui, Vickie; Um, Joanne; Varfolomeev, Eugene; Vucic, Domagoj; Wagner, Andrew J.; Wallweber, Heidi J. A.; Wang, Lan; Ware, Joseph; Wen, Zhaoyang; Wong, Harvey; Wong, Jonathan M.; Wong, Melisa; Wong, Susan; Yu, Ron; Zobel, Kerry; Fairbrother, Wayne J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4101-4113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of compds. were designed and synthesized as antagonists of cIAP1/2, ML-IAP, and XIAP based on the N-terminus, AVPI, of mature Smac.  Compd. (I) (GDC-0152) has the best profile of these compds.; it binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with Ki values of 28, 14, 17, and 43 nM, resp.  These compds. promote degrdn. of cIAP1, induce activation of caspase-3/7, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells.  Compd. I inhibits tumor growth when dosed orally in the MDA-MB-231 breast cancer xenograft model.  Compd. I was advanced to human clin. trials, and it exhibited linear pharmacokinetics over the dose range (0.049 to 1.48 mg/kg) tested.  Mean plasma clearance in humans was 9 ± 3 mL/min/kg, and the vol. of distribution was 0.6 ± 0.2 L/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZSPNVJ5gVWrVg90H21EOLACvtfcHk0ljgBUmfPksVIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Ois74%253D&md5=19452878ea834d3c324d567b39a78fb2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm300060k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300060k%26sid%3Dliteratum%253Aachs%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBudha%26aufirst%3DN.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DI.%2BT.%26aulast%3DCheeti%26aufirst%3DS.%26aulast%3DCohen%26aufirst%3DF.%26aulast%3DDeshayes%26aufirst%3DK.%26aulast%3DDoerner%26aufirst%3DK.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DElliott%26aufirst%3DL.%2BO.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DFranklin%26aufirst%3DM.%2BC.%26aulast%3DReisner%26aufirst%3DS.%2BF.%26aulast%3DGazzard%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DPlise%26aufirst%3DE.%26aulast%3DQuan%26aufirst%3DC.%26aulast%3DStephan%26aufirst%3DJ.%2BP.%26aulast%3DYoung%26aufirst%3DS.%2BG.%26aulast%3DTom%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUm%26aufirst%3DJ.%26aulast%3DVarfolomeev%26aufirst%3DE.%26aulast%3DVucic%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWare%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DZobel%26aufirst%3DK.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520small-molecule%2520antagonist%2520of%2520inhibitor%2520of%2520apoptosis%2520%2528IAP%2529%2520proteins%2520and%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520cancer%2520%2528GDC-0152%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4101%26epage%3D4113%26doi%3D10.1021%2Fjm300060k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Andreeff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assouline, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strair, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popplewell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschbaum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruvolo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blotner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jukofsky, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, K.</span><span> </span><span class="NLM_article-title">Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">876</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F1078-0432.CCR-15-0481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26459177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFGmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=868-876&author=M.+Andreeffauthor=K.+R.+Kellyauthor=K.+Yeeauthor=S.+Assoulineauthor=R.+Strairauthor=L.+Popplewellauthor=D.+Bowenauthor=G.+Martinelliauthor=M.+W.+Drummondauthor=P.+Vyasauthor=M.+Kirschbaumauthor=S.+P.+Iyerauthor=V.+Ruvoloauthor=G.+M.+Gonzalezauthor=X.+Huangauthor=G.+Chenauthor=B.+Gravesauthor=S.+Blotnerauthor=P.+Bridgeauthor=L.+Jukofskyauthor=S.+Middletonauthor=M.+Recknerauthor=R.+Ruegerauthor=J.+Zhiauthor=G.+Nicholsauthor=K.+Kojima&title=Results+of+the+Phase+I+trial+of+RG7112%2C+a+small-molecule+MDM2+antagonist+in+leukemia&doi=10.1158%2F1078-0432.CCR-15-0481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia</span></div><div class="casAuthors">Andreeff, Michael; Kelly, Kevin R.; Yee, Karen; Assouline, Sarit; Strair, Roger; Popplewell, Leslie; Bowen, David; Martinelli, Giovanni; Drummond, Mark W.; Vyas, Paresh; Kirschbaum, Mark; Iyer, Swaminathan Padmanabhan; Ruvolo, Vivian; Gonzalez, Graciela M. Nogueras; Huang, Xuelin; Chen, Gong; Graves, Bradford; Blotner, Steven; Bridge, Peter; Jukofsky, Lori; Middleton, Steve; Reckner, Monica; Rueger, Ruediger; Zhi, Jianguo; Nichols, Gwen; Kojima, Kensuke</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">868-876</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: RG7112 is a small-mol. MDM2 antagonist.  MDM2 is a neg. regulator of the tumor suppressor p53 and frequently overexpressed in leukemias.  Thus, a phase I study of RG7112 in patients with hematol. malignancies was conducted.  Exptl. Design: Primary study objectives included detn. of the dose and safety profile of RG7112.  Secondary objectives included evaluation of pharmacokinetics; pharmacodynamics, such as TP53-mutation status and MDM2 expression; and preliminary clin. activity.  Patients were divided into two cohorts: Stratum A [relapsed/refractory acute myeloid leukemia (AML; except acute promyelocytic leukemia), acute lymphoblastic leukemia, and chronic myelogenous leukemia] and Stratum B (relapsed/refractory chronic lymphocytic leukemia/small cell lymphocytic leukemia; CLL/sCLL).  Some Stratum A patients were treated at the MTD to assess clin. activity.  Results: RG7112 was administered to 116 patients (96 patients in Stratum A and 20 patients in Stratum B).  All patients experienced at least 1 adverse event, and 3 dose-limiting toxicities were reported.  Pharmacokinetic anal. indicated that twice-daily dosing enhanced daily exposure.  Antileukemia activity was obsd. in the 30 patients with AML assessed at the MTD, including 5 patients who met International Working Group (IWG) criteria for response.  Exploratory anal. revealed TP53 mutations in 14% of Stratum A patients and in 40% of Stratum B patients.  Two patients with TP53 mutations exhibited clin. activity. p53 target genes were induced only in TP53 wild-type leukemic cells.  Baseline expression levels of MDM2 correlated pos. with clin. response.  Conclusions: RG7112 demonstrated clin. activity against relapsed/refractory AML and CLL/sCLL.  MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes.  We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clin. responses in hematol. malignancies.  Clin Cancer Res; 22(4); 868-76. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRuwfqK8jXXrVg90H21EOLACvtfcHk0ljgBUmfPksVIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFGmtrs%253D&md5=9fd607f309a6327c163738291413048a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0481%26sid%3Dliteratum%253Aachs%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DYee%26aufirst%3DK.%26aulast%3DAssouline%26aufirst%3DS.%26aulast%3DStrair%26aufirst%3DR.%26aulast%3DPopplewell%26aufirst%3DL.%26aulast%3DBowen%26aufirst%3DD.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DDrummond%26aufirst%3DM.%2BW.%26aulast%3DVyas%26aufirst%3DP.%26aulast%3DKirschbaum%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26aulast%3DRuvolo%26aufirst%3DV.%26aulast%3DGonzalez%26aufirst%3DG.%2BM.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DBlotner%26aufirst%3DS.%26aulast%3DBridge%26aufirst%3DP.%26aulast%3DJukofsky%26aufirst%3DL.%26aulast%3DMiddleton%26aufirst%3DS.%26aulast%3DReckner%26aufirst%3DM.%26aulast%3DRueger%26aufirst%3DR.%26aulast%3DZhi%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DG.%26aulast%3DKojima%26aufirst%3DK.%26atitle%3DResults%2520of%2520the%2520Phase%2520I%2520trial%2520of%2520RG7112%252C%2520a%2520small-molecule%2520MDM2%2520antagonist%2520in%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D868%26epage%3D876%26doi%3D10.1158%2F1078-0432.CCR-15-0481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemunaitis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beryozkina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarapa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhi, J.</span><span> </span><span class="NLM_article-title">Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">595</span><span class="refDoi"> DOI: 10.1007/s00280-015-2830-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs00280-015-2830-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26210682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1amtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2015&pages=587-595&author=A.+Patnaikauthor=A.+Tolcherauthor=M.+Beeramauthor=J.+Nemunaitisauthor=G.+J.+Weissauthor=K.+Bhallaauthor=M.+Agrawalauthor=G.+Nicholsauthor=S.+Middletonauthor=A.+Beryozkinaauthor=N.+Sarapaauthor=R.+Peckauthor=J.+Zhi&title=Clinical+pharmacology+characterization+of+RG7112%2C+an+MDM2+antagonist%2C+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-015-2830-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors</span></div><div class="casAuthors">Patnaik, Amita; Tolcher, Anthony; Beeram, Murali; Nemunaitis, John; Weiss, Glen J.; Bhalla, Kapil; Agrawal, Manish; Nichols, Gwen; Middleton, Steven; Beryozkina, Anna; Sarapa, Nenad; Peck, Richard; Zhi, Jianguo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-595</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: RG7112, the first selective small-mol. MDM2 antagonist in clin. testing, is a non-genotoxic oral p53 activator.  To optimize its dose and schedule, a no. of clin. pharmacol. characteristics were explored in this multicenter trial in patients with advanced solid tumors.  Method: In part 1, the impact of high-energy/high-fat meal and formulations (cryst. and amorphous) on relative bioavailability was examd. in single-dose crossover designs.  In part 2, schedule optimization (4 schedules of drug administration under fasting condition and 2 cohorts with liq. supplementation) was investigated in parallel, dose escalation designs.  Clin. endpoints were pharmacokinetics (PK), pharmacodynamics (PD) including MIC-1 elevation and platelet redn., and safety/tolerability.  Results: With a single-dose treatment, a high-fat/high-energy meal and a new formulation under fasting condition, resp., enhanced overall bioavailability of RG7112 slightly over twofold.  Following multiple-dose administrations, all four schedules yielded the comparable per-cycle (28-d) exposure (AUC), as designed; liq. supplements also enhanced bioavailability.  High-dose treatments of consecutive daily dosing for 5 and 3 days resulted in higher on-treatment-day exposure to RG7112 than both weekly and low-dose/long-duration (20-day) daily schedules.  Serum MIC-1 and blood platelet profiles showed similar patterns to those of PK when the clin. pharmacol. conditions were varied, suggesting the relative importance of treatment-day exposure than overall per-cycle AUC.  Conclusion: Food (both high-fat and low-fat meals) and new formulation enhanced bioavailability.  High-dose consecutive daily treatment for 3-5 days is superior to weekly and low-dose/long-duration (20-day) daily schedules in yielding the sufficiently high drug exposure and PD effects potentially required for cancer treatment efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob0X7kDb-ao7Vg90H21EOLACvtfcHk0ljjJLGQo8rjYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1amtb%252FM&md5=1c6b7aff4b25e12c8e8b92ca966ed95f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs00280-015-2830-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-015-2830-8%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DTolcher%26aufirst%3DA.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DNemunaitis%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DBhalla%26aufirst%3DK.%26aulast%3DAgrawal%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DG.%26aulast%3DMiddleton%26aufirst%3DS.%26aulast%3DBeryozkina%26aufirst%3DA.%26aulast%3DSarapa%26aufirst%3DN.%26aulast%3DPeck%26aufirst%3DR.%26aulast%3DZhi%26aufirst%3DJ.%26atitle%3DClinical%2520pharmacology%2520characterization%2520of%2520RG7112%252C%2520an%2520MDM2%2520antagonist%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2015%26volume%3D76%26spage%3D587%26epage%3D595%26doi%3D10.1007%2Fs00280-015-2830-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Wong, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micel, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagby, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spreafico, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klauck, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blakemore, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tentler, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span> </span><span class="NLM_article-title">Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1007/s10637-016-0398-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs10637-016-0398-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=11-25&author=K.+M.+Wongauthor=L.+N.+Micelauthor=H.+M.+Selbyauthor=A.+C.+Tanauthor=T.+M.+Pittsauthor=S.+M.+Bagbyauthor=A.+Spreaficoauthor=P.+J.+Klauckauthor=S.+J.+Blakemoreauthor=P.+F.+Smithauthor=A.+McDonaldauthor=A.+Bergerauthor=J.+J.+Tentlerauthor=S.+G.+Eckhardt&title=Targeting+the+protein+ubiquitination+machinery+in+melanoma+by+the+NEDD8-activating+enzyme+inhibitor+pevonedistat+%28MLN4924%29&doi=10.1007%2Fs10637-016-0398-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs10637-016-0398-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-016-0398-8%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%2BM.%26aulast%3DMicel%26aufirst%3DL.%2BN.%26aulast%3DSelby%26aufirst%3DH.%2BM.%26aulast%3DTan%26aufirst%3DA.%2BC.%26aulast%3DPitts%26aufirst%3DT.%2BM.%26aulast%3DBagby%26aufirst%3DS.%2BM.%26aulast%3DSpreafico%26aufirst%3DA.%26aulast%3DKlauck%26aufirst%3DP.%2BJ.%26aulast%3DBlakemore%26aufirst%3DS.%2BJ.%26aulast%3DSmith%26aufirst%3DP.%2BF.%26aulast%3DMcDonald%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DTentler%26aufirst%3DJ.%2BJ.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26atitle%3DTargeting%2520the%2520protein%2520ubiquitination%2520machinery%2520in%2520melanoma%2520by%2520the%2520NEDD8-activating%2520enzyme%2520inhibitor%2520pevonedistat%2520%2528MLN4924%2529%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26spage%3D11%26epage%3D25%26doi%3D10.1007%2Fs10637-016-0398-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Shah, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubowiak, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebovic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diefenbach, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faessel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirrell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span> </span><span class="NLM_article-title">Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F1078-0432.CCR-15-1237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26561559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=34-43&author=J.+J.+Shahauthor=A.+J.+Jakubowiakauthor=O.+A.+O%E2%80%99Connorauthor=R.+Z.+Orlowskiauthor=R.+D.+Harveyauthor=M.+R.+Smithauthor=D.+Lebovicauthor=C.+Diefenbachauthor=K.+Kellyauthor=Z.+Huaauthor=A.+J.+Bergerauthor=G.+Mulliganauthor=H.+M.+Faesselauthor=S.+Tirrellauthor=B.+J.+Dezubeauthor=S.+Lonial&title=Phase+I+study+of+the+novel+investigational+NEDD8-activating+enzyme+inhibitor+pevonedistat+%28MLN4924%29+in+patients+with+relapsed%2Frefractory+multiple+myeloma+or+lymphoma&doi=10.1158%2F1078-0432.CCR-15-1237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma</span></div><div class="casAuthors">Shah, Jatin J.; Jakubowiak, Andrzej J.; O'Connor, Owen A.; Orlowski, Robert Z.; Harvey, R. Donald; Smith, Mitchell R.; Lebovic, Daniel; Diefenbach, Catherine; Kelly, Kevin; Hua, Zhaowei; Berger, Allison J.; Mulligan, George; Faessel, Helene M.; Tirrell, Stephen; Dezube, Bruce J.; Lonial, Sagar</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-43</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma.  Exptl. Design: Patients with relapsed/refractory myeloma (n = 17) or lymphoma (n = 27) received i.v. pevonedistat 25 to 147 mg/m2 on days 1, 2, 8, 9 (schedule A; n = 27) or 100 to 261 mg/m2 on days 1, 4, 8, 11 (schedule B; n = 17) of 21-day cycles.  Results: Maximum tolerated doses were 110 mg/m2 (schedule A) and 196 mg/m2 (schedule B).  Dose-limiting toxicities included febrile neutropenia, transaminase elevations, muscle cramps (schedule A), and thrombocytopenia (schedule B).  Common adverse events included fatigue and nausea.  Common grade ≥3 events were anemia (19%; schedule A), and neutropenia and pneumonia (12%; schedule B).  Clin. significant myelosuppression was uncommon.  There were no treatment-related deaths.  Pevonedistat pharmacokinetics exhibited a biphasic disposition phase and approx. dose-proportional increases in systemic exposure.  Consistent with the short mean elimination half-life of approx. 8.5 h, little-to-no drug accumulation in plasma was seen after multiple dosing.  Pharmacodynamic evidence of NAE inhibition included increased skin levels of CDT-1 and NRF-2 (substrates of NAE-dependent ubiquitin ligases), and increased NRF-2-regulated gene transcript levels in whole blood.  Pevonedistat-NEDD8 adduct was detected in bone marrow aspirates, indicating pevonedistat target engagement in the bone marrow compartment.  Three lymphoma patients had partial responses; 30 patients achieved stable disease.  Conclusions: Pevonedistat demonstrated anticipated pharmacodynamic effects in the clin. setting, a tolerable safety profile, and some preliminary evidence that may be suggestive of the potential for activity in relapsed/refractory lymphoma.  Clin Cancer Res; 22(1); 34-43. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrExZAI5ejiqrVg90H21EOLACvtfcHk0ljjJLGQo8rjYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGqsL8%253D&md5=601285c10bd3b286305dc5f052f02cfa</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1237%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DJ.%2BJ.%26aulast%3DJakubowiak%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DO.%2BA.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DHarvey%26aufirst%3DR.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BR.%26aulast%3DLebovic%26aufirst%3DD.%26aulast%3DDiefenbach%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DMulligan%26aufirst%3DG.%26aulast%3DFaessel%26aufirst%3DH.%2BM.%26aulast%3DTirrell%26aufirst%3DS.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DLonial%26aufirst%3DS.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520novel%2520investigational%2520NEDD8-activating%2520enzyme%2520inhibitor%2520pevonedistat%2520%2528MLN4924%2529%2520in%2520patients%2520with%2520relapsed%252Frefractory%2520multiple%2520myeloma%2520or%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D34%26epage%3D43%26doi%3D10.1158%2F1078-0432.CCR-15-1237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazurkiewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillert, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olofsson, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierrou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillertz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvaraju, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhtar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arcy, P.</span><span> </span><span class="NLM_article-title">The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">26979</span><span class="refDoi"> DOI: 10.1038/srep26979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fsrep26979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27264969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsF2qtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=26979&author=X.+Wangauthor=M.+Mazurkiewiczauthor=E.+K.+Hillertauthor=M.+H.+Olofssonauthor=S.+Pierrouauthor=P.+Hillertzauthor=J.+Gullboauthor=K.+Selvarajuauthor=A.+Paulusauthor=S.+Akhtarauthor=F.+Bosslerauthor=A.+C.+Khanauthor=S.+Linderauthor=P.+D%E2%80%99Arcy&title=The+proteasome+deubiquitinase+inhibitor+VLX1570+shows+selectivity+for+ubiquitin-specific+protease-14+and+induces+apoptosis+of+multiple+myeloma+cells&doi=10.1038%2Fsrep26979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells</span></div><div class="casAuthors">Wang, Xin; Mazurkiewicz, Magdalena; Hillert, Ellin-Kristina; Olofsson, Maria Haegg; Pierrou, Stefan; Hillertz, Per; Gullbo, Joachim; Selvaraju, Karthik; Paulus, Aneel; Akhtar, Sharoon; Bossler, Felicitas; Khan, Asher Chanan; Linder, Stig; D'Arcy, Padraig</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26979</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of deubiquitinase (DUB) activity is a promising strategy for cancer therapy.  VLX1570 is an inhibitor of proteasome DUB activity currently in clin. trials for relapsed multiple myeloma.  Here we show that VLX1570 binds to and inhibits the activity of ubiquitin-specific protease-14 (USP14) in vitro, with comparatively weaker inhibitory activity towards UCHL5 (ubiquitin-C-terminal hydrolase-5).  Exposure of multiple myeloma cells to VLX1570 resulted in thermostabilization of USP14 at therapeutically relevant concns.  Transient knockdown of USP14 or UCHL5 expression by electroporation of siRNA reduced the viability of multiple myeloma cells.  Treatment of multiple myeloma cells with VLX1570 induced the accumulation of proteasome-bound high mol. wt. polyubiquitin conjugates and an apoptotic response.  Sensitivity to VLX1570 was moderately affected by altered drug uptake, but was unaffected by overexpression of BCL2-family proteins or inhibitors of caspase activity.  Finally, treatment with VLX1570 was found to lead to extended survival in xenograft models of multiple myeloma.  Our findings demonstrate promising antiproliferative activity of VLX1570 in multiple myeloma, primarily assocd. with inhibition of USP14 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSyNNG3GPEDLVg90H21EOLACvtfcHk0ljo4Q8uw-BeJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsF2qtLg%253D&md5=9826987b387c59f4fc10fa7c2d126011</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsrep26979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep26979%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMazurkiewicz%26aufirst%3DM.%26aulast%3DHillert%26aufirst%3DE.%2BK.%26aulast%3DOlofsson%26aufirst%3DM.%2BH.%26aulast%3DPierrou%26aufirst%3DS.%26aulast%3DHillertz%26aufirst%3DP.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DSelvaraju%26aufirst%3DK.%26aulast%3DPaulus%26aufirst%3DA.%26aulast%3DAkhtar%26aufirst%3DS.%26aulast%3DBossler%26aufirst%3DF.%26aulast%3DKhan%26aufirst%3DA.%2BC.%26aulast%3DLinder%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DP.%26atitle%3DThe%2520proteasome%2520deubiquitinase%2520inhibitor%2520VLX1570%2520shows%2520selectivity%2520for%2520ubiquitin-specific%2520protease-14%2520and%2520induces%2520apoptosis%2520of%2520multiple%2520myeloma%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D26979%26doi%3D10.1038%2Fsrep26979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arcy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulfield, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohanty, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanan-Khan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linder, S.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">1036</span><span class="NLM_x">–</span> <span class="NLM_lpage">1048</span><span class="refDoi"> DOI: 10.1111/cbdd.12571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1111%2Fcbdd.12571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25854145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovV2qu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=1036-1048&author=X.+Wangauthor=P.+D%E2%80%99Arcyauthor=T.+R.+Caulfieldauthor=A.+Paulusauthor=K.+Chittaauthor=C.+Mohantyauthor=J.+Gullboauthor=A.+Chanan-Khanauthor=S.+Linder&title=Synthesis+and+evaluation+of+derivatives+of+the+proteasome+deubiquitinase+inhibitor+b-AP15&doi=10.1111%2Fcbdd.12571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15</span></div><div class="casAuthors">Wang, Xin; D'Arcy, Padraig; Caulfield, Thomas R.; Paulus, Aneel; Chitta, Kasyapa; Mohanty, Chitralekha; Gullbo, Joachim; Chanan-Khan, Asher; Linder, Stig</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1036-1048</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) is increasingly recognized as a therapeutic target for the development of anticancer therapies.  The success of the 20S proteasome core particle (20S CP) inhibitor bortezomib in the clin. management of multiple myeloma has raised the possibility of identifying other UPS components for therapeutic intervention.  We previously identified the small mol. b-AP15 as an inhibitor of 19S proteasome deubiquitinase (DUB) activity.  Building upon our previous data, we performed a structure-activity relation (SAR) study on b-AP15 and identified VLX1570 as an analog with promising properties, including enhanced potency and improved soly. in aq. soln.  In silico modeling was consistent with interaction of VLX1570 with key cysteine residues located at the active sites of the proteasome DUBs USP14 and UCHL5.  VLX1570 was found to inhibit proteasome deubiquitinase activity in vitro in a manner consistent with competitive inhibition.  Furthermore, using active-site-directed probes, VLX1570 also inhibited proteasome DUB activity in exposed cells.  Importantly, VLX1570 did not show inhibitory activity on a panel of recombinant non-proteasome DUBs, on recombinant kinases, or on caspase-3 activity, suggesting that VLX1570 is not an overtly reactive general enzyme inhibitor.  Taken together, our data shows the chem. and biol. properties of VLX1570 as an optimized proteasome DUB inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9jJ_S5YMId7Vg90H21EOLACvtfcHk0ljo4Q8uw-BeJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovV2qu70%253D&md5=353bf1b03a5378ba70f0835a143516f1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12571%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DP.%26aulast%3DCaulfield%26aufirst%3DT.%2BR.%26aulast%3DPaulus%26aufirst%3DA.%26aulast%3DChitta%26aufirst%3DK.%26aulast%3DMohanty%26aufirst%3DC.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DChanan-Khan%26aufirst%3DA.%26aulast%3DLinder%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520derivatives%2520of%2520the%2520proteasome%2520deubiquitinase%2520inhibitor%2520b-AP15%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2015%26volume%3D86%26spage%3D1036%26epage%3D1048%26doi%3D10.1111%2Fcbdd.12571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Paiva, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Silva, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Araujo, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunning, P. T.</span><span> </span><span class="NLM_article-title">Regulating the master regulator: controlling ubiquitination by thinking outside the active site</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+L.+Paivaauthor=S.+R.+da+Silvaauthor=E.+D.+de+Araujoauthor=P.+T.+Gunning&title=Regulating+the+master+regulator%3A+controlling+ubiquitination+by+thinking+outside+the+active+site&doi=10.1021%2Facs.jmedchem.6b01346"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01346%26sid%3Dliteratum%253Aachs%26aulast%3DPaiva%26aufirst%3DS.%2BL.%26aulast%3Dda%2BSilva%26aufirst%3DS.%2BR.%26aulast%3Dde%2BAraujo%26aufirst%3DE.%2BD.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DRegulating%2520the%2520master%2520regulator%253A%2520controlling%2520ubiquitination%2520by%2520thinking%2520outside%2520the%2520active%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26doi%3D10.1021%2Facs.jmedchem.6b01346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Everett, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meredith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kathoria, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, J.</span><span> </span><span class="NLM_article-title">A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1519</span><span class="NLM_x">–</span> <span class="NLM_lpage">1530</span><span class="refDoi"> DOI: 10.1093/emboj/16.7.1519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1093%2Femboj%2F16.7.1519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=9130697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADyaK2sXislKmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=1519-1530&author=R.+D.+Everettauthor=M.+Meredithauthor=A.+Orrauthor=A.+Crossauthor=M.+Kathoriaauthor=J.+Parkinson&title=A+novel+ubiquitin-specific+protease+is+dynamically+associated+with+the+PML+nuclear+domain+and+binds+to+a+herpesvirus+regulatory+protein&doi=10.1093%2Femboj%2F16.7.1519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein</span></div><div class="casAuthors">Everett, Roger D.; Meredith, Michayla; Orr, Anne; Cross, Anne; Kathoria, Meeta; Parkinson, Jane</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1519-1530</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Herpes simplex virus type 1 immediate-early protein Vmw110 is a non-specific activator of gene expression and is required for efficient initiation of the viral lytic cycle.  Since Vmw110-deficient viruses reactivate inefficiently in mouse latency models it has been suggested that Vmw110 plays a role in the balance between the latent and lytic states of the virus.  The mechanisms by which Vmw110 achieves these functions are poorly understood.  Vmw110 migrates to discrete nuclear structures (ND10) which contain the cellular PML protein, and in consequence PML and other constituent proteins are dispersed.  In addn., Vmw110 binds to a cellular protein of ∼135 kDa, and its interactions with the 135-kDa protein and ND10 contribute to this ability to stimulate gene expression and viral lytic growth.  This report identifies the 135-kDa protein as a novel member of the ubiquitin-specific protease family.  The protease is distributed in the nucleus in a micropunctate pattern with a limited no. of larger discrete foci, some of which co-localize with PML in ND10.  At early times of virus infection, the presence of Vmw110 increases the proportion of ND10 which contain the ubiquitin-specific protease.  These results identify a novel, transitory component of ND10 and implicate a previously uncharacterized ubiquitin-dependent pathway in the control of viral gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYxp1O3Xh70LVg90H21EOLACvtfcHk0ljftKfvYzXk1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislKmurk%253D&md5=43c11b7ec8a0c6ab764a16cc52035312</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.7.1519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.7.1519%26sid%3Dliteratum%253Aachs%26aulast%3DEverett%26aufirst%3DR.%2BD.%26aulast%3DMeredith%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DA.%26aulast%3DCross%26aufirst%3DA.%26aulast%3DKathoria%26aufirst%3DM.%26aulast%3DParkinson%26aufirst%3DJ.%26atitle%3DA%2520novel%2520ubiquitin-specific%2520protease%2520is%2520dynamically%2520associated%2520with%2520the%2520PML%2520nuclear%2520domain%2520and%2520binds%2520to%2520a%2520herpesvirus%2520regulatory%2520protein%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D1519%26epage%3D1530%26doi%3D10.1093%2Femboj%2F16.7.1519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suresh Kumar, K. G.</span><span> </span><span class="NLM_article-title">The multifaceted roles of USP7: new therapeutic opportunities</span> <span class="citation_source-journal">Cell Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1007/s12013-011-9185-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs12013-011-9185-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21468693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVGhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=61-68&author=B.+Nicholsonauthor=K.+G.+Suresh+Kumar&title=The+multifaceted+roles+of+USP7%3A+new+therapeutic+opportunities&doi=10.1007%2Fs12013-011-9185-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The Multifaceted Roles of USP7: New Therapeutic Opportunities</span></div><div class="casAuthors">Nicholson, Benjamin; Suresh Kumar, K. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">61-68</span>CODEN:
                <span class="NLM_cas:coden">CBBIFV</span>;
        ISSN:<span class="NLM_cas:issn">1085-9195</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The deubiquitylating enzyme USP7 (HAUSP) sits at a crit. node regulating the activities of numerous proteins broadly characterized as tumor suppressors, DNA repair proteins, immune responders, viral proteins, and epigenetic modulators.  Aberrant USP7 activity may promote oncogenesis and viral disease making it a compelling target for therapeutic intervention.  Disclosed drug discovery programs have identified inhibitors of USP7 such as P005091 with cellular proof of concept and anti-proliferative activity in cancer models.  Taken together, USP7 inhibitors hold promise as a new strategy for the treatment of disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW62HFUQNunrVg90H21EOLACvtfcHk0ljftKfvYzXk1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVGhs7k%253D&md5=c84af523c76e0c756ef2cd37ae6d2a21</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs12013-011-9185-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12013-011-9185-5%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DSuresh%2BKumar%26aufirst%3DK.%2BG.%26atitle%3DThe%2520multifaceted%2520roles%2520of%2520USP7%253A%2520new%2520therapeutic%2520opportunities%26jtitle%3DCell%2520Biochem.%2520Biophys.%26date%3D2011%26volume%3D60%26spage%3D61%26epage%3D68%26doi%3D10.1007%2Fs12013-011-9185-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Kim, R. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sixma, T. K.</span><span> </span><span class="NLM_article-title">Regulation of USP7: a high incidence of E3 complexes</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1016/j.jmb.2017.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.jmb.2017.05.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=R.+Q.+Kimauthor=T.+K.+Sixma&title=Regulation+of+USP7%3A+a+high+incidence+of+E3+complexes&doi=10.1016%2Fj.jmb.2017.05.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2017.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2017.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DR.%2BQ.%26aulast%3DSixma%26aufirst%3DT.%2BK.%26atitle%3DRegulation%2520of%2520USP7%253A%2520a%2520high%2520incidence%2520of%2520E3%2520complexes%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2017%26doi%3D10.1016%2Fj.jmb.2017.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Kon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span> </span><span class="NLM_article-title">Inactivation of HAUSP in vivo modulates p53 function</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1270</span><span class="NLM_x">–</span> <span class="NLM_lpage">1279</span><span class="refDoi"> DOI: 10.1038/onc.2009.427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fonc.2009.427" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=1270-1279&author=N.+Konauthor=Y.+Kobayashiauthor=M.+Liauthor=C.+L.+Brooksauthor=T.+Ludwigauthor=W.+Gu&title=Inactivation+of+HAUSP+in+vivo+modulates+p53+function&doi=10.1038%2Fonc.2009.427"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.427%26sid%3Dliteratum%253Aachs%26aulast%3DKon%26aufirst%3DN.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DBrooks%26aufirst%3DC.%2BL.%26aulast%3DLudwig%26aufirst%3DT.%26aulast%3DGu%26aufirst%3DW.%26atitle%3DInactivation%2520of%2520HAUSP%2520in%2520vivo%2520modulates%2520p53%2520function%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D1270%26epage%3D1279%26doi%3D10.1038%2Fonc.2009.427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Kon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabolcs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canoll, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span> </span><span class="NLM_article-title">Roles of HAUSP-mediated p53 regulation in central nervous system development</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1366</span><span class="NLM_x">–</span> <span class="NLM_lpage">1375</span><span class="refDoi"> DOI: 10.1038/cdd.2011.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fcdd.2011.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21350561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Gku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1366-1375&author=N.+Konauthor=J.+Zhongauthor=Y.+Kobayashiauthor=M.+Liauthor=M.+Szabolcsauthor=T.+Ludwigauthor=P.+D.+Canollauthor=W.+Gu&title=Roles+of+HAUSP-mediated+p53+regulation+in+central+nervous+system+development&doi=10.1038%2Fcdd.2011.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of HAUSP-mediated p53 regulation in central nervous system development</span></div><div class="casAuthors">Kon, N.; Zhong, J.; Kobayashi, Y.; Li, M.; Szabolcs, M.; Ludwig, T.; Canoll, P. D.; Gu, W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1366-1375</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The deubiquitinase HAUSP (herpesvirus-assocd. ubiquitin-specific protease; also called USP7) has a crit. role in regulating the p53-Mdm2 (murine double minute 2) pathway.  By using the conventional knockout approach, we previously showed that hausp inactivation leads to early embryonic lethality.  To fully understand the physiol. functions of hausp, we have generated mice lacking hausp specifically in the brain and examd. the impacts of this manipulation on brain development.  We found that deletion of hausp in neural cells resulted in neonatal lethality.  The brains from these mice displayed hypoplasia and deficiencies in development, which were mainly caused by p53-mediated apoptosis.  Detailed anal. also showed an increase of both p53 levels and p53-dependent transcriptional activation in hausp knockout brains.  Notably, neural cell survival and brain development of hausp-mutant mice can largely be restored in the p53-null background.  Nevertheless, in contrast to the case of mdm2- and mdm4 (murine double minute 4)-mutant mice, inactivation of p53 failed to completely rescue the neonatal lethality of these hausp-mutant mice.  These results indicate that HAUSP-mediated p53 regulation is crucial for brain development, and also suggest that both the p53-dependent and the p53-independent functions of HAUSP contribute to the neonatal lethality of hausp-mutant mice.  Cell Death and Differentiation (2011) 18, 1366-1375; doi:10.1038/cdd.2011.12; published online 25 Feb. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJL6-JdtqU3LVg90H21EOLACvtfcHk0lgF9jP9lhbfrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Gku74%253D&md5=a0c2dabcf8d472a88b8991d225df2512</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2011.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2011.12%26sid%3Dliteratum%253Aachs%26aulast%3DKon%26aufirst%3DN.%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSzabolcs%26aufirst%3DM.%26aulast%3DLudwig%26aufirst%3DT.%26aulast%3DCanoll%26aufirst%3DP.%2BD.%26aulast%3DGu%26aufirst%3DW.%26atitle%3DRoles%2520of%2520HAUSP-mediated%2520p53%2520regulation%2520in%2520central%2520nervous%2520system%2520development%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2011%26volume%3D18%26spage%3D1366%26epage%3D1375%26doi%3D10.1038%2Fcdd.2011.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Hao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fountain, M. D.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fon Tacer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeld, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Caignec, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isidor, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krantz, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noon, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfotenhauer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saenz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potts, P. R.</span><span> </span><span class="NLM_article-title">USP7 acts as a molecular rheostat to promote WASH-dependent endosomal protein recycling and is mutated in a human neurodevelopmental disorder</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">956</span><span class="NLM_x">–</span> <span class="NLM_lpage">969</span><span class="refDoi"> DOI: 10.1016/j.molcel.2015.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.molcel.2015.07.033" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=956-969&author=Y.+H.+Haoauthor=M.+D.+Fountainauthor=K.+Fon+Tacerauthor=F.+Xiaauthor=W.+Biauthor=S.+H.+Kangauthor=A.+Patelauthor=J.+A.+Rosenfeldauthor=C.+Le+Caignecauthor=B.+Isidorauthor=I.+D.+Krantzauthor=S.+E.+Noonauthor=J.+P.+Pfotenhauerauthor=T.+M.+Morganauthor=R.+Moranauthor=R.+C.+Pedersenauthor=M.+S.+Saenzauthor=C.+P.+Schaafauthor=P.+R.+Potts&title=USP7+acts+as+a+molecular+rheostat+to+promote+WASH-dependent+endosomal+protein+recycling+and+is+mutated+in+a+human+neurodevelopmental+disorder&doi=10.1016%2Fj.molcel.2015.07.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DY.%2BH.%26aulast%3DFountain%26aufirst%3DM.%2BD.%26aulast%3DFon%2BTacer%26aufirst%3DK.%26aulast%3DXia%26aufirst%3DF.%26aulast%3DBi%26aufirst%3DW.%26aulast%3DKang%26aufirst%3DS.%2BH.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DRosenfeld%26aufirst%3DJ.%2BA.%26aulast%3DLe%2BCaignec%26aufirst%3DC.%26aulast%3DIsidor%26aufirst%3DB.%26aulast%3DKrantz%26aufirst%3DI.%2BD.%26aulast%3DNoon%26aufirst%3DS.%2BE.%26aulast%3DPfotenhauer%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DT.%2BM.%26aulast%3DMoran%26aufirst%3DR.%26aulast%3DPedersen%26aufirst%3DR.%2BC.%26aulast%3DSaenz%26aufirst%3DM.%2BS.%26aulast%3DSchaaf%26aufirst%3DC.%2BP.%26aulast%3DPotts%26aufirst%3DP.%2BR.%26atitle%3DUSP7%2520acts%2520as%2520a%2520molecular%2520rheostat%2520to%2520promote%2520WASH-dependent%2520endosomal%2520protein%2520recycling%2520and%2520is%2520mutated%2520in%2520a%2520human%2520neurodevelopmental%2520disorder%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D59%26spage%3D956%26epage%3D969%26doi%3D10.1016%2Fj.molcel.2015.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Sanders, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan-Sencicek, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hus, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murtha, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-De-Luca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilguvar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celestino-Soper, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhodapkar, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiCola, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiLullo, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding-Singh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishman, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frahm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garagaloyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammela, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lund, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrew, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdoch, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Roak, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ober, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pottenger, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raubeson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaspan, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkiewicz, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaudet, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantor, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grice, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifton, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mane, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischfield, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledbetter, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fombonne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutcliffe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, E. H.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geschwind, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roeder, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devlin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">State, M. W.</span><span> </span><span class="NLM_article-title">Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams Syndrome region, are strongly associated with autism</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">863</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span><span class="refDoi"> DOI: 10.1016/j.neuron.2011.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.neuron.2011.05.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2011&pages=863-885&author=S.+J.+Sandersauthor=A.+G.+Ercan-Sencicekauthor=V.+Husauthor=R.+Luoauthor=M.+T.+Murthaauthor=D.+Moreno-De-Lucaauthor=S.+H.+Chuauthor=M.+P.+Moreauauthor=A.+R.+Guptaauthor=S.+A.+Thomsonauthor=C.+E.+Masonauthor=K.+Bilguvarauthor=P.+B.+Celestino-Soperauthor=M.+Choiauthor=E.+L.+Crawfordauthor=L.+Davisauthor=N.+R.+Wrightauthor=R.+M.+Dhodapkarauthor=M.+DiColaauthor=N.+M.+DiLulloauthor=T.+V.+Fernandezauthor=V.+Fielding-Singhauthor=D.+O.+Fishmanauthor=S.+Frahmauthor=R.+Garagaloyanauthor=G.+S.+Gohauthor=S.+Kammelaauthor=L.+Kleiauthor=J.+K.+Loweauthor=S.+C.+Lundauthor=A.+D.+McGrewauthor=K.+A.+Meyerauthor=W.+J.+Moffatauthor=J.+D.+Murdochauthor=B.+J.+O%E2%80%99Roakauthor=G.+T.+Oberauthor=R.+S.+Pottengerauthor=M.+J.+Raubesonauthor=Y.+Songauthor=Q.+Wangauthor=B.+L.+Yaspanauthor=T.+W.+Yuauthor=I.+R.+Yurkiewiczauthor=A.+L.+Beaudetauthor=R.+M.+Cantorauthor=M.+Curlandauthor=D.+E.+Griceauthor=M.+Gunelauthor=R.+P.+Liftonauthor=S.+M.+Maneauthor=D.+M.+Martinauthor=C.+A.+Shawauthor=M.+Sheldonauthor=J.+A.+Tischfieldauthor=C.+A.+Walshauthor=E.+M.+Morrowauthor=D.+H.+Ledbetterauthor=E.+Fombonneauthor=C.+Lordauthor=C.+L.+Martinauthor=A.+I.+Brooksauthor=J.+S.+Sutcliffeauthor=E.+H.+Cookauthor=D.+Geschwindauthor=K.+Roederauthor=B.+Devlinauthor=M.+W.+State&title=Multiple+recurrent+de+novo+CNVs%2C+including+duplications+of+the+7q11.23+Williams+Syndrome+region%2C+are+strongly+associated+with+autism&doi=10.1016%2Fj.neuron.2011.05.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2011.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2011.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DSanders%26aufirst%3DS.%2BJ.%26aulast%3DErcan-Sencicek%26aufirst%3DA.%2BG.%26aulast%3DHus%26aufirst%3DV.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DMurtha%26aufirst%3DM.%2BT.%26aulast%3DMoreno-De-Luca%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DS.%2BH.%26aulast%3DMoreau%26aufirst%3DM.%2BP.%26aulast%3DGupta%26aufirst%3DA.%2BR.%26aulast%3DThomson%26aufirst%3DS.%2BA.%26aulast%3DMason%26aufirst%3DC.%2BE.%26aulast%3DBilguvar%26aufirst%3DK.%26aulast%3DCelestino-Soper%26aufirst%3DP.%2BB.%26aulast%3DChoi%26aufirst%3DM.%26aulast%3DCrawford%26aufirst%3DE.%2BL.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DWright%26aufirst%3DN.%2BR.%26aulast%3DDhodapkar%26aufirst%3DR.%2BM.%26aulast%3DDiCola%26aufirst%3DM.%26aulast%3DDiLullo%26aufirst%3DN.%2BM.%26aulast%3DFernandez%26aufirst%3DT.%2BV.%26aulast%3DFielding-Singh%26aufirst%3DV.%26aulast%3DFishman%26aufirst%3DD.%2BO.%26aulast%3DFrahm%26aufirst%3DS.%26aulast%3DGaragaloyan%26aufirst%3DR.%26aulast%3DGoh%26aufirst%3DG.%2BS.%26aulast%3DKammela%26aufirst%3DS.%26aulast%3DKlei%26aufirst%3DL.%26aulast%3DLowe%26aufirst%3DJ.%2BK.%26aulast%3DLund%26aufirst%3DS.%2BC.%26aulast%3DMcGrew%26aufirst%3DA.%2BD.%26aulast%3DMeyer%26aufirst%3DK.%2BA.%26aulast%3DMoffat%26aufirst%3DW.%2BJ.%26aulast%3DMurdoch%26aufirst%3DJ.%2BD.%26aulast%3DO%25E2%2580%2599Roak%26aufirst%3DB.%2BJ.%26aulast%3DOber%26aufirst%3DG.%2BT.%26aulast%3DPottenger%26aufirst%3DR.%2BS.%26aulast%3DRaubeson%26aufirst%3DM.%2BJ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYaspan%26aufirst%3DB.%2BL.%26aulast%3DYu%26aufirst%3DT.%2BW.%26aulast%3DYurkiewicz%26aufirst%3DI.%2BR.%26aulast%3DBeaudet%26aufirst%3DA.%2BL.%26aulast%3DCantor%26aufirst%3DR.%2BM.%26aulast%3DCurland%26aufirst%3DM.%26aulast%3DGrice%26aufirst%3DD.%2BE.%26aulast%3DGunel%26aufirst%3DM.%26aulast%3DLifton%26aufirst%3DR.%2BP.%26aulast%3DMane%26aufirst%3DS.%2BM.%26aulast%3DMartin%26aufirst%3DD.%2BM.%26aulast%3DShaw%26aufirst%3DC.%2BA.%26aulast%3DSheldon%26aufirst%3DM.%26aulast%3DTischfield%26aufirst%3DJ.%2BA.%26aulast%3DWalsh%26aufirst%3DC.%2BA.%26aulast%3DMorrow%26aufirst%3DE.%2BM.%26aulast%3DLedbetter%26aufirst%3DD.%2BH.%26aulast%3DFombonne%26aufirst%3DE.%26aulast%3DLord%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DC.%2BL.%26aulast%3DBrooks%26aufirst%3DA.%2BI.%26aulast%3DSutcliffe%26aufirst%3DJ.%2BS.%26aulast%3DCook%26aufirst%3DE.%2BH.%26aulast%3DGeschwind%26aufirst%3DD.%26aulast%3DRoeder%26aufirst%3DK.%26aulast%3DDevlin%26aufirst%3DB.%26aulast%3DState%26aufirst%3DM.%2BW.%26atitle%3DMultiple%2520recurrent%2520de%2520novo%2520CNVs%252C%2520including%2520duplications%2520of%2520the%25207q11.23%2520Williams%2520Syndrome%2520region%252C%2520are%2520strongly%2520associated%2520with%2520autism%26jtitle%3DNeuron%26date%3D2011%26volume%3D70%26spage%3D863%26epage%3D885%26doi%3D10.1016%2Fj.neuron.2011.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Lecona, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Acebes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Contreras, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruppen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Capetillo, O.</span><span> </span><span class="NLM_article-title">USP7 is a SUMO deubiquitinase essential for DNA replication</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">277</span><span class="refDoi"> DOI: 10.1038/nsmb.3185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnsmb.3185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26950370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsVGmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=270-277&author=E.+Leconaauthor=S.+Rodriguez-Acebesauthor=J.+Specksauthor=A.+J.+Lopez-Contrerasauthor=I.+Ruppenauthor=M.+Murgaauthor=J.+Munozauthor=J.+Mendezauthor=O.+Fernandez-Capetillo&title=USP7+is+a+SUMO+deubiquitinase+essential+for+DNA+replication&doi=10.1038%2Fnsmb.3185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">USP7 is a SUMO deubiquitinase essential for DNA replication</span></div><div class="casAuthors">Lecona, Emilio; Rodriguez-Acebes, Sara; Specks, Julia; Lopez-Contreras, Andres J.; Ruppen, Isabel; Murga, Matilde; Munoz, Javier; Mendez, Juan; Fernandez-Capetillo, Oscar</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">270-277</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Post-translational modification of proteins by ubiquitin (Ub) and Ub-like modifiers regulates DNA replication.  We have previously shown that chromatin around replisomes is rich in SUMO and poor in Ub, whereas mature chromatin exhibits an opposite pattern.  How this SUMO-rich, Ub-poor environment is maintained at sites of DNA replication in mammalian cells remains unexplored.  Here we identify USP7 as a replisome-enriched SUMO deubiquitinase that is essential for DNA replication.  By acting on SUMO and SUMOylated proteins, USP7 counteracts their ubiquitination.  Inhibition or genetic deletion of USP7 leads to the accumulation of Ub on SUMOylated proteins, which are displaced away from replisomes.  Our findings provide a model explaining the differential accumulation of SUMO and Ub at replication forks and identify an essential role of USP7 in DNA replication that should be considered in the development of USP7 inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcwBs_aWMhurVg90H21EOLACvtfcHk0lian-QU2a150A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsVGmsLk%253D&md5=0c1060d0b7dbae85a167a180c15f9741</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3185%26sid%3Dliteratum%253Aachs%26aulast%3DLecona%26aufirst%3DE.%26aulast%3DRodriguez-Acebes%26aufirst%3DS.%26aulast%3DSpecks%26aufirst%3DJ.%26aulast%3DLopez-Contreras%26aufirst%3DA.%2BJ.%26aulast%3DRuppen%26aufirst%3DI.%26aulast%3DMurga%26aufirst%3DM.%26aulast%3DMunoz%26aufirst%3DJ.%26aulast%3DMendez%26aufirst%3DJ.%26aulast%3DFernandez-Capetillo%26aufirst%3DO.%26atitle%3DUSP7%2520is%2520a%2520SUMO%2520deubiquitinase%2520essential%2520for%2520DNA%2520replication%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D270%26epage%3D277%26doi%3D10.1038%2Fnsmb.3185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, F. H.</span><span> </span><span class="NLM_article-title">USP7 promotes cell proliferation through the stabilization of Ki-67 protein in non-small cell lung cancer cells</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1016/j.biocel.2016.08.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.biocel.2016.08.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27590858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyiurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=209-221&author=C.+Zhangauthor=J.+Luauthor=Q.+W.+Zhangauthor=W.+Zhaoauthor=J.+H.+Guoauthor=S.+L.+Liuauthor=Y.+L.+Wuauthor=B.+Jiangauthor=F.+H.+Gao&title=USP7+promotes+cell+proliferation+through+the+stabilization+of+Ki-67+protein+in+non-small+cell+lung+cancer+cells&doi=10.1016%2Fj.biocel.2016.08.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">USP7 promotes cell proliferation through the stabilization of Ki-67 protein in non-small cell lung cancer cells</span></div><div class="casAuthors">Zhang, Chao; Lu, Jing; Zhang, Quan-Wu; Zhao, Wei; Guo, Jia-Hui; Liu, Shan-Ling; Wu, Ying-Li; Jiang, Bin; Gao, Feng-Hou</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Ki-67 antigen (Ki-67) is the most reliable immunohistochem. marker for evaluation of cell proliferation in non-small cell lung cancer.  However, the mechanisms underlying the regulation of protein levels of Ki-67 in non-small cell lung cancer have remained elusive.  In this study, we found that Ki-67 and ubiquitin-specific processing protease 7 (USP7) protein were highly expressed in the nucleus of non-small cell lung cancer cells.  Furthermore, statistical anal. uncovered the existence of a strong correlation between Ki-67 and USP7 levels.  We could also show that the protein levels of Ki-67 in non-small cell lung cancer cells significantly decreased after treatment with P22077, a selective chem. inhibitor of USP7, while the Ki-67 mRNA levels were unperturbed.  Similar results were obtained by knocking down USP7 using short hairpin RNA (shRNA) in lung cancer cells.  Interestingly, we noticed that ubiquitination levels of Ki-67 increased dramatically in USP7-silenced cells.  The tests in vitro and vivo showed a significant delay in tumor cell growth upon knockdown of USP7.  Addnl., drug sensitivity tests indicated that USP7-silenced A549 cells had enhanced sensitivity to paclitaxel and docetaxel, while there was no significant change in sensitivity toward carboplatin and cisplatin.  Taken together, these data strongly suggest that the overexpression of USP7 might promote cell proliferation by deubiquitinating Ki-67 protein, thereby maintaining its high levels in the non-small cell lung cancer.  Our study also hints potential for the development of deubiquitinase-based therapies, esp. those targeting USP7 to improve the condition of patients diagnosed with non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfCNqZdfSwJ7Vg90H21EOLACvtfcHk0lian-QU2a150A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyiurnJ&md5=6c0125120978c298b4f2785b390ba51d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2016.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2016.08.025%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%2BW.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%2BH.%26aulast%3DLiu%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DF.%2BH.%26atitle%3DUSP7%2520promotes%2520cell%2520proliferation%2520through%2520the%2520stabilization%2520of%2520Ki-67%2520protein%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2016%26volume%3D79%26spage%3D209%26epage%3D221%26doi%3D10.1016%2Fj.biocel.2016.08.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Zhan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span> </span><span class="NLM_article-title">Usp7 promotes medulloblastoma cell survival and metastasis by activating Shh pathway</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">484</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2017.01.144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.bbrc.2017.01.144" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=484&publication_year=2017&pages=429-434&author=M.+Zhanauthor=X.+Sunauthor=J.+Liuauthor=Y.+Liauthor=Y.+Liauthor=X.+Heauthor=Z.+Zhouauthor=L.+Lu&title=Usp7+promotes+medulloblastoma+cell+survival+and+metastasis+by+activating+Shh+pathway&doi=10.1016%2Fj.bbrc.2017.01.144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.01.144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.01.144%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DL.%26atitle%3DUsp7%2520promotes%2520medulloblastoma%2520cell%2520survival%2520and%2520metastasis%2520by%2520activating%2520Shh%2520pathway%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D484%26spage%3D429%26epage%3D434%26doi%3D10.1016%2Fj.bbrc.2017.01.144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Tavana, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Califano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashiro, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span> </span><span class="NLM_article-title">HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1180</span><span class="NLM_x">–</span> <span class="NLM_lpage">1186</span><span class="refDoi"> DOI: 10.1038/nm.4180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnm.4180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27618649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2rtb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1180-1186&author=O.+Tavanaauthor=D.+Liauthor=C.+Daiauthor=G.+Lopezauthor=D.+Banerjeeauthor=N.+Konauthor=C.+Chenauthor=A.+Califanoauthor=D.+J.+Yamashiroauthor=H.+Sunauthor=W.+Gu&title=HAUSP+deubiquitinates+and+stabilizes+N-Myc+in+neuroblastoma&doi=10.1038%2Fnm.4180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma</span></div><div class="casAuthors">Tavana, Omid; Li, Dawei; Dai, Chao; Lopez, Gonzalo; Banerjee, Debarshi; Kon, Ning; Chen, Chao; Califano, Andrea; Yamashiro, Darrell J.; Sun, Hongbin; Gu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1180-1186</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The MYCN proto-oncogene is amplified in a no. of advanced-stage human tumors, such as neuroblastomas.  Similar to other members of the MYC family of oncoproteins, MYCN (also known as N-Myc) is a transcription factor, and its stability and activity are tightly controlled by ubiquitination-dependent proteasome degrdn.  Although numerous studies have demonstrated that N-Myc is a driver of neuroblastoma tumorigenesis, therapies that directly suppress N-Myc activity in human tumors are limited.  Here we have identified ubiquitin-specific protease 7 (USP7; also known as HAUSP) as a regulator of N-Myc function in neuroblastoma.  HAUSP interacts with N-Myc, and HAUSP expression induces deubiquitination and subsequent stabilization of N-Myc.  Conversely, RNA interference (RNAi)-mediated knockdown of USP7 in neuroblastoma cancer cell lines, or genetic ablation of Usp7 in the mouse brain, destabilizes N-Myc, which leads to inhibition of N-Myc function.  Notably, HAUSP is more abundant in patients with neuroblastoma who have poorer prognosis, and HAUSP expression substantially correlates with N-Myc transcriptional activity.  Furthermore, small-mol. inhibitors of HAUSP's deubiquitinase activity markedly suppress the growth of MYCN-amplified human neuroblastoma cell lines in xenograft mouse models.  Taken together, our findings demonstrate a crucial role of HAUSP in regulating N-Myc function in vivo and suggest that HAUSP inhibition is a potential therapy for MYCN-amplified tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC4ucMtC9h_7Vg90H21EOLACvtfcHk0lian-QU2a150A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2rtb%252FE&md5=853ba98d5bd2dec31943b78765ed1f0f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnm.4180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4180%26sid%3Dliteratum%253Aachs%26aulast%3DTavana%26aufirst%3DO.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DC.%26aulast%3DLopez%26aufirst%3DG.%26aulast%3DBanerjee%26aufirst%3DD.%26aulast%3DKon%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCalifano%26aufirst%3DA.%26aulast%3DYamashiro%26aufirst%3DD.%2BJ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DW.%26atitle%3DHAUSP%2520deubiquitinates%2520and%2520stabilizes%2520N-Myc%2520in%2520neuroblastoma%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D1180%26epage%3D1186%26doi%3D10.1038%2Fnm.4180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span> </span><span class="NLM_article-title">Molecular mechanism for USP7-mediated DNMT1 stabilization by acetylation</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">7023</span><span class="refDoi"> DOI: 10.1038/ncomms8023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fncomms8023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25960197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2ktrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=7023&author=J.+Chengauthor=H.+Yangauthor=J.+Fangauthor=L.+Maauthor=R.+Gongauthor=P.+Wangauthor=Z.+Liauthor=Y.+Xu&title=Molecular+mechanism+for+USP7-mediated+DNMT1+stabilization+by+acetylation&doi=10.1038%2Fncomms8023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism for USP7-mediated DNMT1 stabilization by acetylation</span></div><div class="casAuthors">Cheng, Jingdong; Yang, Huirong; Fang, Jian; Ma, Lixiang; Gong, Rui; Wang, Ping; Li, Ze; Xu, Yanhui</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7023</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">DNMT1 is an important epigenetic regulator that plays a key role in the maintenance of DNA methylation.  Here we detd. the crystal structure of DNMT1 in complex with USP7 at 2.9 Å resoln.  The interaction between the two proteins is primarily mediated by an acidic pocket in USP7 and Lysine residues within DNMT1's KG linker.  This intermol. interaction is required for USP7-mediated stabilization of DNMT1.  Acetylation of the KG linker Lysine residues impair DNMT1-USP7 interaction and promote the degrdn. of DNMT1.  Treatment with HDAC inhibitors results in an increase in acetylated DNMT1 and decreased total DNMT1 protein.  This neg. correlation is obsd. in differentiated neuronal cells and pancreatic cancer cells.  Our studies reveal that USP7-mediated stabilization of DNMT1 is regulated by acetylation and provide a structural basis for the design of inhibitors, targeting the DNMT1-USP7 interaction surface for therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFGjRM0dWyxLVg90H21EOLACvtfcHk0liGIChDi_W4zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2ktrfP&md5=0375cf6c3f56cb4d8cbd2051750ee462</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fncomms8023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms8023%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DGong%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DMolecular%2520mechanism%2520for%2520USP7-mediated%2520DNMT1%2520stabilization%2520by%2520acetylation%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D7023%26doi%3D10.1038%2Fncomms8023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guryanova, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, S.</span><span> </span><span class="NLM_article-title">Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span><span class="refDoi"> DOI: 10.1038/ncb2153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fncb2153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21258371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlamtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=142-152&author=Z.+Huangauthor=Q.+Wuauthor=O.+A.+Guryanovaauthor=L.+Chengauthor=W.+Shouauthor=J.+N.+Richauthor=S.+Bao&title=Deubiquitylase+HAUSP+stabilizes+REST+and+promotes+maintenance+of+neural+progenitor+cells&doi=10.1038%2Fncb2153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells</span></div><div class="casAuthors">Huang, Zhi; Wu, Qiulian; Guryanova, Olga A.; Cheng, Lin; Shou, Weinian; Rich, Jeremy N.; Bao, Shideng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">142-152</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The repressor element 1-silencing transcription factor (REST) functions as a master regulator to maintain neural stem/progenitor cells (NPCs).  REST undergoes proteasomal degrdn. through β-TrCP-mediated ubiquitylation during neuronal differentiation.  However, reciprocal mechanisms that stabilize REST in NPCs are undefined.  Here we show that the deubiquitylase HAUSP counterbalances REST ubiquitylation and prevents NPC differentiation.  HAUSP expression declines concordantly with REST on neuronal differentiation and reciprocally with β-TrCP levels.  HAUSP knockdown in NPCs decreases REST and induces differentiation.  In contrast, HAUSP overexpression upregulates REST by overriding β-TrCP-mediated ubiquitylation.  A consensus site (310-PYSS-313) in human REST is required for HAUSP-mediated REST deubiquitylation.  Furthermore, REST overexpression in NPCs rescues the differentiation phenotype induced by HAUSP knockdown.  These data demonstrate that HAUSP stabilizes REST through deubiquitylation and antagonizes β-TrCP in regulating REST at the post-translational level.  Thus, HAUSP-mediated deubiquitylation represents a crit. regulatory mechanism involved in the maintenance of NPCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxgn5FrTahmrVg90H21EOLACvtfcHk0liGIChDi_W4zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlamtbo%253D&md5=2ffcdebf63a76ca32e3f5f5ed6f32204</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fncb2153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb2153%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DGuryanova%26aufirst%3DO.%2BA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShou%26aufirst%3DW.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26aulast%3DBao%26aufirst%3DS.%26atitle%3DDeubiquitylase%2520HAUSP%2520stabilizes%2520REST%2520and%2520promotes%2520maintenance%2520of%2520neural%2520progenitor%2520cells%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2011%26volume%3D13%26spage%3D142%26epage%3D152%26doi%3D10.1038%2Fncb2153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">An, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span> </span><span class="NLM_article-title">USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1016/j.bcp.2017.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.bcp.2017.02.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=29-39&author=T.+Anauthor=Y.+Gongauthor=X.+Liauthor=L.+Kongauthor=P.+Maauthor=L.+Gongauthor=H.+Zhuauthor=C.+Yuauthor=J.+Liuauthor=H.+Zhouauthor=B.+Maoauthor=Y.+Li&title=USP7+inhibitor+P5091+inhibits+Wnt+signaling+and+colorectal+tumor+growth&doi=10.1016%2Fj.bcp.2017.02.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DT.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DUSP7%2520inhibitor%2520P5091%2520inhibits%2520Wnt%2520signaling%2520and%2520colorectal%2520tumor%2520growth%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D131%26spage%3D29%26epage%3D39%26doi%3D10.1016%2Fj.bcp.2017.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Wade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, G. M.</span><span> </span><span class="NLM_article-title">MDM2, MDMX and p53 in oncogenesis and cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1038/nrc3430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrc3430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=23303139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvFKmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=83-96&author=M.+Wadeauthor=Y.+C.+Liauthor=G.+M.+Wahl&title=MDM2%2C+MDMX+and+p53+in+oncogenesis+and+cancer+therapy&doi=10.1038%2Fnrc3430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">MDM2, MDMX and p53 in oncogenesis and cancer therapy</span></div><div class="casAuthors">Wade, Mark; Li, Yao-Cheng; Wahl, Geoffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">83-96</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumor suppressor.  However, the MDM proteins modulate and respond to many other signalling networks in which they are embedded.  Recent mechanistic studies and animal models have demonstrated how functional interactions in these networks are crucial for maintaining normal tissue homeostasis, and for detg. responses to oncogenic and therapeutic challenges.  This Review highlights the progress made and pitfalls encountered as the field continues to search for MDM-targeted antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqETvNjDDuV_bVg90H21EOLACvtfcHk0liGIChDi_W4zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvFKmtA%253D%253D&md5=58f901d95696dff8836ee9e7212b3478</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnrc3430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3430%26sid%3Dliteratum%253Aachs%26aulast%3DWade%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%2BC.%26aulast%3DWahl%26aufirst%3DG.%2BM.%26atitle%3DMDM2%252C%2520MDMX%2520and%2520p53%2520in%2520oncogenesis%2520and%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D83%26epage%3D96%26doi%3D10.1038%2Fnrc3430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span> </span><span class="NLM_article-title">A dynamic role of HAUSP in the p53-Mdm2 pathway</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">886</span><span class="refDoi"> DOI: 10.1016/S1097-2765(04)00157-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2FS1097-2765%2804%2900157-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=879-886&author=M.+Liauthor=C.+L.+Brooksauthor=N.+Konauthor=W.+Gu&title=A+dynamic+role+of+HAUSP+in+the+p53-Mdm2+pathway&doi=10.1016%2FS1097-2765%2804%2900157-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2804%2900157-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252804%252900157-1%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DBrooks%26aufirst%3DC.%2BL.%26aulast%3DKon%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DW.%26atitle%3DA%2520dynamic%2520role%2520of%2520HAUSP%2520in%2520the%2520p53-Mdm2%2520pathway%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D879%26epage%3D886%26doi%3D10.1016%2FS1097-2765%2804%2900157-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Meulmeester, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teunisse, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirks, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jochemsen, A. G.</span><span> </span><span class="NLM_article-title">Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">576</span><span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.molcel.2005.04.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=565-576&author=E.+Meulmeesterauthor=M.+M.+Mauriceauthor=C.+Boutellauthor=A.+F.+Teunisseauthor=H.+Ovaaauthor=T.+E.+Abrahamauthor=R.+W.+Dirksauthor=A.+G.+Jochemsen&title=Loss+of+HAUSP-mediated+deubiquitination+contributes+to+DNA+damage-induced+destabilization+of+Hdmx+and+Hdm2&doi=10.1016%2Fj.molcel.2005.04.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DMeulmeester%26aufirst%3DE.%26aulast%3DMaurice%26aufirst%3DM.%2BM.%26aulast%3DBoutell%26aufirst%3DC.%26aulast%3DTeunisse%26aufirst%3DA.%2BF.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DAbraham%26aufirst%3DT.%2BE.%26aulast%3DDirks%26aufirst%3DR.%2BW.%26aulast%3DJochemsen%26aufirst%3DA.%2BG.%26atitle%3DLoss%2520of%2520HAUSP-mediated%2520deubiquitination%2520contributes%2520to%2520DNA%2520damage-induced%2520destabilization%2520of%2520Hdmx%2520and%2520Hdm2%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26spage%3D565%26epage%3D576%26doi%3D10.1016%2Fj.molcel.2005.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Yi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span> </span><span class="NLM_article-title">Stabilization of LSD1 by deubiquitinating enzyme USP7 promotes glioblastoma cell tumorigenesis and metastasis through suppression of the p53 signaling pathway</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">2935</span><span class="NLM_x">–</span> <span class="NLM_lpage">2945</span><span class="refDoi"> DOI: 10.3892/or.2016.5099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.3892%2For.2016.5099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27632941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWksbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=2935-2945&author=L.+Yiauthor=Y.+Cuiauthor=Q.+Xuauthor=Y.+Jiang&title=Stabilization+of+LSD1+by+deubiquitinating+enzyme+USP7+promotes+glioblastoma+cell+tumorigenesis+and+metastasis+through+suppression+of+the+p53+signaling+pathway&doi=10.3892%2For.2016.5099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of LSD1 by deubiquitinating enzyme USP7 promotes glioblastoma cell tumorigenesis and metastasis through suppression of the p53 signaling pathway</span></div><div class="casAuthors">Yi, Lei; Cui, Yan; Xu, Qingfu; Jiang, Yugang</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2935-2945</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The substrates and mechanisms of ubiquitin specific peptidase 7 (USP7) in glioma remain unclear.  Lysine-specific demethylase 1 (LSD1) may undergo proteasomal degrdn.; however, a reciprocal mechanism that stabilizes LSD1 in glioma has not been dertermined.  Here co-immunopptn. and GST pull-down assays revealed that LSD1 is assocd. with USP7 in vivo and in vitro.  USP7 inhibited LSD1 ubiquitination and stabilized LSD1 in A172 and T98G cells.  MTT, EdU proliferation, flow cytometry and Transwell assays indicated that LSD1 played a crit. role in the proliferation and invasion of glioblastoma (GBM) cells.  We defined the mechanism of USP7 in GBM, through counterbalanced LSD1 ubiquitylation.  USP7 caused G0/G1 arrest, promoted tumorigenesis and invasion of A172 and T98G cells.  We also uncovered the suppression of the p53 signaling pathway that mediated the activity of USP7 and LSD1.  Furthermore, USP7 and LSD1 expression levels were higher in the 150 glioma patients than these levels in normal brain tissues and were correlated with glioma progression.  LSD1 was increased concurrently with USP7 during glioblastoma progression and both were predictors for worsened prognosis.  Collectively, our study suggested that USP7-LSD1 affects GBM cell proliferation and invasion and may be valuable as novel therapeutic targets and prognostic tools for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr89DZrK0dq67Vg90H21EOLACvtfcHk0ljZjq7AAkEuYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWksbbN&md5=21358e5aff3d9678bc92f5ab952c7075</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.3892%2For.2016.5099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.5099%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DStabilization%2520of%2520LSD1%2520by%2520deubiquitinating%2520enzyme%2520USP7%2520promotes%2520glioblastoma%2520cell%2520tumorigenesis%2520and%2520metastasis%2520through%2520suppression%2520of%2520the%2520p53%2520signaling%2520pathway%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D36%26spage%3D2935%26epage%3D2945%26doi%3D10.3892%2For.2016.5099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Trotman, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alimonti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teruya-Feldstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carver, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordon-Cardo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdjument-Bromage, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tempst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misteli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span> </span><span class="NLM_article-title">Ubiquitination regulates PTEN nuclear import and tumor suppression</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.11.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.cell.2006.11.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=17218261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptl2hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=141-156&author=L.+C.+Trotmanauthor=X.+Wangauthor=A.+Alimontiauthor=Z.+Chenauthor=J.+Teruya-Feldsteinauthor=H.+Yangauthor=N.+P.+Pavletichauthor=B.+S.+Carverauthor=C.+Cordon-Cardoauthor=H.+Erdjument-Bromageauthor=P.+Tempstauthor=S.+G.+Chiauthor=H.+J.+Kimauthor=T.+Misteliauthor=X.+Jiangauthor=P.+P.+Pandolfi&title=Ubiquitination+regulates+PTEN+nuclear+import+and+tumor+suppression&doi=10.1016%2Fj.cell.2006.11.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitination regulates PTEN nuclear import and tumor suppression</span></div><div class="casAuthors">Trotman, Lloyd C.; Wang, Xinjiang; Alimonti, Andrea; Chen, Zhenbang; Teruya-Feldstein, Julie; Yang, Haijuan; Pavletich, Nikola P.; Carver, Brett S.; Cordon-Cardo, Carlos; Erdjument-Bromage, Hediye; Tempst, Paul; Chi, Sung-Gil; Kim, Hyo-Jong; Misteli, Tom; Jiang, Xuejun; Pandolfi, Pier Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-156</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The PTEN tumor suppressor is frequently affected in cancer cells, and inherited PTEN mutation causes cancer-susceptibility conditions such as Cowden syndrome.  PTEN acts as a plasma-membrane lipid-phosphatase antagonizing the phosphoinositide 3-kinase/AKT cell survival pathway.  However, PTEN is also found in cell nuclei, but mechanism, function, and relevance of nuclear localization remain unclear.  We show that nuclear PTEN is essential for tumor suppression and that PTEN nuclear import is mediated by its mono-ubiquitination.  A lysine mutant of PTEN, K289E assocd. with Cowden syndrome, retains catalytic activity but fails to accumulate in nuclei of patient tissue due to an import defect.  We identify this and another lysine residue as major mono-ubiquitination sites essential for PTEN import.  While nuclear PTEN is stable, poly-ubiquitination leads to its degrdn. in the cytoplasm.  Thus, we identify cancer-assocd. mutations of PTEN that target its posttranslational modification and demonstrate how a discrete mol. mechanism dictates tumor progression by differentiating between degrdn. and protection of PTEN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzkJrjDyqRb7Vg90H21EOLACvtfcHk0ljZjq7AAkEuYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptl2hug%253D%253D&md5=424ea5985c2e8040aeddf861ba23cd2c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.11.040%26sid%3Dliteratum%253Aachs%26aulast%3DTrotman%26aufirst%3DL.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DAlimonti%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DCarver%26aufirst%3DB.%2BS.%26aulast%3DCordon-Cardo%26aufirst%3DC.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DChi%26aufirst%3DS.%2BG.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DMisteli%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26atitle%3DUbiquitination%2520regulates%2520PTEN%2520nuclear%2520import%2520and%2520tumor%2520suppression%26jtitle%3DCell%26date%3D2007%26volume%3D128%26spage%3D141%26epage%3D156%26doi%3D10.1016%2Fj.cell.2006.11.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">van der Horst, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries-Smits, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenkman, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Triest, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Broek, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgering, B. M.</span><span> </span><span class="NLM_article-title">FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1064</span><span class="NLM_x">–</span> <span class="NLM_lpage">1073</span><span class="refDoi"> DOI: 10.1038/ncb1469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fncb1469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16964248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVWqsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=1064-1073&author=A.+van+der+Horstauthor=A.+M.+de+Vries-Smitsauthor=A.+B.+Brenkmanauthor=M.+H.+van+Triestauthor=N.+van+den+Broekauthor=F.+Collandauthor=M.+M.+Mauriceauthor=B.+M.+Burgering&title=FOXO4+transcriptional+activity+is+regulated+by+monoubiquitination+and+USP7%2FHAUSP&doi=10.1038%2Fncb1469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP</span></div><div class="casAuthors">van der Horst, Armando; de Vries-Smits, Alida M. M.; Brenkman, Arjan B.; van Triest, Miranda H.; van den Broek, Niels; Colland, Frederic; Maurice, Madelon M.; Burgering, Boudewijn M. T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1064-1073</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">FOXO (Forkhead box O) transcription factors are important regulators of cellular metab., cell-cycle progression and cell death.  FOXO activity is regulated by multiple post-translational modifications, including phosphorylation, acetylation and polyubiquitination.  Here, we show that FOXO becomes monoubiquitinated in response to increased cellular oxidative stress, resulting in its re-localization to the nucleus and an increase in its transcriptional activity.  Deubiquitination of FOXO requires the deubiquitinating enzyme USP7/HAUSP (herpesvirus-assocd. ubiquitin-specific protease), which interacts with and deubiquitinates FOXO in response to oxidative stress.  Oxidative stress-induced ubiquitination and deubiquitination by USP7 do not influence FOXO protein half-life.  However, USP7 does neg. regulate FOXO transcriptional activity towards endogenous promoters.  Our results demonstrate a novel mechanism of FOXO regulation and indicate that USP7 has an important role in regulating FOXO-mediated stress responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppc5cmFw8HVLVg90H21EOLACvtfcHk0ljRnwSCa-CfLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVWqsLbM&md5=2b6a9c1e5a7f611a923c24b867c7cfb2</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fncb1469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1469%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHorst%26aufirst%3DA.%26aulast%3Dde%2BVries-Smits%26aufirst%3DA.%2BM.%26aulast%3DBrenkman%26aufirst%3DA.%2BB.%26aulast%3Dvan%2BTriest%26aufirst%3DM.%2BH.%26aulast%3Dvan%2Bden%2BBroek%26aufirst%3DN.%26aulast%3DColland%26aufirst%3DF.%26aulast%3DMaurice%26aufirst%3DM.%2BM.%26aulast%3DBurgering%26aufirst%3DB.%2BM.%26atitle%3DFOXO4%2520transcriptional%2520activity%2520is%2520regulated%2520by%2520monoubiquitination%2520and%2520USP7%252FHAUSP%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2006%26volume%3D8%26spage%3D1064%26epage%3D1073%26doi%3D10.1038%2Fncb1469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Song, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmena, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carracedo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo-Coco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teruya-Feldstein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span> </span><span class="NLM_article-title">The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">817</span><span class="refDoi"> DOI: 10.1038/nature07290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnature07290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=18716620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1WktLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=813-817&author=M.+S.+Songauthor=L.+Salmenaauthor=A.+Carracedoauthor=A.+Egiaauthor=F.+Lo-Cocoauthor=J.+Teruya-Feldsteinauthor=P.+P.+Pandolfi&title=The+deubiquitinylation+and+localization+of+PTEN+are+regulated+by+a+HAUSP-PML+network&doi=10.1038%2Fnature07290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network</span></div><div class="casAuthors">Song, Min Sup; Salmena, Leonardo; Carracedo, Arkaitz; Egia, Ainara; Lo-Coco, Francesco; Teruya-Feldstein, Julie; Pandolfi, Pier Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7214</span>),
    <span class="NLM_cas:pages">813-817</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nuclear exclusion of the PTEN (phosphatase and tensin homolog deleted in chromosome 10) tumor suppressor has been assocd. with cancer progression.  However, the mechanisms leading to this aberrant PTEN localization in human cancers are currently unknown.  We have previously reported that ubiquitinylation of PTEN at specific lysine residues regulates its nuclear-cytoplasmic partitioning.  Here we show that functional promyelocytic leukemia protein (PML) nuclear bodies coordinate PTEN localization by opposing the action of a previously unknown PTEN-deubiquitinylating enzyme, herpesvirus-assocd. ubiquitin-specific protease (HAUSP, also known as USP7), and that the integrity of this mol. framework is required for PTEN to be able to enter the nucleus.  We find that PTEN is aberrantly localized in acute promyelocytic leukemia, in which PML function is disrupted by the PML-RARα fusion oncoprotein.  Remarkably, treatment with drugs that trigger PML-RARα degrdn., such as all-trans retinoic acid or arsenic trioxide, restore nuclear PTEN.  We demonstrate that PML opposes the activity of HAUSP towards PTEN through a mechanism involving the adaptor protein DAXX (death domain-assocd. protein).  In support of this paradigm, we show that HAUSP is overexpressed in human prostate cancer and is assocd. with PTEN nuclear exclusion.  Thus, our results delineate a previously unknown PML-DAXX-HAUSP mol. network controlling PTEN deubiquitinylation and trafficking, which is perturbed by oncogenic cues in human cancer, in turn defining a new deubiquitinylation-dependent model for PTEN subcellular compartmentalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfabOED4DeUbVg90H21EOLACvtfcHk0ljRnwSCa-CfLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1WktLjL&md5=0f2f59360b366fb3c24a98f46d9e373a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature07290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07290%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DM.%2BS.%26aulast%3DSalmena%26aufirst%3DL.%26aulast%3DCarracedo%26aufirst%3DA.%26aulast%3DEgia%26aufirst%3DA.%26aulast%3DLo-Coco%26aufirst%3DF.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26atitle%3DThe%2520deubiquitinylation%2520and%2520localization%2520of%2520PTEN%2520are%2520regulated%2520by%2520a%2520HAUSP-PML%2520network%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D813%26epage%3D817%26doi%3D10.1038%2Fnature07290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Cai, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Z. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span> </span><span class="NLM_article-title">Ubiquitin-specific protease 7 accelerates p14(ARF) degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1603</span><span class="NLM_x">–</span> <span class="NLM_lpage">1614</span><span class="refDoi"> DOI: 10.1002/hep.27682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1002%2Fhep.27682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25557975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslWlsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1603-1614&author=J.+B.+Caiauthor=G.+M.+Shiauthor=Z.+R.+Dongauthor=A.+W.+Keauthor=H.+H.+Maauthor=Q.+Gaoauthor=Z.+Z.+Shenauthor=X.+Y.+Huangauthor=H.+Chenauthor=D.+D.+Yuauthor=L.+X.+Liuauthor=P.+F.+Zhangauthor=C.+Zhangauthor=M.+Y.+Huauthor=L.+X.+Yangauthor=Y.+H.+Shiauthor=X.+Y.+Wangauthor=Z.+B.+Dingauthor=S.+J.+Qiuauthor=H.+C.+Sunauthor=J.+Zhouauthor=Y.+G.+Shiauthor=J.+Fan&title=Ubiquitin-specific+protease+7+accelerates+p14%28ARF%29+degradation+by+deubiquitinating+thyroid+hormone+receptor-interacting+protein+12+and+promotes+hepatocellular+carcinoma+progression&doi=10.1002%2Fhep.27682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-specific protease 7 accelerates p14ARF degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression</span></div><div class="casAuthors">Cai, Jia-Bin; Shi, Guo-Ming; Dong, Zhao-Ru; Ke, Ai-Wu; Ma, Hong-Hui; Gao, Qiang; Shen, Zao-Zhuo; Huang, Xiao-Yong; Chen, Hao; Yu, Ding-Dang; Liu, Li-Xin; Zhang, Peng-Fei; Zhang, Chi; Hu, Mei-Yu; Yang, Liu-Xiao; Shi, Ying-Hong; Wang, Xiao-Ying; Ding, Zhen-Bin; Qiu, Shuang-Jian; Sun, Hui-Chuan; Zhou, Jian; Shi, Yujiang G.; Fan, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1603-1614</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The prognosis for hepatocellular carcinoma (HCC) remains dismal in terms of overall survival (OS), and its mol. pathogenesis has not been completely defined.  Here, we report that expression of deubiquitylase ubiquitin-specific protease 7 (USP7) is higher in human HCC tissues than in matched peritumoral tissues.  Ectopic USP7 expression promotes growth of HCC cells in vivo and in vitro.  Mechanistically, USP7 overexpression fosters HCC cell growth by forming a complex with and stabilizing thyroid hormone receptor-interacting protein 12 (TRIP12), which induces constitutive p14ARF ubiquitination.  Clin., USP7 overexpression is significantly correlated with a malignant phenotype, including larger tumor size, multiple tumor, poor differentiation, elevated alpha-fetoprotein, and microvascular invasion.  Moreover, overexpression of USP7 and/or TRIP12 correlates with shorter OS and higher cumulative recurrence rates of HCC.  Conclusion: USP7 stabilizes TRIP12 by deubiquitination, thus constitutively inactivating p14ARF and promoting HCC progression.  This represents a novel marker for predicting prognosis and a potential therapeutic target for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEXgZw-WH7ALVg90H21EOLACvtfcHk0ljRnwSCa-CfLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslWlsL0%253D&md5=c87ad1c5f0d2e6b22447e5b554f0b7a2</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fhep.27682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27682%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DJ.%2BB.%26aulast%3DShi%26aufirst%3DG.%2BM.%26aulast%3DDong%26aufirst%3DZ.%2BR.%26aulast%3DKe%26aufirst%3DA.%2BW.%26aulast%3DMa%26aufirst%3DH.%2BH.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DZ.%2BZ.%26aulast%3DHuang%26aufirst%3DX.%2BY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DD.%2BD.%26aulast%3DLiu%26aufirst%3DL.%2BX.%26aulast%3DZhang%26aufirst%3DP.%2BF.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DM.%2BY.%26aulast%3DYang%26aufirst%3DL.%2BX.%26aulast%3DShi%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DDing%26aufirst%3DZ.%2BB.%26aulast%3DQiu%26aufirst%3DS.%2BJ.%26aulast%3DSun%26aufirst%3DH.%2BC.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%2BG.%26aulast%3DFan%26aufirst%3DJ.%26atitle%3DUbiquitin-specific%2520protease%25207%2520accelerates%2520p14%2528ARF%2529%2520degradation%2520by%2520deubiquitinating%2520thyroid%2520hormone%2520receptor-interacting%2520protein%252012%2520and%2520promotes%2520hepatocellular%2520carcinoma%2520progression%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1603%26epage%3D1614%26doi%3D10.1002%2Fhep.27682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Gil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G.</span><span> </span><span class="NLM_article-title">Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span><span class="refDoi"> DOI: 10.1038/nrm1987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrm1987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16921403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot12ju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=667-677&author=J.+Gilauthor=G.+Peters&title=Regulation+of+the+INK4b-ARF-INK4a+tumour+suppressor+locus%3A+all+for+one+or+one+for+all&doi=10.1038%2Fnrm1987"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the INK4b-ARF-INK4a tumor suppressor locus: all for one or one for all</span></div><div class="casAuthors">Gil, Jesus; Peters, Gordon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">667-677</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The INK4b-ARF-INK4a locus encodes two members of the INK4 family of cyclin-dependent kinase inhibitors, p15INK4b and p16INK4a, and a completely unrelated protein, known as ARF.  All three products participate in major tumor suppressor networks that are disabled in human cancer and influence key physiol. processes such as replicative senescence, apoptosis and stem-cell self-renewal.  Transcription from the locus is therefore kept under strict control.  Mounting evidence suggests that although the individual genes can respond independently to pos. and neg. signals in different contexts, the entire locus might be coordinately suppressed by a cis-acting regulatory domain or by the action of Polycomb group repressor complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpReTaXF8IsJ7Vg90H21EOLACvtfcHk0ljk6-E-_mJlyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot12ju7o%253D&md5=b3fbf0f5ea86da57ced65ce9faf7f884</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fnrm1987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1987%26sid%3Dliteratum%253Aachs%26aulast%3DGil%26aufirst%3DJ.%26aulast%3DPeters%26aufirst%3DG.%26atitle%3DRegulation%2520of%2520the%2520INK4b-ARF-INK4a%2520tumour%2520suppressor%2520locus%253A%2520all%2520for%2520one%2520or%2520one%2520for%2520all%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2006%26volume%3D7%26spage%3D667%26epage%3D677%26doi%3D10.1038%2Fnrm1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Semenza, G. L.</span><span> </span><span class="NLM_article-title">Targeting HIF-1 for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">732</span><span class="refDoi"> DOI: 10.1038/nrc1187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrc1187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=13130303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFCiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=721-732&author=G.+L.+Semenza&title=Targeting+HIF-1+for+cancer+therapy&doi=10.1038%2Fnrc1187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HIF-1 for cancer therapy</span></div><div class="casAuthors">Semenza, Gregg L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">721-732</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes that are involved in crucial aspects of cancer biol., including angiogenesis, cell survival, glucose metab. and invasion.  Intratumoral hypoxia and genetic alterations can lead to HIF-1α overexpression, which has been assocd. with increased patient mortality in several cancer types.  In preclin. studies, inhibition of HIF-1 activity has marked effects on tumor growth.  Efforts are underway to identify inhibitors of HIF-1 and to test their efficacy as anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9RRo9WvLxN7Vg90H21EOLACvtfcHk0ljk6-E-_mJlyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFCiu70%253D&md5=099f0fe5908dc1aae0c177a8aa530047</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnrc1187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1187%26sid%3Dliteratum%253Aachs%26aulast%3DSemenza%26aufirst%3DG.%2BL.%26atitle%3DTargeting%2520HIF-1%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D721%26epage%3D732%26doi%3D10.1038%2Fnrc1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Wu, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teng, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K. J.</span><span> </span><span class="NLM_article-title">K63-polyubiquitinated HAUSP deubiquitinates HIF-1alpha and dictates H3K56 acetylation promoting hypoxia-induced tumour progression</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">13644</span><span class="refDoi"> DOI: 10.1038/ncomms13644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fncomms13644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27934968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFamsLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13644&author=H.+T.+Wuauthor=Y.+C.+Kuoauthor=J.+J.+Hungauthor=C.+H.+Huangauthor=W.+Y.+Chenauthor=T.+Y.+Chouauthor=Y.+Chenauthor=Y.+J.+Chenauthor=Y.+J.+Chenauthor=W.+C.+Chengauthor=S.+C.+Tengauthor=K.+J.+Wu&title=K63-polyubiquitinated+HAUSP+deubiquitinates+HIF-1alpha+and+dictates+H3K56+acetylation+promoting+hypoxia-induced+tumour+progression&doi=10.1038%2Fncomms13644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">K63-polyubiquitinated HAUSP deubiquitinates HIF-1α and dictates H3K56 acetylation promoting hypoxia-induced tumour progression</span></div><div class="casAuthors">Wu, Han-Tsang; Kuo, Yi-Chih; Hung, Jung-Jyh; Huang, Chi-Hung; Chen, Wei-Yi; Chou, Teh-Ying; Chen, Yeh; Chen, Yi-Ju; Chen, Yu-Ju; Cheng, Wei-Chung; Teng, Shu-Chun; Wu, Kou-Juey</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13644</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Intratumoral hypoxia induces HIF-1α and promotes tumor progression, metastasis and treatment resistance.  HIF-1α stability is regulated by VHL-E3 ligase-mediated ubiquitin-dependent degrdn.; however, the hypoxia-regulated deubiquitinase that stabilizes HIF-1α has not been identified.  Here we report that HAUSP (USP7) deubiquitinase deubiquitinates HIF-1α to increase its stability, induce epithelial-mesenchymal transition and promote metastasis.  Hypoxia induces K63-linked polyubiquitinated HAUSP at lysine 443 to enhance its functions.  Knockdown of HAUSP decreases acetylation of histone 3 lysine 56 (H3K56Ac).  K63-polyubiquitinated HAUSP interacts with a ubiquitin receptor CBP to specifically mediate H3K56 acetylation.  ChIP-seq anal. of HAUSP and HIF-1α binding reveals two motifs responsive to hypoxia.  HectH9 is the E3 ligase for HAUSP and a prognostic marker together with HIF-1α.  This report demonstrates that hypoxia-induced K63-polyubiquitinated HAUSP deubiquitinates HIF-1α and causes CBP-mediated H3K56 acetylation on HIF-1α target gene promoters to promote EMT/metastasis, further defining HAUSP as a therapeutic target in hypoxia-induced tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx_5DEryb7CbVg90H21EOLACvtfcHk0ljk6-E-_mJlyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFamsLbL&md5=3d29d0076e11b871e37f79d1a18d742a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fncomms13644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13644%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%2BT.%26aulast%3DKuo%26aufirst%3DY.%2BC.%26aulast%3DHung%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DW.%2BY.%26aulast%3DChou%26aufirst%3DT.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DCheng%26aufirst%3DW.%2BC.%26aulast%3DTeng%26aufirst%3DS.%2BC.%26aulast%3DWu%26aufirst%3DK.%2BJ.%26atitle%3DK63-polyubiquitinated%2520HAUSP%2520deubiquitinates%2520HIF-1alpha%2520and%2520dictates%2520H3K56%2520acetylation%2520promoting%2520hypoxia-induced%2520tumour%2520progression%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13644%26doi%3D10.1038%2Fncomms13644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span> </span><span class="NLM_article-title">Deubiquitination of Ci/Gli by Usp7/HAUSP regulates hedgehog signaling</span> <span class="citation_source-journal">Dev. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1016/j.devcel.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.devcel.2015.05.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=58-72&author=Z.+Zhouauthor=X.+Yaoauthor=S.+Liauthor=Y.+Xiongauthor=X.+Dongauthor=Y.+Zhaoauthor=J.+Jiangauthor=Q.+Zhang&title=Deubiquitination+of+Ci%2FGli+by+Usp7%2FHAUSP+regulates+hedgehog+signaling&doi=10.1016%2Fj.devcel.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DDeubiquitination%2520of%2520Ci%252FGli%2520by%2520Usp7%252FHAUSP%2520regulates%2520hedgehog%2520signaling%26jtitle%3DDev.%2520Cell%26date%3D2015%26volume%3D34%26spage%3D58%26epage%3D72%26doi%3D10.1016%2Fj.devcel.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Liou, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storz, P.</span><span> </span><span class="NLM_article-title">Reactive oxygen species in cancer</span> <span class="citation_source-journal">Free Radical Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span><span class="refDoi"> DOI: 10.3109/10715761003667554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.3109%2F10715761003667554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20370557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVyhu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2010&pages=479-496&author=G.+Y.+Liouauthor=P.+Storz&title=Reactive+oxygen+species+in+cancer&doi=10.3109%2F10715761003667554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species in cancer</span></div><div class="casAuthors">Liou, Geou-Yarh; Storz, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">479-496</span>CODEN:
                <span class="NLM_cas:coden">FRARER</span>;
        ISSN:<span class="NLM_cas:issn">1071-5762</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Elevated rates of reactive oxygen species (ROS) have been detected in almost all cancers, where they promote many aspects of tumor development and progression.  However, tumor cells also express increased levels of antioxidant proteins to detoxify from ROS, suggesting that a delicate balance of intracellular ROS levels is required for cancer cell function.  Further, the radical generated, the location of its generation, as well as the local concn. is important for the cellular functions of ROS in cancer.  A challenge for novel therapeutic strategies will be the fine tuning of intracellular ROS signalling to effectively deprive cells from ROS-induced tumor promoting events, towards tipping the balance to ROS-induced apoptotic signalling.  Alternatively, therapeutic antioxidants may prevent early events in tumor development, where ROS are important.  However, to effectively target cancer cells specific ROS-sensing signalling pathways that mediate the diverse stress-regulated cellular functions need to be identified.  This review discusses the generation of ROS within tumor cells, their detoxification, their cellular effects, as well as the major signalling cascades they utilize, but also provides an outlook on their modulation in therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwtVSe56knA7Vg90H21EOLACvtfcHk0lg-6UZzPrWt3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVyhu78%253D&md5=74d17b013387120ba165302bd7c282df</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.3109%2F10715761003667554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10715761003667554%26sid%3Dliteratum%253Aachs%26aulast%3DLiou%26aufirst%3DG.%2BY.%26aulast%3DStorz%26aufirst%3DP.%26atitle%3DReactive%2520oxygen%2520species%2520in%2520cancer%26jtitle%3DFree%2520Radical%2520Res.%26date%3D2010%26volume%3D44%26spage%3D479%26epage%3D496%26doi%3D10.3109%2F10715761003667554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Bouwman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonkers, J.</span><span> </span><span class="NLM_article-title">The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span><span class="refDoi"> DOI: 10.1038/nrc3342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrc3342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22918414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GhsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=587-598&author=P.+Bouwmanauthor=J.+Jonkers&title=The+effects+of+deregulated+DNA+damage+signalling+on+cancer+chemotherapy+response+and+resistance&doi=10.1038%2Fnrc3342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance</span></div><div class="casAuthors">Bouwman, Peter; Jonkers, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">587-598</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumors with specific DNA repair defects can be completely dependent on back-up DNA repair pathways for their survival.  This dependence can be exploited therapeutically to induce synthetic lethality in tumor cells.  For instance, homologous recombination (HR)-deficient tumors can be effectively targeted by DNA double-strand break-inducing agents.  However, not all HR-defective tumors respond equally well to this type of therapy.  Tumor cells may acquire resistance by invoking biochem. mechanisms that reduce drug action or by acquiring addnl. alterations in DNA damage response pathways.  A thorough understanding of these processes is important for predicting treatment response and for the development of novel treatment strategies that prevent the emergence of therapy-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSTPQO2sEE7Vg90H21EOLACvtfcHk0lg-6UZzPrWt3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GhsLnN&md5=176b61bc1ce31c537067eae10417bf90</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnrc3342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3342%26sid%3Dliteratum%253Aachs%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26atitle%3DThe%2520effects%2520of%2520deregulated%2520DNA%2520damage%2520signalling%2520on%2520cancer%2520chemotherapy%2520response%2520and%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D587%26epage%3D598%26doi%3D10.1038%2Fnrc3342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majid, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brickner, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dango, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosammaparast, N.</span><span> </span><span class="NLM_article-title">Noncanonical regulation of alkylation damage resistance by the OTUD4 deubiquitinase</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1687</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span><span class="refDoi"> DOI: 10.15252/embj.201490497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.15252%2Fembj.201490497" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=1687-1703&author=Y.+Zhaoauthor=M.+C.+Majidauthor=J.+M.+Sollauthor=J.+R.+Bricknerauthor=S.+Dangoauthor=N.+Mosammaparast&title=Noncanonical+regulation+of+alkylation+damage+resistance+by+the+OTUD4+deubiquitinase&doi=10.15252%2Fembj.201490497"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.15252%2Fembj.201490497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembj.201490497%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMajid%26aufirst%3DM.%2BC.%26aulast%3DSoll%26aufirst%3DJ.%2BM.%26aulast%3DBrickner%26aufirst%3DJ.%2BR.%26aulast%3DDango%26aufirst%3DS.%26aulast%3DMosammaparast%26aufirst%3DN.%26atitle%3DNoncanonical%2520regulation%2520of%2520alkylation%2520damage%2520resistance%2520by%2520the%2520OTUD4%2520deubiquitinase%26jtitle%3DEMBO%2520J.%26date%3D2015%26volume%3D34%26spage%3D1687%26epage%3D1703%26doi%3D10.15252%2Fembj.201490497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrasco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulcinniti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodrasov, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingsbury, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minvielle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">358</span><span class="refDoi"> DOI: 10.1016/j.ccr.2012.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.ccr.2012.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22975377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlCju77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=345-358&author=D.+Chauhanauthor=Z.+Tianauthor=B.+Nicholsonauthor=K.+G.+Kumarauthor=B.+Zhouauthor=R.+Carrascoauthor=J.+L.+McDermottauthor=C.+A.+Leachauthor=M.+Fulcinnitiauthor=M.+P.+Kodrasovauthor=J.+Weinstockauthor=W.+D.+Kingsburyauthor=T.+Hideshimaauthor=P.+K.+Shahauthor=S.+Minvielleauthor=M.+Altunauthor=B.+M.+Kesslerauthor=R.+Orlowskiauthor=P.+Richardsonauthor=N.+Munshiauthor=K.+C.+Anderson&title=A+small+molecule+inhibitor+of+ubiquitin-specific+protease-7+induces+apoptosis+in+multiple+myeloma+cells+and+overcomes+bortezomib+resistance&doi=10.1016%2Fj.ccr.2012.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance</span></div><div class="casAuthors">Chauhan, Dharminder; Tian, Ze; Nicholson, Benjamin; Kumar, K. G. Suresh; Zhou, Bin; Carrasco, Ruben; McDermott, Jeffrey L.; Leach, Craig A.; Fulcinniti, Mariaterresa; Kodrasov, Matthew P.; Weinstock, Joseph; Kingsbury, William D.; Hideshima, Teru; Shah, Parantu K.; Minvielle, Stephane; Altun, Mikael; Kessler, Benedikt M.; Orlowski, Robert; Richardson, Paul; Munshi, Nikhil; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-358</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility.  Here, we show that P5091 is an inhibitor of deubiquitylating enzyme USP7, which induces apoptosis in MM cells resistant to conventional and bortezomib therapies.  Biochem. and genetic studies show that blockade of HDM2 and p21 abrogates P5091-induced cytotoxicity.  In animal tumor model studies, P5091 is well tolerated, inhibits tumor growth, and prolongs survival.  Combining P5091 with lenalidomide, HDAC inhibitor SAHA, or dexamethasone triggers synergistic anti-MM activity.  Our preclin. study therefore supports clin. evaluation of USP7 inhibitor, alone or in combination, as a potential MM therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVKqojA-HcmLVg90H21EOLACvtfcHk0lg-6UZzPrWt3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlCju77F&md5=9c70da62de17591850c1e8195d5f97f7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DK.%2BG.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DCarrasco%26aufirst%3DR.%26aulast%3DMcDermott%26aufirst%3DJ.%2BL.%26aulast%3DLeach%26aufirst%3DC.%2BA.%26aulast%3DFulcinniti%26aufirst%3DM.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DWeinstock%26aufirst%3DJ.%26aulast%3DKingsbury%26aufirst%3DW.%2BD.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DShah%26aufirst%3DP.%2BK.%26aulast%3DMinvielle%26aufirst%3DS.%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26aulast%3DOrlowski%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520small%2520molecule%2520inhibitor%2520of%2520ubiquitin-specific%2520protease-7%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%2520and%2520overcomes%2520bortezomib%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D345%26epage%3D358%26doi%3D10.1016%2Fj.ccr.2012.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samanta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatti, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodrasov, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butt, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albelda, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Ubiquitin-specific Protease-7 inhibition impairs Tip60-dependent Foxp3+ T-regulatory cell function and promotes antitumor immunity</span> <span class="citation_source-journal">EBioMedicine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/j.ebiom.2016.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.ebiom.2016.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27769803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC2srltVWmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=99-112&author=L.+Wangauthor=S.+Kumarauthor=S.+Dahiyaauthor=F.+Wangauthor=J.+Wuauthor=K.+Newickauthor=R.+Hanauthor=A.+Samantaauthor=U.+H.+Beierauthor=T.+Akimovaauthor=T.+R.+Bhattiauthor=B.+Nicholsonauthor=M.+P.+Kodrasovauthor=S.+Agarwalauthor=D.+E.+Sternerauthor=W.+Guauthor=J.+Weinstockauthor=T.+R.+Buttauthor=S.+M.+Albeldaauthor=W.+W.+Hancock&title=Ubiquitin-specific+Protease-7+inhibition+impairs+Tip60-dependent+Foxp3%2B+T-regulatory+cell+function+and+promotes+antitumor+immunity&doi=10.1016%2Fj.ebiom.2016.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor Immunity</span></div><div class="casAuthors">Wang Liqing; Dahiya Satinder; Han Rongxiang; Samanta Arabinda; Akimova Tatiana; Bhatti Tricia R; Kumar Suresh; Wang Feng; Wu Jian; Nicholson Benjamin; Kodrasov Mathew P; Agarwal Saket; Sterner David E; Weinstock Joseph; Butt Tauseef R; Newick Kheng; Albelda Steven M; Beier Ulf H; Gu Wei; Hancock Wayne W</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">99-112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Foxp3+ T-regulatory (Treg) cells are known to suppress protective host immune responses to a wide variety of solid tumors, but their therapeutic targeting is largely restricted to their transient depletion or "secondary" modulation, e.g. using anti-CTLA-4 monoclonal antibody.  Our ongoing studies of the post-translational modifications that regulate Foxp3 demonstrated that the histone/protein acetyltransferase, Tip60, plays a dominant role in promoting acetylation, dimerization and function in Treg cells.  We now show that the ubiquitin-specific protease, Usp7, controls Treg function largely by stabilizing the expression and promoting the multimerization of Tip60 and Foxp3.  Genetic or pharmacologic targeting of Usp7 impairs Foxp3+ Treg suppressive functions, while conventional T cell responses remain intact.  As a result, pharmacologic inhibitors of Usp7 can limit tumor growth in immunocompetent mice, and promote the efficacy of antitumor vaccines and immune checkpoint therapy with anti-PD1 monoclonal antibody in murine models.  Hence, pharmacologic therapy with Usp7 inhibitors may have an important role in future cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRx7G_irn6DIPtos8R3JUhXfW6udTcc2eatIy0qQAP5trntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srltVWmsQ%253D%253D&md5=f7456d0d7eddd4188ef4e6e2f3e8d691</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2016.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2016.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DDahiya%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DNewick%26aufirst%3DK.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DSamanta%26aufirst%3DA.%26aulast%3DBeier%26aufirst%3DU.%2BH.%26aulast%3DAkimova%26aufirst%3DT.%26aulast%3DBhatti%26aufirst%3DT.%2BR.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DSterner%26aufirst%3DD.%2BE.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DWeinstock%26aufirst%3DJ.%26aulast%3DButt%26aufirst%3DT.%2BR.%26aulast%3DAlbelda%26aufirst%3DS.%2BM.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DUbiquitin-specific%2520Protease-7%2520inhibition%2520impairs%2520Tip60-dependent%2520Foxp3%252B%2520T-regulatory%2520cell%2520function%2520and%2520promotes%2520antitumor%2520immunity%26jtitle%3DEBioMedicine%26date%3D2016%26volume%3D13%26spage%3D99%26epage%3D112%26doi%3D10.1016%2Fj.ebiom.2016.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Fan, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasudevan, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojas, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shohet, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuchtern, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span> </span><span class="NLM_article-title">USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis</span> <span class="citation_source-journal">Cell Death Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">e867</span><span class="refDoi"> DOI: 10.1038/cddis.2013.400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fcddis.2013.400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24136231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Olu77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=e867&author=Y.+H.+Fanauthor=J.+Chengauthor=S.+A.+Vasudevanauthor=J.+Douauthor=H.+Zhangauthor=R.+H.+Patelauthor=I.+T.+Maauthor=Y.+Rojasauthor=Y.+Zhaoauthor=Y.+Yuauthor=H.+Zhangauthor=J.+M.+Shohetauthor=J.+G.+Nuchternauthor=E.+S.+Kimauthor=J.+Yang&title=USP7+inhibitor+P22077+inhibits+neuroblastoma+growth+via+inducing+p53-mediated+apoptosis&doi=10.1038%2Fcddis.2013.400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis</span></div><div class="casAuthors">Fan, Y.-H.; Cheng, J.; Vasudevan, S. A.; Dou, J.; Zhang, H.; Patel, R. H.; Ma, I. T.; Rojas, Y.; Zhao, Y.; Yu, Y.; Zhang, H.; Shohet, J. M.; Nuchtern, J. G.; Kim, E. S.; Yang, J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">e867</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma (NB) is a common pediatric cancer and contributes to more than 15% of all pediatric cancer-related deaths.  Unlike adult tumors, recurrent somatic mutations in NB, such as tumor protein 53 (p53) mutations, occur with relative paucity.  In addn., p53 downstream function is intact in NB cells with wild-type p53, suggesting that reactivation of p53 may be a viable therapeutic strategy for NB treatment.  Herein, we report that the ubiquitin-specific protease 7 (USP7) inhibitor, P22077, potently induces apoptosis in NB cells with an intact USP7-HDM2-p53 axis but not in NB cells with mutant p53 or without human homolog of MDM2 (HDM2) expression.  In this study, we found that P22077 stabilized p53 by inducing HDM2 protein degrdn. in NB cells.  P22077 also significantly augmented the cytotoxic effects of doxorubicin (Dox) and etoposide (VP-16) in NB cells with an intact USP7-HDM2-p53 axis.  Moreover, P22077 was found to be able to sensitize chemoresistant LA-N-6 NB cells to chemotherapy.  In an in vivo orthotopic NB mouse model, P22077 significantly inhibited the xenograft growth of three NB cell lines.  Database anal. of NB patients shows that high expression of USP7 significantly predicts poor outcomes.  Together, our data strongly suggest that targeting USP7 is a novel concept in the treatment of NB.  USP7-specific inhibitors like P22077 may serve not only as a stand-alone therapy but also as an effective adjunct to current chemotherapeutic regimens for treating NB with an intact USP7-HDM2-p53 axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsoNqHcbJCuLVg90H21EOLACvtfcHk0lgNRnVc0loxPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Olu77J&md5=cd91e66041a54477fe081914da560a22</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.400%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DY.%2BH.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DVasudevan%26aufirst%3DS.%2BA.%26aulast%3DDou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPatel%26aufirst%3DR.%2BH.%26aulast%3DMa%26aufirst%3DI.%2BT.%26aulast%3DRojas%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DShohet%26aufirst%3DJ.%2BM.%26aulast%3DNuchtern%26aufirst%3DJ.%2BG.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DUSP7%2520inhibitor%2520P22077%2520inhibits%2520neuroblastoma%2520growth%2520via%2520inducing%2520p53-mediated%2520apoptosis%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26spage%3De867%26doi%3D10.1038%2Fcddis.2013.400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Qin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span> </span><span class="NLM_article-title">CDDO-Me reveals USP7 as a novel target in ovarian cancer cells</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">77096</span><span class="NLM_x">–</span> <span class="NLM_lpage">77109</span><span class="refDoi"> DOI: 10.18632/oncotarget.12801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.18632%2Foncotarget.12801" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=77096-77109&author=D.+Qinauthor=W.+Wangauthor=H.+Leiauthor=H.+Luoauthor=H.+Caiauthor=C.+Tangauthor=Y.+Wuauthor=Y.+Wangauthor=J.+Jinauthor=W.+Xiaoauthor=T.+Wangauthor=C.+Maauthor=H.+Xuauthor=J.+Zhangauthor=F.+Gaoauthor=Y.+L.+Wu&title=CDDO-Me+reveals+USP7+as+a+novel+target+in+ovarian+cancer+cells&doi=10.18632%2Foncotarget.12801"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12801%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DCDDO-Me%2520reveals%2520USP7%2520as%2520a%2520novel%2520target%2520in%2520ovarian%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D77096%26epage%3D77109%26doi%3D10.18632%2Foncotarget.12801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span> </span><span class="NLM_article-title">Expression of USP7 and MARCH7 is correlated with poor prognosis in epithelial ovarian cancer</span> <span class="citation_source-journal">Tohoku J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">239</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span><span class="refDoi"> DOI: 10.1620/tjem.239.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1620%2Ftjem.239.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27302477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC2s7gtlWhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=239&publication_year=2016&pages=165-175&author=L.+Zhangauthor=H.+Wangauthor=L.+Tianauthor=H.+Li&title=Expression+of+USP7+and+MARCH7+is+correlated+with+poor+prognosis+in+epithelial+ovarian+cancer&doi=10.1620%2Ftjem.239.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of USP7 and MARCH7 Is Correlated with Poor Prognosis in Epithelial Ovarian Cancer</span></div><div class="casAuthors">Zhang Li; Wang Hua; Tian Lin; Li Haixia</div><div class="citationInfo"><span class="NLM_cas:title">The Tohoku journal of experimental medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">239</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epithelial ovarian cancer (EOC) is one of the worst malignancies in females with poor overall survival due to the rapid metastasis and the absence of ideal biomarkers.  Ubiquitin-specific protease 7 (USP7), an important deubiquitinating enzyme, was reported to be upregulated in several cancers, including liver, prostate and colon cancers.  Membrane associated RING-CH protein 7 (MARCH7) belongs to the member of the E3 ubiquitin ligases.  In addition, MARCH7 regulates T cell proliferation and the neuronal development and participates in the membrane trafficking and protein degradation.  Importantly, MARCH7 itself is ubiquitinated and acts as a potential substrate of USP7.  However, the roles of USP7 and MARCH7 in EOC remain to be investigated.  We collected 121 EOC patients and analyzed the expression levels of USP7 and MARCH7 in tumor tissues with immunohistochemical staining.  We found that the high expression of the two proteins was correlated with lymph node metastasis in EOC patients.  Univariate and multivariate analyses revealed that the patients with high expression of the two proteins showed poorer prognosis compared with other patients.  Subsequently, using SKOV3 human ovarian adenocarcinoma cells, we showed that either USP7 or MARCH7 enhanced the proliferation and invasion abilities.  Moreover, USP7 could regulate the expression levels of E-cadherin and β-catenin through the MARCH7 signaling pathway.  Our findings indicate that USP7 and MARCH7 are involved in the progression of EOC.  In conclusion, analyzing the expression of USP7 and MARCH7 has high prognostic value in predicting EOC prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREyDgJgIFkExjv2lLSLOxFfW6udTcc2eaqvOKgXjutdbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7gtlWhtg%253D%253D&md5=e12b5798bb6d224a1a955b6d4e5fedff</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1620%2Ftjem.239.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1620%252Ftjem.239.165%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DExpression%2520of%2520USP7%2520and%2520MARCH7%2520is%2520correlated%2520with%2520poor%2520prognosis%2520in%2520epithelial%2520ovarian%2520cancer%26jtitle%3DTohoku%2520J.%2520Exp.%2520Med.%26date%3D2016%26volume%3D239%26spage%3D165%26epage%3D175%26doi%3D10.1620%2Ftjem.239.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span> </span><span class="NLM_article-title">Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">2205</span><span class="NLM_x">–</span> <span class="NLM_lpage">2220</span><span class="refDoi"> DOI: 10.1172/JCI85747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1172%2FJCI85747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=27183383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FgtVChuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2016&pages=2205-2220&author=Q.+Wangauthor=S.+Maauthor=N.+Songauthor=X.+Liauthor=L.+Liuauthor=S.+Yangauthor=X.+Dingauthor=L.+Shanauthor=X.+Zhouauthor=D.+Suauthor=Y.+Wangauthor=Q.+Zhangauthor=X.+Liuauthor=N.+Yuauthor=K.+Zhangauthor=Y.+Shangauthor=Z.+Yaoauthor=L.+Shi&title=Stabilization+of+histone+demethylase+PHF8+by+USP7+promotes+breast+carcinogenesis&doi=10.1172%2FJCI85747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis</span></div><div class="casAuthors">Wang Qian; Ma Shuai; Song Nan; Li Xin; Liu Ling; Yang Shangda; Ding Xiang; Shan Lin; Zhou Xing; Su Dongxue; Wang Yue; Zhang Qi; Liu Xinhua; Yu Na; Zhang Kai; Shang Yongfeng; Yao Zhi; Shi Lei</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2205-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The histone demethylase PHF8 has been implicated in multiple pathological disorders, including X-linked mental retardation and tumorigenesis.  However, it is not clear how the abundance and function of PHF8 are regulated.  Here, we report that PHF8 physically associates with the deubiquitinase USP7.  Specifically, we demonstrated that USP7 promotes deubiquitination and stabilization of PHF8, leading to the upregulation of a group of genes, including cyclin A2, that are critical for cell growth and proliferation.  The USP7-encoding gene was also transcriptionally regulated by PHF8, via positive feedback.  USP7 was overexpressed in breast carcinomas, and the level of expression positively correlated with expression of PHF8 and cyclin A2 and with the histological grade of breast cancer.  We showed that USP7 promotes breast carcinogenesis by stabilizing PHF8 and upregulating cyclin A2 and that the interaction between USP7 and PHF8 is augmented during DNA damage.  Moreover, USP7-promoted PHF8 stabilization conferred cellular resistance to genotoxic insults and was required for the recruitment of BLM and KU70, which are both essential for DNA double-strand break repair.  Our study mechanistically links USP7 to epigenetic regulation and DNA repair.  Moreover, these data support the pursuit of USP7 and PHF8 as potential targets for breast cancer intervention, especially in combination with chemo- or radiotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcuqLndLpKaOLt9HypzAgQfW6udTcc2eaqvOKgXjutdbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FgtVChuw%253D%253D&md5=b4704b72507d1926c48b5c6da8d868bf</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1172%2FJCI85747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI85747%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DShan%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DShang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DStabilization%2520of%2520histone%2520demethylase%2520PHF8%2520by%2520USP7%2520promotes%2520breast%2520carcinogenesis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2016%26volume%3D126%26spage%3D2205%26epage%3D2220%26doi%3D10.1172%2FJCI85747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Zhao, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, F. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J. Y.</span><span> </span><span class="NLM_article-title">USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1721</span><span class="NLM_x">–</span> <span class="NLM_lpage">1729</span><span class="refDoi"> DOI: 10.1007/s13277-014-2773-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs13277-014-2773-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25519684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOrs7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=1721-1729&author=G.+Y.+Zhaoauthor=Z.+W.+Linauthor=C.+L.+Luauthor=J.+Guauthor=Y.+F.+Yuanauthor=F.+K.+Xuauthor=R.+H.+Liuauthor=D.+Geauthor=J.+Y.+Ding&title=USP7+overexpression+predicts+a+poor+prognosis+in+lung+squamous+cell+carcinoma+and+large+cell+carcinoma&doi=10.1007%2Fs13277-014-2773-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma</span></div><div class="casAuthors">Zhao, Guang-Yin; Lin, Zong-Wu; Lu, Chun-Lai; Gu, Jie; Yuan, Yun-Feng; Xu, Feng-Kai; Liu, Rong-Hua; Ge, Di; Ding, Jian-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1721-1729</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In non-small cell lung cancer (NSCLC), both USP7 expression and p53 gene status were reported to be an indicator of poor prognosis in adenocarcinoma patients; however, its roles and mechanisms in lung squamous cell carcinoma and large cell carcinoma need to be clarified.  The USP7 expression was examd. in NSCLC tumors (excluding adenocarcinoma), their corresponding non-tumorous tissues, and NSCLC cells.  Then, the prognostic role of USP7 was analyzed in 110 NSCLC samples (excluding the adenocarcinoma).  Finally, the roles and mechanisms of USP7 in the proliferation, metastasis, and invasion of a NSCLC cell were assessed using a specific vshRNA.  The USP7 expression was higher in NSCLC tissues compared to non-tumorous samples, accordingly, the high level of USP7 was detected in NSCLC cell lines compared with HBE cell.  After the USP7 downregulation, the H460 cells exhibited decreased metastasis/invasion in vitro and in vivo.  The preliminary mechanism study indicated overexpression of USP7 might regulate the p53-MDM2 pathway by inducing the MDM2 de-ubiquitination and subsequent stabilization, which resulted in the upregulation of the Bad phosphorylation.  Addnl., we also found that USP7 might induce cell epithelial-mesenchymal transition to enhance the cell invasive ability.  Clin., USP7 overexpression significantly correlated with malignant phenotype.  Furthermore, the 5-yr overall survival in patients with USP7low was higher than that of USP7high.  Multivariate anal. showed USP7 overexpression was an independent prognostic marker for these cancers.  USP7 overexpression may regulate the survival and invasive properties of squamous cell carcinoma and large cell carcinoma cells, and may serve as a mol. target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF7saboNrUWrVg90H21EOLACvtfcHk0ljLyQpwdt6Q7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOrs7fI&md5=4bd47ff37c19acbaddb3c0b6940a71e6</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs13277-014-2773-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-014-2773-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%2BY.%26aulast%3DLin%26aufirst%3DZ.%2BW.%26aulast%3DLu%26aufirst%3DC.%2BL.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DY.%2BF.%26aulast%3DXu%26aufirst%3DF.%2BK.%26aulast%3DLiu%26aufirst%3DR.%2BH.%26aulast%3DGe%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DJ.%2BY.%26atitle%3DUSP7%2520overexpression%2520predicts%2520a%2520poor%2520prognosis%2520in%2520lung%2520squamous%2520cell%2520carcinoma%2520and%2520large%2520cell%2520carcinoma%26jtitle%3DTumor%2520Biol.%26date%3D2015%26volume%3D36%26spage%3D1721%26epage%3D1729%26doi%3D10.1007%2Fs13277-014-2773-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Samkari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packer, R.</span><span> </span><span class="NLM_article-title">Shh inhibitors for the treatment of medulloblastoma</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">763</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span><span class="refDoi"> DOI: 10.1586/14737175.2015.1052796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1586%2F14737175.2015.1052796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26027634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKntbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=763-770&author=A.+Samkariauthor=J.+Whiteauthor=R.+Packer&title=Shh+inhibitors+for+the+treatment+of+medulloblastoma&doi=10.1586%2F14737175.2015.1052796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">SHH inhibitors for the treatment of medulloblastoma</span></div><div class="casAuthors">Samkari, Ayman; White, Jason; Packer, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">763-770</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Medulloblastoma is the most common malignant brain tumor of childhood.  It is currently stratified into four mol. variants through the advances in transcriptional profiling.  They include: wingless, sonic hedgehog (SHH), Group III, and Group IV.  The SHH group is characterized by constitutive activation of the SHH signaling pathway, and genetically characterized by mutations in patched homolog 1 (PTCH1) or other downstream pathway mutations.  SHH inhibitors have become of great clin. interest in treating SHH-driven medulloblastoma.  Many inhibitors are currently in different stages of development, some already approved for other SHH-driven cancers, such as basal cell carcinoma.  In vitro and in vivo medulloblastoma studies have shown efficacy and these findings have been translated into Phase I and II clin. trials.  In this review, we present an overview of SHH medulloblastoma, as well as a discussion of currently available SHH inhibitors, and the challenges assocd. with their use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ9NSFcovDXbVg90H21EOLACvtfcHk0lj9wknXYINomw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKntbfO&md5=3a5af11e9f2cb451e84908bbf4e25bf8</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1586%2F14737175.2015.1052796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2015.1052796%26sid%3Dliteratum%253Aachs%26aulast%3DSamkari%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DPacker%26aufirst%3DR.%26atitle%3DShh%2520inhibitors%2520for%2520the%2520treatment%2520of%2520medulloblastoma%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2015%26volume%3D15%26spage%3D763%26epage%3D770%26doi%3D10.1586%2F14737175.2015.1052796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Woo, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goletz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlienger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coukos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">June, C. H.</span><span> </span><span class="NLM_article-title">Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">4766</span><span class="NLM_x">–</span> <span class="NLM_lpage">4772</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4766-4772&author=E.+Y.+Wooauthor=C.+S.+Chuauthor=T.+J.+Goletzauthor=K.+Schliengerauthor=H.+Yehauthor=G.+Coukosauthor=S.+C.+Rubinauthor=L.+R.+Kaiserauthor=C.+H.+June&title=Regulatory+CD4%28%2B%29CD25%28%2B%29+T+cells+in+tumors+from+patients+with+early-stage+non-small+cell+lung+cancer+and+late-stage+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DE.%2BY.%26aulast%3DChu%26aufirst%3DC.%2BS.%26aulast%3DGoletz%26aufirst%3DT.%2BJ.%26aulast%3DSchlienger%26aufirst%3DK.%26aulast%3DYeh%26aufirst%3DH.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DRubin%26aufirst%3DS.%2BC.%26aulast%3DKaiser%26aufirst%3DL.%2BR.%26aulast%3DJune%26aufirst%3DC.%2BH.%26atitle%3DRegulatory%2520CD4%2528%252B%2529CD25%2528%252B%2529%2520T%2520cells%2520in%2520tumors%2520from%2520patients%2520with%2520early-stage%2520non-small%2520cell%2520lung%2520cancer%2520and%2520late-stage%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4766%26epage%3D4772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Petersen, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campa, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperlazza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conlon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpole, D. H.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patz, E. F.,  Jr.</span><span> </span><span class="NLM_article-title">Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">2866</span><span class="NLM_x">–</span> <span class="NLM_lpage">2872</span><span class="refDoi"> DOI: 10.1002/cncr.22282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1002%2Fcncr.22282" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=2866-2872&author=R.+P.+Petersenauthor=M.+J.+Campaauthor=J.+Sperlazzaauthor=D.+Conlonauthor=M.+B.+Joshiauthor=D.+H.+Harpoleauthor=E.+F.+Patz&title=Tumor+infiltrating+Foxp3%2B+regulatory+T-cells+are+associated+with+recurrence+in+pathologic+stage+I+NSCLC+patients&doi=10.1002%2Fcncr.22282"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fcncr.22282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.22282%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DR.%2BP.%26aulast%3DCampa%26aufirst%3DM.%2BJ.%26aulast%3DSperlazza%26aufirst%3DJ.%26aulast%3DConlon%26aufirst%3DD.%26aulast%3DJoshi%26aufirst%3DM.%2BB.%26aulast%3DHarpole%26aufirst%3DD.%2BH.%26aulast%3DPatz%26aufirst%3DE.%2BF.%26atitle%3DTumor%2520infiltrating%2520Foxp3%252B%2520regulatory%2520T-cells%2520are%2520associated%2520with%2520recurrence%2520in%2520pathologic%2520stage%2520I%2520NSCLC%2520patients%26jtitle%3DCancer%26date%3D2006%26volume%3D107%26spage%3D2866%26epage%3D2872%26doi%3D10.1002%2Fcncr.22282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">O’Callaghan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rexhepaj, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gately, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coate, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K. J.</span><span> </span><span class="NLM_article-title">Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1762</span><span class="NLM_x">–</span> <span class="NLM_lpage">1772</span><span class="refDoi"> DOI: 10.1183/13993003.00176-2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1183%2F13993003.00176-2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26541534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVWhtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=1762-1772&author=D.+S.+O%E2%80%99Callaghanauthor=E.+Rexhepajauthor=K.+Gatelyauthor=L.+Coateauthor=D.+Delaneyauthor=D.+M.+O%E2%80%99Donnellauthor=E.+Kayauthor=F.+O%E2%80%99Connellauthor=W.+M.+Gallagherauthor=K.+J.+O%E2%80%99Byrne&title=Tumour+islet+Foxp3%2B+T-cell+infiltration+predicts+poor+outcome+in+nonsmall+cell+lung+cancer&doi=10.1183%2F13993003.00176-2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer</span></div><div class="casAuthors">O'Callaghan, Dermot S.; Rexhepaj, Elton; Gately, Kathy; Coate, Linda; Delaney, David; O'Donnell, Dearbhaile. M.; Kay, Elaine; O'Connell, Finbarr; Gallagher, William. M.; O'Byrne, Kenneth J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1762-1772</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">The impact of host immunity on outcome in nonsmall cell lung cancer (NSCLC) is controversial.  We examd. the relationship between lymphoid infiltration patterns in NSCLC and prognosis.Tumor- and stroma-infiltrating CD3+, CD8+ and forkhead box P3 (Foxp3)+ T-lymphocytes were identified using immunohistochem. and a novel image anal. algorithm to assess total, cytotoxic and regulatory T-lymphocyte counts, resp., in 196 NSCLC cases.  The median cell count was selected as a cut-point to define patient subgroups and the ratio of the corresponding tumor islet:stroma (TI/S) counts was detd.  There was a pos. assocn. between overall survival and increased CD8+ TI/S ratio (hazard ratio (HR) for death 0.44, p<0.001) but an inverse relationship between Foxp3+ TI/S ratio and overall survival (HR 4.86, p<0.001).  Patients with high CD8+ islet (HR 0.48, p<0.001) and Foxp3+ stromal (HR 0.23, p<0.001) counts had better survival, whereas high CD3+ and CD8+ stromal counts and high Foxp3+ islet infiltration conferred a worse survival (HR 1.55, 2.19 and 3.14, resp.).  By multivariate anal., a high CD8+ TI/S ratio conferred an improved survival (HR 0.48, p=0.002) but a high Foxp3+ TI/S ratio was assocd. with worse survival (HR 3.91, p<0.001).  Microlocalisation of infiltrating T-lymphocytes is a powerful predictor of outcome in resected NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ULB0eO97ALVg90H21EOLACvtfcHk0lj9wknXYINomw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVWhtbw%253D&md5=aa9d82dc27b34752d108e3213e04ac90</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1183%2F13993003.00176-2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.00176-2014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DD.%2BS.%26aulast%3DRexhepaj%26aufirst%3DE.%26aulast%3DGately%26aufirst%3DK.%26aulast%3DCoate%26aufirst%3DL.%26aulast%3DDelaney%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DD.%2BM.%26aulast%3DKay%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DF.%26aulast%3DGallagher%26aufirst%3DW.%2BM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26atitle%3DTumour%2520islet%2520Foxp3%252B%2520T-cell%2520infiltration%2520predicts%2520poor%2520outcome%2520in%2520nonsmall%2520cell%2520lung%2520cancer%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3D1762%26epage%3D1772%26doi%3D10.1183%2F13993003.00176-2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Z.</span><span> </span><span class="NLM_article-title">Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients</span> <span class="citation_source-journal">Digestion</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1159/000342801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1159%2F000342801" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=329-337&author=Y.+Huangauthor=F.+M.+Wangauthor=T.+Wangauthor=Y.+J.+Wangauthor=Z.+Y.+Zhuauthor=Y.+T.+Gaoauthor=Z.+Du&title=Tumor-infiltrating+FoxP3%2B+Tregs+and+CD8%2B+T+cells+affect+the+prognosis+of+hepatocellular+carcinoma+patients&doi=10.1159%2F000342801"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1159%2F000342801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000342801%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%2BM.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DZhu%26aufirst%3DZ.%2BY.%26aulast%3DGao%26aufirst%3DY.%2BT.%26aulast%3DDu%26aufirst%3DZ.%26atitle%3DTumor-infiltrating%2520FoxP3%252B%2520Tregs%2520and%2520CD8%252B%2520T%2520cells%2520affect%2520the%2520prognosis%2520of%2520hepatocellular%2520carcinoma%2520patients%26jtitle%3DDigestion%26date%3D2012%26volume%3D86%26spage%3D329%26epage%3D337%26doi%3D10.1159%2F000342801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Shou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span> </span><span class="NLM_article-title">Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs: a systematic review and meta-analysis</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">687</span><span class="refDoi"> DOI: 10.1186/s12885-016-2732-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1186%2Fs12885-016-2732-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=687&author=J.+Shouauthor=Z.+Zhangauthor=Y.+Laiauthor=Z.+Chenauthor=J.+Huang&title=Worse+outcome+in+breast+cancer+with+higher+tumor-infiltrating+FOXP3%2B+Tregs%3A+a+systematic+review+and+meta-analysis&doi=10.1186%2Fs12885-016-2732-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1186%2Fs12885-016-2732-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-016-2732-0%26sid%3Dliteratum%253Aachs%26aulast%3DShou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DWorse%2520outcome%2520in%2520breast%2520cancer%2520with%2520higher%2520tumor-infiltrating%2520FOXP3%252B%2520Tregs%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DBMC%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D687%26doi%3D10.1186%2Fs12885-016-2732-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Golovina, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonderheide, R. H.</span><span> </span><span class="NLM_article-title">Regulatory T cells: overcoming suppression of T-cell immunity</span> <span class="citation_source-journal">Cancer J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span><span class="refDoi"> DOI: 10.1097/PPO.0b013e3181eb336d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1097%2FPPO.0b013e3181eb336d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20693845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGnurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=342-347&author=T.+N.+Golovinaauthor=R.+H.+Vonderheide&title=Regulatory+T+cells%3A+overcoming+suppression+of+T-cell+immunity&doi=10.1097%2FPPO.0b013e3181eb336d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory cells: overcoming suppression of T-cell immunity</span></div><div class="casAuthors">Golovina, Tatiana N.; Vonderheide, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">342-347</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Regulatory T cells inhibit cellular immunity and represent an obstacle for the development of cancer immunotherapy.  The understanding of Treg cellular biol. has exponentially increased during the last 10 years, driven primarily by elegant in vivo studies of mouse models systems and in vitro studies of human cells.  Numerous clin. strategies are under active investigation to achieve Treg depletion or inhibition in patients with cancer, including low-dose cyclophosphamide and interleukin-2 or anti-interleukin-2R immunotoxins.  To date, only modest results have been reported in patients.  Our preliminary data suggest that the antihuman CD25 monoclonal daclizumab may be useful as an alternative approach for in vivo Treg depletion, but the mechanism of action of this effect remains to be elucidated.  Certain immune modulatory agents may indirectly affect Tregs in patients with cancer but not necessarily in the desired direction for the therapeutic setting.  More sophisticated techniques that have become available for Treg anal. in patients will assist in this important translational effort.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreGroQIxmYLrVg90H21EOLACvtfcHk0ljJVJgItKSHig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGnurvF&md5=0adf2d5310765517a86ad50685f0811c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1097%2FPPO.0b013e3181eb336d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0b013e3181eb336d%26sid%3Dliteratum%253Aachs%26aulast%3DGolovina%26aufirst%3DT.%2BN.%26aulast%3DVonderheide%26aufirst%3DR.%2BH.%26atitle%3DRegulatory%2520T%2520cells%253A%2520overcoming%2520suppression%2520of%2520T-cell%2520immunity%26jtitle%3DCancer%2520J.%26date%3D2010%26volume%3D16%26spage%3D342%26epage%3D347%26doi%3D10.1097%2FPPO.0b013e3181eb336d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Ireland, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissick, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beilharz, M. W.</span><span> </span><span class="NLM_article-title">The role of regulatory T Cells in mesothelioma</span> <span class="citation_source-journal">Cancer Microenviron.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span><span class="refDoi"> DOI: 10.1007/s12307-012-0100-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1007%2Fs12307-012-0100-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22302659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=165-172&author=D.+J.+Irelandauthor=H.+T.+Kissickauthor=M.+W.+Beilharz&title=The+role+of+regulatory+T+Cells+in+mesothelioma&doi=10.1007%2Fs12307-012-0100-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Regulatory T Cells in Mesothelioma</span></div><div class="casAuthors">Ireland, Demelza J.; Kissick, Haydn T.; Beilharz, Manfred W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Microenvironment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-172</span>CODEN:
                <span class="NLM_cas:coden">CMAICW</span>;
        ISSN:<span class="NLM_cas:issn">1875-2284</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Malignant mesothelioma (MM) appears to be responsive to immunotherapy.  The lack of complete tumor cure as a result of many immunotherapies tested to date suggests that the immune response to MM is complex and multi-parametric.  Regulatory T (Treg) cells are prevalent within murine and human mesotheliomas with their removal shown to result in tumor growth inhibition and the release of anti-tumor effector T cells from immunosuppression.  The targeting of immune checkpoints as treatments for various solid tumors has recently shown promise in clin. settings.  In addn., synergy between chemotherapy and immunotherapy has been demonstrated for many cancers, including mesothelioma.  Here we demonstrate Treg cells as crit. mediators of the anti-tumor immune response to MM and potential targets for anti-tumor immunotherapy; though the timing and dosage of Treg cell manipulating immunotherapies need to be optimized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQefJT95tQJ7Vg90H21EOLACvtfcHk0ljJVJgItKSHig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7nL&md5=b7a1e85b818d9d4f16184969538910fc</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs12307-012-0100-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12307-012-0100-4%26sid%3Dliteratum%253Aachs%26aulast%3DIreland%26aufirst%3DD.%2BJ.%26aulast%3DKissick%26aufirst%3DH.%2BT.%26aulast%3DBeilharz%26aufirst%3DM.%2BW.%26atitle%3DThe%2520role%2520of%2520regulatory%2520T%2520Cells%2520in%2520mesothelioma%26jtitle%3DCancer%2520Microenviron.%26date%3D2012%26volume%3D5%26spage%3D165%26epage%3D172%26doi%3D10.1007%2Fs12307-012-0100-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Schabowsky, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madireddi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yolcu, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirwan, H.</span><span> </span><span class="NLM_article-title">Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1002</span><span class="NLM_x">–</span> <span class="NLM_lpage">1008</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=1002-1008&author=R.+H.+Schabowskyauthor=S.+Madireddiauthor=R.+Sharmaauthor=E.+S.+Yolcuauthor=H.+Shirwan&title=Targeting+CD4%2BCD25%2BFoxP3%2B+regulatory+T-cells+for+the+augmentation+of+cancer+immunotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchabowsky%26aufirst%3DR.%2BH.%26aulast%3DMadireddi%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DYolcu%26aufirst%3DE.%2BS.%26aulast%3DShirwan%26aufirst%3DH.%26atitle%3DTargeting%2520CD4%252BCD25%252BFoxP3%252B%2520regulatory%2520T-cells%2520for%2520the%2520augmentation%2520of%2520cancer%2520immunotherapy%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D8%26spage%3D1002%26epage%3D1008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Wang, R. F.</span><span> </span><span class="NLM_article-title">Functional control of regulatory T cells and cancer immunotherapy</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1016/j.semcancer.2005.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.semcancer.2005.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16423537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVGisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=106-114&author=R.+F.+Wang&title=Functional+control+of+regulatory+T+cells+and+cancer+immunotherapy&doi=10.1016%2Fj.semcancer.2005.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Functional control of regulatory T cells and cancer immunotherapy</span></div><div class="casAuthors">Wang, Rong-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">106-114</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Regulatory T (Treg) cells induce immune tolerance by suppressing host immune responses against self- or non-self-antigens.  Hence, they not only play crit. roles in preventing autoimmune diseases, but also may have detrimental effects on vaccines directed to cancer and infectious diseases.  Understanding the antigen specificity and functional control of Treg cells will be crucial to the development of effective cancer immunotherapy.  This review will discuss different subsets of Treg cells, the factors that contribute to Treg cell generation and suppressive function, and the ability of signaling through Toll-like receptor 8 to reverse the suppressive function of Treg cells.  Importantly, this TLR pathway does not depend on interaction with dendritic cells, but operates independently in Treg cells, relying on TLR8 (with MyD88 as its sole receptor-proximal adaptor) to transduce signals generated by TLR8 ligands.  Linking TLR signaling to the functional control of Treg cells opens intriguing opportunities to shift the balance between CD4+ T-helper and Treg cells, in ways that may improve the outcome of cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSr0A_aJetF7Vg90H21EOLACvtfcHk0licXX85iGI-rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVGisrg%253D&md5=817b48162077cb82b4b5033e3f7f57f7</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2005.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2005.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%2BF.%26atitle%3DFunctional%2520control%2520of%2520regulatory%2520T%2520cells%2520and%2520cancer%2520immunotherapy%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D106%26epage%3D114%26doi%3D10.1016%2Fj.semcancer.2005.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Williams, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudensky, A. Y.</span><span> </span><span class="NLM_article-title">Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1038/ni1437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fni1437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=17220892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslWmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=277-284&author=L.+M.+Williamsauthor=A.+Y.+Rudensky&title=Maintenance+of+the+Foxp3-dependent+developmental+program+in+mature+regulatory+T+cells+requires+continued+expression+of+Foxp3&doi=10.1038%2Fni1437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3</span></div><div class="casAuthors">Williams, Luke M.; Rudensky, Alexander Y.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-284</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The transcription factor Foxp3 is required for the development of regulatory T cells (Treg cell).  Here the authors report that induced ablation of a loxP-flanked Foxp3 allele in mature Treg cells resulted in the loss of their suppressive function in vivo and acquisition of the ability to produce interleukin 2 and T helper type 1 cytokines.  Furthermore, after adoptive transfer in the absence of functional Treg cells into lymphopenic hosts, Treg cells with deletion of Foxp3 proliferated and were predominant among tissue-infiltrating T cells.  In agreement with those results, the authors found deregulation of Foxp3 target gene expression after Foxp3 deletion.  Thus, continued Foxp3 expression in mature Treg cells is needed to maintain the transcriptional and functional program established during Treg cell development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrne9sUBpH4FLVg90H21EOLACvtfcHk0licXX85iGI-rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslWmsrk%253D&md5=bfbc7deccecf86e6a04a808e91cb023f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fni1437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1437%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DL.%2BM.%26aulast%3DRudensky%26aufirst%3DA.%2BY.%26atitle%3DMaintenance%2520of%2520the%2520Foxp3-dependent%2520developmental%2520program%2520in%2520mature%2520regulatory%2520T%2520cells%2520requires%2520continued%2520expression%2520of%2520Foxp3%26jtitle%3DNat.%2520Immunol.%26date%3D2007%26volume%3D8%26spage%3D277%26epage%3D284%26doi%3D10.1038%2Fni1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Fontenot, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudensky, A. Y.</span><span> </span><span class="NLM_article-title">Foxp3 programs the development and function of CD4+CD25+ regulatory T cells</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">330</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/ni904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fni904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=12612578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlyqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=330-336&author=J.+D.+Fontenotauthor=M.+A.+Gavinauthor=A.+Y.+Rudensky&title=Foxp3+programs+the+development+and+function+of+CD4%2BCD25%2B+regulatory+T+cells&doi=10.1038%2Fni904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Foxp3 programs the development and function of CD4+CD25+ regulatory T cells</span></div><div class="casAuthors">Fontenot, Jason D.; Gavin, Marc A.; Rudensky, Alexander Y.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">330-336</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CD4+CD25+ regulatory T cells are essential for the active suppression of autoimmunity.  Here the authors report that the forkhead transcription factor Foxp3 is specifically expressed in CD4+CD25+ regulatory T cells and is required for their development.  The lethal autoimmune syndrome obsd. in Foxp3-mutant scurfy mice and Foxp3-null mice results from a CD4+CD25+ regulatory T cell deficiency and not from a cell-intrinsic defect of CD4+CD25- T cells.  CD4+CD25+ regulatory T cells rescue disease development and preferentially expand when transferred into neonatal Foxp3-deficient mice.  Furthermore, ectopic expression of Foxp3 confers suppressor function on peripheral CD4+CD25- T cells.  Thus, Foxp3 is a crit. regulator of CD4+CD25+ regulatory T cell development and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriHBlgR28euLVg90H21EOLACvtfcHk0licXX85iGI-rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlyqs74%253D&md5=e923b4054210b2902140bd155e8a7daf</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fni904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni904%26sid%3Dliteratum%253Aachs%26aulast%3DFontenot%26aufirst%3DJ.%2BD.%26aulast%3DGavin%26aufirst%3DM.%2BA.%26aulast%3DRudensky%26aufirst%3DA.%2BY.%26atitle%3DFoxp3%2520programs%2520the%2520development%2520and%2520function%2520of%2520CD4%252BCD25%252B%2520regulatory%2520T%2520cells%26jtitle%3DNat.%2520Immunol.%26date%3D2003%26volume%3D4%26spage%3D330%26epage%3D336%26doi%3D10.1038%2Fni904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Chatila, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaeser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voulgaropoulos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helms, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowcock, A. M.</span><span> </span><span class="NLM_article-title">JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">R75</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1172/JCI11679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1172%2FJCI11679" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2000&pages=R75-81&author=T.+A.+Chatilaauthor=F.+Blaeserauthor=N.+Hoauthor=H.+M.+Ledermanauthor=C.+Voulgaropoulosauthor=C.+Helmsauthor=A.+M.+Bowcock&title=JM2%2C+encoding+a+fork+head-related+protein%2C+is+mutated+in+X-linked+autoimmunity-allergic+disregulation+syndrome&doi=10.1172%2FJCI11679"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1172%2FJCI11679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI11679%26sid%3Dliteratum%253Aachs%26aulast%3DChatila%26aufirst%3DT.%2BA.%26aulast%3DBlaeser%26aufirst%3DF.%26aulast%3DHo%26aufirst%3DN.%26aulast%3DLederman%26aufirst%3DH.%2BM.%26aulast%3DVoulgaropoulos%26aufirst%3DC.%26aulast%3DHelms%26aufirst%3DC.%26aulast%3DBowcock%26aufirst%3DA.%2BM.%26atitle%3DJM2%252C%2520encoding%2520a%2520fork%2520head-related%2520protein%252C%2520is%2520mutated%2520in%2520X-linked%2520autoimmunity-allergic%2520disregulation%2520syndrome%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2000%26volume%3D106%26spage%3DR75%26epage%3D81%26doi%3D10.1172%2FJCI11679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lough, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samanta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, M. I.</span><span> </span><span class="NLM_article-title">Dynamic interactions between TIP60 and p300 regulate FOXP3 function through a structural switch defined by a single lysine on TIP60</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1471</span><span class="NLM_x">–</span> <span class="NLM_lpage">1480</span><span class="refDoi"> DOI: 10.1016/j.celrep.2014.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.celrep.2014.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24835996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFGlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=1471-1480&author=Y.+Xiaoauthor=Y.+Nagaiauthor=G.+Dengauthor=T.+Ohtaniauthor=Z.+Zhuauthor=Z.+Zhouauthor=H.+Zhangauthor=M.+Q.+Jiauthor=J.+W.+Loughauthor=A.+Samantaauthor=W.+W.+Hancockauthor=M.+I.+Greene&title=Dynamic+interactions+between+TIP60+and+p300+regulate+FOXP3+function+through+a+structural+switch+defined+by+a+single+lysine+on+TIP60&doi=10.1016%2Fj.celrep.2014.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic Interactions between TIP60 and p300 Regulate FOXP3 Function through a Structural Switch Defined by a Single Lysine on TIP60</span></div><div class="casAuthors">Xiao, Yan; Nagai, Yasuhiro; Deng, Guoping; Ohtani, Takuya; Zhu, Zhiqiang; Zhou, Zhaocai; Zhang, Hongtao; Ji, Mei Q.; Lough, John W.; Samanta, Arabinda; Hancock, Wayne W.; Greene, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1471-1480</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The human FOXP3 mol. is an oligomeric transcriptional factor able to mediate activities that characterize T regulatory cells, a class of lymphocytes central to the regulation of immune responses.  The activity of FOXP3 is regulated at the posttranslational level, in part by two histone acetyltransferases (HATs): TIP60 and p300.  TIP60 and p300 work cooperatively to regulate FOXP3 activity.  Initially, p300 and TIP60 interactions lead to the activation of TIP60 and facilitate acetylation of K327 of TIP60, which functions as a mol. switch to allow TIP60 to change binding partners.  Subsequently, p300 is released from this complex, and TIP60 interacts with and acetylates FOXP3.  Maximal induction of FOXP3 activities is obsd. when both p300 and TIP60 are able to undergo cooperative interactions.  Conditional knockout of TIP60 in Treg cells significantly decreases the Treg population in the peripheral immune organs, leading to a scurfy-like fatal autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoisEBghRHaSrVg90H21EOLACvtfcHk0lhGjuHtfxADwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFGlsbw%253D&md5=4d3ed5d4713140bd2e17e6288ad9f1af</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2014.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2014.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DG.%26aulast%3DOhtani%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DM.%2BQ.%26aulast%3DLough%26aufirst%3DJ.%2BW.%26aulast%3DSamanta%26aufirst%3DA.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26aulast%3DGreene%26aufirst%3DM.%2BI.%26atitle%3DDynamic%2520interactions%2520between%2520TIP60%2520and%2520p300%2520regulate%2520FOXP3%2520function%2520through%2520a%2520structural%2520switch%2520defined%2520by%2520a%2520single%2520lysine%2520on%2520TIP60%26jtitle%3DCell%2520Rep.%26date%3D2014%26volume%3D7%26spage%3D1471%26epage%3D1480%26doi%3D10.1016%2Fj.celrep.2014.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">van Loosdregt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleskens, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenkman, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekker, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pals, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meerding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sijts, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalkhoven, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakken, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaiss, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffer, P. J.</span><span> </span><span class="NLM_article-title">Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span><span class="refDoi"> DOI: 10.1016/j.immuni.2013.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.immuni.2013.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=23973222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCgtr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=259-271&author=J.+van+Loosdregtauthor=V.+Fleskensauthor=J.+Fuauthor=A.+B.+Brenkmanauthor=C.+P.+Bekkerauthor=C.+E.+Palsauthor=J.+Meerdingauthor=C.+R.+Berkersauthor=J.+Barbiauthor=A.+Groneauthor=A.+J.+Sijtsauthor=M.+M.+Mauriceauthor=E.+Kalkhovenauthor=B.+J.+Prakkenauthor=H.+Ovaaauthor=F.+Panauthor=D.+M.+Zaissauthor=P.+J.+Coffer&title=Stabilization+of+the+transcription+factor+Foxp3+by+the+deubiquitinase+USP7+increases+Treg-cell-suppressive+capacity&doi=10.1016%2Fj.immuni.2013.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilization of the Transcription Factor Foxp3 by the Deubiquitinase USP7 Increases Treg-Cell-Suppressive Capacity</span></div><div class="casAuthors">van Loosdregt, Jorg; Fleskens, Veerle; Fu, Juan; Brenkman, Arjan B.; Bekker, Cornelis P. J.; Pals, Cornelieke E. G. M.; Meerding, Jenny; Berkers, Celia R.; Barbi, Joseph; Grone, Andrea; Sijts, Alice J. A. M.; Maurice, Madelon M.; Kalkhoven, Eric; Prakken, Berent J.; Ovaa, Huib; Pan, Fan; Zaiss, Dietmar M. W.; Coffer, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-271</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Stable Foxp3 expression is required for the development of functional regulatory T (Treg) cells.  Here, we demonstrate that the expression of the transcription factor Foxp3 can be regulated through the polyubiquitination of multiple lysine residues, resulting in proteasome-mediated degrdn.  Expression of the deubiquitinase (DUB) USP7 was found to be upregulated and active in Treg cells, being assocd. with Foxp3 in the nucleus.  Ectopic expression of USP7 decreased Foxp3 polyubiquitination and increased Foxp3 expression.  Conversely, either treatment with DUB inhibitor or USP7 knockdown decreased endogenous Foxp3 protein expression and decreased Treg-cell-mediated suppression in vitro.  Furthermore, in a murine adoptive-transfer-induced colitis model, either inhibition of DUB activity or USP7 knockdown in Treg cells abrogated their ability to resolve inflammation in vivo.  Our data reveal a mol. mechanism in which rapid temporal control of Foxp3 expression in Treg cells can be regulated by USP7, thereby modulating Treg cell nos. and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Zpb6_zouu7Vg90H21EOLACvtfcHk0lhGjuHtfxADwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCgtr3F&md5=78bd3e51a661ecac49461a3811d2e768</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2013.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2013.05.018%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BLoosdregt%26aufirst%3DJ.%26aulast%3DFleskens%26aufirst%3DV.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DBrenkman%26aufirst%3DA.%2BB.%26aulast%3DBekker%26aufirst%3DC.%2BP.%26aulast%3DPals%26aufirst%3DC.%2BE.%26aulast%3DMeerding%26aufirst%3DJ.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DBarbi%26aufirst%3DJ.%26aulast%3DGrone%26aufirst%3DA.%26aulast%3DSijts%26aufirst%3DA.%2BJ.%26aulast%3DMaurice%26aufirst%3DM.%2BM.%26aulast%3DKalkhoven%26aufirst%3DE.%26aulast%3DPrakken%26aufirst%3DB.%2BJ.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DZaiss%26aufirst%3DD.%2BM.%26aulast%3DCoffer%26aufirst%3DP.%2BJ.%26atitle%3DStabilization%2520of%2520the%2520transcription%2520factor%2520Foxp3%2520by%2520the%2520deubiquitinase%2520USP7%2520increases%2520Treg-cell-suppressive%2520capacity%26jtitle%3DImmunity%26date%3D2013%26volume%3D39%26spage%3D259%26epage%3D271%26doi%3D10.1016%2Fj.immuni.2013.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatti, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Foxp3+ T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">3631</span><span class="NLM_x">–</span> <span class="NLM_lpage">3639</span><span class="refDoi"> DOI: 10.1182/blood-2012-08-451765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1182%2Fblood-2012-08-451765" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=3631-3639&author=L.+Wangauthor=Y.+Liuauthor=U.+H.+Beierauthor=R.+Hanauthor=T.+R.+Bhattiauthor=T.+Akimovaauthor=W.+W.+Hancock&title=Foxp3%2B+T-regulatory+cells+require+DNA+methyltransferase+1+expression+to+prevent+development+of+lethal+autoimmunity&doi=10.1182%2Fblood-2012-08-451765"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-08-451765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-08-451765%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBeier%26aufirst%3DU.%2BH.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DBhatti%26aufirst%3DT.%2BR.%26aulast%3DAkimova%26aufirst%3DT.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DFoxp3%252B%2520T-regulatory%2520cells%2520require%2520DNA%2520methyltransferase%25201%2520expression%2520to%2520prevent%2520development%2520of%2520lethal%2520autoimmunity%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26spage%3D3631%26epage%3D3639%26doi%3D10.1182%2Fblood-2012-08-451765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group">Obata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furusawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atarashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otsubo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamura, Y. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masumoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohara, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koseki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hase, K.</span><span> </span><span class="NLM_article-title">The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">571</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span><span class="refDoi"> DOI: 10.1038/ni.2886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fni.2886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24777532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvFSjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=571-579&author=Y.+Obataauthor=Y.+Furusawaauthor=T.+A.+Endoauthor=J.+Sharifauthor=D.+Takahashiauthor=K.+Atarashiauthor=M.+Nakayamaauthor=S.+Onawaauthor=Y.+Fujimuraauthor=M.+Takahashiauthor=T.+Ikawaauthor=T.+Otsuboauthor=Y.+I.+Kawamuraauthor=T.+Dohiauthor=S.+Tajimaauthor=H.+Masumotoauthor=O.+Oharaauthor=K.+Hondaauthor=S.+Horiauthor=H.+Ohnoauthor=H.+Kosekiauthor=K.+Hase&title=The+epigenetic+regulator+Uhrf1+facilitates+the+proliferation+and+maturation+of+colonic+regulatory+T+cells&doi=10.1038%2Fni.2886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells</span></div><div class="casAuthors">Obata, Yuuki; Furusawa, Yukihiro; Endo, Takaho A.; Sharif, Jafar; Takahashi, Daisuke; Atarashi, Koji; Nakayama, Manabu; Onawa, Satoshi; Fujimura, Yumiko; Takahashi, Masumi; Ikawa, Tomokatsu; Otsubo, Takeshi; Kawamura, Yuki I.; Dohi, Taeko; Tajima, Shoji; Masumoto, Hiroshi; Ohara, Osamu; Honda, Kenya; Hori, Shohei; Ohno, Hiroshi; Koseki, Haruhiko; Hase, Koji</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">571-579</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Intestinal regulatory T cells (Treg cells) are necessary for the suppression of excessive immune responses to commensal bacteria.  However, the mol. machinery that controls the homeostasis of intestinal Treg cells has remained largely unknown.  Here we report that colonization of germ-free mice with gut microbiota upregulated expression of the DNA-methylation adaptor Uhrf1 in Treg cells.  Mice with T cell-specific deficiency in Uhrf1 (Uhrf1fl/flCd4-Cre mice) showed defective proliferation and functional maturation of colonic Treg cells.  Uhrf1 deficiency resulted in derepression of the gene (Cdkn1a) that encodes the cyclin-dependent kinase inhibitor p21 due to hypomethylation of its promoter region, which resulted in cell-cycle arrest of Treg cells.  As a consequence, Uhrf1fl/flCd4-Cre mice spontaneously developed severe colitis.  Thus, Uhrf1-dependent epigenetic silencing of Cdkn1a was required for the maintenance of gut immunol. homeostasis.  This mechanism enforces symbiotic host-microbe interactions without an inflammatory response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9DFM1a_urd7Vg90H21EOLACvtfcHk0lhYREbVU9Rp2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvFSjt7s%253D&md5=667da544031f317df47c8f8a777838ef</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1038%2Fni.2886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2886%26sid%3Dliteratum%253Aachs%26aulast%3DObata%26aufirst%3DY.%26aulast%3DFurusawa%26aufirst%3DY.%26aulast%3DEndo%26aufirst%3DT.%2BA.%26aulast%3DSharif%26aufirst%3DJ.%26aulast%3DTakahashi%26aufirst%3DD.%26aulast%3DAtarashi%26aufirst%3DK.%26aulast%3DNakayama%26aufirst%3DM.%26aulast%3DOnawa%26aufirst%3DS.%26aulast%3DFujimura%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DIkawa%26aufirst%3DT.%26aulast%3DOtsubo%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DY.%2BI.%26aulast%3DDohi%26aufirst%3DT.%26aulast%3DTajima%26aufirst%3DS.%26aulast%3DMasumoto%26aufirst%3DH.%26aulast%3DOhara%26aufirst%3DO.%26aulast%3DHonda%26aufirst%3DK.%26aulast%3DHori%26aufirst%3DS.%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DKoseki%26aufirst%3DH.%26aulast%3DHase%26aufirst%3DK.%26atitle%3DThe%2520epigenetic%2520regulator%2520Uhrf1%2520facilitates%2520the%2520proliferation%2520and%2520maturation%2520of%2520colonic%2520regulatory%2520T%2520cells%26jtitle%3DNat.%2520Immunol.%26date%3D2014%26volume%3D15%26spage%3D571%26epage%3D579%26doi%3D10.1038%2Fni.2886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Pacholczyk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kern, J.</span><span> </span><span class="NLM_article-title">The T-cell receptor repertoire of regulatory T cells</span> <span class="citation_source-journal">Immunology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">450</span><span class="NLM_x">–</span> <span class="NLM_lpage">458</span><span class="refDoi"> DOI: 10.1111/j.1365-2567.2008.02992.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1111%2Fj.1365-2567.2008.02992.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2008&pages=450-458&author=R.+Pacholczykauthor=J.+Kern&title=The+T-cell+receptor+repertoire+of+regulatory+T+cells&doi=10.1111%2Fj.1365-2567.2008.02992.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2567.2008.02992.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2567.2008.02992.x%26sid%3Dliteratum%253Aachs%26aulast%3DPacholczyk%26aufirst%3DR.%26aulast%3DKern%26aufirst%3DJ.%26atitle%3DThe%2520T-cell%2520receptor%2520repertoire%2520of%2520regulatory%2520T%2520cells%26jtitle%3DImmunology%26date%3D2008%26volume%3D125%26spage%3D450%26epage%3D458%26doi%3D10.1111%2Fj.1365-2567.2008.02992.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Pfoh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacdao, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georges, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frappier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saridakis, V.</span><span> </span><span class="NLM_article-title">Crystal structure of USP7 ubiquitin-like domains with an ICP0 peptide reveals a novel mechanism used by viral and cellular proteins to target USP7</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1004950</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1004950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1371%2Fjournal.ppat.1004950" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1004950&author=R.+Pfohauthor=I.+K.+Lacdaoauthor=A.+A.+Georgesauthor=A.+Caparauthor=H.+Zhengauthor=L.+Frappierauthor=V.+Saridakis&title=Crystal+structure+of+USP7+ubiquitin-like+domains+with+an+ICP0+peptide+reveals+a+novel+mechanism+used+by+viral+and+cellular+proteins+to+target+USP7&doi=10.1371%2Fjournal.ppat.1004950"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004950%26sid%3Dliteratum%253Aachs%26aulast%3DPfoh%26aufirst%3DR.%26aulast%3DLacdao%26aufirst%3DI.%2BK.%26aulast%3DGeorges%26aufirst%3DA.%2BA.%26aulast%3DCapar%26aufirst%3DA.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DFrappier%26aufirst%3DL.%26aulast%3DSaridakis%26aufirst%3DV.%26atitle%3DCrystal%2520structure%2520of%2520USP7%2520ubiquitin-like%2520domains%2520with%2520an%2520ICP0%2520peptide%2520reveals%2520a%2520novel%2520mechanism%2520used%2520by%2520viral%2520and%2520cellular%2520proteins%2520to%2520target%2520USP7%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26spage%3De1004950%26doi%3D10.1371%2Fjournal.ppat.1004950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Reddy, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Knaap, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bot, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohd-Sarip, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekkers, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmermans, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martens, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demmers, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verrijzer, C. P.</span><span> </span><span class="NLM_article-title">Nucleotide biosynthetic enzyme GMP synthase is a TRIM21-controlled relay of p53 stabilization</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">458</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span><span class="refDoi"> DOI: 10.1016/j.molcel.2013.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.molcel.2013.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24462112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=458-470&author=B.+A.+Reddyauthor=J.+A.+van+der+Knaapauthor=A.+G.+Botauthor=A.+Mohd-Saripauthor=D.+H.+Dekkersauthor=M.+A.+Timmermansauthor=J.+W.+Martensauthor=J.+A.+Demmersauthor=C.+P.+Verrijzer&title=Nucleotide+biosynthetic+enzyme+GMP+synthase+is+a+TRIM21-controlled+relay+of+p53+stabilization&doi=10.1016%2Fj.molcel.2013.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleotide Biosynthetic Enzyme GMP Synthase Is a TRIM21-Controlled Relay of p53 Stabilization</span></div><div class="casAuthors">Reddy, B. Ashok; van der Knaap, Jan A.; Bot, Alice G. M.; Mohd-Sarip, Adone; Dekkers, Dick H. W.; Timmermans, Mieke A.; Martens, John W. M.; Demmers, Jeroen A. A.; Verrijzer, C. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">458-470</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Nucleotide biosynthesis is fundamental to normal cell proliferation as well as to oncogenesis.  Tumor suppressor p53, which prevents aberrant cell proliferation, is destabilized through ubiquitylation by MDM2.  Ubiquitin-specific protease 7 (USP7) plays a dualistic role in p53 regulation and has been proposed to deubiquitylate either p53 or MDM2.  Here, we show that GMP synthase (GMPS) is required for USP7-mediated stabilization of p53.  Normally, most GMPS is sequestered in the cytoplasm, sepd. from nuclear USP7 and p53.  In response to genotoxic stress or nucleotide deprivation, GMPS becomes nuclear and facilitates p53 stabilization by promoting its transfer from MDM2 to a GMPS-USP7 deubiquitylation complex.  Intriguingly, cytoplasmic sequestration of GMPS requires ubiquitylation by TRIM21, a ubiquitin ligase assocd. with autoimmune disease.  These results implicate a classic nucleotide biosynthetic enzyme and a ubiquitin ligase, better known for its role in autoimmune disease, in p53 control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6TeSvWWHlkrVg90H21EOLACvtfcHk0lhYREbVU9Rp2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GnsrY%253D&md5=dce70456374b51d74254766bb0867cec</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DB.%2BA.%26aulast%3Dvan%2Bder%2BKnaap%26aufirst%3DJ.%2BA.%26aulast%3DBot%26aufirst%3DA.%2BG.%26aulast%3DMohd-Sarip%26aufirst%3DA.%26aulast%3DDekkers%26aufirst%3DD.%2BH.%26aulast%3DTimmermans%26aufirst%3DM.%2BA.%26aulast%3DMartens%26aufirst%3DJ.%2BW.%26aulast%3DDemmers%26aufirst%3DJ.%2BA.%26aulast%3DVerrijzer%26aufirst%3DC.%2BP.%26atitle%3DNucleotide%2520biosynthetic%2520enzyme%2520GMP%2520synthase%2520is%2520a%2520TRIM21-controlled%2520relay%2520of%2520p53%2520stabilization%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D53%26spage%3D458%26epage%3D470%26doi%3D10.1016%2Fj.molcel.2013.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Faesen, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirac, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanmugham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrakis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sixma, T. K.</span><span> </span><span class="NLM_article-title">Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.molcel.2011.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.molcel.2011.06.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21981925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12gtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2011&pages=147-159&author=A.+C.+Faesenauthor=A.+M.+Diracauthor=A.+Shanmughamauthor=H.+Ovaaauthor=A.+Perrakisauthor=T.+K.+Sixma&title=Mechanism+of+USP7%2FHAUSP+activation+by+its+C-terminal+ubiquitin-like+domain+and+allosteric+regulation+by+GMP-synthetase&doi=10.1016%2Fj.molcel.2011.06.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of USP7/HAUSP Activation by Its C-Terminal Ubiquitin-like Domain and Allosteric Regulation by GMP-Synthetase</span></div><div class="casAuthors">Faesen, Alex C.; Dirac, Annette M. G.; Shanmugham, Anitha; Ovaa, Huib; Perrakis, Anastassis; Sixma, Titia K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-159</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The ubiquitin-specific protease USP7/HAUSP regulates p53 and MDM2 levels and cellular localization of FOXO4 and PTEN, and hence is critically important for their role in cellular processes.  Here we show how the 64 kDa C-terminal region of USP7 can pos. regulate deubiquitinating activity.  We present the crystal structure of this USP7/HAUSP ubiquitin-like domain (HUBL) comprised of five ubiquitin-like (Ubl) domains organized in 2-1-2 Ubl units.  The last di-Ubl unit, HUBL-45, is sufficient to activate USP7 through binding to a "switching" loop in the catalytic domain, which promotes ubiquitin binding and increases activity 100-fold.  This activation can be enhanced allosterically by the metabolic enzyme GMPS.  It binds to the first three Ubl domains (HUBL-123) and hyperactivates USP7 by stabilization of the HUBL-45-dependent active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYdH4sjakohbVg90H21EOLACvtfcHk0lgH93D6iqyJCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12gtrrE&md5=ec58186e658876ab9e2b83f9fde82fb9</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2011.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2011.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DFaesen%26aufirst%3DA.%2BC.%26aulast%3DDirac%26aufirst%3DA.%2BM.%26aulast%3DShanmugham%26aufirst%3DA.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DPerrakis%26aufirst%3DA.%26aulast%3DSixma%26aufirst%3DT.%2BK.%26atitle%3DMechanism%2520of%2520USP7%252FHAUSP%2520activation%2520by%2520its%2520C-terminal%2520ubiquitin-like%2520domain%2520and%2520allosteric%2520regulation%2520by%2520GMP-synthetase%26jtitle%3DMol.%2520Cell%26date%3D2011%26volume%3D44%26spage%3D147%26epage%3D159%26doi%3D10.1016%2Fj.molcel.2011.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Sheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saridakis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkari, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frappier, L.</span><span> </span><span class="NLM_article-title">Molecular recognition of p53 and MDM2 by USP7/HAUSP</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span><span class="refDoi"> DOI: 10.1038/nsmb1067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnsmb1067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=16474402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=285-291&author=Y.+Shengauthor=V.+Saridakisauthor=F.+Sarkariauthor=S.+Duanauthor=T.+Wuauthor=C.+H.+Arrowsmithauthor=L.+Frappier&title=Molecular+recognition+of+p53+and+MDM2+by+USP7%2FHAUSP&doi=10.1038%2Fnsmb1067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular recognition of p53 and MDM2 by USP7/HAUSP</span></div><div class="casAuthors">Sheng, Yi; Saridakis, Vivian; Sarkari, Feroz; Duan, Shili; Wu, Tianne; Arrowsmith, Cheryl H.; Frappier, Lori</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-291</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ubiquitin-specific protease, USP7, has key roles in the p53 pathway whereby it stabilizes both p53 and MDM2.  We show that the N-terminal domain of USP7 binds two closely spaced 4-residue sites in both p53 and MDM2, falling between p53 residues 359-367 and MDM2 residues 147-159.  Cocrystal structures with USP7 were detd. for both p53 peptides and for one MDM2 peptide.  These peptides bind the same surface of USP7 as Epstein-Barr nuclear antigen-1, explaining the competitive nature of the interactions.  The structures and mutagenesis data indicate a preference for a P/AXXS motif in peptides that bind USP7.  Contacts made by serine are identical and crucial for all peptides, and Trp165 in the peptide-binding pocket of USP7 is also crucial.  These results help to elucidate the mechanism of substrate recognition by USP7 and the regulation of the p53 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppxsEZ-TJFZrVg90H21EOLACvtfcHk0lgH93D6iqyJCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOltr8%253D&md5=09d2f534fbd4fdb60bbc27a99d01e781</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fnsmb1067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb1067%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DY.%26aulast%3DSaridakis%26aufirst%3DV.%26aulast%3DSarkari%26aufirst%3DF.%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DFrappier%26aufirst%3DL.%26atitle%3DMolecular%2520recognition%2520of%2520p53%2520and%2520MDM2%2520by%2520USP7%252FHAUSP%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D285%26epage%3D291%26doi%3D10.1038%2Fnsmb1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span> </span><span class="NLM_article-title">Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">e27</span><span class="refDoi"> DOI: 10.1371/journal.pbio.0040027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1371%2Fjournal.pbio.0040027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=e27&author=M.+Huauthor=L.+Guauthor=M.+Liauthor=P.+D.+Jeffreyauthor=W.+Guauthor=Y.+Shi&title=Structural+basis+of+competitive+recognition+of+p53+and+MDM2+by+HAUSP%2FUSP7%3A+implications+for+the+regulation+of+the+p53-MDM2+pathway&doi=10.1371%2Fjournal.pbio.0040027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.0040027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.0040027%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520basis%2520of%2520competitive%2520recognition%2520of%2520p53%2520and%2520MDM2%2520by%2520HAUSP%252FUSP7%253A%2520implications%2520for%2520the%2520regulation%2520of%2520the%2520p53-MDM2%2520pathway%26jtitle%3DPLoS%2520Biol.%26date%3D2006%26volume%3D4%26spage%3De27%26doi%3D10.1371%2Fjournal.pbio.0040027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lor, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy-Wilson, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinnamon, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span> </span><span class="NLM_article-title">C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site</span> <span class="citation_source-journal">Arch. Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">503</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1016/j.abb.2010.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.abb.2010.08.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2010&pages=207-212&author=J.+Maauthor=J.+D.+Martinauthor=Y.+Xueauthor=L.+A.+Lorauthor=K.+M.+Kennedy-Wilsonauthor=R.+H.+Sinnamonauthor=T.+F.+Hoauthor=G.+Zhangauthor=B.+Schwartzauthor=P.+J.+Tumminoauthor=Z.+Lai&title=C-terminal+region+of+USP7%2FHAUSP+is+critical+for+deubiquitination+activity+and+contains+a+second+mdm2%2Fp53+binding+site&doi=10.1016%2Fj.abb.2010.08.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2010.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2010.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DJ.%2BD.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DLor%26aufirst%3DL.%2BA.%26aulast%3DKennedy-Wilson%26aufirst%3DK.%2BM.%26aulast%3DSinnamon%26aufirst%3DR.%2BH.%26aulast%3DHo%26aufirst%3DT.%2BF.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DLai%26aufirst%3DZ.%26atitle%3DC-terminal%2520region%2520of%2520USP7%252FHAUSP%2520is%2520critical%2520for%2520deubiquitination%2520activity%2520and%2520contains%2520a%2520second%2520mdm2%252Fp53%2520binding%2520site%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2010%26volume%3D503%26spage%3D207%26epage%3D212%26doi%3D10.1016%2Fj.abb.2010.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Ndubaku, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span> </span><span class="NLM_article-title">Inhibiting the deubiquitinating enzymes (DUBs)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1581</span><span class="NLM_x">–</span> <span class="NLM_lpage">1595</span><span class="refDoi"> DOI: 10.1021/jm501061a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501061a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1581-1595&author=C.+Ndubakuauthor=V.+Tsui&title=Inhibiting+the+deubiquitinating+enzymes+%28DUBs%29&doi=10.1021%2Fjm501061a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the Deubiquitinating Enzymes (DUBs)</span></div><div class="casAuthors">Ndubaku, Chudi; Tsui, Vickie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1581-1595</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The diverse roles of deubiquitinating enzymes, or DUBs, in detg. the fate of specific proteins continue to unfold.  Concurrent with the revelation of DUBs as potential therapeutic targets are publications of small mol. inhibitors of these enzymes.  In this review, we summarize these mols. and their assocd. data and suggest addnl. expts. to further validate and characterize these compds.  We believe the field of drug discovery against DUBs is still in its infancy, but advances in assay development, biophys. techniques, and screening libraries hold promise for identifying suitable agents that could advance into the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsiPtPfBsxNrVg90H21EOLACvtfcHk0lhiHxu1QYQAUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLrL&md5=8ec54b033ba6fd8acb3187e4fc004296</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm501061a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501061a%26sid%3Dliteratum%253Aachs%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DTsui%26aufirst%3DV.%26atitle%3DInhibiting%2520the%2520deubiquitinating%2520enzymes%2520%2528DUBs%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1581%26epage%3D1595%26doi%3D10.1021%2Fjm501061a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Kemp, M.</span><span> </span><span class="NLM_article-title">Recent advances in the discovery of deubiquitinating enzyme inhibitors</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1016/bs.pmch.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fbs.pmch.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26852935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC28nos1KmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=149-192&author=M.+Kemp&title=Recent+advances+in+the+discovery+of+deubiquitinating+enzyme+inhibitors&doi=10.1016%2Fbs.pmch.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors</span></div><div class="casAuthors">Kemp Mark</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">149-92</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOLsGcWRMxs691pGlMMoT5fW6udTcc2eZhZ7NjXeQPBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nos1KmsQ%253D%253D&md5=e2e3691b281395ca076f4ac93b577f75</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DKemp%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520deubiquitinating%2520enzyme%2520inhibitors%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D55%26spage%3D149%26epage%3D192%26doi%3D10.1016%2Fbs.pmch.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span> </span><span class="NLM_article-title">Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1041</span><span class="NLM_x">–</span> <span class="NLM_lpage">1054</span><span class="refDoi"> DOI: 10.1016/S0092-8674(02)01199-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2FS0092-8674%2802%2901199-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=12507430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1Kiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2002&pages=1041-1054&author=M.+Huauthor=P.+Liauthor=M.+Liauthor=W.+Liauthor=T.+Yaoauthor=J.+W.+Wuauthor=W.+Guauthor=R.+E.+Cohenauthor=Y.+Shi&title=Crystal+structure+of+a+UBP-family+deubiquitinating+enzyme+in+isolation+and+in+complex+with+ubiquitin+aldehyde&doi=10.1016%2FS0092-8674%2802%2901199-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde</span></div><div class="casAuthors">Hu, Min; Li, Pingwei; Li, Muyang; Li, Wenyu; Yao, Tingting; Wu, Jia-Wei; Gu, Wei; Cohen, Robert E.; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1041-1054</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The ubiquitin-specific processing protease (UBP) family of deubiquitinating enzymes plays an essential role in numerous cellular processes.  HAUSP, a representative UBP, specifically deubiquitinates and hence stabilizes the tumor suppressor protein p53.  Here, we report the crystal structures of the 40 kDa catalytic core domain of HAUSP in isolation and in complex with ubiquitin aldehyde.  These studies reveal that the UBP deubiquitinating enzymes exhibit a conserved three-domain architecture, comprising Fingers, Palm, and Thumb.  The leaving ubiquitin moiety is specifically coordinated by the Fingers, with its C terminus placed in the active site between the Palm and the Thumb.  Binding by ubiquitin aldehyde induces a drastic conformational change in the active site that realigns the catalytic triad residues for catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqIQcIuHlub7Vg90H21EOLACvtfcHk0lhiHxu1QYQAUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1Kiug%253D%253D&md5=5f781c94cc2e89f6776533ae0ca3df03</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2901199-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252901199-6%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%2BW.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DCohen%26aufirst%3DR.%2BE.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DCrystal%2520structure%2520of%2520a%2520UBP-family%2520deubiquitinating%2520enzyme%2520in%2520isolation%2520and%2520in%2520complex%2520with%2520ubiquitin%2520aldehyde%26jtitle%3DCell%26date%3D2002%26volume%3D111%26spage%3D1041%26epage%3D1054%26doi%3D10.1016%2FS0092-8674%2802%2901199-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Komander, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clague, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbe, S.</span><span> </span><span class="NLM_article-title">Breaking the chains: structure and function of the deubiquitinases</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">563</span><span class="refDoi"> DOI: 10.1038/nrm2731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrm2731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=19626045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFSru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=550-563&author=D.+Komanderauthor=M.+J.+Clagueauthor=S.+Urbe&title=Breaking+the+chains%3A+structure+and+function+of+the+deubiquitinases&doi=10.1038%2Fnrm2731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Breaking the chains: structure and function of the deubiquitinases</span></div><div class="casAuthors">Komander, David; Clague, Michael J.; Urbe, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">550-563</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ubiquitination is a reversible protein modification that is implicated in many cellular functions.  Recently, much progress has been made in the characterization of a superfamily of isopeptidases that remove ubiquitin: the deubiquitinases (DUBs; also known as deubiquitinating enzymes).  Far from being uniform in structure and function, these enzymes display a myriad of distinct mechanistic features.  The small no. (<100) of DUBs might at 1st suggest a low degree of selectivity; however, DUBs are subject to multiple layers of regulation that modulate both their activity and their specificity.  Due to their wide-ranging involvement in key regulatory processes, these enzymes might provide new therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8Woj6hOAP5rVg90H21EOLACvtfcHk0lijI5Ut41RHzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFSru74%253D&md5=9268e6c24101ff8137937a5c851d5bb8</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnrm2731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2731%26sid%3Dliteratum%253Aachs%26aulast%3DKomander%26aufirst%3DD.%26aulast%3DClague%26aufirst%3DM.%2BJ.%26aulast%3DUrbe%26aufirst%3DS.%26atitle%3DBreaking%2520the%2520chains%253A%2520structure%2520and%2520function%2520of%2520the%2520deubiquitinases%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2009%26volume%3D10%26spage%3D550%26epage%3D563%26doi%3D10.1038%2Fnrm2731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Dang, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melandri, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R. L.</span><span> </span><span class="NLM_article-title">Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1868</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span><span class="refDoi"> DOI: 10.1021/bi9723360</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi9723360" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADyaK1cXms1OjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=1868-1879&author=L.+C.+Dangauthor=F.+D.+Melandriauthor=R.+L.+Stein&title=Kinetic+and+mechanistic+studies+on+the+hydrolysis+of+ubiquitin+C-terminal+7-amido-4-methylcoumarin+by+deubiquitinating+enzymes&doi=10.1021%2Fbi9723360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic and Mechanistic Studies on the Hydrolysis of Ubiquitin C-Terminal 7-Amido-4-Methylcoumarin by Deubiquitinating Enzymes</span></div><div class="casAuthors">Dang, Luan C.; Melandri, Francesco D.; Stein, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1868-1879</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Deubiquitinating enzymes constitute a family of cysteine hydrolases that specifically cleave ubiquitin-derived substrates of general structure Ub-X, where X can be any no. of leaving groups ranging from small thiols and amines to Ub and other proteins (Ub, ubiquitin).  We have developed a general assay for deubiquitinating enzymes based on the substrate ubiquitin C-terminal 7-amido-4-methylcoumarin (Ub-AMC).  Ub-AMC is efficiently hydrolyzed with liberation of highly fluorescent AMC by two rabbit reticulocyte deubiquitinating enzymes: isopeptidase T (IPaseT), a member of the gene family of ubiquitin-specific processing enzymes, and UCH-L3, a member of the family of ubiquitin C-terminal hydrolases.  We used this new assay to probe kinetic and mechanistic aspects of catalysis by IPaseT and UCH-L3.  Results from four series of expts. are discussed: (1) For UCH-L3, we detd. steady-state kinetic parameters that suggest a diffusion-limited reaction of UCH-L3 with Ub-AMC.  To probe this, we detd. the viscosity dependence of kc/Km, as well as kc.  We found complex viscosity dependencies and interpreted these in the context of a model in which assocn. and acylation are viscosity-dependent but deacylation is viscosity-independent.  (2) The kinetics of inhibition of UCH-L3 by ubiquitin C-terminal aldehyde (Ub-H) were detd. and reveal a Ki that is less than 10-14 M.  Several mechanisms are considered to account for the extreme inhibition.  (3) The IPaseT-catalyzed hydrolysis of Ub-AMC is modulated by Ub with activation at low [Ub] and inhibition at high [Ub].  (4) Finally, we compare kc/Km values for deubiquitinating enzyme-catalyzed hydrolysis of Ub-AMC and Z-Leu-Arg-Gly-Gly-AMC.  For IPaseT, the ratio of rate consts. is 104, while for UCH-L3 this ratio is >107.  These results suggest the following: (i) Deubiquitinating enzymes are able to utilize the free energy that is released from remote interactions with Ub-contg. substrates for stabilization of catalytic transition states, and (ii) UCHs are more efficient at utilizing the energy from these interactions, presumably because they do not possess a binding domain for a Ub "leaving group".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpMDRjOWV2LVg90H21EOLACvtfcHk0lijI5Ut41RHzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms1OjsA%253D%253D&md5=078fe0b916c22ef4ea7d4fc77aca75c1</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fbi9723360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9723360%26sid%3Dliteratum%253Aachs%26aulast%3DDang%26aufirst%3DL.%2BC.%26aulast%3DMelandri%26aufirst%3DF.%2BD.%26aulast%3DStein%26aufirst%3DR.%2BL.%26atitle%3DKinetic%2520and%2520mechanistic%2520studies%2520on%2520the%2520hydrolysis%2520of%2520ubiquitin%2520C-terminal%25207-amido-4-methylcoumarin%2520by%2520deubiquitinating%2520enzymes%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D1868%26epage%3D1879%26doi%3D10.1021%2Fbi9723360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Hassiepen, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eidhoff, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meder, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulber, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodendorf, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorthiois, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martoglio, B.</span><span> </span><span class="NLM_article-title">A sensitive fluorescence intensity assay for deubiquitinating proteases using ubiquitin-rhodamine110-glycine as substrate</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span><span class="refDoi"> DOI: 10.1016/j.ab.2007.07.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.ab.2007.07.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=17869210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1GlurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2007&pages=201-207&author=U.+Hassiepenauthor=U.+Eidhoffauthor=G.+Mederauthor=J.+F.+Bulberauthor=A.+Heinauthor=U.+Bodendorfauthor=E.+Lorthioisauthor=B.+Martoglio&title=A+sensitive+fluorescence+intensity+assay+for+deubiquitinating+proteases+using+ubiquitin-rhodamine110-glycine+as+substrate&doi=10.1016%2Fj.ab.2007.07.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">A sensitive fluorescence intensity assay for deubiquitinating proteases using ubiquitin-rhodamine110-glycine as substrate</span></div><div class="casAuthors">Hassiepen, Ulrich; Eidhoff, Ulf; Meder, Gabriele; Bulber, Jean-Francois; Hein, Andreas; Bodendorf, Ursula; Lorthiois, Edwige; Martoglio, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-207</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The dynamic modification of proteins with ubiquitin is a key regulation paradigm in eukaryotic cells that controls stability, localization, and function of the vast majority of intracellular proteins.  Here we describe a robust fluorescence intensity assay for monitoring the enzymic activity of deubiquitinating proteases, which reverse ubiquitin modifications and comprise over 100 members in humans.  The assay was developed for the catalytic domain of human ubiquitin-specific protease 2 (USP2) and human ubiquitin carboxyterminal hydrolase L3 (UCH-L3), and makes use of the novel substrate ubiquitin-rhodamine110-glycine.  The latter combines the advantages of a high dynamic range and beneficial optical properties.  Its enzymic behavior is characterized by the kinetic consts. Km = 1.5 μM, kcat = 0.53 s-1 and kcat/Km = 3.5×105 M-1 s-1 for USP2 and Km = 34 nM, kcat = 4.72 s-1, and kcat/Km = 1.4×108 M-1 s-1 for UCH-L3.  This new assay is suitable for inhibitor screening and characterizations, and has been established for the 384-well plate format using protease concns. of 120 pM for USP2 and 1 pM for UCH-L3 and substrate concns. of 100 nM for both enzymes.  Due to the low protease concns. and high sensitivity, this assay would allow the detn. of inhibitory consts. in the subnanomolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2_cU_l6AT7Vg90H21EOLACvtfcHk0lijI5Ut41RHzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1GlurjK&md5=e9a430d206d99d4b8bef17030139e61a</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2007.07.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2007.07.034%26sid%3Dliteratum%253Aachs%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DEidhoff%26aufirst%3DU.%26aulast%3DMeder%26aufirst%3DG.%26aulast%3DBulber%26aufirst%3DJ.%2BF.%26aulast%3DHein%26aufirst%3DA.%26aulast%3DBodendorf%26aufirst%3DU.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DMartoglio%26aufirst%3DB.%26atitle%3DA%2520sensitive%2520fluorescence%2520intensity%2520assay%2520for%2520deubiquitinating%2520proteases%2520using%2520ubiquitin-rhodamine110-glycine%2520as%2520substrate%26jtitle%3DAnal.%2520Biochem.%26date%3D2007%26volume%3D371%26spage%3D201%26epage%3D207%26doi%3D10.1016%2Fj.ab.2007.07.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Orcutt, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eddins, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickler, J. E.</span><span> </span><span class="NLM_article-title">Bioluminescence assay platform for selective and sensitive detection of Ub/Ubl proteases</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1823</span><span class="NLM_x">, </span> <span class="NLM_fpage">2079</span><span class="NLM_x">–</span> <span class="NLM_lpage">2086</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2012.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.bbamcr.2012.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22705352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVOrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1823&publication_year=2012&pages=2079-2086&author=S.+J.+Orcuttauthor=J.+Wuauthor=M.+J.+Eddinsauthor=C.+A.+Leachauthor=J.+E.+Strickler&title=Bioluminescence+assay+platform+for+selective+and+sensitive+detection+of+Ub%2FUbl+proteases&doi=10.1016%2Fj.bbamcr.2012.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Bioluminescence assay platform for selective and sensitive detection of Ub/Ubl proteases</span></div><div class="casAuthors">Orcutt, Steven J.; Wu, Jian; Eddins, Michael J.; Leach, Craig A.; Strickler, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1823</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2079-2086</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As the importance of ubiquitylation in certain disease states becomes increasingly apparent, the enzymes responsible for removal of ubiquitin (Ub) from target proteins, deubiquitylases (DUBs), are becoming attractive targets for drug discovery.  For rapid identification of compds. that alter DUB function, in vitro assays must be able to provide statistically robust data over a wide dynamic range of both substrate and enzyme concns. during high throughput screening HTS.  The most established reagents for HTS are Ubs with a quenched fluorophore conjugated to the C-terminus; however, a luciferase-based strategy for detecting DUB activity (DUB-Glo, Promega) provides a wider dynamic range than traditional fluorogenic reagents.  Unfortunately, this assay requires high enzyme concns. and lacks specificity for DUBs over other isopeptidases, e.g., desumoylases, as it is based on an aminoluciferin AML deriv. of a peptide derived from the C-terminus of Ub (Z-RLRGG-).  Conjugation of aminoluciferin to a full-length Ub, Ub-AML yields a substrate that has a wide dynamic range, yet displays detection limits for DUBs 100- to 1000-fold lower than obsd. with DUB-Glo.  Ub-AML was even a sensitive substrate for DUBs (e.g., JosD1 and USP14) that do not show appreciable activity with DUB-Glo.  Aminoluciferin derivs. of hSUMO2 and NEDD8 were also shown to be sensitive substrates for desumoylases and deneddylases, resp.  Ub/Ubl-AML substrates are amenable to HTS (Z' = 0.67) yielding robust signal, and providing an alternative drug discovery platform for Ub/Ubl isopeptidases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0tLNzEwt2ubVg90H21EOLACvtfcHk0lijI5Ut41RHzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVOrsbc%253D&md5=4b1e6e9a2e44f49e121c03bb8081842d</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2012.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2012.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DOrcutt%26aufirst%3DS.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DEddins%26aufirst%3DM.%2BJ.%26aulast%3DLeach%26aufirst%3DC.%2BA.%26aulast%3DStrickler%26aufirst%3DJ.%2BE.%26atitle%3DBioluminescence%2520assay%2520platform%2520for%2520selective%2520and%2520sensitive%2520detection%2520of%2520Ub%252FUbl%2520proteases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2012%26volume%3D1823%26spage%3D2079%26epage%3D2086%26doi%3D10.1016%2Fj.bbamcr.2012.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodrasov, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattern, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butt, T. R.</span><span> </span><span class="NLM_article-title">Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span><span class="refDoi"> DOI: 10.1110/ps.083450408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1110%2Fps.083450408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=18424514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvFKhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1035-1043&author=B.+Nicholsonauthor=C.+A.+Leachauthor=S.+J.+Goldenbergauthor=D.+M.+Francisauthor=M.+P.+Kodrasovauthor=X.+Tianauthor=J.+Shanksauthor=D.+E.+Sternerauthor=A.+Bernalauthor=M.+R.+Matternauthor=K.+D.+Wilkinsonauthor=T.+R.+Butt&title=Characterization+of+ubiquitin+and+ubiquitin-like-protein+isopeptidase+activities&doi=10.1110%2Fps.083450408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities</span></div><div class="casAuthors">Nicholson, Benjamin; Leach, Craig A.; Goldenberg, Seth J.; Francis, Dana M.; Kodrasov, Matthew P.; Tian, Xufan; Shanks, John; Sterner, David E.; Bernal, Alejandro; Mattern, Michael R.; Wilkinson, Keith D.; Butt, Tauseef R.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1035-1043</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Conjugation or deconjugation of ubiquitin (Ub) or ubiquitin-like proteins (UBLs) to or from cellular proteins is a multifaceted and universal means of regulating cellular physiol., controlling the lifetime, localization, and activity of many crit. proteins.  Deconjugation of Ub or UBL from proteins is performed by a class of proteases called isopeptidases.  Herein is described a readily quantifiable novel isopeptidase assay platform consisting of Ub or UBL fused to the reporter enzyme phospholipase A2 (PLA2).  Isopeptidase activity releases PLA2, which cleaves its substrate, generating a signal that is linear with deubiquitylase (DUB) concn. and is able to discriminate DUB, deSUMOylase, deNEDDylase, and deISGylase activities.  The power and sensitivity of the UBL-PLA2 assay are demonstrated by its ability to differentiate the contrasting deISGylase and DUB activities of two coronavirus proteases: severe acute respiratory syndrome papain-like protease (SARS-CoV PLpro) and NL63 CoV papain-like protease 2 (PLP2).  Furthermore, direct comparisons with the current Ub-7-amino-4-methylcoumarin (Ub-AMC) assay demonstrated that the Ub-PLA2 assay is an effective tool for characterizing modulators of isopeptidase activity.  This observation was expanded by profiling the inhibitory activity of the nonselective isopeptidase inhibitor NSC 632839 against DUBs and deSUMOylases.  Taken together, these studies illustrate the utility of the reporter-based approach to measuring isopeptidase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8B_bxI25uwbVg90H21EOLACvtfcHk0ljeq9MXxn_jXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvFKhtLo%253D&md5=eae8fac2cc0e3c82aa7a75c982c635cd</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1110%2Fps.083450408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.083450408%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DLeach%26aufirst%3DC.%2BA.%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DFrancis%26aufirst%3DD.%2BM.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DShanks%26aufirst%3DJ.%26aulast%3DSterner%26aufirst%3DD.%2BE.%26aulast%3DBernal%26aufirst%3DA.%26aulast%3DMattern%26aufirst%3DM.%2BR.%26aulast%3DWilkinson%26aufirst%3DK.%2BD.%26aulast%3DButt%26aufirst%3DT.%2BR.%26atitle%3DCharacterization%2520of%2520ubiquitin%2520and%2520ubiquitin-like-protein%2520isopeptidase%2520activities%26jtitle%3DProtein%2520Sci.%26date%3D2008%26volume%3D17%26spage%3D1035%26epage%3D1043%26doi%3D10.1110%2Fps.083450408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Tian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isamiddinova, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peroutka, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattern, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C.</span><span> </span><span class="NLM_article-title">Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span><span class="refDoi"> DOI: 10.1089/adt.2010.0317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1089%2Fadt.2010.0317" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=165-173&author=X.+Tianauthor=N.+S.+Isamiddinovaauthor=R.+J.+Peroutkaauthor=S.+J.+Goldenbergauthor=M.+R.+Matternauthor=B.+Nicholsonauthor=C.+Leach&title=Characterization+of+selective+ubiquitin+and+ubiquitin-like+protease+inhibitors+using+a+fluorescence-based+multiplex+assay+format&doi=10.1089%2Fadt.2010.0317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1089%2Fadt.2010.0317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2010.0317%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DX.%26aulast%3DIsamiddinova%26aufirst%3DN.%2BS.%26aulast%3DPeroutka%26aufirst%3DR.%2BJ.%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DMattern%26aufirst%3DM.%2BR.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DLeach%26aufirst%3DC.%26atitle%3DCharacterization%2520of%2520selective%2520ubiquitin%2520and%2520ubiquitin-like%2520protease%2520inhibitors%2520using%2520a%2520fluorescence-based%2520multiplex%2520assay%2520format%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2011%26volume%3D9%26spage%3D165%26epage%3D173%26doi%3D10.1089%2Fadt.2010.0317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Geurink, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Oualid, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hameed, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span> </span><span class="NLM_article-title">A general chemical ligation approach towards isopeptide-linked ubiquitin and ubiquitin-like assay reagents</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span><span class="refDoi"> DOI: 10.1002/cbic.201100706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1002%2Fcbic.201100706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22213387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1OiurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=293-297&author=P.+P.+Geurinkauthor=F.+El+Oualidauthor=A.+Jonkerauthor=D.+S.+Hameedauthor=H.+Ovaa&title=A+general+chemical+ligation+approach+towards+isopeptide-linked+ubiquitin+and+ubiquitin-like+assay+reagents&doi=10.1002%2Fcbic.201100706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">A General Chemical Ligation Approach Towards Isopeptide-Linked Ubiquitin and Ubiquitin-Like Assay Reagents</span></div><div class="casAuthors">Geurink, Paul P.; El Oualid, Farid; Jonker, Anika; Hameed, Dharjath S.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-297</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The 5-thiolysine-mediated ligation can be used to generate a wide range of isopeptide-linked ubiquitin Ub(I)-based FP (fluorescence anisotropy/flourescence polarization) assay reagents.  These are powerful tools for measuring Ub(I) deconjugating activity.  The methodol. can be adapted to any ubiquitin-like proteins (Ubl) for which the E1 enzyme is available.  In contrast to any other reagent, it is possible to incorporate substrate-based peptide sequences.  This is a major advantage, as it offers the possibility of more physiol. relevant assay reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqou4rjkVgI1rVg90H21EOLACvtfcHk0ljeq9MXxn_jXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1OiurrJ&md5=4c7d4048b95b1218a340123dd71d9716</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201100706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201100706%26sid%3Dliteratum%253Aachs%26aulast%3DGeurink%26aufirst%3DP.%2BP.%26aulast%3DEl%2BOualid%26aufirst%3DF.%26aulast%3DJonker%26aufirst%3DA.%26aulast%3DHameed%26aufirst%3DD.%2BS.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DA%2520general%2520chemical%2520ligation%2520approach%2520towards%2520isopeptide-linked%2520ubiquitin%2520and%2520ubiquitin-like%2520assay%2520reagents%26jtitle%3DChemBioChem%26date%3D2012%26volume%3D13%26spage%3D293%26epage%3D297%26doi%3D10.1002%2Fcbic.201100706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Bozza, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, Z.</span><span> </span><span class="NLM_article-title">Transient kinetic analysis of USP2-catalyzed deubiquitination reveals a conformational rearrangement in the K48-linked diubiquitin substrate</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">10075</span><span class="NLM_x">–</span> <span class="NLM_lpage">10086</span><span class="refDoi"> DOI: 10.1021/bi3009104</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi3009104" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=10075-10086&author=W.+P.+Bozzaauthor=Q.+Liangauthor=P.+Gongauthor=Z.+Zhuang&title=Transient+kinetic+analysis+of+USP2-catalyzed+deubiquitination+reveals+a+conformational+rearrangement+in+the+K48-linked+diubiquitin+substrate&doi=10.1021%2Fbi3009104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fbi3009104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi3009104%26sid%3Dliteratum%253Aachs%26aulast%3DBozza%26aufirst%3DW.%2BP.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DZhuang%26aufirst%3DZ.%26atitle%3DTransient%2520kinetic%2520analysis%2520of%2520USP2-catalyzed%2520deubiquitination%2520reveals%2520a%2520conformational%2520rearrangement%2520in%2520the%2520K48-linked%2520diubiquitin%2520substrate%26jtitle%3DBiochemistry%26date%3D2012%26volume%3D51%26spage%3D10075%26epage%3D10086%26doi%3D10.1021%2Fbi3009104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Ritorto, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Oliva, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knebel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wightman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virdee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrice, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trost, M.</span><span> </span><span class="NLM_article-title">Screening of DUB activity and specificity by MALDI-TOF mass spectrometry</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">4763</span><span class="refDoi"> DOI: 10.1038/ncomms5763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fncomms5763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25159004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFentro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4763&author=M.+S.+Ritortoauthor=R.+Ewanauthor=A.+B.+Perez-Olivaauthor=A.+Knebelauthor=S.+J.+Buhrlageauthor=M.+Wightmanauthor=S.+M.+Kellyauthor=N.+T.+Woodauthor=S.+Virdeeauthor=N.+S.+Grayauthor=N.+A.+Morriceauthor=D.+R.+Alessiauthor=M.+Trost&title=Screening+of+DUB+activity+and+specificity+by+MALDI-TOF+mass+spectrometry&doi=10.1038%2Fncomms5763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Screening of DUB activity and specificity by MALDI-TOF mass spectrometry</span></div><div class="casAuthors">Ritorto, Maria Stella; Ewan, Richard; Perez-Oliva, Ana B.; Knebel, Axel; Buhrlage, Sara J.; Wightman, Melanie; Kelly, Sharon M.; Wood, Nicola T.; Virdee, Satpal; Gray, Nathanael S.; Morrice, Nicholas A.; Alessi, Dario R.; Trost, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4763</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Deubiquitylases (DUBs) are key regulators of the ubiquitin system which cleave ubiquitin moieties from proteins and polyubiquitin chains.  Several DUBs have been implicated in various diseases and are attractive drug targets.  We have developed a sensitive and fast assay to quantify in vitro DUB enzyme activity using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.  Unlike other current assays, this method uses unmodified substrates, such as diubiquitin topoisomers.  By analyzing 42 human DUBs against all diubiquitin topoisomers we provide an extensive characterization of DUB activity and specificity.  Our results confirm the high specificity of many members of the OTU and JAB/MPN/Mov34 metalloenzyme DUB families and highlight that all USPs tested display low linkage selectivity.  We also demonstrate that this assay can be deployed to assess the potency and specificity of DUB inhibitors by profiling 11 compds. against a panel of 32 DUBs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf9lg-hgw78rVg90H21EOLACvtfcHk0lgRCHpviwtx3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFentro%253D&md5=614edc01e83206811d3e27a2ca11ae3b</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fncomms5763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms5763%26sid%3Dliteratum%253Aachs%26aulast%3DRitorto%26aufirst%3DM.%2BS.%26aulast%3DEwan%26aufirst%3DR.%26aulast%3DPerez-Oliva%26aufirst%3DA.%2BB.%26aulast%3DKnebel%26aufirst%3DA.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DWightman%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DS.%2BM.%26aulast%3DWood%26aufirst%3DN.%2BT.%26aulast%3DVirdee%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DMorrice%26aufirst%3DN.%2BA.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DTrost%26aufirst%3DM.%26atitle%3DScreening%2520of%2520DUB%2520activity%2520and%2520specificity%2520by%2520MALDI-TOF%2520mass%2520spectrometry%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D4763%26doi%3D10.1038%2Fncomms5763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Altun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willems, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konietzny, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackeen, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGouran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoronenkova, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dianov, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, B. M.</span><span> </span><span class="NLM_article-title">Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1412</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2011.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.chembiol.2011.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22118674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFeqs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1401-1412&author=M.+Altunauthor=H.+B.+Kramerauthor=L.+I.+Willemsauthor=J.+L.+McDermottauthor=C.+A.+Leachauthor=S.+J.+Goldenbergauthor=K.+G.+Kumarauthor=R.+Konietznyauthor=R.+Fischerauthor=E.+Koganauthor=M.+M.+Mackeenauthor=J.+McGouranauthor=S.+V.+Khoronenkovaauthor=J.+L.+Parsonsauthor=G.+L.+Dianovauthor=B.+Nicholsonauthor=B.+M.+Kessler&title=Activity-based+chemical+proteomics+accelerates+inhibitor+development+for+deubiquitylating+enzymes&doi=10.1016%2Fj.chembiol.2011.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes</span></div><div class="casAuthors">Altun, Mikael; Kramer, Holger B.; Willems, Lianne I.; McDermott, Jeffrey L.; Leach, Craig A.; Goldenberg, Seth J.; Kumar, K. G. Suresh; Konietzny, Rebecca; Fischer, Roman; Kogan, Edward; Mackeen, Mukram M.; McGouran, Joanna; Khoronenkova, Svetlana V.; Parsons, Jason L.; Dianov, Grigory L.; Nicholson, Benjamin; Kessler, Benedikt M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1401-1412</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Converting lead compds. into drug candidates is a crucial step in drug development, requiring early assessment of potency, selectivity, and off-target effects.  We have utilized activity-based chem. proteomics to det. the potency and selectivity of deubiquitylating enzyme (DUB) inhibitors in cell culture models.  Importantly, we characterized the small mol. PR-619 as a broad-range DUB inhibitor, and P22077 as a USP7 inhibitor with potential for further development as a chemotherapeutic agent in cancer therapy.  A striking accumulation of polyubiquitylated proteins was obsd. after both selective and general inhibition of cellular DUB activity without direct impairment of proteasomal proteolysis.  The repertoire of ubiquitylated substrates was analyzed by tandem mass spectrometry, identifying distinct subsets for general or specific inhibition of DUBs.  This enabled identification of previously unknown functional links between USP7 and enzymes involved in DNA repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK4Gf8r60zILVg90H21EOLACvtfcHk0lgRCHpviwtx3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFeqs7nP&md5=6988660c27e71f2e92d021de887b720d</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DH.%2BB.%26aulast%3DWillems%26aufirst%3DL.%2BI.%26aulast%3DMcDermott%26aufirst%3DJ.%2BL.%26aulast%3DLeach%26aufirst%3DC.%2BA.%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DKumar%26aufirst%3DK.%2BG.%26aulast%3DKonietzny%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DR.%26aulast%3DKogan%26aufirst%3DE.%26aulast%3DMackeen%26aufirst%3DM.%2BM.%26aulast%3DMcGouran%26aufirst%3DJ.%26aulast%3DKhoronenkova%26aufirst%3DS.%2BV.%26aulast%3DParsons%26aufirst%3DJ.%2BL.%26aulast%3DDianov%26aufirst%3DG.%2BL.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26atitle%3DActivity-based%2520chemical%2520proteomics%2520accelerates%2520inhibitor%2520development%2520for%2520deubiquitylating%2520enzymes%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D1401%26epage%3D1412%26doi%3D10.1016%2Fj.chembiol.2011.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Jafari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almqvist, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelsson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ignatushchenko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundback, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordlund, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez Molina, D.</span><span> </span><span class="NLM_article-title">The cellular thermal shift assay for evaluating drug target interactions in cells</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2100</span><span class="NLM_x">–</span> <span class="NLM_lpage">2122</span><span class="refDoi"> DOI: 10.1038/nprot.2014.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnprot.2014.138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25101824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2100-2122&author=R.+Jafariauthor=H.+Almqvistauthor=H.+Axelssonauthor=M.+Ignatushchenkoauthor=T.+Lundbackauthor=P.+Nordlundauthor=D.+Martinez+Molina&title=The+cellular+thermal+shift+assay+for+evaluating+drug+target+interactions+in+cells&doi=10.1038%2Fnprot.2014.138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">The cellular thermal shift assay for evaluating drug target interactions in cells</span></div><div class="casAuthors">Jafari, Rozbeh; Almqvist, Helena; Axelsson, Hanna; Ignatushchenko, Marina; Lundbaeck, Thomas; Nordlund, Paer; Molina, Daniel Martinez</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2100-2122</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thermal shift assays are used to study thermal stabilization of proteins upon ligand binding.  Such assays have been used extensively on purified proteins in the drug discovery industry and in academia to detect interactions.  Recently, we published a proof-of-principle study describing the implementation of thermal shift assays in a cellular format, which we call the cellular thermal shift assay (CETSA).  The method allows studies of target engagement of drug candidates in a cellular context, herein exemplified with exptl. data on the human kinases p38α and ERK1/2.  The assay involves treatment of cells with a compd. of interest, heating to denature and ppt. proteins, cell lysis, and the sepn. of cell debris and aggregates from the sol. protein fraction.  Whereas unbound proteins denature and ppt. at elevated temps., ligand-bound proteins remain in soln.  We describe two procedures for detecting the stabilized protein in the sol. fraction of the samples.  One approach involves sample workup and detection using quant. western blotting, whereas the second is performed directly in soln. and relies on the induced proximity of two target-directed antibodies upon binding to sol. protein.  The latter protocol has been optimized to allow an increased throughput, as potential applications require large nos. of samples.  Both approaches can be completed in a day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzarqomAK6eLVg90H21EOLACvtfcHk0lhtywYmBed5QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12msrfJ&md5=e7852e1a306bca1698a8e8463ae566b1</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2014.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2014.138%26sid%3Dliteratum%253Aachs%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DAlmqvist%26aufirst%3DH.%26aulast%3DAxelsson%26aufirst%3DH.%26aulast%3DIgnatushchenko%26aufirst%3DM.%26aulast%3DLundback%26aufirst%3DT.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DMartinez%2BMolina%26aufirst%3DD.%26atitle%3DThe%2520cellular%2520thermal%2520shift%2520assay%2520for%2520evaluating%2520drug%2520target%2520interactions%2520in%2520cells%26jtitle%3DNat.%2520Protoc.%26date%3D2014%26volume%3D9%26spage%3D2100%26epage%3D2122%26doi%3D10.1038%2Fnprot.2014.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Colland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Formstecher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacq, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reverdy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planquette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trouplin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aushev, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camonis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg-Capra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sippl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boissy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedat, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delansorne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daviet, L.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2286</span><span class="NLM_x">–</span> <span class="NLM_lpage">2295</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1158%2F1535-7163.MCT-09-0097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=19671755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2286-2295&author=F.+Collandauthor=E.+Formstecherauthor=X.+Jacqauthor=C.+Reverdyauthor=C.+Planquetteauthor=S.+Conrathauthor=V.+Trouplinauthor=J.+Bianchiauthor=V.+N.+Aushevauthor=J.+Camonisauthor=A.+Calabreseauthor=C.+Borg-Capraauthor=W.+Sipplauthor=V.+Colluraauthor=G.+Boissyauthor=J.+C.+Rainauthor=P.+Guedatauthor=R.+Delansorneauthor=L.+Daviet&title=Small-molecule+inhibitor+of+USP7%2FHAUSP+ubiquitin+protease+stabilizes+and+activates+p53+in+cells&doi=10.1158%2F1535-7163.MCT-09-0097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells</span></div><div class="casAuthors">Colland, Frederic; Formstecher, Etienne; Jacq, Xavier; Reverdy, Celine; Planquette, Cecile; Conrath, Susan; Trouplin, Virginie; Bianchi, Julie; Aushev, Vasily N.; Camonis, Jacques; Calabrese, Alessandra; Borg-Capra, Catherine; Sippl, Wolfgang; Collura, Vincent; Boissy, Guillaume; Rain, Jean-Christophe; Guedat, Philippe; Delansorne, Remi; Daviet, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2286-2295</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulation of the ubiquitin/proteasome system has been implicated in the pathogenesis of many human diseases, including cancer.  Ubiquitin-specific proteases (USP) are cysteine proteases involved in the deubiquitination of protein substrates.  Functional connections between USP7 and essential viral proteins and oncogenic pathways, such as the p53/Mdm2 and phosphatidylinositol 3-kinase/protein kinase B networks, strongly suggest that the targeting of USP7 with small-mol. inhibitors may be useful for the treatment of cancers and viral diseases.  Using high-throughput screening, we have discovered HBX 41,108, a small-mol. compd. that inhibits USP7 deubiquitinating activity with an IC50 in the submicromolar range.  Kinetics data indicate an uncompetitive reversible inhibition mechanism.  HBX 41,108 was shown to affect USP7-mediated p53 deubiquitination in vitro and in cells.  As RNA interference-mediated USP7 silencing in cancer cells, HBX 41,108 treatment stabilized p53, activated the transcription of a p53 target gene without inducing genotoxic stress, and inhibited cancer cell growth.  Finally, HBX 41,108 induced p53-dependent apoptosis as shown in p53 wild-type and null isogenic cancer cell lines.  We thus report the identification of the first lead-like inhibitor against USP7, providing a structural basis for the development of new anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN5f2O-cNWmbVg90H21EOLACvtfcHk0lhtywYmBed5QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCmsrw%253D&md5=bb84e2bd3cf54d0a6842b39e2784eea9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0097%26sid%3Dliteratum%253Aachs%26aulast%3DColland%26aufirst%3DF.%26aulast%3DFormstecher%26aufirst%3DE.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DReverdy%26aufirst%3DC.%26aulast%3DPlanquette%26aufirst%3DC.%26aulast%3DConrath%26aufirst%3DS.%26aulast%3DTrouplin%26aufirst%3DV.%26aulast%3DBianchi%26aufirst%3DJ.%26aulast%3DAushev%26aufirst%3DV.%2BN.%26aulast%3DCamonis%26aufirst%3DJ.%26aulast%3DCalabrese%26aufirst%3DA.%26aulast%3DBorg-Capra%26aufirst%3DC.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DCollura%26aufirst%3DV.%26aulast%3DBoissy%26aufirst%3DG.%26aulast%3DRain%26aufirst%3DJ.%2BC.%26aulast%3DGuedat%26aufirst%3DP.%26aulast%3DDelansorne%26aufirst%3DR.%26aulast%3DDaviet%26aufirst%3DL.%26atitle%3DSmall-molecule%2520inhibitor%2520of%2520USP7%252FHAUSP%2520ubiquitin%2520protease%2520stabilizes%2520and%2520activates%2520p53%2520in%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2286%26epage%3D2295%26doi%3D10.1158%2F1535-7163.MCT-09-0097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peretto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacq, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedat, P.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">552</span><span class="NLM_x">–</span> <span class="NLM_lpage">558</span><span class="refDoi"> DOI: 10.1002/cmdc.200900409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1002%2Fcmdc.200900409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20186914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFyqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=552-558&author=M.+Colomboauthor=S.+Valleseauthor=I.+Perettoauthor=X.+Jacqauthor=J.+C.+Rainauthor=F.+Collandauthor=P.+Guedat&title=Synthesis+and+biological+evaluation+of+9-oxo-9H-indeno%5B1%2C2-b%5Dpyrazine-2%2C3-dicarbonitrile+analogues+as+potential+inhibitors+of+deubiquitinating+enzymes&doi=10.1002%2Fcmdc.200900409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile Analogues as Potential Inhibitors of Deubiquitinating Enzymes</span></div><div class="casAuthors">Colombo, Matteo; Vallese, Stefania; Peretto, Ilaria; Jacq, Xavier; Rain, Jean-Christophe; Colland, Frederic; Guedat, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">552-558</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">High-throughput screening highlighted 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile (1) as an active inhibitor of ubiquitin-specific proteases (USPs), a family of hydrolytic enzymes involved in the removal of ubiquitin from protein substrates.  The chem. behavior of compd. 1 was examd.  Moreover, the synthesis and in vitro evaluation of new compds., analogs of 1, led to the identification of potent and selective inhibitors of the deubiquitinating enzyme USP8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG5ve4XfTip7Vg90H21EOLACvtfcHk0lhtywYmBed5QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFyqt7k%253D&md5=b30b6569922a1eac1ab8b5d011ea0d21</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900409%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DVallese%26aufirst%3DS.%26aulast%3DPeretto%26aufirst%3DI.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DRain%26aufirst%3DJ.%2BC.%26aulast%3DColland%26aufirst%3DF.%26aulast%3DGuedat%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25209-oxo-9H-indeno%255B1%252C2-b%255Dpyrazine-2%252C3-dicarbonitrile%2520analogues%2520as%2520potential%2520inhibitors%2520of%2520deubiquitinating%2520enzymes%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D552%26epage%3D558%26doi%3D10.1002%2Fcmdc.200900409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Lopez, R.; Collura, V.; Wolfgang, S.; Colland, F.</span><span> </span><span class="NLM_article-title">Novel Specific Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions thereof and their Therapeutic Applications</span>. International Patent WO2010081783,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=R.+Lopez&author=V.+Collura&author=S.+Wolfgang&author=F.+Colland&title=Novel+Specific+Inhibitors+of+Ubiquitin+Specific+Protease+7%2C+the+Pharmaceutical+Compositions+thereof+and+their+Therapeutic+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DR.%26atitle%3DNovel%2520Specific%2520Inhibitors%2520of%2520Ubiquitin%2520Specific%2520Protease%25207%252C%2520the%2520Pharmaceutical%2520Compositions%2520thereof%2520and%2520their%2520Therapeutic%2520Applications%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Reverdy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planquette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atmanene, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivat, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sippl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colland, F.</span><span> </span><span class="NLM_article-title">Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.chembiol.2012.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22520753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFyruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=467-477&author=C.+Reverdyauthor=S.+Conrathauthor=R.+Lopezauthor=C.+Planquetteauthor=C.+Atmaneneauthor=V.+Colluraauthor=J.+Harponauthor=V.+Battagliaauthor=V.+Vivatauthor=W.+Sipplauthor=F.+Colland&title=Discovery+of+specific+inhibitors+of+human+USP7%2FHAUSP+deubiquitinating+enzyme&doi=10.1016%2Fj.chembiol.2012.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Specific Inhibitors of Human USP7/HAUSP Deubiquitinating Enzyme</span></div><div class="casAuthors">Reverdy, Celine; Conrath, Susan; Lopez, Roman; Planquette, Cecile; Atmanene, Cedric; Collura, Vincent; Harpon, Jane; Battaglia, Veronique; Vivat, Valerie; Sippl, Wolfgang; Colland, Frederic</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">467-477</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The human USP7 deubiquitinating enzyme was shown to regulate many proteins involved in the cell cycle, as well as tumor suppressors and oncogenes.  Thus, USP7 offers a promising, strategic target for cancer therapy.  Using biochem. assays and activity-based protein profiling in living systems, we identified small-mol. antagonists of USP7 and demonstrated USP7 inhibitor occupancy and selectivity in cancer cell lines.  These compds. bind USP7 in the active site through a covalent mechanism.  In cancer cells, these active-site-targeting inhibitors were shown to regulate the level of several USP7 substrates and thus recapitulated the USP7 knockdown phenotype that leads to G1 arrest in colon cancer cells.  The data presented in this report provide proof of principle that USP7 inhibitors may be a valuable therapeutic for cancer.  In addn., the discovery of such mols. offers interesting tools for studying deubiquitination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt0GVteDWstbVg90H21EOLACvtfcHk0lgJ1KqKhNNfEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFyruro%253D&md5=f5e3497c9893342571e3c97ae85d1361</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DReverdy%26aufirst%3DC.%26aulast%3DConrath%26aufirst%3DS.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DPlanquette%26aufirst%3DC.%26aulast%3DAtmanene%26aufirst%3DC.%26aulast%3DCollura%26aufirst%3DV.%26aulast%3DHarpon%26aufirst%3DJ.%26aulast%3DBattaglia%26aufirst%3DV.%26aulast%3DVivat%26aufirst%3DV.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DColland%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520specific%2520inhibitors%2520of%2520human%2520USP7%252FHAUSP%2520deubiquitinating%2520enzyme%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D467%26epage%3D477%26doi%3D10.1016%2Fj.chembiol.2012.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Menard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulea, T.</span><span> </span><span class="NLM_article-title">Selective inhibition of USP7</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">438</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.chembiol.2012.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=22520747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFylurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=437-438&author=R.+Menardauthor=T.+Sulea&title=Selective+inhibition+of+USP7&doi=10.1016%2Fj.chembiol.2012.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of USP7</span></div><div class="casAuthors">Menard, Robert; Sulea, Traian</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-438</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The deubiquitinating enzyme USP7 is an emerging oncol. and antiviral target.  Reverdy et al., in this issue of Chem. & Biol., disclose the first small-mol. inhibitor selective for USP7, which recapitulates its knockdown in cancer cells and hence demonstrates the therapeutic feasibility of USP7 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPZVMDrXlaYLVg90H21EOLACvtfcHk0lgJ1KqKhNNfEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFylurs%253D&md5=46a1a0aa80568e64f60814d3184b370d</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DMenard%26aufirst%3DR.%26aulast%3DSulea%26aufirst%3DT.%26atitle%3DSelective%2520inhibition%2520of%2520USP7%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D437%26epage%3D438%26doi%3D10.1016%2Fj.chembiol.2012.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Colland, F.; Gourdel, M.-E.</span><span> </span><span class="NLM_article-title">Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7</span>. International Patent WO2013030218,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Colland&author=M.-E.+Gourdel&title=Selective+and+Reversible+Inhibitors+of+Ubiquitin+Specific+Protease+7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DColland%26aufirst%3DF.%26atitle%3DSelective%2520and%2520Reversible%2520Inhibitors%2520of%2520Ubiquitin%2520Specific%2520Protease%25207%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Kessler, B. M.</span><span> </span><span class="NLM_article-title">Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span><span class="refDoi"> DOI: 10.1517/13543776.2014.882320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1517%2F13543776.2014.882320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24456106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=597-602&author=B.+M.+Kessler&title=Selective+and+reversible+inhibitors+of+ubiquitin-specific+protease+7%3A+a+patent+evaluation+%28WO2013030218%29&doi=10.1517%2F13543776.2014.882320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218)</span></div><div class="casAuthors">Kessler, Benedikt M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">597-602</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The invention described in this review (WO2013030218) relates to compds. based on the quinazolin-4-one scaffold, their process of prepn. and applications to inhibit the ubiquitin-specific protease 7 (USP7), a deubiquitinating enzyme (DUB), which is considered a potentially important new drug target for treating cancer and immunol. disorders.  Data are presented indicating that these small-mol. compds. are useful as selective and reversible inhibitors of USP7 in vitro and also in a cellular context, although the panel of other enzymes tested was limited.  The synthesis strategy allows for the generation of a considerable variety of compds., although similar properties of selective USP7 inhibition were reported for other related compd. classes, thereby increasing the complexity of the patenting process.  However, structural patterns that contribute to the selectivity of USP7 and other DUB enzyme inhibition are starting to emerge.  Practical implications involve the treatment of cancer, neurodegenerative diseases, immunol. disorders, diabetes, bone and joint diseases, cardiovascular diseases and viral and bacterial infections.  The quality of these findings and a comparison to other compd. classes with similar properties, as well as the potential for further development toward clin. exploitation are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCEfdSzsMM37Vg90H21EOLACvtfcHk0lgJ1KqKhNNfEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu7c%253D&md5=a1dec5801ef0354471f799a8869fbfc4</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.882320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.882320%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DB.%2BM.%26atitle%3DSelective%2520and%2520reversible%2520inhibitors%2520of%2520ubiquitin-specific%2520protease%25207%253A%2520a%2520patent%2520evaluation%2520%2528WO2013030218%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D597%26epage%3D602%26doi%3D10.1517%2F13543776.2014.882320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Zaman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, S.</span><span> </span><span class="NLM_article-title">Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor necrosis factor alpha-induced apoptosis</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">4971</span><span class="NLM_x">–</span> <span class="NLM_lpage">4984</span><span class="refDoi"> DOI: 10.1128/MCB.00465-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1128%2FMCB.00465-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=24144979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FosVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=4971-4984&author=M.+M.+Zamanauthor=T.+Nomuraauthor=T.+Takagiauthor=T.+Okamuraauthor=W.+Jinauthor=T.+Shinagawaauthor=Y.+Tanakaauthor=S.+Ishii&title=Ubiquitination-deubiquitination+by+the+TRIM27-USP7+complex+regulates+tumor+necrosis+factor+alpha-induced+apoptosis&doi=10.1128%2FMCB.00465-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor necrosis factor alpha-induced apoptosis</span></div><div class="casAuthors">Zaman Mohammad Mahabub-Uz; Nomura Teruaki; Takagi Tsuyoshi; Okamura Tomoo; Jin Wanzhu; Shinagawa Toshie; Tanaka Yasunori; Ishii Shunsuke</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and cellular biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4971-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tumor necrosis factor alpha (TNF-α) plays a role in apoptosis and proliferation in multiple types of cells, and defects in TNF-α-induced apoptosis are associated with various autoimmune diseases.  Here, we show that TRIM27, a tripartite motif (TRIM) protein containing RING finger, B-box, and coiled-coil domains, positively regulates TNF-α-induced apoptosis.  Trim27-deficient mice are resistant to TNF-α-d-galactosamine-induced hepatocyte apoptosis.  Trim27-deficient mouse embryonic fibroblasts (MEFs) are also resistant to TNF-α-cycloheximide-induced apoptosis.  TRIM27 forms a complex with and ubiquitinates the ubiquitin-specific protease USP7, which deubiquitinates receptor-interacting protein 1 (RIP1), resulting in the positive regulation of TNF-α-induced apoptosis.  Our findings indicate that the ubiquitination-deubiquitination cascade mediated by the TRIM27-USP7 complex plays an important role in TNF-α-induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpTLZW3DBytnWEEzDrymxmfW6udTcc2ea0sjTkSUfizbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FosVKgtQ%253D%253D&md5=cdd23694f3168c85be13d6cc58a7e087</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1128%2FMCB.00465-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00465-13%26sid%3Dliteratum%253Aachs%26aulast%3DZaman%26aufirst%3DM.%2BM.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DOkamura%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DShinagawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DS.%26atitle%3DUbiquitination-deubiquitination%2520by%2520the%2520TRIM27-USP7%2520complex%2520regulates%2520tumor%2520necrosis%2520factor%2520alpha-induced%2520apoptosis%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2013%26volume%3D33%26spage%3D4971%26epage%3D4984%26doi%3D10.1128%2FMCB.00465-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, A. A.</span><span> </span><span class="NLM_article-title">Ubiquitin-specific protease 7 regulates nucleotide excision repair through deubiquitinating XPC protein and preventing XPC protein from undergoing ultraviolet light-induced and VCP/p97 protein-regulated proteolysis</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">27278</span><span class="NLM_x">–</span> <span class="NLM_lpage">27289</span><span class="refDoi"> DOI: 10.1074/jbc.M114.589812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1074%2Fjbc.M114.589812" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=27278-27289&author=J.+Heauthor=Q.+Zhuauthor=G.+Waniauthor=N.+Sharmaauthor=C.+Hanauthor=J.+Qianauthor=K.+Pentzauthor=Q.+E.+Wangauthor=A.+A.+Wani&title=Ubiquitin-specific+protease+7+regulates+nucleotide+excision+repair+through+deubiquitinating+XPC+protein+and+preventing+XPC+protein+from+undergoing+ultraviolet+light-induced+and+VCP%2Fp97+protein-regulated+proteolysis&doi=10.1074%2Fjbc.M114.589812"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.589812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.589812%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DWani%26aufirst%3DG.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DPentz%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DQ.%2BE.%26aulast%3DWani%26aufirst%3DA.%2BA.%26atitle%3DUbiquitin-specific%2520protease%25207%2520regulates%2520nucleotide%2520excision%2520repair%2520through%2520deubiquitinating%2520XPC%2520protein%2520and%2520preventing%2520XPC%2520protein%2520from%2520undergoing%2520ultraviolet%2520light-induced%2520and%2520VCP%252Fp97%2520protein-regulated%2520proteolysis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D27278%26epage%3D27289%26doi%3D10.1074%2Fjbc.M114.589812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, A. A.</span><span> </span><span class="NLM_article-title">USP7 modulates UV-induced PCNA monoubiquitination by regulating DNA polymerase eta stability</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">4791</span><span class="NLM_x">–</span> <span class="NLM_lpage">4796</span><span class="refDoi"> DOI: 10.1038/onc.2014.394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fonc.2014.394" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=4791-4796&author=J.+Qianauthor=K.+Pentzauthor=Q.+Zhuauthor=Q.+Wangauthor=J.+Heauthor=A.+K.+Srivastavaauthor=A.+A.+Wani&title=USP7+modulates+UV-induced+PCNA+monoubiquitination+by+regulating+DNA+polymerase+eta+stability&doi=10.1038%2Fonc.2014.394"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.394%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DPentz%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DSrivastava%26aufirst%3DA.%2BK.%26aulast%3DWani%26aufirst%3DA.%2BA.%26atitle%3DUSP7%2520modulates%2520UV-induced%2520PCNA%2520monoubiquitination%2520by%2520regulating%2520DNA%2520polymerase%2520eta%2520stability%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26spage%3D4791%26epage%3D4796%26doi%3D10.1038%2Fonc.2014.394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, A. A.</span><span> </span><span class="NLM_article-title">USP7 deubiquitinase promotes ubiquitin-dependent DNA damage signaling by stabilizing RNF168</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1413</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span><span class="refDoi"> DOI: 10.1080/15384101.2015.1007785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1080%2F15384101.2015.1007785" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1413-1425&author=Q.+Zhuauthor=N.+Sharmaauthor=J.+Heauthor=G.+Waniauthor=A.+A.+Wani&title=USP7+deubiquitinase+promotes+ubiquitin-dependent+DNA+damage+signaling+by+stabilizing+RNF168&doi=10.1080%2F15384101.2015.1007785"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1007785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1007785%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DWani%26aufirst%3DG.%26aulast%3DWani%26aufirst%3DA.%2BA.%26atitle%3DUSP7%2520deubiquitinase%2520promotes%2520ubiquitin-dependent%2520DNA%2520damage%2520signaling%2520by%2520stabilizing%2520RNF168%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26spage%3D1413%26epage%3D1425%26doi%3D10.1080%2F15384101.2015.1007785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Hirano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshitane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozuka-Hata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanjakornsiripan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukada, Y.</span><span> </span><span class="NLM_article-title">USP7 and TDP-43: pleiotropic regulation of cryptochrome protein stability paces the oscillation of the mammalian circadian clock</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0154263</span><span class="refDoi"> DOI: 10.1371/journal.pone.0154263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1371%2Fjournal.pone.0154263" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0154263&author=A.+Hiranoauthor=T.+Nakagawaauthor=H.+Yoshitaneauthor=M.+Oyamaauthor=H.+Kozuka-Hataauthor=D.+Lanjakornsiripanauthor=Y.+Fukada&title=USP7+and+TDP-43%3A+pleiotropic+regulation+of+cryptochrome+protein+stability+paces+the+oscillation+of+the+mammalian+circadian+clock&doi=10.1371%2Fjournal.pone.0154263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0154263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0154263%26sid%3Dliteratum%253Aachs%26aulast%3DHirano%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DYoshitane%26aufirst%3DH.%26aulast%3DOyama%26aufirst%3DM.%26aulast%3DKozuka-Hata%26aufirst%3DH.%26aulast%3DLanjakornsiripan%26aufirst%3DD.%26aulast%3DFukada%26aufirst%3DY.%26atitle%3DUSP7%2520and%2520TDP-43%253A%2520pleiotropic%2520regulation%2520of%2520cryptochrome%2520protein%2520stability%2520paces%2520the%2520oscillation%2520of%2520the%2520mammalian%2520circadian%2520clock%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0154263%26doi%3D10.1371%2Fjournal.pone.0154263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Lee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baek, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. G.</span><span> </span><span class="NLM_article-title">Herpesvirus-associated ubiquitin-specific protease (HAUSP) modulates peroxisome proliferator-activated receptor gamma (PPARgamma) stability through its deubiquitinating activity</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">32886</span><span class="NLM_x">–</span> <span class="NLM_lpage">32896</span><span class="refDoi"> DOI: 10.1074/jbc.M113.496331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1074%2Fjbc.M113.496331" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=32886-32896&author=K.+W.+Leeauthor=J.+G.+Choauthor=C.+M.+Kimauthor=A.+Y.+Kangauthor=M.+Kimauthor=B.+Y.+Ahnauthor=S.+S.+Chungauthor=K.+H.+Limauthor=K.+H.+Baekauthor=J.+H.+Sungauthor=K.+S.+Parkauthor=S.+G.+Park&title=Herpesvirus-associated+ubiquitin-specific+protease+%28HAUSP%29+modulates+peroxisome+proliferator-activated+receptor+gamma+%28PPARgamma%29+stability+through+its+deubiquitinating+activity&doi=10.1074%2Fjbc.M113.496331"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.496331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.496331%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DCho%26aufirst%3DJ.%2BG.%26aulast%3DKim%26aufirst%3DC.%2BM.%26aulast%3DKang%26aufirst%3DA.%2BY.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DB.%2BY.%26aulast%3DChung%26aufirst%3DS.%2BS.%26aulast%3DLim%26aufirst%3DK.%2BH.%26aulast%3DBaek%26aufirst%3DK.%2BH.%26aulast%3DSung%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DK.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BG.%26atitle%3DHerpesvirus-associated%2520ubiquitin-specific%2520protease%2520%2528HAUSP%2529%2520modulates%2520peroxisome%2520proliferator-activated%2520receptor%2520gamma%2520%2528PPARgamma%2529%2520stability%2520through%2520its%2520deubiquitinating%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D32886%26epage%3D32896%26doi%3D10.1074%2Fjbc.M113.496331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Lecona, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narendra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinberg, D.</span><span> </span><span class="NLM_article-title">USP7 cooperates with SCML2 to regulate the activity of PRC1</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1168</span><span class="refDoi"> DOI: 10.1128/MCB.01197-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1128%2FMCB.01197-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25605328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvFKgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1157-1168&author=E.+Leconaauthor=V.+Narendraauthor=D.+Reinberg&title=USP7+cooperates+with+SCML2+to+regulate+the+activity+of+PRC1&doi=10.1128%2FMCB.01197-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">USP7 cooperates with SCML2 to regulate the activity of PRC1</span></div><div class="casAuthors">Lecona, Emilio; Narendra, Varun; Reinberg, Danny</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1157-1168</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">USP7 is a protein deubiquitinase with an essential role in development.  Here, we provide evidence that USP7 regulates the activity of Polycomb repressive complex 1 (PRC1) in coordination with SCML2.  There are six versions of PRC1 defined by the assocn. of one of the PCGF homologues (PCGF1 to PCGF6) with the common catalytic subunit RING1B.  First, we show that SCML2, a Polycomb group protein that assocs. with PRC1.2 (contg. PCGF2/MEL18) and PRC1.4 (contg. PCGF4/ BMI1), modulates the localization of USP7 and bridges USP7 with PRC1.4, allowing for the stabilization of BMI1.  Chromatin immunopptn. (ChIP) expts. demonstrate that USP7 is found at SCML2 and BMI1 target genes.  Second, inhibition of USP7 leads to a redn. in the level of ubiquitinated histone H2A (H2Aub), the catalytic product of PRC1 and key for its repressive activity.  USP7 regulates the posttranslational status of RING1B and BMI1, a specific component of PRC1.4.  Thus, not only does USP7 stabilize PRC1 components, its catalytic activity is also necessary to maintain a functional PRC1, thereby ensuring appropriate levels of repressive H2Aub.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXtU7vBWEzwbVg90H21EOLACvtfcHk0ljLnQCY6l0VjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvFKgs7Y%253D&md5=5a0e624eb19f2228ab39ea5ab545a9bd</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1128%2FMCB.01197-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01197-14%26sid%3Dliteratum%253Aachs%26aulast%3DLecona%26aufirst%3DE.%26aulast%3DNarendra%26aufirst%3DV.%26aulast%3DReinberg%26aufirst%3DD.%26atitle%3DUSP7%2520cooperates%2520with%2520SCML2%2520to%2520regulate%2520the%2520activity%2520of%2520PRC1%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D1157%26epage%3D1168%26doi%3D10.1128%2FMCB.01197-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Weinstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingsbury, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodrasov, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKelvey, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suresh Kumar, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattern, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span> </span><span class="NLM_article-title">Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1021/ml200276j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200276j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=789-792&author=J.+Weinstockauthor=J.+Wuauthor=P.+Caoauthor=W.+D.+Kingsburyauthor=J.+L.+McDermottauthor=M.+P.+Kodrasovauthor=D.+M.+McKelveyauthor=K.+G.+Suresh+Kumarauthor=S.+J.+Goldenbergauthor=M.+R.+Matternauthor=B.+Nicholson&title=Selective+dual+inhibitors+of+the+cancer-related+deubiquitylating+proteases+USP7+and+USP47&doi=10.1021%2Fml200276j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fml200276j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200276j%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstock%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DKingsbury%26aufirst%3DW.%2BD.%26aulast%3DMcDermott%26aufirst%3DJ.%2BL.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DMcKelvey%26aufirst%3DD.%2BM.%26aulast%3DSuresh%2BKumar%26aufirst%3DK.%2BG.%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DMattern%26aufirst%3DM.%2BR.%26aulast%3DNicholson%26aufirst%3DB.%26atitle%3DSelective%2520dual%2520inhibitors%2520of%2520the%2520cancer-related%2520deubiquitylating%2520proteases%2520USP7%2520and%2520USP47%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D789%26epage%3D792%26doi%3D10.1021%2Fml200276j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Weinstock, J.; Wu, J.; Kumar, K. G. S.; Wang, F.; Kodrasov, M. P.; Agarwal, S.</span><span> </span><span class="NLM_article-title">Covalent Irreversible Inhibitors of USP7 as Anti-Cancer Agents</span>. International Patent WO2017023684,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+Weinstock&author=J.+Wu&author=K.+G.+S.+Kumar&author=F.+Wang&author=M.+P.+Kodrasov&author=S.+Agarwal&title=Covalent+Irreversible+Inhibitors+of+USP7+as+Anti-Cancer+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstock%26aufirst%3DJ.%26atitle%3DCovalent%2520Irreversible%2520Inhibitors%2520of%2520USP7%2520as%2520Anti-Cancer%2520Agents%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Ioannidis, S.; Talbot, A. C.; Follows, B.; Buckmelter, A. J.; Wang, M.; Campbell, A.-M.; Schmidt, D. R.; Guerin, D. J.; Caravella, J. A.; Diebold, R. B.; Ericsson, A.; Lancia, D.,  Jr.</span><span> </span><span class="NLM_article-title">Preparation of Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors</span>. International Patent WO2016109515,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ioannidis&author=A.+C.+Talbot&author=B.+Follows&author=A.+J.+Buckmelter&author=M.+Wang&author=A.-M.+Campbell&author=D.+R.+Schmidt&author=D.+J.+Guerin&author=J.+A.+Caravella&author=R.+B.+Diebold&author=A.+Ericsson&author=D.+Lancia&title=Preparation+of+Pyrrolo+and+Pyrazolopyrimidines+as+Ubiquitin-Specific+Protease+7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Pyrrolo%2520and%2520Pyrazolopyrimidines%2520as%2520Ubiquitin-Specific%2520Protease%25207%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Ioannidis, S.; Talbot, A. C.; Follows, B.; Buckmelter, A. J.; Wang, M.; Campbell, A.-M.; Schmidt, D. R.; Guerin, D. J.; Caravella, J. A.; Diebold, R. B.; Ericsson, A.; Lancia, D.,  Jr.</span><span> </span><span class="NLM_article-title">Preparation of Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors</span>. International Patent WO2016109480,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ioannidis&author=A.+C.+Talbot&author=B.+Follows&author=A.+J.+Buckmelter&author=M.+Wang&author=A.-M.+Campbell&author=D.+R.+Schmidt&author=D.+J.+Guerin&author=J.+A.+Caravella&author=R.+B.+Diebold&author=A.+Ericsson&author=D.+Lancia&title=Preparation+of+Pyrrolotriazinones+and+Imidazotriazinones+as+Ubiquitin-Specific+Protease+7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Pyrrolotriazinones%2520and%2520Imidazotriazinones%2520as%2520Ubiquitin-Specific%2520Protease%25207%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Ioannidis, S.; Talbot, A. C.; Follows, B.; Buckmelter, A. J.; Wang, M.; Campbell, A.-M.; Lancia, D.,  Jr.</span><span> </span><span class="NLM_article-title">Preparation of (Aza)quinazolinones as Ubiquitin-Specific Protease 7 Inhibitors</span>. International Patent WO2016126926,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ioannidis&author=A.+C.+Talbot&author=B.+Follows&author=A.+J.+Buckmelter&author=M.+Wang&author=A.-M.+Campbell&author=D.+Lancia&title=Preparation+of+%28Aza%29quinazolinones+as+Ubiquitin-Specific+Protease+7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520%2528Aza%2529quinazolinones%2520as%2520Ubiquitin-Specific%2520Protease%25207%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Ioannidis, S.; Talbot, A. C.; Follows, B.; Buckmelter, A. J.; Wang, M.; Campbell, A.-M.; Lancia, D.,  Jr.</span><span> </span><span class="NLM_article-title">Preparation of Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors</span>. International Patent WO2016126929,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ioannidis&author=A.+C.+Talbot&author=B.+Follows&author=A.+J.+Buckmelter&author=M.+Wang&author=A.-M.+Campbell&author=D.+Lancia&title=Preparation+of+Thienopyrimidinones+as+Ubiquitin-Specific+Protease+7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Thienopyrimidinones%2520as%2520Ubiquitin-Specific%2520Protease%25207%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Ioannidis, S.; Talbot, A. C.; Follows, B.; Buckmelter, A. J.; Wang, M.; Campbell, A.-M.</span><span> </span><span class="NLM_article-title">Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors</span>. International Patent WO2016126935,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ioannidis&author=A.+C.+Talbot&author=B.+Follows&author=A.+J.+Buckmelter&author=M.+Wang&author=A.-M.+Campbell&title=Isothiazolopyrimidinones%2C+Pyrazolopyrimidinones%2C+and+Pyrrolopyrimidinones+as+Ubiquitin-Specific+Protease+7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DIsothiazolopyrimidinones%252C%2520Pyrazolopyrimidinones%252C%2520and%2520Pyrrolopyrimidinones%2520as%2520Ubiquitin-Specific%2520Protease%25207%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Blake, R.; Di, L. P.; Drummond, J.; Heideker, C. J.; Kategaya, L.; Maurer, T.; Murray, J. M.; Ndubaku, C.; Pastor, R.; Rouge, L.; Tsui, V.; Wertz, I. E.; Yu, K.</span><span> </span><span class="NLM_article-title">Arylpyridinamines as USP7 Inhibitor Compounds and their Preparation</span>. U.S. Patent US20160272588,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=R.+Blake&author=L.+P.+Di&author=J.+Drummond&author=C.+J.+Heideker&author=L.+Kategaya&author=T.+Maurer&author=J.+M.+Murray&author=C.+Ndubaku&author=R.+Pastor&author=L.+Rouge&author=V.+Tsui&author=I.+E.+Wertz&author=K.+Yu&title=Arylpyridinamines+as+USP7+Inhibitor+Compounds+and+their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DR.%26atitle%3DArylpyridinamines%2520as%2520USP7%2520Inhibitor%2520Compounds%2520and%2520their%2520Preparation%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">845</span><span class="NLM_x">–</span> <span class="NLM_lpage">849</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.bmcl.2017.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=28108249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlamurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=845-849&author=C.+Chenauthor=J.+Songauthor=J.+Wangauthor=C.+Xuauthor=C.+Chenauthor=W.+Guauthor=H.+Sunauthor=X.+Wen&title=Synthesis+and+biological+evaluation+of+thiazole+derivatives+as+novel+USP7+inhibitors&doi=10.1016%2Fj.bmcl.2017.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors</span></div><div class="casAuthors">Chen, Chao; Song, Jiemei; Wang, Jinzheng; Xu, Chang; Chen, Caiping; Gu, Wei; Sun, Hongbin; Wen, Xiaoan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">845-849</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herpesvirus-assocd. Ubiquitin-Specific Protease (HAUSP, also called USP7) interacts with and stabilizes Mdm2, and represents one of the first examples that deubiquitinases oncogenic proteins.  USP7 has been regarded as a potential drug target for cancer therapy.  Inhibitors of USP7 have been recently shown to suppress tumor cell growth in vitro and in vivo.  Based on leading USP7 inhibitors P5091 and P22077, we designed and synthesized a series of thiazole derivs.  The results of in vitro assays showed that the thiazole compds., e.g., I, exhibited low micromolar inhibition activity against both USP7 enzyme and cancer cell lines.  The compds. induced cell death in a p53-dependent and p53-independent manner.  Taken together, this study may provide thiazole compds. as a new class of USP7 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDDE4EusDZFbVg90H21EOLACvtfcHk0lglgkjBrB_0Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlamurY%253D&md5=ff5533266d3634bc921c39cab4a76820</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DWen%26aufirst%3DX.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520thiazole%2520derivatives%2520as%2520novel%2520USP7%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D845%26epage%3D849%26doi%3D10.1016%2Fj.bmcl.2017.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Sun, H.; Song, J.; Chen, C.; Wang, J.; Xu, C.; Wen, X.; Gu, W.</span><span> </span><span class="NLM_article-title">Thiazole Compounds as Antitumor Agents and their Preparation, Pharmaceutical Compositions and Use in the Treatment of Cancer</span>. International Patent WO2015127797,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+Sun&author=J.+Song&author=C.+Chen&author=J.+Wang&author=C.+Xu&author=X.+Wen&author=W.+Gu&title=Thiazole+Compounds+as+Antitumor+Agents+and+their+Preparation%2C+Pharmaceutical+Compositions+and+Use+in+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26atitle%3DThiazole%2520Compounds%2520as%2520Antitumor%2520Agents%2520and%2520their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Cancer%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Yamaguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodrasov, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotinsulu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Losung, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangindaan, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Voogd, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokosawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span> </span><span class="NLM_article-title">Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3884</span><span class="NLM_x">–</span> <span class="NLM_lpage">3886</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.04.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.bmcl.2013.04.066" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3884-3886&author=M.+Yamaguchiauthor=M.+Miyazakiauthor=M.+P.+Kodrasovauthor=H.+Rotinsuluauthor=F.+Losungauthor=R.+E.+Mangindaanauthor=N.+J.+de+Voogdauthor=H.+Yokosawaauthor=B.+Nicholsonauthor=S.+Tsukamoto&title=Spongiacidin+C%2C+a+pyrrole+alkaloid+from+the+marine+sponge+Stylissa+massa%2C+functions+as+a+USP7+inhibitor&doi=10.1016%2Fj.bmcl.2013.04.066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.04.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.04.066%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DRotinsulu%26aufirst%3DH.%26aulast%3DLosung%26aufirst%3DF.%26aulast%3DMangindaan%26aufirst%3DR.%2BE.%26aulast%3Dde%2BVoogd%26aufirst%3DN.%2BJ.%26aulast%3DYokosawa%26aufirst%3DH.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DTsukamoto%26aufirst%3DS.%26atitle%3DSpongiacidin%2520C%252C%2520a%2520pyrrole%2520alkaloid%2520from%2520the%2520marine%2520sponge%2520Stylissa%2520massa%252C%2520functions%2520as%2520a%2520USP7%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3884%26epage%3D3886%26doi%3D10.1016%2Fj.bmcl.2013.04.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thunnissen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleverley, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salinas, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biernat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelkow, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span> </span><span class="NLM_article-title">Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1016/S1074-5521(00)00063-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2FS1074-5521%2800%2900063-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10662688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFertA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=51-63&author=L.+Meijerauthor=A.+M.+Thunnissenauthor=A.+W.+Whiteauthor=M.+Garnierauthor=M.+Nikolicauthor=L.+H.+Tsaiauthor=J.+Walterauthor=K.+E.+Cleverleyauthor=P.+C.+Salinasauthor=Y.+Z.+Wuauthor=J.+Biernatauthor=E.+M.+Mandelkowauthor=S.+H.+Kimauthor=G.+R.+Pettit&title=Inhibition+of+cyclin-dependent+kinases%2C+GSK-3beta+and+CK1+by+hymenialdisine%2C+a+marine+sponge+constituent&doi=10.1016%2FS1074-5521%2800%2900063-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent</span></div><div class="casAuthors">Meijer, L.; Thunnissen, A. M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S. H.; Pettit, G. R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-63</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Over 2000 protein kinases regulate cellular functions.  Screening for inhibitors of some of these kinases has already yielded some potent and selective compds. with promising potential for the treatment of human diseases.  Here, the marine sponge constituent, hymenialdisine (I), was found to be a potent inhibitor of cyclin-dependent kinases (CDKs), glycogen synthase kinase-3β (GSK-3β), and casein kinase 1 (CK1).  I was found to compete with ATP for binding to these kinases.  A CDK2-I complex crystal structure showed that 3 H-bonds linked I to the Glu-81 and Leu-83 residues of CDK2, as obsd. with other inhibitors.  I inhibited CDK5/p35 in vivo as demonstrated by the lack of phosphorylation/down-regulation of Pak1 kinase in E18 rat cortical neurons, and also inhibited GSK-3 in vivo as shown by the inhibition of microtubule-assocd. protein-1B phosphorylation.  I also blocked the in vivo phosphorylation of the microtubule-binding protein, tau, at sites that were hyperphosphorylated by GSK-3 and CDK5/p35 in Alzheimer's disease (cross-reacting with Alzheimer's-specific AT100 antibodies) and blocked presenilin-2 phosphorylation in vitro.  Thus, the natural product, I, is a new kinase inhibitor with promising potential applications for treating neurodegenerative disorders such as Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp80sKXSk6kF7Vg90H21EOLACvtfcHk0lhyDKDVJtB40Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFertA%253D%253D&md5=62a4e11bc0d13980751cadd2d1ec723a</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2800%2900063-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252800%252900063-6%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DThunnissen%26aufirst%3DA.%2BM.%26aulast%3DWhite%26aufirst%3DA.%2BW.%26aulast%3DGarnier%26aufirst%3DM.%26aulast%3DNikolic%26aufirst%3DM.%26aulast%3DTsai%26aufirst%3DL.%2BH.%26aulast%3DWalter%26aufirst%3DJ.%26aulast%3DCleverley%26aufirst%3DK.%2BE.%26aulast%3DSalinas%26aufirst%3DP.%2BC.%26aulast%3DWu%26aufirst%3DY.%2BZ.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3DMandelkow%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26atitle%3DInhibition%2520of%2520cyclin-dependent%2520kinases%252C%2520GSK-3beta%2520and%2520CK1%2520by%2520hymenialdisine%252C%2520a%2520marine%2520sponge%2520constituent%26jtitle%3DChem.%2520Biol.%26date%3D2000%26volume%3D7%26spage%3D51%26epage%3D63%26doi%3D10.1016%2FS1074-5521%2800%2900063-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Tanokashira, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nehira, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angkouw, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangindaan, R. E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Voogd, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span> </span><span class="NLM_article-title">Petroquinones: trimeric and dimeric Xestoquinone derivatives isolated from the marine sponge Petrosia alfiani</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5530</span><span class="NLM_x">–</span> <span class="NLM_lpage">5540</span><span class="refDoi"> DOI: 10.1016/j.tet.2016.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.tet.2016.07.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=5530-5540&author=N.+Tanokashiraauthor=S.+Kukitaauthor=H.+Katoauthor=T.+Nehiraauthor=E.+D.+Angkouwauthor=R.+E.+P.+Mangindaanauthor=N.+J.+de+Voogdauthor=S.+Tsukamoto&title=Petroquinones%3A+trimeric+and+dimeric+Xestoquinone+derivatives+isolated+from+the+marine+sponge+Petrosia+alfiani&doi=10.1016%2Fj.tet.2016.07.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2016.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2016.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DTanokashira%26aufirst%3DN.%26aulast%3DKukita%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DNehira%26aufirst%3DT.%26aulast%3DAngkouw%26aufirst%3DE.%2BD.%26aulast%3DMangindaan%26aufirst%3DR.%2BE.%2BP.%26aulast%3Dde%2BVoogd%26aufirst%3DN.%2BJ.%26aulast%3DTsukamoto%26aufirst%3DS.%26atitle%3DPetroquinones%253A%2520trimeric%2520and%2520dimeric%2520Xestoquinone%2520derivatives%2520isolated%2520from%2520the%2520marine%2520sponge%2520Petrosia%2520alfiani%26jtitle%3DTetrahedron%26date%3D2016%26volume%3D72%26spage%3D5530%26epage%3D5540%26doi%3D10.1016%2Fj.tet.2016.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Wang, W.; Wu, Y.; Liu, M.; Jing, B.</span><span> </span><span class="NLM_article-title">Application of Pentacyclic Triterpenoid in Preparation of USP7 Inhibitor</span>. China Patent CN105534991A,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=W.+Wang&author=Y.+Wu&author=M.+Liu&author=B.+Jing&title=Application+of+Pentacyclic+Triterpenoid+in+Preparation+of+USP7+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26atitle%3DApplication%2520of%2520Pentacyclic%2520Triterpenoid%2520in%2520Preparation%2520of%2520USP7%2520Inhibitor%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Wang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S. F.</span><span> </span><span class="NLM_article-title">Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2075</span><span class="NLM_x">–</span> <span class="NLM_lpage">2088</span><span class="refDoi"> DOI: 10.2147/DDDT.S68872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.2147%2FDDDT.S68872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=25364233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOlsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=2075-2088&author=Y.+Y.+Wangauthor=Y.+X.+Yangauthor=H.+Zheauthor=Z.+X.+Heauthor=S.+F.+Zhou&title=Bardoxolone+methyl+%28CDDO-Me%29+as+a+therapeutic+agent%3A+an+update+on+its+pharmacokinetic+and+pharmacodynamic+properties&doi=10.2147%2FDDDT.S68872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties</span></div><div class="casAuthors">Wang, Yan-Yang; Yang, Yin-Xue; Zhe, Hong; He, Zhi-Xu; Zhou, Shu-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2075-2088, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Triterpenoids have been used for medicinal purposes in many Asian countries because of their anti-inflammatory, antioxidant, antiproliferative, anticancer, and anticarcinogenic properties.  Bardoxolone Me, the C-28 Me ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) known as CDDO-Me or RTA 402, is one of the derivs. of synthetic triterpenoids.  CDDO-Me has been used for the treatment of chronic kidney disease, cancer (including leukemia and solid tumors), and other diseases.  In this review, we will update our knowledge of the clin. pharmacokinetics and pharmacodynamics of CDDO-Me, highlighting its clin. benefits and the underlying mechanisms involved.  The role of the Kelch-like erythroid cell-derived protein with CNC homol.-assocd. protein 1 (Keap1)/the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in the therapeutic activities of CDDO-Me will be discussed.  CDDO-Me contains α,β-unsatd. carbonyl groups on rings A and C that can generate reversible adducts with the thiol groups of Cys residues in target proteins such as Keap1 and IκB kinase.  At low nanomolar concns., CDDO-Me protects the cells against oxidative stress via inhibition of reactive oxygen species generation, while CDDO-Me at low micromolar concns. induces apoptosis by increasing reactive oxygen species and decreasinging intracellular glutathione levels.  Through Keap1/Nrf2 and nuclear factor-κB pathways, this agent can modulate the activities of a no. of important proteins that regulate inflammation, redox balance, cell proliferation and programmed cell death.  In a Phase I trial in cancer patients, CDDO-Me was found to have a slow and saturable oral absorption, a relatively long terminal phase half-life (39 h at 900 mg/day), nonlinearity (dose-dependent) at high doses (600-1,300 mg/day), and high interpatient variability.  As a multifunctional agent, CDDO-Me has improved the renal function in patients with chronic kidney disease assocd. with type 2 diabetes.  CDDO-Me has shown a promising anticancer effect in a Phase I trial.  This agent is generally well tolerated, but it may increase adverse cardiovascular events.  Presently, it is being further tested for the treatment of patients with chronic kidney disease, cancer, and pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBzXblYw_T8bVg90H21EOLACvtfcHk0lhyDKDVJtB40Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOlsLvI&md5=75feb541785ab658bee232d7e5a6f073</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S68872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S68872%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BY.%26aulast%3DYang%26aufirst%3DY.%2BX.%26aulast%3DZhe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DZ.%2BX.%26aulast%3DZhou%26aufirst%3DS.%2BF.%26atitle%3DBardoxolone%2520methyl%2520%2528CDDO-Me%2529%2520as%2520a%2520therapeutic%2520agent%253A%2520an%2520update%2520on%2520its%2520pharmacokinetic%2520and%2520pharmacodynamic%2520properties%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D2075%26epage%3D2088%26doi%3D10.2147%2FDDDT.S68872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span><span class="refDoi"> DOI: 10.1038/nrd2130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrd2130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=17016424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+a+multikinase+inhibitor+for+treating+cancer&doi=10.1038%2Fnrd2130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span></div><div class="casAuthors">Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways.  The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process.  Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature.  The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compd. to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WjjfgNSCtbVg90H21EOLACvtfcHk0lgnzVNk9GsObg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM&md5=490d4995170f3a7270ae9bbdd24b12e5</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1038%2Fnrd2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2130%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520a%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D835%26epage%3D844%26doi%3D10.1038%2Fnrd2130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Broekman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannetti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: multi-targeted or single-targeted?</span> <span class="citation_source-journal">World J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.5306/wjco.v2.i2.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.5306%2Fwjco.v2.i2.80" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21603317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A280%3ADC%252BC3Mrkt1arsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=80-93&author=F.+Broekmanauthor=E.+Giovannettiauthor=G.+J.+Peters&title=Tyrosine+kinase+inhibitors%3A+multi-targeted+or+single-targeted%3F&doi=10.5306%2Fwjco.v2.i2.80"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors: Multi-targeted or single-targeted?</span></div><div class="casAuthors">Broekman Fleur; Giovannetti Elisa; Peters Godefridus J</div><div class="citationInfo"><span class="NLM_cas:title">World journal of clinical oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">80-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since in most tumors multiple signaling pathways are involved, many of the inhibitors in clinical development are designed to affect a wide range of targeted kinases.  The most important tyrosine kinase families in the development of tyrosine kinase inhibitors are the ABL, SCR, platelet derived growth factor, vascular endothelial growth factor receptor and epidermal growth factor receptor families.  Both multi-kinase inhibitors and single-kinase inhibitors have advantages and disadvantages, which are related to potential resistance mechanisms, pharmacokinetics, selectivity and tumor environment.  In different malignancies various tyrosine kinases are mutated or overexpressed and several resistance mechanisms exist.  Pharmacokinetics is influenced by interindividual differences and differs for two single targeted inhibitors or between patients treated by the same tyrosine kinase inhibitor.  Different tyrosine kinase inhibitors have various mechanisms to achieve selectivity, while differences in gene expression exist between tumor and stromal cells.  Considering these aspects, one type of inhibitor can generally not be preferred above the other, but will depend on the specific genetic constitution of the patient and the tumor, allowing personalized therapy.  The most effective way of cancer treatment by using tyrosine kinase inhibitors is to consider each patient/tumor individually and to determine the strategy that specifically targets the consequences of altered (epi)genetics of the tumor.  This strategy might result in treatment by a single multi kinase inhibitor for one patient, but in treatment by a couple of single kinase inhibitors for other patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUsa5qqJaBY_csfMJQC1ZdfW6udTcc2eYSAI9fxrl7u7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mrkt1arsw%253D%253D&md5=683eaad679244b5efc5813d1ffaaaf57</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.5306%2Fwjco.v2.i2.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5306%252Fwjco.v2.i2.80%26sid%3Dliteratum%253Aachs%26aulast%3DBroekman%26aufirst%3DF.%26aulast%3DGiovannetti%26aufirst%3DE.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520multi-targeted%2520or%2520single-targeted%253F%26jtitle%3DWorld%2520J.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D2%26spage%3D80%26epage%3D93%26doi%3D10.5306%2Fwjco.v2.i2.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Goldenberg, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butt, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattern, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span> </span><span class="NLM_article-title">Strategies for the identification of novel inhibitors of deubiquitinating enzymes</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">828</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1042/BST0360828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1042%2FBST0360828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=18793145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSrt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=828-832&author=S.+J.+Goldenbergauthor=J.+L.+McDermottauthor=T.+R.+Buttauthor=M.+R.+Matternauthor=B.+Nicholson&title=Strategies+for+the+identification+of+novel+inhibitors+of+deubiquitinating+enzymes&doi=10.1042%2FBST0360828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for the identification of novel inhibitors of deubiquitinating enzymes</span></div><div class="casAuthors">Goldenberg, Seth J.; McDermott, Jeffrey L.; Butt, Tauseef R.; Mattern, Michael R.; Nicholson, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">828-832</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Dysregulation of the UPS (ubiquitin-proteasome system) has been implicated in a wide range of pathologies including cancer, neurodegeneration and viral infection.  Inhibiting the proteasome has been shown to be an effective therapeutic strategy in humans; yet toxicity with this target remains high.  DUBs (deubiquitinating enzymes) represent an alternative target in the UPS with low predicted toxicity.  Currently, there are no DUB inhibitors that have been used clin.  To address this situation, Progenra has developed a novel assay to measure the proteolytic cleavage of Ub (ubiquitin) or UBL (Ub-like protein) conjugates such as SUMO (small Ub-related modifier), NEDD8 (neural-precursor-cell-expressed, developmentally down-regulated 8) or ISG15 (interferon-stimulated gene 15) by isopeptidases.  In this review, current platforms for detecting DUB inhibitors are discussed and the advantages and disadvantages of the approaches are underlined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-0x67KYwgCbVg90H21EOLACvtfcHk0lgnzVNk9GsObg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSrt77J&md5=b8ec5a0826d6b233130156418afc1b2e</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1042%2FBST0360828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0360828%26sid%3Dliteratum%253Aachs%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DMcDermott%26aufirst%3DJ.%2BL.%26aulast%3DButt%26aufirst%3DT.%2BR.%26aulast%3DMattern%26aufirst%3DM.%2BR.%26aulast%3DNicholson%26aufirst%3DB.%26atitle%3DStrategies%2520for%2520the%2520identification%2520of%2520novel%2520inhibitors%2520of%2520deubiquitinating%2520enzymes%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2008%26volume%3D36%26spage%3D828%26epage%3D832%26doi%3D10.1042%2FBST0360828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lj3VjNsZ50dGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Burger, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedeschi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robak, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bairey, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillmen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosicki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devereux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quach, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaidano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maslyak, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polliack, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clow, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Styles, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipps, T. J.</span><span> </span><span class="NLM_article-title">Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">2425</span><span class="NLM_x">–</span> <span class="NLM_lpage">2437</span><span class="refDoi"> DOI: 10.1056/NEJMoa1509388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1056%2FNEJMoa1509388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26639149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit10%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2425-2437&author=J.+A.+Burgerauthor=A.+Tedeschiauthor=P.+M.+Barrauthor=T.+Robakauthor=C.+Owenauthor=P.+Ghiaauthor=O.+Baireyauthor=P.+Hillmenauthor=N.+L.+Bartlettauthor=J.+Liauthor=D.+Simpsonauthor=S.+Grosickiauthor=S.+Devereuxauthor=H.+McCarthyauthor=S.+Coutreauthor=H.+Quachauthor=G.+Gaidanoauthor=Z.+Maslyakauthor=D.+A.+Stevensauthor=A.+Janssensauthor=F.+Offnerauthor=J.+Mayerauthor=M.+O%E2%80%99Dwyerauthor=A.+Hellmannauthor=A.+Schuhauthor=T.+Siddiqiauthor=A.+Polliackauthor=C.+S.+Tamauthor=D.+Suriauthor=M.+Chengauthor=F.+Clowauthor=L.+Stylesauthor=D.+F.+Jamesauthor=T.+J.+Kipps&title=Ibrutinib+as+initial+therapy+for+patients+with+chronic+lymphocytic+leukemia&doi=10.1056%2FNEJMoa1509388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia</span></div><div class="casAuthors">Burger, J. A.; Tedeschi, A.; Barr, P. M.; Robak, T.; Owen, C.; Ghia, P.; Bairey, O.; Hillmen, P.; Bartlett, N. L.; Li, J.; Simpson, D.; Grosicki, S.; Devereux, S.; McCarthy, H.; Coutre, S.; Quach, H.; Gaidano, G.; Maslyak, Z.; Stevens, D. A.; Janssens, A.; Offner, F.; Mayer, J.; O'Dwyer, M.; Hellmann, A.; Schuh, A.; Siddiqi, T.; Polliack, A.; Tam, C. S.; Suri, D.; Cheng, M.; Clow, F.; Styles, L.; James, D. F.; Kipps, T. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2425-2437</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addn. to disease-related immunosuppression and myelosuppression.  We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma.  Methods We randomly assigned 269 previously untreated patients who were 65 years of age or older and had CLL or small lymphocytic lymphoma to receive ibrutinib or chlorambucil.  The primary end point was progression-free survival as assessed by an independent review committee. results The median age of the patients was 73 years.  During a median follow-up period of 18.4 mo, ibrutinib resulted in significantly longer progression-free survival than did chlorambucil (median, not reached vs. 18.9 mo), with a risk of progression or death that was 84% lower with ibrutinib than that with chlorambucil (hazard ratio, 0.16; P<0.001).  Ibrutinib significantly prolonged overall survival; the estd. survival rate at 24 mo was 98% with ibrutinib vs. 85% with chlorambucil, with a relative risk of death that was 84% lower in the ibrutinib group than in the chlorambucil group (hazard ratio, 0.16; P = 0.001).  The overall response rate was higher with ibrutinib than with chlorambucil (86% vs. 35%, P<0.001).  The rates of sustained increases from baseline values in the Hb and platelet levels were higher with ibrutinib.  Adverse events of any grade that occurred in at least 20% of the patients receiving ibrutinib included diarrhea, fatigue, cough, and nausea; adverse events occurring in at least 20% of those receiving chlorambucil included nausea, fatigue, neutropenia, anemia, and vomiting.  In the ibrutinib group, four patients had a grade 3 hemorrhage and one had a grade 4 hemorrhage.  A total of 87% of the patients in the ibrutinib group are continuing to take ibrutinib. conclusions Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematol. variables.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMCNq9IoqJj7Vg90H21EOLACvtfcHk0lj3VjNsZ50dGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit10%253D&md5=7f6c13e398a31d067951c094abb84e65</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509388%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DTedeschi%26aufirst%3DA.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DOwen%26aufirst%3DC.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBairey%26aufirst%3DO.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DBartlett%26aufirst%3DN.%2BL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSimpson%26aufirst%3DD.%26aulast%3DGrosicki%26aufirst%3DS.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DMcCarthy%26aufirst%3DH.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DQuach%26aufirst%3DH.%26aulast%3DGaidano%26aufirst%3DG.%26aulast%3DMaslyak%26aufirst%3DZ.%26aulast%3DStevens%26aufirst%3DD.%2BA.%26aulast%3DJanssens%26aufirst%3DA.%26aulast%3DOffner%26aufirst%3DF.%26aulast%3DMayer%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DM.%26aulast%3DHellmann%26aufirst%3DA.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3DSiddiqi%26aufirst%3DT.%26aulast%3DPolliack%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DSuri%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DStyles%26aufirst%3DL.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26atitle%3DIbrutinib%2520as%2520initial%2520therapy%2520for%2520patients%2520with%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2425%26epage%3D2437%26doi%3D10.1056%2FNEJMoa1509388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span><span class="refDoi"> DOI: 10.1016/j.phrs.2015.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.1016%2Fj.phrs.2015.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=26529477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2016&pages=26-48&author=R.+Roskoski&title=Classification+of+small+molecule+protein+kinase+inhibitors+based+upon+the+structures+of+their+drug-enzyme+complexes&doi=10.1016%2Fj.phrs.2015.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-48</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Because dysregulation and mutations of protein kinases play causal roles in human disease, this family of enzymes has become one of the most important drug targets over the past two decades.  The X-ray crystal structures of 21 of the 27 FDA-approved small mol. inhibitors bound to their target protein kinases are depicted in this paper.  The structure of the enzyme-bound antagonist complex is used in the classification of these inhibitors.  Type I inhibitors bind to the active protein kinase conformation (DFG-Asp in, αC-helix in).  Type I1/2 inhibitors bind to a DFG-Asp in inactive conformation while Type II inhibitors bind to a DFG-Asp out inactive conformation.  Type I, I1/2, and type II inhibitors occupy part of the adenine binding pocket and form hydrogen bonds with the hinge region connecting the small and large lobes of the enzyme.  Type III inhibitors bind next to the ATP-binding pocket and type IV inhibitors do not bind to the ATP or peptide substrate binding sites.  Type III and IV inhibitors are allosteric in nature.  Type V inhibitors bind to two different regions of the protein kinase domain and are therefore bivalent inhibitors.  The type I-V inhibitors are reversible.  In contrast, type VI inhibitors bind covalently to their target enzyme.  Type I, I1/2, and II inhibitors are divided into A and B subtypes.  The type A inhibitors bind in the front cleft, the back cleft, and near the gatekeeper residue, all of which occur within the region sepg. the small and large lobes of the protein kinase.  The type B inhibitors bind in the front cleft and gate area but do not extend into the back cleft.  An anal. of the limited available data indicates that type A inhibitors have a long residence time (minutes to hours) while the type B inhibitors have a short residence time (seconds to minutes).  The catalytic spine includes residues from the small and large lobes and interacts with the adenine ring of ATP.  Nearly all of the approved protein kinase inhibitors occupy the adenine-binding pocket; thus it is not surprising that these inhibitors interact with nearby catalytic spine (CS) residues.  Moreover, a significant no. of approved drugs also interact with regulatory spine (RS) residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0COwqC0CabVg90H21EOLACvtfcHk0lj3VjNsZ50dGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN&md5=e6b45c8644e322f30f898e763780c64b</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DClassification%2520of%2520small%2520molecule%2520protein%2520kinase%2520inhibitors%2520based%2520upon%2520the%2520structures%2520of%2520their%2520drug-enzyme%2520complexes%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D103%26spage%3D26%26epage%3D48%26doi%3D10.1016%2Fj.phrs.2015.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Johnson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerapana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span><span class="refDoi"> DOI: 10.4155/fmc.10.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.+S.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors&doi=10.4155%2Ffmc.10.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0lhH7gvJ7zRf3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964%26doi%3D10.4155%2Ffmc.10.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WPI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WPI','PDB','4WPI'); return false;">PDB: 4WPI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FOO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FOO','PDB','2FOO'); return false;">PDB: 2FOO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FOP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FOP','PDB','2FOP'); return false;">PDB: 2FOP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4M5X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4M5X','PDB','4M5X'); return false;">PDB: 4M5X</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JTV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JTV','PDB','5JTV'); return false;">PDB: 5JTV</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i22"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00498">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_65403"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00498">10.1021/acs.jmedchem.7b00498</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00498/suppl_file/jm7b00498_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00498/suppl_file/jm7b00498_si_001.csv">jm7b00498_si_001.csv (3.38 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00498&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-2%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00498%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00498" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799bea9ee923c46","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
